返回首页 在线留言 联系我们
首页 > 产品展示 > > 所有 > LKT Labs A8812AWD 131-138 191 GABA-A

产品中心

LKT Labs A8812AWD 131-138 191 GABA-A

  • 型   号:
  • 价   格:

LKT Labs 是一家专注于防癌抗癌特殊化学品研究和开发的公司。主要提供:癌症药物、药物发现试剂盒、天然产物、广泛的生命科学研究试剂、定制合成。
美国LKT Labs 是1988年在美国成立的,为全球提供先端的药物研发试剂、试剂盒、委托合成,并为药物生产企业提供原料,最近几年在农药、水产养殖业有很大程度的开发。LKT Labs A8812AWD 131-138 191 GABA-A

分享到:

LKT Labs 是一家专注于防癌抗癌特殊化学品研究和开发的公司。主要提供:癌症药物、药物发现试剂盒、天然产物、广泛的生命科学研究试剂、定制合成。
美国LKT Labs 是1988年在美国成立的,为全球提供先端的药物研发试剂、试剂盒、委托合成,并为药物生产企业提供原料,最近几年在农药、水产养殖业有很大程度的开发。在LKT Labs 可以找到在其他地方找不到的产品。

LKT Labs A8812 AWD 131-138 191 GABA-A

LKT Labs A8812 AWD 131-138 191 GABA-A

 

LKT G7442 GSK-343 1 mg 78.9 EZH2 HMT inhibitor. 1346704-33-3 ≥98% 541.69 C31H39N7O2 CCCC1=C(C(=O)NC(=C1)C)CNC(=O)C2=C3C=NN(C3=CC(=C2)C4=CC(=NC=C4)N5CCN(CC5)C)C(C)C Ambient 4°C Ethanol (2 mg/ml), DMSO (15 mg/ml), DMF (25 mg/ml) Amatangelo MD, Garipov A, Li H, et al. Three-dimensional culture sensitizes epithelial ovarian cancer cells to EZH2 methyltransferase inhibition. Cell Cycle. 2013 Jul 1;12(13):2113-9. PMID: 23759589. Not dangerous goods.

LKT G7442 GSK-343 5 mg 212.3 EZH2 HMT inhibitor. 1346704-33-3 ≥98% 541.69 C31H39N7O2 CCCC1=C(C(=O)NC(=C1)C)CNC(=O)C2=C3C=NN(C3=CC(=C2)C4=CC(=NC=C4)N5CCN(CC5)C)C(C)C Ambient 4°C Ethanol (2 mg/ml), DMSO (15 mg/ml), DMF (25 mg/ml) Amatangelo MD, Garipov A, Li H, et al. Three-dimensional culture sensitizes epithelial ovarian cancer cells to EZH2 methyltransferase inhibition. Cell Cycle. 2013 Jul 1;12(13):2113-9. PMID: 23759589. Not dangerous goods.

LKT G7442 GSK-343 10 mg 345.8 EZH2 HMT inhibitor. 1346704-33-3 ≥98% 541.69 C31H39N7O2 CCCC1=C(C(=O)NC(=C1)C)CNC(=O)C2=C3C=NN(C3=CC(=C2)C4=CC(=NC=C4)N5CCN(CC5)C)C(C)C Ambient 4°C Ethanol (2 mg/ml), DMSO (15 mg/ml), DMF (25 mg/ml) Amatangelo MD, Garipov A, Li H, et al. Three-dimensional culture sensitizes epithelial ovarian cancer cells to EZH2 methyltransferase inhibition. Cell Cycle. 2013 Jul 1;12(13):2113-9. PMID: 23759589. Not dangerous goods.

LKT G1210 GDC-0623 1 mg 118.9 MEK inhibitor. 1168091-68-6 ≥98% 456.21 C16H14FIN4O3 C1=CC(=C(C=C1I)F)NC2=C(C=CC3=CN=CN32)C(=O)NOCCO Ambient 4°C Hatzivassiliou G, Haling JR, Chen H, et al. Mechanism of MEK inhibition determines efficacy in mutant KRAS- versus BRAF-driven cancers. Nature. 2013 Sep 12;501(7466):232-6. PMID: 23934108. Not dangerous goods.

LKT G1210 GDC-0623 5 mg 394.4 MEK inhibitor. 1168091-68-6 ≥98% 456.21 C16H14FIN4O3 C1=CC(=C(C=C1I)F)NC2=C(C=CC3=CN=CN32)C(=O)NOCCO Ambient 4°C Hatzivassiliou G, Haling JR, Chen H, et al. Mechanism of MEK inhibition determines efficacy in mutant KRAS- versus BRAF-driven cancers. Nature. 2013 Sep 12;501(7466):232-6. PMID: 23934108. Not dangerous goods.

LKT G1210 GDC-0623 10 mg 630.9 MEK inhibitor. 1168091-68-6 ≥98% 456.21 C16H14FIN4O3 C1=CC(=C(C=C1I)F)NC2=C(C=CC3=CN=CN32)C(=O)NOCCO Ambient 4°C Hatzivassiliou G, Haling JR, Chen H, et al. Mechanism of MEK inhibition determines efficacy in mutant KRAS- versus BRAF-driven cancers. Nature. 2013 Sep 12;501(7466):232-6. PMID: 23934108. Not dangerous goods.

LKT C5600 CO-1686 1 mg 115.3 EGFR (WT, T790M) inhibitor. N-(3-((2-((4-(4-Acetylpiperazin-1-yl)-2-methoxyphenyl)amino)-5-(trifluoromethyl)pyrimidin-4-yl)amino)phenyl)prop-2-enamide AVL-301; Rociletinib 1374640-70-6 ≥98% 555.55 C27H28F3N7O3 CC(=O)N1CCN(CC1)C2=CC(=C(C=C2)NC3=NC=C(C(=N3)NC4=CC(=CC=C4)NC(=O)C=C)C(F)(F)F)OC Ambient 4°C "Walter AO, Sjin RT, Haringsma HJ, et al. Discovery of a mutant-selective covalent inhibitor of EGFR that overcomes T790M-mediated resistance in NSCLC. Cancer Discov. 2013 Dec;3(12):1404-15. PMID: 24065731.

 

Yu HA, Riely GJ. Second-generation epidermal growth factor receptor tyrosine kinase inhibitors in lung cancers. J Natl Compr Canc Netw. 2013 Feb 1;11(2):161-9. PMID: 23411383.

" Not dangerous goods.

LKT C5600 CO-1686 5 mg 242.7 EGFR (WT, T790M) inhibitor. N-(3-((2-((4-(4-Acetylpiperazin-1-yl)-2-methoxyphenyl)amino)-5-(trifluoromethyl)pyrimidin-4-yl)amino)phenyl)prop-2-enamide AVL-301; Rociletinib 1374640-70-6 ≥98% 555.55 C27H28F3N7O3 CC(=O)N1CCN(CC1)C2=CC(=C(C=C2)NC3=NC=C(C(=N3)NC4=CC(=CC=C4)NC(=O)C=C)C(F)(F)F)OC Ambient 4°C "Walter AO, Sjin RT, Haringsma HJ, et al. Discovery of a mutant-selective covalent inhibitor of EGFR that overcomes T790M-mediated resistance in NSCLC. Cancer Discov. 2013 Dec;3(12):1404-15. PMID: 24065731.

 

Yu HA, Riely GJ. Second-generation epidermal growth factor receptor tyrosine kinase inhibitors in lung cancers. J Natl Compr Canc Netw. 2013 Feb 1;11(2):161-9. PMID: 23411383.

" Not dangerous goods.

LKT C5600 CO-1686 10 mg 406.5 EGFR (WT, T790M) inhibitor. N-(3-((2-((4-(4-Acetylpiperazin-1-yl)-2-methoxyphenyl)amino)-5-(trifluoromethyl)pyrimidin-4-yl)amino)phenyl)prop-2-enamide AVL-301; Rociletinib 1374640-70-6 ≥98% 555.55 C27H28F3N7O3 CC(=O)N1CCN(CC1)C2=CC(=C(C=C2)NC3=NC=C(C(=N3)NC4=CC(=CC=C4)NC(=O)C=C)C(F)(F)F)OC Ambient 4°C "Walter AO, Sjin RT, Haringsma HJ, et al. Discovery of a mutant-selective covalent inhibitor of EGFR that overcomes T790M-mediated resistance in NSCLC. Cancer Discov. 2013 Dec;3(12):1404-15. PMID: 24065731.

 

Yu HA, Riely GJ. Second-generation epidermal growth factor receptor tyrosine kinase inhibitors in lung cancers. J Natl Compr Canc Netw. 2013 Feb 1;11(2):161-9. PMID: 23411383.

" Not dangerous goods.

LKT A9710 AZD-2014 1 mg 118.9 mTOR inhibitor. 1009298-59-2 ≥98% 462.54 C25H30N6O3 CC1COCCN1C2=NC(=NC3=C2C=CC(=N3)C4=CC(=CC=C4)C(=O)NC)N5CCOCC5C Ambient 4°C Huo HZ, Zhou ZY, Wang B, et al. Dramatic suppression of colorectal cancer cell growth by the dual mTORC1 and mTORC2 inhibitor AZD-2014. Biochem Biophys Res Commun. 2014 Jan 10;443(2):406-12. PMID: 24309100. Not dangerous goods.

LKT A9710 AZD-2014 5 mg 260.9 mTOR inhibitor. 1009298-59-2 ≥98% 462.54 C25H30N6O3 CC1COCCN1C2=NC(=NC3=C2C=CC(=N3)C4=CC(=CC=C4)C(=O)NC)N5CCOCC5C Ambient 4°C Huo HZ, Zhou ZY, Wang B, et al. Dramatic suppression of colorectal cancer cell growth by the dual mTORC1 and mTORC2 inhibitor AZD-2014. Biochem Biophys Res Commun. 2014 Jan 10;443(2):406-12. PMID: 24309100. Not dangerous goods.

LKT A9710 AZD-2014 10 mg 467.1 mTOR inhibitor. 1009298-59-2 ≥98% 462.54 C25H30N6O3 CC1COCCN1C2=NC(=NC3=C2C=CC(=N3)C4=CC(=CC=C4)C(=O)NC)N5CCOCC5C Ambient 4°C Huo HZ, Zhou ZY, Wang B, et al. Dramatic suppression of colorectal cancer cell growth by the dual mTORC1 and mTORC2 inhibitor AZD-2014. Biochem Biophys Res Commun. 2014 Jan 10;443(2):406-12. PMID: 24309100. Not dangerous goods.

LKT A9708 AZD-1208 1 mg 118.9 Pim-1 inhibitor. 1204144-28-4 ≥98% 379.48 C21H21N3O2S C1CC(CN(C1)C2=C(C=CC=C2C=C3C(=O)NC(=O)S3)C4=CC=CC=C4)N Ambient 4°C "Kirschner AN, Wang J, van der Meer R, et al. PIM kinase inhibitor AZD1208 for treatment of MYC-driven prostate cancer. J Natl Cancer Inst. 2014 Dec 13;107(2). PMID: 25505253.

 

Keeton EK, McEachern K, Dillman KS, et al. AZD1208, a potent and selective pan-Pim kinase inhibitor, demonstrates efficacy in preclinical models of acute myeloid leukemia. Blood. 2014 Feb 6;123(6):905-13. PMID: 24363397." Not dangerous goods.

LKT A9708 AZD-1208 5 mg 345.8 Pim-1 inhibitor. 1204144-28-4 ≥98% 379.48 C21H21N3O2S C1CC(CN(C1)C2=C(C=CC=C2C=C3C(=O)NC(=O)S3)C4=CC=CC=C4)N Ambient 4°C "Kirschner AN, Wang J, van der Meer R, et al. PIM kinase inhibitor AZD1208 for treatment of MYC-driven prostate cancer. J Natl Cancer Inst. 2014 Dec 13;107(2). PMID: 25505253.

 

Keeton EK, McEachern K, Dillman KS, et al. AZD1208, a potent and selective pan-Pim kinase inhibitor, demonstrates efficacy in preclinical models of acute myeloid leukemia. Blood. 2014 Feb 6;123(6):905-13. PMID: 24363397." Not dangerous goods.

LKT A9708 AZD-1208 10 mg 637 Pim-1 inhibitor. 1204144-28-4 ≥98% 379.48 C21H21N3O2S C1CC(CN(C1)C2=C(C=CC=C2C=C3C(=O)NC(=O)S3)C4=CC=CC=C4)N Ambient 4°C "Kirschner AN, Wang J, van der Meer R, et al. PIM kinase inhibitor AZD1208 for treatment of MYC-driven prostate cancer. J Natl Cancer Inst. 2014 Dec 13;107(2). PMID: 25505253.

 

Keeton EK, McEachern K, Dillman KS, et al. AZD1208, a potent and selective pan-Pim kinase inhibitor, demonstrates efficacy in preclinical models of acute myeloid leukemia. Blood. 2014 Feb 6;123(6):905-13. PMID: 24363397." Not dangerous goods.

LKT S0928 SCH-900776 1 mg 118.9 CHK1 inhibitor. 891494-63-6 ≥98% 376.25 C15H18BrN7 CN1C=C(C=N1)C2=C3N=C(C(=C(N3N=C2)N)Br)C4CCCNC4 Ambient 4°C "Dai Y, Chen S, Kmieciak M, et al. The novel Chk1 inhibitor MK-8776 sensitizes human leukemia cells to HDAC inhibitors by targeting the intra-S checkpoint and DNA replication and repair. Mol Cancer Ther. 2013 Jun;12(6):878-89. PMID: 23536721.

 

Karp JE, Thomas BM, Greer JM, et al. Phase I and pharmacologic trial of cytosine arabinoside with the selective checkpoint 1 inhibitor Sch 900776 in refractory acute leukemias. Clin Cancer Res. 2012 Dec 15;18(24):6723-31. PMID: 23092873.

 

Guzi TJ, Paruch K, Dwyer MP, et al. Targeting the replication checkpoint using SCH 900776, a potent and functionally selective CHK1 inhibitor identified via high content screening. Mol Cancer Ther. 2011 Apr;10(4):591-602. PMID: 21321066.

" Not dangerous goods.

LKT S0928 SCH-900776 5 mg 236.6 CHK1 inhibitor. 891494-63-6 ≥98% 376.25 C15H18BrN7 CN1C=C(C=N1)C2=C3N=C(C(=C(N3N=C2)N)Br)C4CCCNC4 Ambient 4°C "Dai Y, Chen S, Kmieciak M, et al. The novel Chk1 inhibitor MK-8776 sensitizes human leukemia cells to HDAC inhibitors by targeting the intra-S checkpoint and DNA replication and repair. Mol Cancer Ther. 2013 Jun;12(6):878-89. PMID: 23536721.

 

Karp JE, Thomas BM, Greer JM, et al. Phase I and pharmacologic trial of cytosine arabinoside with the selective checkpoint 1 inhibitor Sch 900776 in refractory acute leukemias. Clin Cancer Res. 2012 Dec 15;18(24):6723-31. PMID: 23092873.

 

Guzi TJ, Paruch K, Dwyer MP, et al. Targeting the replication checkpoint using SCH 900776, a potent and functionally selective CHK1 inhibitor identified via high content screening. Mol Cancer Ther. 2011 Apr;10(4):591-602. PMID: 21321066.

" Not dangerous goods.

LKT S0928 SCH-900776 10 mg 394.4 CHK1 inhibitor. 891494-63-6 ≥98% 376.25 C15H18BrN7 CN1C=C(C=N1)C2=C3N=C(C(=C(N3N=C2)N)Br)C4CCCNC4 Ambient 4°C "Dai Y, Chen S, Kmieciak M, et al. The novel Chk1 inhibitor MK-8776 sensitizes human leukemia cells to HDAC inhibitors by targeting the intra-S checkpoint and DNA replication and repair. Mol Cancer Ther. 2013 Jun;12(6):878-89. PMID: 23536721.

 

Karp JE, Thomas BM, Greer JM, et al. Phase I and pharmacologic trial of cytosine arabinoside with the selective checkpoint 1 inhibitor Sch 900776 in refractory acute leukemias. Clin Cancer Res. 2012 Dec 15;18(24):6723-31. PMID: 23092873.

 

Guzi TJ, Paruch K, Dwyer MP, et al. Targeting the replication checkpoint using SCH 900776, a potent and functionally selective CHK1 inhibitor identified via high content screening. Mol Cancer Ther. 2011 Apr;10(4):591-602. PMID: 21321066.

" Not dangerous goods.

LKT E6398 EPZ-5676 1 mg 115.3 DOT1L HMT inhibitor. 1380288-87-8 ≥98% 562.71 C30H42N8O3 CC(C)N(CC1C(C(C(O1)N2C=NC3=C2N=CN=C3N)O)O)C4CC(C4)CCC5=NC6=C(N5)C=C(C=C6)C(C)(C)C Ambient 4°C "Basavapathruni A, Olhava EJ, Daigle SR, et al. Nonclinical pharmacokinetics and metabolism of EPZ-5676, a novel DOT1L histone methyltransferase inhibitor. Biopharm Drug Dispos. 2014 Jan 10. [Epub ahead of print]. PMID: 24415392.

 

Daigle SR, Olhava EJ, Therkelsen CA, et al. Potent inhibition of DOT1L as treatment of MLL-fusion leukemia. Blood. 2013 Aug 8;122(6):1017-25. PMID: 23801631.

" Not dangerous goods.

LKT E6398 EPZ-5676 5 mg 200.2 DOT1L HMT inhibitor. 1380288-87-8 ≥98% 562.71 C30H42N8O3 CC(C)N(CC1C(C(C(O1)N2C=NC3=C2N=CN=C3N)O)O)C4CC(C4)CCC5=NC6=C(N5)C=C(C=C6)C(C)(C)C Ambient 4°C "Basavapathruni A, Olhava EJ, Daigle SR, et al. Nonclinical pharmacokinetics and metabolism of EPZ-5676, a novel DOT1L histone methyltransferase inhibitor. Biopharm Drug Dispos. 2014 Jan 10. [Epub ahead of print]. PMID: 24415392.

 

Daigle SR, Olhava EJ, Therkelsen CA, et al. Potent inhibition of DOT1L as treatment of MLL-fusion leukemia. Blood. 2013 Aug 8;122(6):1017-25. PMID: 23801631.

" Not dangerous goods.

LKT E6398 EPZ-5676 10 mg 313 DOT1L HMT inhibitor. 1380288-87-8 ≥98% 562.71 C30H42N8O3 CC(C)N(CC1C(C(C(O1)N2C=NC3=C2N=CN=C3N)O)O)C4CC(C4)CCC5=NC6=C(N5)C=C(C=C6)C(C)(C)C Ambient 4°C "Basavapathruni A, Olhava EJ, Daigle SR, et al. Nonclinical pharmacokinetics and metabolism of EPZ-5676, a novel DOT1L histone methyltransferase inhibitor. Biopharm Drug Dispos. 2014 Jan 10. [Epub ahead of print]. PMID: 24415392.

 

Daigle SR, Olhava EJ, Therkelsen CA, et al. Potent inhibition of DOT1L as treatment of MLL-fusion leukemia. Blood. 2013 Aug 8;122(6):1017-25. PMID: 23801631.

" Not dangerous goods.

LKT A0777 ABT-263 1 mg 54.6 BH3 mimetic; Bcl-2 and Bcl-xl inhibitor. Navitoclax, A-855071 923564-51-6 ≥98% 974.61 C47H55ClF3N5O6S3 CC1(CCC(=C(C1)CN2CCN(CC2)C3=CC=C(C=C3)C(=O)NS(=O)(=O)C4=CC(=C(C=C4)NC(CCN5CCOCC5)CSC6=CC=CC=C6)S(=O)(=O)C(F)(F)F)C7=CC=C(C=C7)Cl)C Ambient 4°C "Debrincat MA, Pleines I, Lebois M, et al. BCL-2 is dispensable for thrombopoiesis and platelet survival. Cell Death Dis. 2015 Apr 16;6:e1721. PMID: 25880088.

 

Khaw SL, Mérino D, Anderson MA, et al. Both leukaemic and normal peripheral B lymphoid cells are highly sensitive to the selective pharmacological inhibition of prosurvival Bcl-2 with ABT-199. Leukemia. 2014 Jan 9. [Epub ahead of print]. PMID: 24402163.

 

Balakrishnan K, Gandhi V. Bcl-2 antagonists: a proof of concept for CLL therapy. Invest New Drugs. 2013 Oct;31(5):1384-94. PMID: 23907405.

 

Rudin CM, Hann CL, Garon EB, et al. Phase II study of single-agent navitoclax (ABT-263) and biomarker correlates in patients with relapsed small cell lung cancer. Clin Cancer Res. 2012 Jun 1;18(11):3163-9. PMID: 22496272.

 

Chen J, Jin S, Abraham V, et al. The Bcl-2/Bcl-X(L)/Bcl-w inhibitor, navitoclax, enhances the activity of chemotherapeutic agents in vitro and in vivo. Mol Cancer Ther. 2011 Dec;10(12):2340-9. PMID: 21914853.

" Not dangerous goods.

LKT A0777 ABT-263 5 mg 139.5 BH3 mimetic; Bcl-2 and Bcl-xl inhibitor. Navitoclax, A-855071 923564-51-6 ≥98% 974.61 C47H55ClF3N5O6S3 CC1(CCC(=C(C1)CN2CCN(CC2)C3=CC=C(C=C3)C(=O)NS(=O)(=O)C4=CC(=C(C=C4)NC(CCN5CCOCC5)CSC6=CC=CC=C6)S(=O)(=O)C(F)(F)F)C7=CC=C(C=C7)Cl)C Ambient 4°C "Debrincat MA, Pleines I, Lebois M, et al. BCL-2 is dispensable for thrombopoiesis and platelet survival. Cell Death Dis. 2015 Apr 16;6:e1721. PMID: 25880088.

 

Khaw SL, Mérino D, Anderson MA, et al. Both leukaemic and normal peripheral B lymphoid cells are highly sensitive to the selective pharmacological inhibition of prosurvival Bcl-2 with ABT-199. Leukemia. 2014 Jan 9. [Epub ahead of print]. PMID: 24402163.

 

Balakrishnan K, Gandhi V. Bcl-2 antagonists: a proof of concept for CLL therapy. Invest New Drugs. 2013 Oct;31(5):1384-94. PMID: 23907405.

 

Rudin CM, Hann CL, Garon EB, et al. Phase II study of single-agent navitoclax (ABT-263) and biomarker correlates in patients with relapsed small cell lung cancer. Clin Cancer Res. 2012 Jun 1;18(11):3163-9. PMID: 22496272.

 

Chen J, Jin S, Abraham V, et al. The Bcl-2/Bcl-X(L)/Bcl-w inhibitor, navitoclax, enhances the activity of chemotherapeutic agents in vitro and in vivo. Mol Cancer Ther. 2011 Dec;10(12):2340-9. PMID: 21914853.

" Not dangerous goods.

LKT A0777 ABT-263 10 mg 248.7 BH3 mimetic; Bcl-2 and Bcl-xl inhibitor. Navitoclax, A-855071 923564-51-6 ≥98% 974.61 C47H55ClF3N5O6S3 CC1(CCC(=C(C1)CN2CCN(CC2)C3=CC=C(C=C3)C(=O)NS(=O)(=O)C4=CC(=C(C=C4)NC(CCN5CCOCC5)CSC6=CC=CC=C6)S(=O)(=O)C(F)(F)F)C7=CC=C(C=C7)Cl)C Ambient 4°C "Debrincat MA, Pleines I, Lebois M, et al. BCL-2 is dispensable for thrombopoiesis and platelet survival. Cell Death Dis. 2015 Apr 16;6:e1721. PMID: 25880088.

 

Khaw SL, Mérino D, Anderson MA, et al. Both leukaemic and normal peripheral B lymphoid cells are highly sensitive to the selective pharmacological inhibition of prosurvival Bcl-2 with ABT-199. Leukemia. 2014 Jan 9. [Epub ahead of print]. PMID: 24402163.

 

Balakrishnan K, Gandhi V. Bcl-2 antagonists: a proof of concept for CLL therapy. Invest New Drugs. 2013 Oct;31(5):1384-94. PMID: 23907405.

 

Rudin CM, Hann CL, Garon EB, et al. Phase II study of single-agent navitoclax (ABT-263) and biomarker correlates in patients with relapsed small cell lung cancer. Clin Cancer Res. 2012 Jun 1;18(11):3163-9. PMID: 22496272.

 

Chen J, Jin S, Abraham V, et al. The Bcl-2/Bcl-X(L)/Bcl-w inhibitor, navitoclax, enhances the activity of chemotherapeutic agents in vitro and in vivo. Mol Cancer Ther. 2011 Dec;10(12):2340-9. PMID: 21914853.

" Not dangerous goods.

LKT A0776 ABT-199 1 mg 54.6 BH3 mimetic; Bcl-2 inhibitor. GDC-0199, Venectoclax 1257044-40-8 ≥98% 868.44 C45H50ClN7O7S CC1(CCC(=C(C1)C2=CC=C(C=C2)Cl)CN3CCN(CC3)C4=CC(=C(C=C4)C(=O)NS(=O)(=O)C5=CC(=C(C=C5)NCC6CCOCC6)[N+](=O)[O-])OC7=CN=C8C(=C7)C=CN8)C Ambient 4°C Soluble in DMSO. "Khaw SL, Mérino D, Anderson MA, et al. Both leukaemic and normal peripheral B lymphoid cells are highly sensitive to the selective pharmacological inhibition of prosurvival Bcl-2 with ABT-199. Leukemia. 2014 Jan 9. [Epub ahead of print]. PMID: 24402163.

 

Pan R, Hogdal LJ, Benito JM, et al. Selective BCL-2 Inhibition by ABT-199 Causes On-Target Cell Death in Acute Myeloid Leukemia. Cancer Discov. 2014 Feb 13. [Epub ahead of print]. PMID: 24346116.

 

Vandenberg CJ, Cory S. ABT-199, a new Bcl-2-specific BH3 mimetic, has in vivo efficacy against aggressive Myc-driven mouse lymphomas without provoking thrombocytopenia. Blood. 2013 Mar 21;121(12):2285-8. PMID: 23341542.

 

Souers AJ, Leverson JD, Boghaert ER, et al. ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets. Nat Med. 2013 Feb;19(2):202-8. PMID: 23291630.

" Not dangerous goods

LKT A0776 ABT-199 5 mg 139.5 BH3 mimetic; Bcl-2 inhibitor. GDC-0199, Venectoclax 1257044-40-8 ≥98% 868.44 C45H50ClN7O7S CC1(CCC(=C(C1)C2=CC=C(C=C2)Cl)CN3CCN(CC3)C4=CC(=C(C=C4)C(=O)NS(=O)(=O)C5=CC(=C(C=C5)NCC6CCOCC6)[N+](=O)[O-])OC7=CN=C8C(=C7)C=CN8)C Ambient 4°C Soluble in DMSO. "Khaw SL, Mérino D, Anderson MA, et al. Both leukaemic and normal peripheral B lymphoid cells are highly sensitive to the selective pharmacological inhibition of prosurvival Bcl-2 with ABT-199. Leukemia. 2014 Jan 9. [Epub ahead of print]. PMID: 24402163.

 

Pan R, Hogdal LJ, Benito JM, et al. Selective BCL-2 Inhibition by ABT-199 Causes On-Target Cell Death in Acute Myeloid Leukemia. Cancer Discov. 2014 Feb 13. [Epub ahead of print]. PMID: 24346116.

 

Vandenberg CJ, Cory S. ABT-199, a new Bcl-2-specific BH3 mimetic, has in vivo efficacy against aggressive Myc-driven mouse lymphomas without provoking thrombocytopenia. Blood. 2013 Mar 21;121(12):2285-8. PMID: 23341542.

 

Souers AJ, Leverson JD, Boghaert ER, et al. ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets. Nat Med. 2013 Feb;19(2):202-8. PMID: 23291630.

" Not dangerous goods

LKT A0776 ABT-199 10 mg 248.7 BH3 mimetic; Bcl-2 inhibitor. GDC-0199, Venectoclax 1257044-40-8 ≥98% 868.44 C45H50ClN7O7S CC1(CCC(=C(C1)C2=CC=C(C=C2)Cl)CN3CCN(CC3)C4=CC(=C(C=C4)C(=O)NS(=O)(=O)C5=CC(=C(C=C5)NCC6CCOCC6)[N+](=O)[O-])OC7=CN=C8C(=C7)C=CN8)C Ambient 4°C Soluble in DMSO. "Khaw SL, Mérino D, Anderson MA, et al. Both leukaemic and normal peripheral B lymphoid cells are highly sensitive to the selective pharmacological inhibition of prosurvival Bcl-2 with ABT-199. Leukemia. 2014 Jan 9. [Epub ahead of print]. PMID: 24402163.

 

Pan R, Hogdal LJ, Benito JM, et al. Selective BCL-2 Inhibition by ABT-199 Causes On-Target Cell Death in Acute Myeloid Leukemia. Cancer Discov. 2014 Feb 13. [Epub ahead of print]. PMID: 24346116.

 

Vandenberg CJ, Cory S. ABT-199, a new Bcl-2-specific BH3 mimetic, has in vivo efficacy against aggressive Myc-driven mouse lymphomas without provoking thrombocytopenia. Blood. 2013 Mar 21;121(12):2285-8. PMID: 23341542.

 

Souers AJ, Leverson JD, Boghaert ER, et al. ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets. Nat Med. 2013 Feb;19(2):202-8. PMID: 23291630.

" Not dangerous goods

LKT O7332 OSI-027 1 mg 54.6 mTOR inhibitor. 936890-98-1 ≥98% 406.44 C21H22N6O3 COC1=CC=CC2=CC(=C3C4=C(N=CNN4C(=N3)C5CCC(CC5)C(=O)O)N)N=C21 Ambient 4°C "Li H, Lin J, Wang X, et al. Targeting of mTORC2 prevents cell migration and promotes apoptosis in breast cancer. Breast Cancer Res Treat. 2012 Aug;134(3):1057-66. PMID: 22476852.

 

Gupta M, Hendrickson AE, Yun SS, et al. Dual mTORC1/mTORC2 inhibition diminishes Akt activation and induces Puma-dependent apoptosis in lymphoid malignancies. Blood. 2012 Jan 12;119(2):476-87. PMID: 22080480.

 

Falcon BL, Barr S, Gokhale PC, et al. Reduced VEGF production, angiogenesis, and vascular regrowth contribute to the antitumor properties of dual mTORC1/mTORC2 inhibitors. Cancer Res. 2011 Mar 1;71(5):1573-83. PMID: 21363918.

 

Vakana E, Sassano A, Platanias LC. Induction of autophagy by dual mTORC1-mTORC2 inhibition in BCR-ABL-expressing leukemic cells. Autophagy. 2010 Oct;6(7):966-7. PMID: 20699667.

" Not dangerous goods.

LKT O7332 OSI-027 5 mg 139.5 mTOR inhibitor. 936890-98-1 ≥98% 406.44 C21H22N6O3 COC1=CC=CC2=CC(=C3C4=C(N=CNN4C(=N3)C5CCC(CC5)C(=O)O)N)N=C21 Ambient 4°C "Li H, Lin J, Wang X, et al. Targeting of mTORC2 prevents cell migration and promotes apoptosis in breast cancer. Breast Cancer Res Treat. 2012 Aug;134(3):1057-66. PMID: 22476852.

 

Gupta M, Hendrickson AE, Yun SS, et al. Dual mTORC1/mTORC2 inhibition diminishes Akt activation and induces Puma-dependent apoptosis in lymphoid malignancies. Blood. 2012 Jan 12;119(2):476-87. PMID: 22080480.

 

Falcon BL, Barr S, Gokhale PC, et al. Reduced VEGF production, angiogenesis, and vascular regrowth contribute to the antitumor properties of dual mTORC1/mTORC2 inhibitors. Cancer Res. 2011 Mar 1;71(5):1573-83. PMID: 21363918.

 

Vakana E, Sassano A, Platanias LC. Induction of autophagy by dual mTORC1-mTORC2 inhibition in BCR-ABL-expressing leukemic cells. Autophagy. 2010 Oct;6(7):966-7. PMID: 20699667.

" Not dangerous goods.

LKT O7332 OSI-027 10 mg 236.6 mTOR inhibitor. 936890-98-1 ≥98% 406.44 C21H22N6O3 COC1=CC=CC2=CC(=C3C4=C(N=CNN4C(=N3)C5CCC(CC5)C(=O)O)N)N=C21 Ambient 4°C "Li H, Lin J, Wang X, et al. Targeting of mTORC2 prevents cell migration and promotes apoptosis in breast cancer. Breast Cancer Res Treat. 2012 Aug;134(3):1057-66. PMID: 22476852.

 

Gupta M, Hendrickson AE, Yun SS, et al. Dual mTORC1/mTORC2 inhibition diminishes Akt activation and induces Puma-dependent apoptosis in lymphoid malignancies. Blood. 2012 Jan 12;119(2):476-87. PMID: 22080480.

 

Falcon BL, Barr S, Gokhale PC, et al. Reduced VEGF production, angiogenesis, and vascular regrowth contribute to the antitumor properties of dual mTORC1/mTORC2 inhibitors. Cancer Res. 2011 Mar 1;71(5):1573-83. PMID: 21363918.

 

Vakana E, Sassano A, Platanias LC. Induction of autophagy by dual mTORC1-mTORC2 inhibition in BCR-ABL-expressing leukemic cells. Autophagy. 2010 Oct;6(7):966-7. PMID: 20699667.

" Not dangerous goods.

LKT I6132 IPI-145 1 mg 103.1 p110δ PI3K inhibitor. INK1197; Duvelisib 1201438-56-3 ≥98% 416.86 C22H17ClN6O CC(C1=CC2=C(C(=CC=C2)Cl)C(=O)N1C3=CC=CC=C3)NC4=NC=NC5=C4NC=N5 Ambient 4°C "Balakrishnan K, Peluso M, Fu M, et al. The phosphoinositide-3-kinase (PI3K)-delta and gamma inhibitor, IPI-145 (Duvelisib), overcomes signals from the PI3K/AKT/S6 pathway and promotes apoptosis in CLL. Leukemia. 2015 Apr 28. [Epub ahead of print]. PMID: 25917267.

 

IPI-145 Shows Promise in CLL Patients. Cancer Discov. 2014 Feb;4(2):136. PMID: 24501284.

 

Boyle DL, Kim HR, Topolewski K, et al. Novel phosphoinositide 3-kinase δ,γ inhibitor: potent anti-inflammatory effects and joint protection in models of rheumatoid arthritis. J Pharmacol Exp Ther. 2014 Feb;348(2):271-80. PMID: 24244039.

 

Winkler DG, Faia KL, DiNitto JP, et al. PI3K-δ and PI3K-γ inhibition by IPI-145 abrogates immune responses and suppresses activity in autoimmune and inflammatory disease models. Chem Biol. 2013 Nov 21;20(11):1364-74. PMID: 24211136.

" Not dangerous goods.

LKT I6132 IPI-145 5 mg 176 p110δ PI3K inhibitor. INK1197; Duvelisib 1201438-56-3 ≥98% 416.86 C22H17ClN6O CC(C1=CC2=C(C(=CC=C2)Cl)C(=O)N1C3=CC=CC=C3)NC4=NC=NC5=C4NC=N5 Ambient 4°C "Balakrishnan K, Peluso M, Fu M, et al. The phosphoinositide-3-kinase (PI3K)-delta and gamma inhibitor, IPI-145 (Duvelisib), overcomes signals from the PI3K/AKT/S6 pathway and promotes apoptosis in CLL. Leukemia. 2015 Apr 28. [Epub ahead of print]. PMID: 25917267.

 

IPI-145 Shows Promise in CLL Patients. Cancer Discov. 2014 Feb;4(2):136. PMID: 24501284.

 

Boyle DL, Kim HR, Topolewski K, et al. Novel phosphoinositide 3-kinase δ,γ inhibitor: potent anti-inflammatory effects and joint protection in models of rheumatoid arthritis. J Pharmacol Exp Ther. 2014 Feb;348(2):271-80. PMID: 24244039.

 

Winkler DG, Faia KL, DiNitto JP, et al. PI3K-δ and PI3K-γ inhibition by IPI-145 abrogates immune responses and suppresses activity in autoimmune and inflammatory disease models. Chem Biol. 2013 Nov 21;20(11):1364-74. PMID: 24211136.

" Not dangerous goods.

LKT I6132 IPI-145 10 mg 260.9 p110δ PI3K inhibitor. INK1197; Duvelisib 1201438-56-3 ≥98% 416.86 C22H17ClN6O CC(C1=CC2=C(C(=CC=C2)Cl)C(=O)N1C3=CC=CC=C3)NC4=NC=NC5=C4NC=N5 Ambient 4°C "Balakrishnan K, Peluso M, Fu M, et al. The phosphoinositide-3-kinase (PI3K)-delta and gamma inhibitor, IPI-145 (Duvelisib), overcomes signals from the PI3K/AKT/S6 pathway and promotes apoptosis in CLL. Leukemia. 2015 Apr 28. [Epub ahead of print]. PMID: 25917267.

 

IPI-145 Shows Promise in CLL Patients. Cancer Discov. 2014 Feb;4(2):136. PMID: 24501284.

 

Boyle DL, Kim HR, Topolewski K, et al. Novel phosphoinositide 3-kinase δ,γ inhibitor: potent anti-inflammatory effects and joint protection in models of rheumatoid arthritis. J Pharmacol Exp Ther. 2014 Feb;348(2):271-80. PMID: 24244039.

 

Winkler DG, Faia KL, DiNitto JP, et al. PI3K-δ and PI3K-γ inhibition by IPI-145 abrogates immune responses and suppresses activity in autoimmune and inflammatory disease models. Chem Biol. 2013 Nov 21;20(11):1364-74. PMID: 24211136.

" Not dangerous goods.

LKT I0800 IC-87114 1 mg 42.4 p110δ PI3K inhibitor. 371242-69-2 ≥98% 397.43 C22H19N7O CC1=C2C(=CC=C1)N=C(N(C2=O)C3=CC=CC=C3C)CN4C=NC5=C4N=CN=C5N Ambient 4°C "Durand CA, Richer MJ, Brenker K, et al. Selective pharmacological inhibition of phosphoinositide 3-kinase p110delta opposes the progression of autoimmune diabetes in non-obese diabetic (NOD) mice. Autoimmunity. 2013 Feb;46(1):62-73. PMID: 23039284.

 

Bekhite MM, Finkensieper A, Binas S, et al. VEGF-mediated PI3K class IA and PKC signaling in cardiomyogenesis and vasculogenesis of mouse embryonic stem cells. J Cell Sci. 2011 Jun 1;124(Pt 11):1819-30. PMID: 21540297.

 

Park SJ, Lee KS, Kim SR, et al. Phosphoinositide 3-kinase δ inhibitor suppresses interleukin-17 expression in a murine asthma model. Eur Respir J. 2010 Dec;36(6):1448-59. PMID: 20351038.

" Not dangerous goods.

LKT I0800 IC-87114 5 mg 97 p110δ PI3K inhibitor. 371242-69-2 ≥98% 397.43 C22H19N7O CC1=C2C(=CC=C1)N=C(N(C2=O)C3=CC=CC=C3C)CN4C=NC5=C4N=CN=C5N Ambient 4°C "Durand CA, Richer MJ, Brenker K, et al. Selective pharmacological inhibition of phosphoinositide 3-kinase p110delta opposes the progression of autoimmune diabetes in non-obese diabetic (NOD) mice. Autoimmunity. 2013 Feb;46(1):62-73. PMID: 23039284.

 

Bekhite MM, Finkensieper A, Binas S, et al. VEGF-mediated PI3K class IA and PKC signaling in cardiomyogenesis and vasculogenesis of mouse embryonic stem cells. J Cell Sci. 2011 Jun 1;124(Pt 11):1819-30. PMID: 21540297.

 

Park SJ, Lee KS, Kim SR, et al. Phosphoinositide 3-kinase δ inhibitor suppresses interleukin-17 expression in a murine asthma model. Eur Respir J. 2010 Dec;36(6):1448-59. PMID: 20351038.

" Not dangerous goods.

LKT I0800 IC-87114 10 mg 176 p110δ PI3K inhibitor. 371242-69-2 ≥98% 397.43 C22H19N7O CC1=C2C(=CC=C1)N=C(N(C2=O)C3=CC=CC=C3C)CN4C=NC5=C4N=CN=C5N Ambient 4°C "Durand CA, Richer MJ, Brenker K, et al. Selective pharmacological inhibition of phosphoinositide 3-kinase p110delta opposes the progression of autoimmune diabetes in non-obese diabetic (NOD) mice. Autoimmunity. 2013 Feb;46(1):62-73. PMID: 23039284.

 

Bekhite MM, Finkensieper A, Binas S, et al. VEGF-mediated PI3K class IA and PKC signaling in cardiomyogenesis and vasculogenesis of mouse embryonic stem cells. J Cell Sci. 2011 Jun 1;124(Pt 11):1819-30. PMID: 21540297.

 

Park SJ, Lee KS, Kim SR, et al. Phosphoinositide 3-kinase δ inhibitor suppresses interleukin-17 expression in a murine asthma model. Eur Respir J. 2010 Dec;36(6):1448-59. PMID: 20351038.

" Not dangerous goods.

LKT G1209 GDC-0980 1 mg 78.9 PI3K and mTOR inhibitor. RG7422 1032754-93-0 ≥98% 498.6 C23H30N8O3S CC1=C(SC2=C1N=C(N=C2N3CCOCC3)C4=CN=C(N=C4)N)CN5CCN(CC5)C(=O)C(C)O Ambient 4°C "English DP, Bellone S, Cocco E, et al. Oncogenic PIK3CA gene mutations and HER2/neu gene amplifications determine the sensitivity of uterine serous carcinoma cell lines to GDC-0980, a selective inhibitor of Class I PI3 kinase and mTOR kinase (TORC1/2). Am J Obstet Gynecol. 2013 Nov;209(5):465.e1-9. PMID: 23891627.

 

Sampath D, Oeh J, Wyatt SK, et al. Multimodal microvascular imaging reveals that selective inhibition of class I PI3K is sufficient to induce an antivascular response. Neoplasia. 2013 Jul;15(7):694-711. PMID: 23814482.

 

Wallin JJ, Edgar KA, Guan J, et al. GDC-0980 is a novel class I PI3K/mTOR kinase inhibitor with robust activity in cancer modeLSriven by the PI3K pathway. Mol Cancer Ther. 2011 Dec;10(12):2426-36. PMID: 21998291.

" Not dangerous goods.

LKT G1209 GDC-0980 5 mg 133.5 PI3K and mTOR inhibitor. RG7422 1032754-93-0 ≥98% 498.6 C23H30N8O3S CC1=C(SC2=C1N=C(N=C2N3CCOCC3)C4=CN=C(N=C4)N)CN5CCN(CC5)C(=O)C(C)O Ambient 4°C "English DP, Bellone S, Cocco E, et al. Oncogenic PIK3CA gene mutations and HER2/neu gene amplifications determine the sensitivity of uterine serous carcinoma cell lines to GDC-0980, a selective inhibitor of Class I PI3 kinase and mTOR kinase (TORC1/2). Am J Obstet Gynecol. 2013 Nov;209(5):465.e1-9. PMID: 23891627.

 

Sampath D, Oeh J, Wyatt SK, et al. Multimodal microvascular imaging reveals that selective inhibition of class I PI3K is sufficient to induce an antivascular response. Neoplasia. 2013 Jul;15(7):694-711. PMID: 23814482.

 

Wallin JJ, Edgar KA, Guan J, et al. GDC-0980 is a novel class I PI3K/mTOR kinase inhibitor with robust activity in cancer modeLSriven by the PI3K pathway. Mol Cancer Ther. 2011 Dec;10(12):2426-36. PMID: 21998291.

" Not dangerous goods.

LKT G1209 GDC-0980 10 mg 236.6 PI3K and mTOR inhibitor. RG7422 1032754-93-0 ≥98% 498.6 C23H30N8O3S CC1=C(SC2=C1N=C(N=C2N3CCOCC3)C4=CN=C(N=C4)N)CN5CCN(CC5)C(=O)C(C)O Ambient 4°C "English DP, Bellone S, Cocco E, et al. Oncogenic PIK3CA gene mutations and HER2/neu gene amplifications determine the sensitivity of uterine serous carcinoma cell lines to GDC-0980, a selective inhibitor of Class I PI3 kinase and mTOR kinase (TORC1/2). Am J Obstet Gynecol. 2013 Nov;209(5):465.e1-9. PMID: 23891627.

 

Sampath D, Oeh J, Wyatt SK, et al. Multimodal microvascular imaging reveals that selective inhibition of class I PI3K is sufficient to induce an antivascular response. Neoplasia. 2013 Jul;15(7):694-711. PMID: 23814482.

 

Wallin JJ, Edgar KA, Guan J, et al. GDC-0980 is a novel class I PI3K/mTOR kinase inhibitor with robust activity in cancer modeLSriven by the PI3K pathway. Mol Cancer Ther. 2011 Dec;10(12):2426-36. PMID: 21998291.

" Not dangerous goods.

LKT C0044 CAL101 1 mg 42.4 p110δ PI3K inhibitor. Idelalisib, GS1101, CAL-101 870281-82-6 ≥98% 415.42 C22H18FN7O CCC(C1=NC2=C(C(=CC=C2)F)C(=O)N1C3=CC=CC=C3)NC4=NC=NC5=C4NC=N5 Ambient 4°C "Sanford DS, Wierda WG, Burger JA, et al. Three Newly Approved Drugs for Chronic Lymphocytic Leukemia: Incorporating Ibrutinib, Idelalisib, and Obinutuzumab into Clinical Practice. Clin Lymphoma Myeloma Leuk. 2015 Feb 19. [Epub ahead of print]. PMID: 25817936.

 

Chiron D, Martin P, Di Liberto M, et al. Induction of prolonged early G1 arrest by CDK4/CDK6 inhibition reprograms lymphoma cells for durable PI3Kδ inhibition through PIK3IP1. Cell Cycle. 2013 Jun 15;12(12):1892-900. PMID: 23676220.

 

Meadows SA, Vega F, Kashishian A, Johnson D, et al. PI3Kδ inhibitor, GS-1101 (CAL-101), attenuates pathway signaling, induces apoptosis, and overcomes signals from the microenvironment in cellular models of Hodgkin lymphoma. Blood. 2012 Feb 23;119(8):1897-900. PMID: 22210877.

 

Hoellenriegel J, Meadows SA, Sivina M, et al. The phosphoinositide 3'-kinase delta inhibitor, CAL-101, inhibits B-cell receptor signaling and chemokine networks in chronic lymphocytic leukemia. Blood. 2011 Sep 29;118(13):3603-12. PMID: 21803855.

" Not dangerous goods.

LKT C0044 CAL101 5 mg 91 p110δ PI3K inhibitor. Idelalisib, GS1101, CAL-101 870281-82-6 ≥98% 415.42 C22H18FN7O CCC(C1=NC2=C(C(=CC=C2)F)C(=O)N1C3=CC=CC=C3)NC4=NC=NC5=C4NC=N5 Ambient 4°C "Sanford DS, Wierda WG, Burger JA, et al. Three Newly Approved Drugs for Chronic Lymphocytic Leukemia: Incorporating Ibrutinib, Idelalisib, and Obinutuzumab into Clinical Practice. Clin Lymphoma Myeloma Leuk. 2015 Feb 19. [Epub ahead of print]. PMID: 25817936.

 

Chiron D, Martin P, Di Liberto M, et al. Induction of prolonged early G1 arrest by CDK4/CDK6 inhibition reprograms lymphoma cells for durable PI3Kδ inhibition through PIK3IP1. Cell Cycle. 2013 Jun 15;12(12):1892-900. PMID: 23676220.

 

Meadows SA, Vega F, Kashishian A, Johnson D, et al. PI3Kδ inhibitor, GS-1101 (CAL-101), attenuates pathway signaling, induces apoptosis, and overcomes signals from the microenvironment in cellular models of Hodgkin lymphoma. Blood. 2012 Feb 23;119(8):1897-900. PMID: 22210877.

 

Hoellenriegel J, Meadows SA, Sivina M, et al. The phosphoinositide 3'-kinase delta inhibitor, CAL-101, inhibits B-cell receptor signaling and chemokine networks in chronic lymphocytic leukemia. Blood. 2011 Sep 29;118(13):3603-12. PMID: 21803855.

" Not dangerous goods.

LKT C0044 CAL101 10 mg 163.8 p110δ PI3K inhibitor. Idelalisib, GS1101, CAL-101 870281-82-6 ≥98% 415.42 C22H18FN7O CCC(C1=NC2=C(C(=CC=C2)F)C(=O)N1C3=CC=CC=C3)NC4=NC=NC5=C4NC=N5 Ambient 4°C "Sanford DS, Wierda WG, Burger JA, et al. Three Newly Approved Drugs for Chronic Lymphocytic Leukemia: Incorporating Ibrutinib, Idelalisib, and Obinutuzumab into Clinical Practice. Clin Lymphoma Myeloma Leuk. 2015 Feb 19. [Epub ahead of print]. PMID: 25817936.

 

Chiron D, Martin P, Di Liberto M, et al. Induction of prolonged early G1 arrest by CDK4/CDK6 inhibition reprograms lymphoma cells for durable PI3Kδ inhibition through PIK3IP1. Cell Cycle. 2013 Jun 15;12(12):1892-900. PMID: 23676220.

 

Meadows SA, Vega F, Kashishian A, Johnson D, et al. PI3Kδ inhibitor, GS-1101 (CAL-101), attenuates pathway signaling, induces apoptosis, and overcomes signals from the microenvironment in cellular models of Hodgkin lymphoma. Blood. 2012 Feb 23;119(8):1897-900. PMID: 22210877.

 

Hoellenriegel J, Meadows SA, Sivina M, et al. The phosphoinositide 3'-kinase delta inhibitor, CAL-101, inhibits B-cell receptor signaling and chemokine networks in chronic lymphocytic leukemia. Blood. 2011 Sep 29;118(13):3603-12. PMID: 21803855.

" Not dangerous goods.

LKT B4248 BKM120 1 mg 54.6 PI3K inhibitor, microtubule polymerization inhibitor. Buparlisib, NVP-BKM120 944396-07-0 ≥98% 410.39 C18H21F3N6O2 C1COCCN1C2=NC(=NC(=C2)C3=CN=C(C=C3C(F)(F)F)N)N4CCOCC4 Ambient 4°C "Bonelli MA, Cavazzoni A, Saccani F, et al. Inhibition of PI3K pathway reduces invasiveness and epithelial-to-mesenchymal transition in squamous lung cancer cell lines harboring PIK3CA gene alterations. Mol Cancer Ther. 2015 May 26. [Epub ahead of print]. PMID: 26013318.

 

Wachsberger PR, Lawrence YR, Liu Y, et al. Hsp90 inhibition enhances PI-3 kinase inhibition and radiosensitivity in glioblastoma. J Cancer Res Clin Oncol. 2014 Feb 6. [Epub ahead of print]. PMID: 24500492.

 

Ando Y, Inada-Inoue M, Mitsuma A, et al. Phase I dose-escalation study of buparlisib (BKM120), an oral pan-class I PI3K inhibitor, in Japanese patients with advanced solid tumors. Cancer Sci. 2014 Jan 10. [Epub ahead of print]. PMID: 24405565.

 

Ren H, Zhao L, Li Y, et al. The PI3 kinase inhibitor NVP-BKM120 induces GSK3/FBXW7-dependent Mcl-1 degradation, contributing to induction of apoptosis and enhancement of TRAIL-induced apoptosis. Cancer Lett. 2013 Sep 28;338(2):229-38. PMID: 23562472.

 

Brachmann SM, Kleylein-Sohn J, Gaulis S, et al. Characterization of the mechanism of action of the pan class I PI3K inhibitor NVP-BKM120 across a broad range of concentrations. Mol Cancer Ther. 2012 Aug;11(8):1747-57. PMID: 22653967.

" Not dangerous goods.

LKT B4248 BKM120 5 mg 151.7 PI3K inhibitor, microtubule polymerization inhibitor. Buparlisib, NVP-BKM120 944396-07-0 ≥98% 410.39 C18H21F3N6O2 C1COCCN1C2=NC(=NC(=C2)C3=CN=C(C=C3C(F)(F)F)N)N4CCOCC4 Ambient 4°C "Bonelli MA, Cavazzoni A, Saccani F, et al. Inhibition of PI3K pathway reduces invasiveness and epithelial-to-mesenchymal transition in squamous lung cancer cell lines harboring PIK3CA gene alterations. Mol Cancer Ther. 2015 May 26. [Epub ahead of print]. PMID: 26013318.

 

Wachsberger PR, Lawrence YR, Liu Y, et al. Hsp90 inhibition enhances PI-3 kinase inhibition and radiosensitivity in glioblastoma. J Cancer Res Clin Oncol. 2014 Feb 6. [Epub ahead of print]. PMID: 24500492.

 

Ando Y, Inada-Inoue M, Mitsuma A, et al. Phase I dose-escalation study of buparlisib (BKM120), an oral pan-class I PI3K inhibitor, in Japanese patients with advanced solid tumors. Cancer Sci. 2014 Jan 10. [Epub ahead of print]. PMID: 24405565.

 

Ren H, Zhao L, Li Y, et al. The PI3 kinase inhibitor NVP-BKM120 induces GSK3/FBXW7-dependent Mcl-1 degradation, contributing to induction of apoptosis and enhancement of TRAIL-induced apoptosis. Cancer Lett. 2013 Sep 28;338(2):229-38. PMID: 23562472.

 

Brachmann SM, Kleylein-Sohn J, Gaulis S, et al. Characterization of the mechanism of action of the pan class I PI3K inhibitor NVP-BKM120 across a broad range of concentrations. Mol Cancer Ther. 2012 Aug;11(8):1747-57. PMID: 22653967.

" Not dangerous goods.

LKT T1968 Terpinen-4-ol 5 g 42.4 Monoterpene found in various plant sources. 562-74-3 ≥98% 154.25 C10H18O CC1=CCC(CC1)(C(C)C)O Ambient Ambient "Banjerdpongchai R, Khaw-On P. Terpinen-4-ol Induces Autophagic and Apoptotic Cell Death in Human Leukemic HL-60 Cells. Asian Pac J Cancer Prev. 2013;14(12):7537-42. PMID: 24460330.

 

Kurekci C, Padmanabha J, Bishop-Hurley SL, et al. Antimicrobial activity of essential oils and five terpenoid compounds against Campylobacter jejuni in pure and mixed culture experiments. Int J Food Microbiol. 2013 Sep 16;166(3):450-7. PMID: 24041998.

 

Ninomiya K, Hayama K, Ishijima SA, et al. Suppression of inflammatory reactions by terpinen-4-ol, a main constituent of tea tree oil, in a murine model of oral candidiasis and its suppressive activity to cytokine production of macrophages in vitro. Biol Pharm Bull. 2013;36(5):838-44. PMID: 23649340.

 

Morcia C, Malnati M, Terzi V. In vitro antifungal activity of terpinen-4-ol, eugenol, carvone, 1,8-cineole (eucalyptol) and thymol against mycotoxigenic plant pathogens. Food Addit Contam Part A Chem Anal Control Expo Risk Assess. 2012;29(3):415-22. PMID: 22257275.

 

Wu CS, Chen YJ, Chen JJ, et al. Terpinen-4-ol Induces Apoptosis in Human Nonsmall Cell Lung Cancer In Vitro and In Vivo. Evid Based Complement Alternat Med. 2012;2012:818261. PMID: 21760828.

" Not dangerous goods.

LKT T1968 Terpinen-4-ol 25 g 94.6 Monoterpene found in various plant sources. 562-74-3 ≥98% 154.25 C10H18O CC1=CCC(CC1)(C(C)C)O Ambient Ambient "Banjerdpongchai R, Khaw-On P. Terpinen-4-ol Induces Autophagic and Apoptotic Cell Death in Human Leukemic HL-60 Cells. Asian Pac J Cancer Prev. 2013;14(12):7537-42. PMID: 24460330.

 

Kurekci C, Padmanabha J, Bishop-Hurley SL, et al. Antimicrobial activity of essential oils and five terpenoid compounds against Campylobacter jejuni in pure and mixed culture experiments. Int J Food Microbiol. 2013 Sep 16;166(3):450-7. PMID: 24041998.

 

Ninomiya K, Hayama K, Ishijima SA, et al. Suppression of inflammatory reactions by terpinen-4-ol, a main constituent of tea tree oil, in a murine model of oral candidiasis and its suppressive activity to cytokine production of macrophages in vitro. Biol Pharm Bull. 2013;36(5):838-44. PMID: 23649340.

 

Morcia C, Malnati M, Terzi V. In vitro antifungal activity of terpinen-4-ol, eugenol, carvone, 1,8-cineole (eucalyptol) and thymol against mycotoxigenic plant pathogens. Food Addit Contam Part A Chem Anal Control Expo Risk Assess. 2012;29(3):415-22. PMID: 22257275.

 

Wu CS, Chen YJ, Chen JJ, et al. Terpinen-4-ol Induces Apoptosis in Human Nonsmall Cell Lung Cancer In Vitro and In Vivo. Evid Based Complement Alternat Med. 2012;2012:818261. PMID: 21760828.

" Not dangerous goods.

LKT E7356 Esomeprazole Magnesium Trihydrate 50 mg 60.7 S-isomer of omeprazole; H+/K+ ATPase inhibitor. 217087-09-7 ≥98% 767.17 2(C17H18N3O3S) Mg 3H2O CC1=CN=C(C(=C1OC)C)CS(=O)C2=NC3=C([N-]2)C=CC(=C3)OC.CC1=CN=C(C(=C1OC)C)CS(=O)C2=NC3=C([N-]2)C=CC(=C3)OC.O.O.O.[Mg+2] Ambient Ambient "Sugano K, Choi MG, Lin JT, et al. Multinational, double-blind, randomised, placebo-controlled, prospective study of esomeprazole in the prevention of recurrent peptic ulcer in low-dose acetylsalicylic acid users: the LAVENDER study. Gut. 2013 Dec 10. [Epub ahead of print]. PMID: 24326741.

 

Costa-Rodrigues J, Reis S, Teixeira S, et al. Dose-dependent inhibitory effects of proton pump inhibitors on human osteoclastic and osteoblastic cell activity. FEBS J. 2013 Oct;280(20):5052-64. PMID: 23937530.

 

Petzer A, Pienaar A, Petzer JP. The inhibition of monoamine oxidase by esomeprazole. Drug Res (Stuttg). 2013 Sep;63(9):462-7. PMID: 23677700.

 

Marino ML, Fais S, Djavaheri-Mergny M, et al. Proton pump inhibition induces autophagy as a survival mechanism following oxidative stress in human melanoma cells. Cell Death Dis. 2010 Oct 21;1:e87. PMID: 21368860.

 

Saccar CL. The pharmacology of esomeprazole and its role in gastric acid related diseases. Expert Opin Drug Metab Toxicol. 2009 Sep;5(9):1113-24. PMID: 19606942.

" Not dangerous goods.

LKT E7356 Esomeprazole Magnesium Trihydrate 250 mg 212.3 S-isomer of omeprazole; H+/K+ ATPase inhibitor. 217087-09-7 ≥98% 767.17 2(C17H18N3O3S) Mg 3H2O CC1=CN=C(C(=C1OC)C)CS(=O)C2=NC3=C([N-]2)C=CC(=C3)OC.CC1=CN=C(C(=C1OC)C)CS(=O)C2=NC3=C([N-]2)C=CC(=C3)OC.O.O.O.[Mg+2] Ambient Ambient "Sugano K, Choi MG, Lin JT, et al. Multinational, double-blind, randomised, placebo-controlled, prospective study of esomeprazole in the prevention of recurrent peptic ulcer in low-dose acetylsalicylic acid users: the LAVENDER study. Gut. 2013 Dec 10. [Epub ahead of print]. PMID: 24326741.

 

Costa-Rodrigues J, Reis S, Teixeira S, et al. Dose-dependent inhibitory effects of proton pump inhibitors on human osteoclastic and osteoblastic cell activity. FEBS J. 2013 Oct;280(20):5052-64. PMID: 23937530.

 

Petzer A, Pienaar A, Petzer JP. The inhibition of monoamine oxidase by esomeprazole. Drug Res (Stuttg). 2013 Sep;63(9):462-7. PMID: 23677700.

 

Marino ML, Fais S, Djavaheri-Mergny M, et al. Proton pump inhibition induces autophagy as a survival mechanism following oxidative stress in human melanoma cells. Cell Death Dis. 2010 Oct 21;1:e87. PMID: 21368860.

 

Saccar CL. The pharmacology of esomeprazole and its role in gastric acid related diseases. Expert Opin Drug Metab Toxicol. 2009 Sep;5(9):1113-24. PMID: 19606942.

" Not dangerous goods.

LKT E7356 Esomeprazole Magnesium Trihydrate 1 g 546 S-isomer of omeprazole; H+/K+ ATPase inhibitor. 217087-09-7 ≥98% 767.17 2(C17H18N3O3S) Mg 3H2O CC1=CN=C(C(=C1OC)C)CS(=O)C2=NC3=C([N-]2)C=CC(=C3)OC.CC1=CN=C(C(=C1OC)C)CS(=O)C2=NC3=C([N-]2)C=CC(=C3)OC.O.O.O.[Mg+2] Ambient Ambient "Sugano K, Choi MG, Lin JT, et al. Multinational, double-blind, randomised, placebo-controlled, prospective study of esomeprazole in the prevention of recurrent peptic ulcer in low-dose acetylsalicylic acid users: the LAVENDER study. Gut. 2013 Dec 10. [Epub ahead of print]. PMID: 24326741.

 

Costa-Rodrigues J, Reis S, Teixeira S, et al. Dose-dependent inhibitory effects of proton pump inhibitors on human osteoclastic and osteoblastic cell activity. FEBS J. 2013 Oct;280(20):5052-64. PMID: 23937530.

 

Petzer A, Pienaar A, Petzer JP. The inhibition of monoamine oxidase by esomeprazole. Drug Res (Stuttg). 2013 Sep;63(9):462-7. PMID: 23677700.

 

Marino ML, Fais S, Djavaheri-Mergny M, et al. Proton pump inhibition induces autophagy as a survival mechanism following oxidative stress in human melanoma cells. Cell Death Dis. 2010 Oct 21;1:e87. PMID: 21368860.

 

Saccar CL. The pharmacology of esomeprazole and its role in gastric acid related diseases. Expert Opin Drug Metab Toxicol. 2009 Sep;5(9):1113-24. PMID: 19606942.

" Not dangerous goods.

LKT I7478 Istradefylline 5 mg 60.7 Adenosine A2A antagonist. (E)-8-(3,4-Dimethoxystyryl)-1,3-diethyl-7-methylxanthine 8-[(1E)-2-(3,4-Dimethoxyphenyl)ethenyl]-1,3-diethyl-3,7-dihydro-7-methyl-1H-purine-2,6-dione, KW-6002 155270-99-8 ≥98% 384.43 C20H24N4O4 CCN1C2=C(C(=O)N(C1=O)CC)N(C(=N2)C=CC3=CC(=C(C=C3)OC)OC)C Ambient Ambient "Kadowaki Horita T, Kobayashi M, Mori A, et al. Effects of the adenosine A2A antagonist istradefylline on cognitive performance in rats with a 6-OHDA lesion in prefrontal cortex. Psychopharmacology (Berl). 2013 Dec;230(3):345-52. PMID: 23748382.

 

Saki M, Yamada K, Koshimura E, et al. In vitro pharmacological profile of the A2A receptor antagonist istradefylline. Naunyn Schmiedebergs Arch Pharmacol. 2013 Nov;386(11):963-72. PMID: 23812646.

 

Mizuno Y, Hasegawa K, Kondo T, et al. Clinical efficacy of istradefylline (KW-6002) in Parkinson's disease: a randomized, controlled study. Mov Disord. 2010 Jul 30;25(10):1437-43. PMID: 20629136.

 

Salamone JD, Betz AJ, Ishiwari K, et al. Tremorolytic effects of adenosine A2A antagonists: implications for parkinsonism. Front Biosci. 2008 May 1;13:3594-605. PMID: 18508458.

 

Harper LK, Beckett SR, Marsden CA, et al. Effects of the A 2A adenosine receptor antagonist KW6002 in the nucleus accumbens in vitro and in vivo. Pharmacol Biochem Behav. 2006 Jan;83(1):114-21. PMID: 16451807.

" "UN number: 2811     Class:  6.1     Packing group:  III

Proper shipping name:  Toxic solids, organic, n.o.s. (Istradefylline)     Marine pollutant:  No     Poison Inhalation hazard:  No"

LKT I7478 Istradefylline 25 mg 242.7 Adenosine A2A antagonist. (E)-8-(3,4-Dimethoxystyryl)-1,3-diethyl-7-methylxanthine 8-[(1E)-2-(3,4-Dimethoxyphenyl)ethenyl]-1,3-diethyl-3,7-dihydro-7-methyl-1H-purine-2,6-dione, KW-6002 155270-99-8 ≥98% 384.43 C20H24N4O4 CCN1C2=C(C(=O)N(C1=O)CC)N(C(=N2)C=CC3=CC(=C(C=C3)OC)OC)C Ambient Ambient "Kadowaki Horita T, Kobayashi M, Mori A, et al. Effects of the adenosine A2A antagonist istradefylline on cognitive performance in rats with a 6-OHDA lesion in prefrontal cortex. Psychopharmacology (Berl). 2013 Dec;230(3):345-52. PMID: 23748382.

 

Saki M, Yamada K, Koshimura E, et al. In vitro pharmacological profile of the A2A receptor antagonist istradefylline. Naunyn Schmiedebergs Arch Pharmacol. 2013 Nov;386(11):963-72. PMID: 23812646.

 

Mizuno Y, Hasegawa K, Kondo T, et al. Clinical efficacy of istradefylline (KW-6002) in Parkinson's disease: a randomized, controlled study. Mov Disord. 2010 Jul 30;25(10):1437-43. PMID: 20629136.

 

Salamone JD, Betz AJ, Ishiwari K, et al. Tremorolytic effects of adenosine A2A antagonists: implications for parkinsonism. Front Biosci. 2008 May 1;13:3594-605. PMID: 18508458.

 

Harper LK, Beckett SR, Marsden CA, et al. Effects of the A 2A adenosine receptor antagonist KW6002 in the nucleus accumbens in vitro and in vivo. Pharmacol Biochem Behav. 2006 Jan;83(1):114-21. PMID: 16451807.

" "UN number: 2811     Class:  6.1     Packing group:  III

Proper shipping name:  Toxic solids, organic, n.o.s. (Istradefylline)     Marine pollutant:  No     Poison Inhalation hazard:  No"

LKT I7478 Istradefylline 100 mg 910 Adenosine A2A antagonist. (E)-8-(3,4-Dimethoxystyryl)-1,3-diethyl-7-methylxanthine 8-[(1E)-2-(3,4-Dimethoxyphenyl)ethenyl]-1,3-diethyl-3,7-dihydro-7-methyl-1H-purine-2,6-dione, KW-6002 155270-99-8 ≥98% 384.43 C20H24N4O4 CCN1C2=C(C(=O)N(C1=O)CC)N(C(=N2)C=CC3=CC(=C(C=C3)OC)OC)C Ambient Ambient "Kadowaki Horita T, Kobayashi M, Mori A, et al. Effects of the adenosine A2A antagonist istradefylline on cognitive performance in rats with a 6-OHDA lesion in prefrontal cortex. Psychopharmacology (Berl). 2013 Dec;230(3):345-52. PMID: 23748382.

 

Saki M, Yamada K, Koshimura E, et al. In vitro pharmacological profile of the A2A receptor antagonist istradefylline. Naunyn Schmiedebergs Arch Pharmacol. 2013 Nov;386(11):963-72. PMID: 23812646.

 

Mizuno Y, Hasegawa K, Kondo T, et al. Clinical efficacy of istradefylline (KW-6002) in Parkinson's disease: a randomized, controlled study. Mov Disord. 2010 Jul 30;25(10):1437-43. PMID: 20629136.

 

Salamone JD, Betz AJ, Ishiwari K, et al. Tremorolytic effects of adenosine A2A antagonists: implications for parkinsonism. Front Biosci. 2008 May 1;13:3594-605. PMID: 18508458.

 

Harper LK, Beckett SR, Marsden CA, et al. Effects of the A 2A adenosine receptor antagonist KW6002 in the nucleus accumbens in vitro and in vivo. Pharmacol Biochem Behav. 2006 Jan;83(1):114-21. PMID: 16451807.

" "UN number: 2811     Class:  6.1     Packing group:  III

Proper shipping name:  Toxic solids, organic, n.o.s. (Istradefylline)     Marine pollutant:  No     Poison Inhalation hazard:  No"

LKT E7758 Etomidate 10 mg 84.9 GABA-A agonist. Amidate 33125-97-2 ≥98% 244.29 C14H16N2O2 CCOC(=O)C1=CN=CN1C(C)C2=CC=CC=C2 Ambient Ambient "Herring BE, McMillan K, Pike CM, et al. Etomidate and propofol inhibit the neurotransmitter release machinery at different sites. J Physiol. 2011 Mar 1;589(Pt 5):1103-15. Erratum in: J Physiol. 2011 Sep 15;589(Pt 18):4633.  PMID: 21173083.

 

Martin LJ, Oh GH, Orser BA. Etomidate targets alpha5 gamma-aminobutyric acid subtype A receptors to regulate synaptic plasticity and memory blockade. Anesthesiology. 2009 Nov;111(5):1025-35. PMID: 19809285.

 

Sohn JT, Kim HJ, Cho HC, et al. Effect of etomidate on endothelium-dependent relaxation induced by acetylcholine in rat aorta. Anaesth Intensive Care. 2004 Aug;32(4):476-81. PMID: 15682522.

" "UN number: 3077     Class: 9     Packing Group: III

Proper shipping name: Environmentally hazardous substance, solid, n.o.s. (Etomidate)"

LKT E7758 Etomidate 25 mg 169.9 GABA-A agonist. Amidate 33125-97-2 ≥98% 244.29 C14H16N2O2 CCOC(=O)C1=CN=CN1C(C)C2=CC=CC=C2 Ambient Ambient "Herring BE, McMillan K, Pike CM, et al. Etomidate and propofol inhibit the neurotransmitter release machinery at different sites. J Physiol. 2011 Mar 1;589(Pt 5):1103-15. Erratum in: J Physiol. 2011 Sep 15;589(Pt 18):4633.  PMID: 21173083.

 

Martin LJ, Oh GH, Orser BA. Etomidate targets alpha5 gamma-aminobutyric acid subtype A receptors to regulate synaptic plasticity and memory blockade. Anesthesiology. 2009 Nov;111(5):1025-35. PMID: 19809285.

 

Sohn JT, Kim HJ, Cho HC, et al. Effect of etomidate on endothelium-dependent relaxation induced by acetylcholine in rat aorta. Anaesth Intensive Care. 2004 Aug;32(4):476-81. PMID: 15682522.

" "UN number: 3077     Class: 9     Packing Group: III

Proper shipping name: Environmentally hazardous substance, solid, n.o.s. (Etomidate)"

LKT E7758 Etomidate 100 mg 655.2 GABA-A agonist. Amidate 33125-97-2 ≥98% 244.29 C14H16N2O2 CCOC(=O)C1=CN=CN1C(C)C2=CC=CC=C2 Ambient Ambient "Herring BE, McMillan K, Pike CM, et al. Etomidate and propofol inhibit the neurotransmitter release machinery at different sites. J Physiol. 2011 Mar 1;589(Pt 5):1103-15. Erratum in: J Physiol. 2011 Sep 15;589(Pt 18):4633.  PMID: 21173083.

 

Martin LJ, Oh GH, Orser BA. Etomidate targets alpha5 gamma-aminobutyric acid subtype A receptors to regulate synaptic plasticity and memory blockade. Anesthesiology. 2009 Nov;111(5):1025-35. PMID: 19809285.

 

Sohn JT, Kim HJ, Cho HC, et al. Effect of etomidate on endothelium-dependent relaxation induced by acetylcholine in rat aorta. Anaesth Intensive Care. 2004 Aug;32(4):476-81. PMID: 15682522.

" "UN number: 3077     Class: 9     Packing Group: III

Proper shipping name: Environmentally hazardous substance, solid, n.o.s. (Etomidate)"

LKT T7232 S-Trityl-L-cysteine 5 g 66.8 Organosulfur found in garlic; kinesin Eg5 inhibitor. S-(Triphenylmethyl)-L-cysteine NSC83265 2799-07-7 ≥98% 363.47 C22H21NO2S C1=CC=C(C=C1)C(C2=CC=CC=C2)(C3=CC=CC=C3)SCC(C(=O)O)N Ambient Ambient "Abualhasan MN, Good JA, Wittayanarakul K, et al. Doing the methylene shuffle--further insights into the inhibition of mitotic kinesin Eg5 with S-trityl L-cysteine. Eur J Med Chem. 2012 Aug;54:483-98. PMID: 22749640.

 

Shimizu M, Ishii H, Ogo N, et al. S-trityl-L-cysteine derivative induces caspase-independent cell death in K562 human chronic myeloid leukemia cell line. Cancer Lett. 2010 Dec 1;298(1):99-106. PMID: 20619960.

 

Kozielski F, Skoufias DA, Indorato RL, et al. Proteome analysis of apoptosis signaling by S-trityl-L-cysteine, a potent reversible inhibitor of human mitotic kinesin Eg5. Proteomics. 2008 Jan;8(2):289-300. PMID: 18186019.

 

Skoufias DA, DeBonis S, Saoudi Y, et al. S-trityl-L-cysteine is a reversible, tight binding inhibitor of the human kinesin Eg5 that specifically blocks mitotic progression. J Biol Chem. 2006 Jun 30;281(26):17559-69. PMID: 16507573.

" Not dangerous goods.

LKT T7232 S-Trityl-L-cysteine 25 g 260.9 Organosulfur found in garlic; kinesin Eg5 inhibitor. S-(Triphenylmethyl)-L-cysteine NSC83265 2799-07-7 ≥98% 363.47 C22H21NO2S C1=CC=C(C=C1)C(C2=CC=CC=C2)(C3=CC=CC=C3)SCC(C(=O)O)N Ambient Ambient "Abualhasan MN, Good JA, Wittayanarakul K, et al. Doing the methylene shuffle--further insights into the inhibition of mitotic kinesin Eg5 with S-trityl L-cysteine. Eur J Med Chem. 2012 Aug;54:483-98. PMID: 22749640.

 

Shimizu M, Ishii H, Ogo N, et al. S-trityl-L-cysteine derivative induces caspase-independent cell death in K562 human chronic myeloid leukemia cell line. Cancer Lett. 2010 Dec 1;298(1):99-106. PMID: 20619960.

 

Kozielski F, Skoufias DA, Indorato RL, et al. Proteome analysis of apoptosis signaling by S-trityl-L-cysteine, a potent reversible inhibitor of human mitotic kinesin Eg5. Proteomics. 2008 Jan;8(2):289-300. PMID: 18186019.

 

Skoufias DA, DeBonis S, Saoudi Y, et al. S-trityl-L-cysteine is a reversible, tight binding inhibitor of the human kinesin Eg5 that specifically blocks mitotic progression. J Biol Chem. 2006 Jun 30;281(26):17559-69. PMID: 16507573.

" Not dangerous goods.

LKT T7232 S-Trityl-L-cysteine 100 g 1031.4 Organosulfur found in garlic; kinesin Eg5 inhibitor. S-(Triphenylmethyl)-L-cysteine NSC83265 2799-07-7 ≥98% 363.47 C22H21NO2S C1=CC=C(C=C1)C(C2=CC=CC=C2)(C3=CC=CC=C3)SCC(C(=O)O)N Ambient Ambient "Abualhasan MN, Good JA, Wittayanarakul K, et al. Doing the methylene shuffle--further insights into the inhibition of mitotic kinesin Eg5 with S-trityl L-cysteine. Eur J Med Chem. 2012 Aug;54:483-98. PMID: 22749640.

 

Shimizu M, Ishii H, Ogo N, et al. S-trityl-L-cysteine derivative induces caspase-independent cell death in K562 human chronic myeloid leukemia cell line. Cancer Lett. 2010 Dec 1;298(1):99-106. PMID: 20619960.

 

Kozielski F, Skoufias DA, Indorato RL, et al. Proteome analysis of apoptosis signaling by S-trityl-L-cysteine, a potent reversible inhibitor of human mitotic kinesin Eg5. Proteomics. 2008 Jan;8(2):289-300. PMID: 18186019.

 

Skoufias DA, DeBonis S, Saoudi Y, et al. S-trityl-L-cysteine is a reversible, tight binding inhibitor of the human kinesin Eg5 that specifically blocks mitotic progression. J Biol Chem. 2006 Jun 30;281(26):17559-69. PMID: 16507573.

" Not dangerous goods.

LKT B3472 4,4′-(1,1′-Biphenyl-4,4′-diyldioxy)dianiline 5 g 54.6 Potential VEGFR2, Met, RET, Axl, Ron, PDGFR, FGFR1, FLT1/3/4 inhibitor. 4,4’-Bis(4-aminophenoxy)biphenyl 13080-85-8 ≥98% 368.43 C24H20N2O2 C1=CC(=CC=C1C2=CC=C(C=C2)OC3=CC=C(C=C3)N)OC4=CC=C(C=C4)N Ambient Ambient Not dangerous goods.

LKT B3472 4,4′-(1,1′-Biphenyl-4,4′-diyldioxy)dianiline 25 g 151.7 Potential VEGFR2, Met, RET, Axl, Ron, PDGFR, FGFR1, FLT1/3/4 inhibitor. 4,4’-Bis(4-aminophenoxy)biphenyl 13080-85-8 ≥98% 368.43 C24H20N2O2 C1=CC(=CC=C1C2=CC=C(C=C2)OC3=CC=C(C=C3)N)OC4=CC=C(C=C4)N Ambient Ambient Not dangerous goods.

LKT B3472 4,4′-(1,1′-Biphenyl-4,4′-diyldioxy)dianiline 100 g 424.7 Potential VEGFR2, Met, RET, Axl, Ron, PDGFR, FGFR1, FLT1/3/4 inhibitor. 4,4’-Bis(4-aminophenoxy)biphenyl 13080-85-8 ≥98% 368.43 C24H20N2O2 C1=CC(=CC=C1C2=CC=C(C=C2)OC3=CC=C(C=C3)N)OC4=CC=C(C=C4)N Ambient Ambient Not dangerous goods.

LKT T5720 Tofacitinib Citrate 5 mg 84.9 JAK1/2/3 inhibitor. 3-[(3R,4R)-4-methyl-3-[methyl(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino]piperidin-1-yl]-3-oxopropanenitrile citrate salt CP-690550-10, Tasocitinib citrate salt 540737-29-9 ≥99% 504.49 C16H20N6O C6H8O7 CC1CCN(CC1N(C)C2=NC=NC3=C2C=CN3)C(=O)CC#N.C(C(=O)O)C(CC(=O)O)(C(=O)O)O Ambient Ambient "Gavegnano C, Detorio M, Montero C, et al. Ruxolitinib and Tofacitinib are Potent and Selective Inhibitors of HIV-1 Replication and Virus Reactivation in Vitro. Antimicrob Agents Chemother. 2014 Jan 13. [Epub ahead of print]. PMID: 24419350.

 

Yamaoka K, Tanaka Y. Targeting the Janus kinases in rheumatoid arthritis: focus on tofacitinib. Expert Opin Pharmacother. 2014 Jan;15(1):103-13. PMID: 4188100.

 

Tak PP, Kalden JR. Advances in rheumatology: new targeted therapeutics. Arthritis Res Ther. 2011 May 25;13 Suppl 1:S5. PMID: 21624184.

 

Ghoreschi K, Jesson MI, Li X, et al. Modulation of innate and adaptive immune responses by tofacitinib (CP-690,550). J Immunol. 2011 Apr 1;186(7):4234-43. PMID: 21383241.

" Not dangerous goods.

LKT T5720 Tofacitinib Citrate 25 mg 364 JAK1/2/3 inhibitor. 3-[(3R,4R)-4-methyl-3-[methyl(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino]piperidin-1-yl]-3-oxopropanenitrile citrate salt CP-690550-10, Tasocitinib citrate salt 540737-29-9 ≥99% 504.49 C16H20N6O C6H8O7 CC1CCN(CC1N(C)C2=NC=NC3=C2C=CN3)C(=O)CC#N.C(C(=O)O)C(CC(=O)O)(C(=O)O)O Ambient Ambient "Gavegnano C, Detorio M, Montero C, et al. Ruxolitinib and Tofacitinib are Potent and Selective Inhibitors of HIV-1 Replication and Virus Reactivation in Vitro. Antimicrob Agents Chemother. 2014 Jan 13. [Epub ahead of print]. PMID: 24419350.

 

Yamaoka K, Tanaka Y. Targeting the Janus kinases in rheumatoid arthritis: focus on tofacitinib. Expert Opin Pharmacother. 2014 Jan;15(1):103-13. PMID: 4188100.

 

Tak PP, Kalden JR. Advances in rheumatology: new targeted therapeutics. Arthritis Res Ther. 2011 May 25;13 Suppl 1:S5. PMID: 21624184.

 

Ghoreschi K, Jesson MI, Li X, et al. Modulation of innate and adaptive immune responses by tofacitinib (CP-690,550). J Immunol. 2011 Apr 1;186(7):4234-43. PMID: 21383241.

" Not dangerous goods.

LKT T5720 Tofacitinib Citrate 100 mg 1334.8 JAK1/2/3 inhibitor. 3-[(3R,4R)-4-methyl-3-[methyl(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino]piperidin-1-yl]-3-oxopropanenitrile citrate salt CP-690550-10, Tasocitinib citrate salt 540737-29-9 ≥99% 504.49 C16H20N6O C6H8O7 CC1CCN(CC1N(C)C2=NC=NC3=C2C=CN3)C(=O)CC#N.C(C(=O)O)C(CC(=O)O)(C(=O)O)O Ambient Ambient "Gavegnano C, Detorio M, Montero C, et al. Ruxolitinib and Tofacitinib are Potent and Selective Inhibitors of HIV-1 Replication and Virus Reactivation in Vitro. Antimicrob Agents Chemother. 2014 Jan 13. [Epub ahead of print]. PMID: 24419350.

 

Yamaoka K, Tanaka Y. Targeting the Janus kinases in rheumatoid arthritis: focus on tofacitinib. Expert Opin Pharmacother. 2014 Jan;15(1):103-13. PMID: 4188100.

 

Tak PP, Kalden JR. Advances in rheumatology: new targeted therapeutics. Arthritis Res Ther. 2011 May 25;13 Suppl 1:S5. PMID: 21624184.

 

Ghoreschi K, Jesson MI, Li X, et al. Modulation of innate and adaptive immune responses by tofacitinib (CP-690,550). J Immunol. 2011 Apr 1;186(7):4234-43. PMID: 21383241.

" Not dangerous goods.

LKT L4796 LY-294002 5 mg 118.9 PI3K inhibitor. 154447-36-6 ≥99% 307.34 C19H17NO3 C1COCCN1C2=CC(=O)C3=C(O2)C(=CC=C3)C4=CC=CC=C4 Ambient Ambient "Avni D, Glucksam Y, Zor T. The phosphatidylinositol 3-kinase (PI3K) inhibitor LY294002 modulates cytokine expression in macrophages via p50 nuclear factor κB inhibition, in a PI3K-independent mechanism. Biochem Pharmacol. 2012 Jan 1;83(1):106-14. PMID: 22005520.

 

Salh B, Wagey R, Marotta A, et al. Activation of phosphatidylinositol 3-kinase, protein kinase B, and p70 S6 kinases in lipopolysaccharide-stimulated Raw 264.7 cells: differential effects of rapamycin, Ly294002, and wortmannin on nitric oxide production. J Immunol. 1998 Dec 15;161(12):6947-54. PMID: 9862729.

 

Nakamura I, Sasaki T, Tanaka S, et al. Phosphatidylinositol-3 kinase is involved in ruffled border formation in osteoclasts. J Cell Physiol. 1997 Aug;172(2):230-9. PMID: 9258344.

 

Rosenzweig KE, Youmell MB, Palayoor ST, et al. Radiosensitization of human tumor cells by the phosphatidylinositol3-kinase inhibitors wortmannin and LY294002 correlates with inhibition of DNA-dependent protein kinase and prolonged G2-M delay. Clin Cancer Res. 1997 Jul;3(7):1149-56. PMID: 9815794.

" Not dangerous goods.

LKT L4796 LY-294002 25 mg 424.7 PI3K inhibitor. 154447-36-6 ≥99% 307.34 C19H17NO3 C1COCCN1C2=CC(=O)C3=C(O2)C(=CC=C3)C4=CC=CC=C4 Ambient Ambient "Avni D, Glucksam Y, Zor T. The phosphatidylinositol 3-kinase (PI3K) inhibitor LY294002 modulates cytokine expression in macrophages via p50 nuclear factor κB inhibition, in a PI3K-independent mechanism. Biochem Pharmacol. 2012 Jan 1;83(1):106-14. PMID: 22005520.

 

Salh B, Wagey R, Marotta A, et al. Activation of phosphatidylinositol 3-kinase, protein kinase B, and p70 S6 kinases in lipopolysaccharide-stimulated Raw 264.7 cells: differential effects of rapamycin, Ly294002, and wortmannin on nitric oxide production. J Immunol. 1998 Dec 15;161(12):6947-54. PMID: 9862729.

 

Nakamura I, Sasaki T, Tanaka S, et al. Phosphatidylinositol-3 kinase is involved in ruffled border formation in osteoclasts. J Cell Physiol. 1997 Aug;172(2):230-9. PMID: 9258344.

 

Rosenzweig KE, Youmell MB, Palayoor ST, et al. Radiosensitization of human tumor cells by the phosphatidylinositol3-kinase inhibitors wortmannin and LY294002 correlates with inhibition of DNA-dependent protein kinase and prolonged G2-M delay. Clin Cancer Res. 1997 Jul;3(7):1149-56. PMID: 9815794.

" Not dangerous goods.

LKT L4796 LY-294002 100 mg 1189.1 PI3K inhibitor. 154447-36-6 ≥99% 307.34 C19H17NO3 C1COCCN1C2=CC(=O)C3=C(O2)C(=CC=C3)C4=CC=CC=C4 Ambient Ambient "Avni D, Glucksam Y, Zor T. The phosphatidylinositol 3-kinase (PI3K) inhibitor LY294002 modulates cytokine expression in macrophages via p50 nuclear factor κB inhibition, in a PI3K-independent mechanism. Biochem Pharmacol. 2012 Jan 1;83(1):106-14. PMID: 22005520.

 

Salh B, Wagey R, Marotta A, et al. Activation of phosphatidylinositol 3-kinase, protein kinase B, and p70 S6 kinases in lipopolysaccharide-stimulated Raw 264.7 cells: differential effects of rapamycin, Ly294002, and wortmannin on nitric oxide production. J Immunol. 1998 Dec 15;161(12):6947-54. PMID: 9862729.

 

Nakamura I, Sasaki T, Tanaka S, et al. Phosphatidylinositol-3 kinase is involved in ruffled border formation in osteoclasts. J Cell Physiol. 1997 Aug;172(2):230-9. PMID: 9258344.

 

Rosenzweig KE, Youmell MB, Palayoor ST, et al. Radiosensitization of human tumor cells by the phosphatidylinositol3-kinase inhibitors wortmannin and LY294002 correlates with inhibition of DNA-dependent protein kinase and prolonged G2-M delay. Clin Cancer Res. 1997 Jul;3(7):1149-56. PMID: 9815794.

" Not dangerous goods.

LKT G5320 GNF-2 5 mg 176 Abl inhibitor. 778270-11-4 ≥98% 374.32 C18H13F3N4O2 C1=CC(=CC(=C1)C(=O)N)C2=CC(=NC=N2)NC3=CC=C(C=C3)OC(F)(F)F Ambient Ambient "Kim HJ, Yoon HJ, Choi JY, et al. The tyrosine kinase inhibitor NF-2 suppresses osteoclast formation and activity. J Leukoc Biol. 2014 Feb;95(2):337-45. PMID: 24130113.

 

Greuber EK, Pendergast AM. Abl family kinases regulate FcγR-mediated phagocytosis in murine macrophages. J Immunol. 2012 Dec 1;189(11):5382-92. PMID: 23100514.

 

Mian AA, Metodieva A, Najajreh Y, et al. p185(BCR/ABL) has a lower sensitivity than p210(BCR/ABL) to the allosteric inhibitor NF-2 in Philadelphia chromosome-positive acute lymphatic leukemia. Haematologica. 2012 Feb;97(2):251-7. PMID: 22058195.

 

Deng X, Okram B, Ding Q, et al. Expanding the diversity of allosteric bcr-abl inhibitors. J Med Chem. 2010 Oct 14;53(19):6934-46. PMID: 20828158.

 

Adrián FJ, Ding Q, Sim T, et al. Allosteric inhibitors of Bcr-abl-dependent cell proliferation. Nat Chem Biol. 2006 Feb;2(2):95-102. PMID: 16415863.

" Not dangerous goods.

LKT G5320 GNF-2 25 mg 564.3 Abl inhibitor. 778270-11-4 ≥98% 374.32 C18H13F3N4O2 C1=CC(=CC(=C1)C(=O)N)C2=CC(=NC=N2)NC3=CC=C(C=C3)OC(F)(F)F Ambient Ambient "Kim HJ, Yoon HJ, Choi JY, et al. The tyrosine kinase inhibitor NF-2 suppresses osteoclast formation and activity. J Leukoc Biol. 2014 Feb;95(2):337-45. PMID: 24130113.

 

Greuber EK, Pendergast AM. Abl family kinases regulate FcγR-mediated phagocytosis in murine macrophages. J Immunol. 2012 Dec 1;189(11):5382-92. PMID: 23100514.

 

Mian AA, Metodieva A, Najajreh Y, et al. p185(BCR/ABL) has a lower sensitivity than p210(BCR/ABL) to the allosteric inhibitor NF-2 in Philadelphia chromosome-positive acute lymphatic leukemia. Haematologica. 2012 Feb;97(2):251-7. PMID: 22058195.

 

Deng X, Okram B, Ding Q, et al. Expanding the diversity of allosteric bcr-abl inhibitors. J Med Chem. 2010 Oct 14;53(19):6934-46. PMID: 20828158.

 

Adrián FJ, Ding Q, Sim T, et al. Allosteric inhibitors of Bcr-abl-dependent cell proliferation. Nat Chem Biol. 2006 Feb;2(2):95-102. PMID: 16415863.

" Not dangerous goods.

LKT I5992 IOX2 5 mg 87.4 Prolyl hydroxylase inhibitor. 931398-72-0 ≥98% 352.34 C19H16N2O5 C1=CC=C(C=C1)CN2C3=CC=CC=C3C(=C(C2=O)C(=O)NCC(=O)O)O Ambient Ambient Sen A, Ren S, Lerchenmüller C, et al. MicroRNA-138 regulates hypoxia-induced endothelial cell dysfunction by targeting S100A1. PLoS One. 2013 Nov 11;8(11):e78684. PMID: 24244340. Not dangerous goods.

LKT I5992 IOX2 25 mg 394.4 Prolyl hydroxylase inhibitor. 931398-72-0 ≥98% 352.34 C19H16N2O5 C1=CC=C(C=C1)CN2C3=CC=CC=C3C(=C(C2=O)C(=O)NCC(=O)O)O Ambient Ambient Sen A, Ren S, Lerchenmüller C, et al. MicroRNA-138 regulates hypoxia-induced endothelial cell dysfunction by targeting S100A1. PLoS One. 2013 Nov 11;8(11):e78684. PMID: 24244340. Not dangerous goods.

LKT I5992 IOX2 100 mg 1122.3 Prolyl hydroxylase inhibitor. 931398-72-0 ≥98% 352.34 C19H16N2O5 C1=CC=C(C=C1)CN2C3=CC=CC=C3C(=C(C2=O)C(=O)NCC(=O)O)O Ambient Ambient Sen A, Ren S, Lerchenmüller C, et al. MicroRNA-138 regulates hypoxia-induced endothelial cell dysfunction by targeting S100A1. PLoS One. 2013 Nov 11;8(11):e78684. PMID: 24244340. Not dangerous goods.

LKT K1679 (+)-Ketanserin Tartrate 10 mg 54.6 5-HT2A and TRPV1 antagonist, potential α1-adrenergic antagonist. 83846-83-7 ≥98% 545.52 C22H22FN3O3 C4H6O6 C1CN(CCC1C(=O)C2=CC=C(C=C2)F)CCN3C(=O)C4=CC=CC=C4NC3=O.C(C(C(=O)O)O)(C(=O)O)O Ambient -20°C "Yu JG, Zhang EH, Liu AJ, et al. Ketanserin improves cardiac performance after myocardial infarction in spontaneously hypertensive rats partially through restoration of baroreflex function. Acta Pharmacol Sin. 2013 Dec;34(12):1508-14. PMID: 24241347.

 

Loyd DR, Chen PB, Hargreaves KM. Anti-hyperalgesic effects of anti-serotonergic compounds on serotonin- and capsaicin-evoked thermal hyperalgesia in the rat. Neuroscience. 2012 Feb 17;203:207-15. PMID: 22209919.

 

van Zwieten PA, Blauw GJ, van Brummelen P. Serotonergic receptors and drugs in hypertension. Pharmacol Toxicol. 1992 Jun;70(6 Pt 2):S17-22. PMID: 1354865.

 

Koss MC. Mechanism of ketanserin-induced sympatho-inhibition. Eur J Pharmacol. 1991 Mar 5;194(2-3):161-6. PMID: 1676374.

" "UN number: 2811     Class: 6.1     Packing Group: III

Proper shipping name: Toxic solid, organic, n.o.s. (Ketanserin tartrate)"

LKT K1679 (+)-Ketanserin Tartrate 50 mg 121.4 5-HT2A and TRPV1 antagonist, potential α1-adrenergic antagonist. 83846-83-7 ≥98% 545.52 C22H22FN3O3 C4H6O6 C1CN(CCC1C(=O)C2=CC=C(C=C2)F)CCN3C(=O)C4=CC=CC=C4NC3=O.C(C(C(=O)O)O)(C(=O)O)O Ambient -20°C "Yu JG, Zhang EH, Liu AJ, et al. Ketanserin improves cardiac performance after myocardial infarction in spontaneously hypertensive rats partially through restoration of baroreflex function. Acta Pharmacol Sin. 2013 Dec;34(12):1508-14. PMID: 24241347.

 

Loyd DR, Chen PB, Hargreaves KM. Anti-hyperalgesic effects of anti-serotonergic compounds on serotonin- and capsaicin-evoked thermal hyperalgesia in the rat. Neuroscience. 2012 Feb 17;203:207-15. PMID: 22209919.

 

van Zwieten PA, Blauw GJ, van Brummelen P. Serotonergic receptors and drugs in hypertension. Pharmacol Toxicol. 1992 Jun;70(6 Pt 2):S17-22. PMID: 1354865.

 

Koss MC. Mechanism of ketanserin-induced sympatho-inhibition. Eur J Pharmacol. 1991 Mar 5;194(2-3):161-6. PMID: 1676374.

" "UN number: 2811     Class: 6.1     Packing Group: III

Proper shipping name: Toxic solid, organic, n.o.s. (Ketanserin tartrate)"

LKT K1679 (+)-Ketanserin Tartrate 250 mg 515.7 5-HT2A and TRPV1 antagonist, potential α1-adrenergic antagonist. 83846-83-7 ≥98% 545.52 C22H22FN3O3 C4H6O6 C1CN(CCC1C(=O)C2=CC=C(C=C2)F)CCN3C(=O)C4=CC=CC=C4NC3=O.C(C(C(=O)O)O)(C(=O)O)O Ambient -20°C "Yu JG, Zhang EH, Liu AJ, et al. Ketanserin improves cardiac performance after myocardial infarction in spontaneously hypertensive rats partially through restoration of baroreflex function. Acta Pharmacol Sin. 2013 Dec;34(12):1508-14. PMID: 24241347.

 

Loyd DR, Chen PB, Hargreaves KM. Anti-hyperalgesic effects of anti-serotonergic compounds on serotonin- and capsaicin-evoked thermal hyperalgesia in the rat. Neuroscience. 2012 Feb 17;203:207-15. PMID: 22209919.

 

van Zwieten PA, Blauw GJ, van Brummelen P. Serotonergic receptors and drugs in hypertension. Pharmacol Toxicol. 1992 Jun;70(6 Pt 2):S17-22. PMID: 1354865.

 

Koss MC. Mechanism of ketanserin-induced sympatho-inhibition. Eur J Pharmacol. 1991 Mar 5;194(2-3):161-6. PMID: 1676374.

" "UN number: 2811     Class: 6.1     Packing Group: III

Proper shipping name: Toxic solid, organic, n.o.s. (Ketanserin tartrate)"

LKT K1679 (+)-Ketanserin Tartrate 500 mg 910 5-HT2A and TRPV1 antagonist, potential α1-adrenergic antagonist. 83846-83-7 ≥98% 545.52 C22H22FN3O3 C4H6O6 C1CN(CCC1C(=O)C2=CC=C(C=C2)F)CCN3C(=O)C4=CC=CC=C4NC3=O.C(C(C(=O)O)O)(C(=O)O)O Ambient -20°C "Yu JG, Zhang EH, Liu AJ, et al. Ketanserin improves cardiac performance after myocardial infarction in spontaneously hypertensive rats partially through restoration of baroreflex function. Acta Pharmacol Sin. 2013 Dec;34(12):1508-14. PMID: 24241347.

 

Loyd DR, Chen PB, Hargreaves KM. Anti-hyperalgesic effects of anti-serotonergic compounds on serotonin- and capsaicin-evoked thermal hyperalgesia in the rat. Neuroscience. 2012 Feb 17;203:207-15. PMID: 22209919.

 

van Zwieten PA, Blauw GJ, van Brummelen P. Serotonergic receptors and drugs in hypertension. Pharmacol Toxicol. 1992 Jun;70(6 Pt 2):S17-22. PMID: 1354865.

 

Koss MC. Mechanism of ketanserin-induced sympatho-inhibition. Eur J Pharmacol. 1991 Mar 5;194(2-3):161-6. PMID: 1676374.

" "UN number: 2811     Class: 6.1     Packing Group: III

Proper shipping name: Toxic solid, organic, n.o.s. (Ketanserin tartrate)"

LKT P7218 Pseudoprotodioscin 5 mg 54.6 Steroidal saponin found in Tribulus, Trigonella, Similax. 102115-79-7 ≥98% 1031.18 C51H82O21 Ambient 4°C "Kawabata T, Cui MY, Hasegawa T, et al. Anti-inflammatory and anti-melanogenic steroidal saponin glycosides from Fenugreek (Trigonella foenum-graecum L.) seeds. Planta Med. 2011 May;77(7):705-10. PMID: 20979021.

 

Dinchev D, Janda B, Evstatieva L, et al. Distribution of steroidal saponins in Tribulus terrestris from different geographical regions. Phytochemistry. 2008 Jan;69(1):176-86. PMID: 17719068.

 

Dong M, Feng XZ, Wu LJ, et al. Two new steroidal saponins from the rhizomes of Dioscorea panthaica and their cytotoxic activity. Planta Med. 2001 Dec;67(9):853-7. PMID: 11745024.

" Not dangerous goods.

LKT P7218 Pseudoprotodioscin 25 mg 200.2 Steroidal saponin found in Tribulus, Trigonella, Similax. 102115-79-7 ≥98% 1031.18 C51H82O21 Ambient 4°C "Kawabata T, Cui MY, Hasegawa T, et al. Anti-inflammatory and anti-melanogenic steroidal saponin glycosides from Fenugreek (Trigonella foenum-graecum L.) seeds. Planta Med. 2011 May;77(7):705-10. PMID: 20979021.

 

Dinchev D, Janda B, Evstatieva L, et al. Distribution of steroidal saponins in Tribulus terrestris from different geographical regions. Phytochemistry. 2008 Jan;69(1):176-86. PMID: 17719068.

 

Dong M, Feng XZ, Wu LJ, et al. Two new steroidal saponins from the rhizomes of Dioscorea panthaica and their cytotoxic activity. Planta Med. 2001 Dec;67(9):853-7. PMID: 11745024.

" Not dangerous goods.

LKT P7218 Pseudoprotodioscin 100 mg 424.7 Steroidal saponin found in Tribulus, Trigonella, Similax. 102115-79-7 ≥98% 1031.18 C51H82O21 Ambient 4°C "Kawabata T, Cui MY, Hasegawa T, et al. Anti-inflammatory and anti-melanogenic steroidal saponin glycosides from Fenugreek (Trigonella foenum-graecum L.) seeds. Planta Med. 2011 May;77(7):705-10. PMID: 20979021.

 

Dinchev D, Janda B, Evstatieva L, et al. Distribution of steroidal saponins in Tribulus terrestris from different geographical regions. Phytochemistry. 2008 Jan;69(1):176-86. PMID: 17719068.

 

Dong M, Feng XZ, Wu LJ, et al. Two new steroidal saponins from the rhizomes of Dioscorea panthaica and their cytotoxic activity. Planta Med. 2001 Dec;67(9):853-7. PMID: 11745024.

" Not dangerous goods.

LKT A0025 17-Allylaminogeldanamycin 25 mg 200.2 Geldanamycin derivative; HSP90 inhibitor. 17-(Allylamino)-17-desmethoxy-geldanamycin; allylaminogeldanamycin; 17-AAG; telatinib. 75747-14-7 ≥97% 585.69 C31H43N3O8 CC1CC(C(C(C=C(C(C(C=CC=C(C(=O)NC2=CC(=O)C(=C(C1)C2=O)NCC=C)C)OC)OC(=O)N)C)C)O)OC Protect from light. Ambient 4°C Soluble in DMSO or methanol. "Thangjam GS, Dimitropoulou C, Joshi AD, et al. Novel mechanism of attenuation of LPS-induced NF-κB activation by the heat shock protein 90 inhibitor, 17-N-allylamino-17-demethoxygeldanamycin, in human lung microvascular endothelial cells. Am J Respir Cell Mol Biol. 2014 May;50(5):942-52. PMID: 24303801.

 

Powers MV, Valenti M, Miranda S, et al. Mode of cell death induced by the HSP90 inhibitor 17-AAG (tanespimycin) is dependent on the expression of pro-apoptotic BAX. Oncotarget. 2013 Nov;4(11):1963-75. PMID: 24185264.

 

Evers DL, Chao CF, Zhang Z, et al. 17-allylamino-17-(demethoxy)geldanamycin (17-AAG) is a potent and effective inhibitor of human cytomegalovirus replication in primary fibroblast cells. Arch Virol. 2012 Oct;157(10):1971-4. PMID: 22711259.

 

Gloesenkamp C, Nitzsche B, Lim AR, et al. Heat shock protein 90 is a promising target for effective growth inhibition of gastrointestinal neuroendocrine tumors. Int J Oncol. 2012 May;40(5):1659-67. PMID: 22246317." Not dangerous goods.

LKT S0344 Salermide 5 mg 84.9 SIRT inhibitor. 1105698-15-4 ≥98% 394.47 C26H22N2O2 CC(C1=CC=CC=C1)C(=O)NC2=CC=CC(=C2)NC=C3C(=O)C=CC4=CC=CC=C43 Ambient -20°C "Lancelot J, Caby S, Dubois-Abdesselem F, et al. Schistosoma mansoni Sirtuins: characterization and potential as chemotherapeutic targets. PLoS Negl Trop Dis. 2013 Sep 12;7(9):e2428. PMID: 24069483.

 

Dastjerdi MN, Salahshoor MR, Mardani M, et al. The apoptotic effects of sirtuin1 inhibitor on the MCF-7 and MRC-5 cell lines. Res Pharm Sci. 2013 Apr;8(2):79-89. PMID: 24019817.

 

Liu G, Su L, Hao X, et al. Salermide up-regulates death receptor 5 expression through the ATF4-ATF3-CHOP axis and leads to apoptosis in human cancer cells. J Cell Mol Med. 2012 Jul;16(7):1618-28. PMID: 21801305.

 

Lara E, Mai A, Calvanese V, Altucci L, et al. Salermide, a Sirtuin inhibitor with a strong cancer-specific proapoptotic effect. Oncogene. 2009 Feb 12;28(6):781-91. Erratum in: Oncogene. 2009 Feb 26;28(8):1168. Inhof, A [corrected to Imhof, A]. PMID: 19060927.

" Not dangerous goods.

LKT S0344 Salermide 10 mg 133.5 SIRT inhibitor. 1105698-15-4 ≥98% 394.47 C26H22N2O2 CC(C1=CC=CC=C1)C(=O)NC2=CC=CC(=C2)NC=C3C(=O)C=CC4=CC=CC=C43 Ambient -20°C "Lancelot J, Caby S, Dubois-Abdesselem F, et al. Schistosoma mansoni Sirtuins: characterization and potential as chemotherapeutic targets. PLoS Negl Trop Dis. 2013 Sep 12;7(9):e2428. PMID: 24069483.

 

Dastjerdi MN, Salahshoor MR, Mardani M, et al. The apoptotic effects of sirtuin1 inhibitor on the MCF-7 and MRC-5 cell lines. Res Pharm Sci. 2013 Apr;8(2):79-89. PMID: 24019817.

 

Liu G, Su L, Hao X, et al. Salermide up-regulates death receptor 5 expression through the ATF4-ATF3-CHOP axis and leads to apoptosis in human cancer cells. J Cell Mol Med. 2012 Jul;16(7):1618-28. PMID: 21801305.

 

Lara E, Mai A, Calvanese V, Altucci L, et al. Salermide, a Sirtuin inhibitor with a strong cancer-specific proapoptotic effect. Oncogene. 2009 Feb 12;28(6):781-91. Erratum in: Oncogene. 2009 Feb 26;28(8):1168. Inhof, A [corrected to Imhof, A]. PMID: 19060927.

" Not dangerous goods.

LKT S0344 Salermide 25 mg 327.6 SIRT inhibitor. 1105698-15-4 ≥98% 394.47 C26H22N2O2 CC(C1=CC=CC=C1)C(=O)NC2=CC=CC(=C2)NC=C3C(=O)C=CC4=CC=CC=C43 Ambient -20°C "Lancelot J, Caby S, Dubois-Abdesselem F, et al. Schistosoma mansoni Sirtuins: characterization and potential as chemotherapeutic targets. PLoS Negl Trop Dis. 2013 Sep 12;7(9):e2428. PMID: 24069483.

 

Dastjerdi MN, Salahshoor MR, Mardani M, et al. The apoptotic effects of sirtuin1 inhibitor on the MCF-7 and MRC-5 cell lines. Res Pharm Sci. 2013 Apr;8(2):79-89. PMID: 24019817.

 

Liu G, Su L, Hao X, et al. Salermide up-regulates death receptor 5 expression through the ATF4-ATF3-CHOP axis and leads to apoptosis in human cancer cells. J Cell Mol Med. 2012 Jul;16(7):1618-28. PMID: 21801305.

 

Lara E, Mai A, Calvanese V, Altucci L, et al. Salermide, a Sirtuin inhibitor with a strong cancer-specific proapoptotic effect. Oncogene. 2009 Feb 12;28(6):781-91. Erratum in: Oncogene. 2009 Feb 26;28(8):1168. Inhof, A [corrected to Imhof, A]. PMID: 19060927.

" Not dangerous goods.

LKT C0048 Cambinol 5 mg 163.8 SIRT inhibitor. SIRT 1/2 inhibitor IV, SIRT1 Inhibitor II, NSC112546, SIRT2 Inhibitor VI. 14513-15-6 ≥98% 360.43 C21H16N2O2S C1=CC=C(C=C1)C2=C(C(=O)NC(=S)N2)CC3=C(C=CC4=CC=CC=C43)O Ambient -20°C "Lugrin J, Ciarlo E, Santos A, et al. The sirtuin inhibitor cambinol impairs MAPK signaling, inhibits inflammatory and innate immune responses and protects from septic shock. Biochim Biophys Acta. 2013 Jun;1833(6):1498-510. PMID: 23499872.

 

Portmann S, Fahrner R, Lechleiter A, et al. Antitumor effect of SIRT1 inhibition in human HCC tumor models in vitro and in vivo. Mol Cancer Ther. 2013 Apr;12(4):499-508. PMID: 23339189.

 

Heltweg B, Gatbonton T, Schuler AD, et al. Antitumor activity of a small-molecule inhibitor of human silent information regulator 2 enzymes. Cancer Res. 2006 Apr 15;66(8):4368-77. PMID: 16618762.

" Not dangerous goods.

LKT C0048 Cambinol 25 mg 679.5 SIRT inhibitor. SIRT 1/2 inhibitor IV, SIRT1 Inhibitor II, NSC112546, SIRT2 Inhibitor VI. 14513-15-6 ≥98% 360.43 C21H16N2O2S C1=CC=C(C=C1)C2=C(C(=O)NC(=S)N2)CC3=C(C=CC4=CC=CC=C43)O Ambient -20°C "Lugrin J, Ciarlo E, Santos A, et al. The sirtuin inhibitor cambinol impairs MAPK signaling, inhibits inflammatory and innate immune responses and protects from septic shock. Biochim Biophys Acta. 2013 Jun;1833(6):1498-510. PMID: 23499872.

 

Portmann S, Fahrner R, Lechleiter A, et al. Antitumor effect of SIRT1 inhibition in human HCC tumor models in vitro and in vivo. Mol Cancer Ther. 2013 Apr;12(4):499-508. PMID: 23339189.

 

Heltweg B, Gatbonton T, Schuler AD, et al. Antitumor activity of a small-molecule inhibitor of human silent information regulator 2 enzymes. Cancer Res. 2006 Apr 15;66(8):4368-77. PMID: 16618762.

" Not dangerous goods.

LKT M5610 Moclobemide 10 mg 78.9 MAO-A inhibitor. 71320-77-9 ≥98% 268.74 C13H17ClN2O2 C1COCCN1CCNC(=O)C2=CC=C(C=C2)Cl Ambient Ambient "Bielecka AM, Paul-Samojedny M, Obuchowicz E. Moclobemide exerts anti-inflammatory effect in lipopolysaccharide-activated primary mixed glial cell culture. Naunyn Schmiedebergs Arch Pharmacol. 2010 Dec;382(5-6):409-17. PMID: 20811738.

 

Li YF, Zhang YZ, Liu YQ, et al. Moclobemide up-regulates proliferation of hippocampal progenitor cells in chronically stressed mice. Acta Pharmacol Sin. 2004 Nov;25(11):1408-12. PMID: 15525460.

 

Schreiber S, Getslev V, Weizman A, et al. The antinociceptive effect of moclobemide in mice is mediated by noradrenergic pathways. Neurosci Lett. 1998 Sep 11;253(3):183-6. PMID: 9792241.

 

Ferigolo M, Barros HM, Marquardt AR, et al. Comparison of behavioral effects of moclobemide and deprenyl during forced swimming. Pharmacol Biochem Behav. 1998 Jun;60(2):431-7. PMID: 9632226.

" Not dangerous goods.

LKT M5610 Moclobemide 25 mg 145.6 MAO-A inhibitor. 71320-77-9 ≥98% 268.74 C13H17ClN2O2 C1COCCN1CCNC(=O)C2=CC=C(C=C2)Cl Ambient Ambient "Bielecka AM, Paul-Samojedny M, Obuchowicz E. Moclobemide exerts anti-inflammatory effect in lipopolysaccharide-activated primary mixed glial cell culture. Naunyn Schmiedebergs Arch Pharmacol. 2010 Dec;382(5-6):409-17. PMID: 20811738.

 

Li YF, Zhang YZ, Liu YQ, et al. Moclobemide up-regulates proliferation of hippocampal progenitor cells in chronically stressed mice. Acta Pharmacol Sin. 2004 Nov;25(11):1408-12. PMID: 15525460.

 

Schreiber S, Getslev V, Weizman A, et al. The antinociceptive effect of moclobemide in mice is mediated by noradrenergic pathways. Neurosci Lett. 1998 Sep 11;253(3):183-6. PMID: 9792241.

 

Ferigolo M, Barros HM, Marquardt AR, et al. Comparison of behavioral effects of moclobemide and deprenyl during forced swimming. Pharmacol Biochem Behav. 1998 Jun;60(2):431-7. PMID: 9632226.

" Not dangerous goods.

LKT M5610 Moclobemide 100 mg 424.7 MAO-A inhibitor. 71320-77-9 ≥98% 268.74 C13H17ClN2O2 C1COCCN1CCNC(=O)C2=CC=C(C=C2)Cl Ambient Ambient "Bielecka AM, Paul-Samojedny M, Obuchowicz E. Moclobemide exerts anti-inflammatory effect in lipopolysaccharide-activated primary mixed glial cell culture. Naunyn Schmiedebergs Arch Pharmacol. 2010 Dec;382(5-6):409-17. PMID: 20811738.

 

Li YF, Zhang YZ, Liu YQ, et al. Moclobemide up-regulates proliferation of hippocampal progenitor cells in chronically stressed mice. Acta Pharmacol Sin. 2004 Nov;25(11):1408-12. PMID: 15525460.

 

Schreiber S, Getslev V, Weizman A, et al. The antinociceptive effect of moclobemide in mice is mediated by noradrenergic pathways. Neurosci Lett. 1998 Sep 11;253(3):183-6. PMID: 9792241.

 

Ferigolo M, Barros HM, Marquardt AR, et al. Comparison of behavioral effects of moclobemide and deprenyl during forced swimming. Pharmacol Biochem Behav. 1998 Jun;60(2):431-7. PMID: 9632226.

" Not dangerous goods.

LKT I5212 Indirubin 5 mg 60.7 Bisindole isomer of indigo found in Indigo naturalis; potential EGFR and CDK inhibitor. 479-41-4 ≥98% 262.26 C16H10N2O2 C1=CC=C2C(=C1)C(=C3C(=O)C4=CC=CC=C4N3)C(=O)N2 Ambient 4°C "Kim MH, Choi YY, Yang G, et al. Indirubin, a purple 3,2- bisindole, inhibited allergic contact dermatitis via regulating T helper (Th)-mediated immune system in DNCB-induced model. J Ethnopharmacol. 2013 Jan 9;145(1):214-9. PMID: 23149289.

 

Hsieh WL, Lin YK, Tsai CN, et al. Indirubin, an acting component of indigo naturalis, inhibits EGFR activation and EGF-induced CDC25B gene expression in epidermal keratinocytes. J Dermatol Sci. 2012 Aug;67(2):140-6. PMID: 22721997.

 

Zhang X, Song Y, Wu Y, et al. Indirubin inhibits tumor growth by antitumor angiogenesis via blocking VEGFR2-mediated JAK/STAT3 signaling in endothelial cell. Int J Cancer. 2011 Nov 15;129(10):2502-11. PMID: 21207415.

 

Kim SH, Choi SJ, Kim YC, et al. Anti-tumor activity of noble indirubin derivatives in human solid tumor models in vitro. Arch Pharm Res. 2009 Jun;32(6):915-22. PMID: 19557370.

 

Sethi G, Ahn KS, Sandur SK, et al. Indirubin enhances tumor necrosis factor-induced apoptosis through modulation of nuclear factor-kappa B signaling pathway. J Biol Chem. 2006 Aug 18;281(33):23425-35. PMID: 16785236.

" Not dangerous goods.

LKT I5212 Indirubin 25 mg 248.7 Bisindole isomer of indigo found in Indigo naturalis; potential EGFR and CDK inhibitor. 479-41-4 ≥98% 262.26 C16H10N2O2 C1=CC=C2C(=C1)C(=C3C(=O)C4=CC=CC=C4N3)C(=O)N2 Ambient 4°C "Kim MH, Choi YY, Yang G, et al. Indirubin, a purple 3,2- bisindole, inhibited allergic contact dermatitis via regulating T helper (Th)-mediated immune system in DNCB-induced model. J Ethnopharmacol. 2013 Jan 9;145(1):214-9. PMID: 23149289.

 

Hsieh WL, Lin YK, Tsai CN, et al. Indirubin, an acting component of indigo naturalis, inhibits EGFR activation and EGF-induced CDC25B gene expression in epidermal keratinocytes. J Dermatol Sci. 2012 Aug;67(2):140-6. PMID: 22721997.

 

Zhang X, Song Y, Wu Y, et al. Indirubin inhibits tumor growth by antitumor angiogenesis via blocking VEGFR2-mediated JAK/STAT3 signaling in endothelial cell. Int J Cancer. 2011 Nov 15;129(10):2502-11. PMID: 21207415.

 

Kim SH, Choi SJ, Kim YC, et al. Anti-tumor activity of noble indirubin derivatives in human solid tumor models in vitro. Arch Pharm Res. 2009 Jun;32(6):915-22. PMID: 19557370.

 

Sethi G, Ahn KS, Sandur SK, et al. Indirubin enhances tumor necrosis factor-induced apoptosis through modulation of nuclear factor-kappa B signaling pathway. J Biol Chem. 2006 Aug 18;281(33):23425-35. PMID: 16785236.

" Not dangerous goods.

LKT I5212 Indirubin 100 mg 728.1 Bisindole isomer of indigo found in Indigo naturalis; potential EGFR and CDK inhibitor. 479-41-4 ≥98% 262.26 C16H10N2O2 C1=CC=C2C(=C1)C(=C3C(=O)C4=CC=CC=C4N3)C(=O)N2 Ambient 4°C "Kim MH, Choi YY, Yang G, et al. Indirubin, a purple 3,2- bisindole, inhibited allergic contact dermatitis via regulating T helper (Th)-mediated immune system in DNCB-induced model. J Ethnopharmacol. 2013 Jan 9;145(1):214-9. PMID: 23149289.

 

Hsieh WL, Lin YK, Tsai CN, et al. Indirubin, an acting component of indigo naturalis, inhibits EGFR activation and EGF-induced CDC25B gene expression in epidermal keratinocytes. J Dermatol Sci. 2012 Aug;67(2):140-6. PMID: 22721997.

 

Zhang X, Song Y, Wu Y, et al. Indirubin inhibits tumor growth by antitumor angiogenesis via blocking VEGFR2-mediated JAK/STAT3 signaling in endothelial cell. Int J Cancer. 2011 Nov 15;129(10):2502-11. PMID: 21207415.

 

Kim SH, Choi SJ, Kim YC, et al. Anti-tumor activity of noble indirubin derivatives in human solid tumor models in vitro. Arch Pharm Res. 2009 Jun;32(6):915-22. PMID: 19557370.

 

Sethi G, Ahn KS, Sandur SK, et al. Indirubin enhances tumor necrosis factor-induced apoptosis through modulation of nuclear factor-kappa B signaling pathway. J Biol Chem. 2006 Aug 18;281(33):23425-35. PMID: 16785236.

" Not dangerous goods.

LKT V3278 Vitamin E Acetate 25 g 30.3 Vitamin E, antioxidant. DL-alpha-tocopherol acetate 58-95-7 ≥98% 472.74 C31H52O3 CC1=C2C(=C(C(=C1C)OC(=O)C)C)CCC(O2)(C)CCCC(C)CCCC(C)CCCC(C)C Ambient 4°C "Morani AS, Bodhankar SL. Early co-administration of vitamin E acetate and methylcobalamin improves thermal hyperalgesia and motor nerve conduction velocity following sciatic nerve crush injury in rats. Pharmacol Rep. 2010 Mar-Apr;62(2):405-9. PMID: 20508297.

 

Chandra AK, Ghosh R, Chatterjee A, et al. Amelioration of vanadium-induced testicular toxicity and adrenocortical hyperactivity by vitamin E acetate in rats. Mol Cell Biochem. 2007 Dec;306(1-2):189-200. PMID: 17668152.

 

Berton TR, Conti CJ, Mitchell DL, et al. The effect of vitamin E acetate on ultraviolet-induced mouse skin carcinogenesis. Mol Carcinog. 1998 Nov;23(3):175-84. PMID: 9833778.

" Not dangerous goods.

LKT V3278 Vitamin E Acetate 100 g 92.2 Vitamin E, antioxidant. DL-alpha-tocopherol acetate 58-95-7 ≥98% 472.74 C31H52O3 CC1=C2C(=C(C(=C1C)OC(=O)C)C)CCC(O2)(C)CCCC(C)CCCC(C)CCCC(C)C Ambient 4°C "Morani AS, Bodhankar SL. Early co-administration of vitamin E acetate and methylcobalamin improves thermal hyperalgesia and motor nerve conduction velocity following sciatic nerve crush injury in rats. Pharmacol Rep. 2010 Mar-Apr;62(2):405-9. PMID: 20508297.

 

Chandra AK, Ghosh R, Chatterjee A, et al. Amelioration of vanadium-induced testicular toxicity and adrenocortical hyperactivity by vitamin E acetate in rats. Mol Cell Biochem. 2007 Dec;306(1-2):189-200. PMID: 17668152.

 

Berton TR, Conti CJ, Mitchell DL, et al. The effect of vitamin E acetate on ultraviolet-induced mouse skin carcinogenesis. Mol Carcinog. 1998 Nov;23(3):175-84. PMID: 9833778.

" Not dangerous goods.

LKT Z4900 ZM-447439 Trihydrate 5 mg 121.4 AurKA/B inhibitor. 331771-20-1 ≥98% 567.63 C29H31N5O4 3H2O COC1=C(C=C2C(=C1)C(=NC=N2)NC3=CC=C(C=C3)NC(=O)C4=CC=CC=C4)OCCCN5CCOCC5 Ambient -20°C "Tavanti E, Sero V, Vella S, et al. Preclinical validation of Aurora kinases-targeting drugs in osteosarcoma. Br J Cancer. 2013 Nov 12;109(10):2607-18. PMID: 24129234.

 

Baldini E, Tuccilli C, Prinzi N, et al. The dual Aurora kinase inhibitor ZM447439 prevents anaplastic thyroid cancer cell growth and tumorigenicity. J Biol Regul Homeost Agents. 2013 Jul-Sep;27(3):705-15. PMID: 24152827.

 

Crispi S, Fagliarone C, Biroccio A, et al. Antiproliferative effect of Aurora kinase targeting in mesothelioma. Lung Cancer. 2010 Dec;70(3):271-9. PMID: 20371132.

" Not dangerous goods.

LKT Z4900 ZM-447439 Trihydrate 25 mg 467.1 AurKA/B inhibitor. 331771-20-1 ≥98% 567.63 C29H31N5O4 3H2O COC1=C(C=C2C(=C1)C(=NC=N2)NC3=CC=C(C=C3)NC(=O)C4=CC=CC=C4)OCCCN5CCOCC5 Ambient -20°C "Tavanti E, Sero V, Vella S, et al. Preclinical validation of Aurora kinases-targeting drugs in osteosarcoma. Br J Cancer. 2013 Nov 12;109(10):2607-18. PMID: 24129234.

 

Baldini E, Tuccilli C, Prinzi N, et al. The dual Aurora kinase inhibitor ZM447439 prevents anaplastic thyroid cancer cell growth and tumorigenicity. J Biol Regul Homeost Agents. 2013 Jul-Sep;27(3):705-15. PMID: 24152827.

 

Crispi S, Fagliarone C, Biroccio A, et al. Antiproliferative effect of Aurora kinase targeting in mesothelioma. Lung Cancer. 2010 Dec;70(3):271-9. PMID: 20371132.

" Not dangerous goods.

LKT X4400 XL-228 1 mg 84.9 Abl (T315I) inhibitor. 898280-07-4 ≥98% 437.54 C22H31N9O CC(C)C1=NOC(=C1)CNC2=NC(=CC(=N2)NC3=NNC(=C3)C4CC4)N5CCN(CC5)C Ambient -20°C Noronha G, Cao J, Chow CP, et al. Inhibitors of ABL and the ABL-T315I mutation. Curr Top Med Chem. 2008;8(10):905-21. PMID: 18673174.

LKT X4400 XL-228 5 mg 179.6 Abl (T315I) inhibitor. 898280-07-4 ≥98% 437.54 C22H31N9O CC(C)C1=NOC(=C1)CNC2=NC(=CC(=N2)NC3=NNC(=C3)C4CC4)N5CCN(CC5)C Ambient -20°C Noronha G, Cao J, Chow CP, et al. Inhibitors of ABL and the ABL-T315I mutation. Curr Top Med Chem. 2008;8(10):905-21. PMID: 18673174.

LKT X4400 XL-228 10 mg 288.8 Abl (T315I) inhibitor. 898280-07-4 ≥98% 437.54 C22H31N9O CC(C)C1=NOC(=C1)CNC2=NC(=CC(=N2)NC3=NNC(=C3)C4CC4)N5CCN(CC5)C Ambient -20°C Noronha G, Cao J, Chow CP, et al. Inhibitors of ABL and the ABL-T315I mutation. Curr Top Med Chem. 2008;8(10):905-21. PMID: 18673174.

LKT W9600 WZ-4002 5 mg 103.1 EGFR (T790M) inhibitor. 1213269-23-8 ≥98% 494.97 C25H27ClN6O3 CN1CCN(CC1)C2=CC(=C(C=C2)NC3=NC=C(C(=N3)OC4=CC=CC(=C4)NC(=O)C=C)Cl)OC Ambient -20°C "Nakagawa T, Takeuchi S, Yamada T, et al. Combined therapy with mutant-selective EGFR inhibitor and Met kinase inhibitor for overcoming erlotinib resistance in EGFR-mutant lung cancer. Mol Cancer Ther. 2012 Oct;11(10):2149-57. PMID: 22844075.

 

Sakuma Y, Yamazaki Y, Nakamura Y, et al. WZ4002, a third-generation EGFR inhibitor, can overcome anoikis resistance in EGFR-mutant lung adenocarcinomas more efficiently than Src inhibitors. Lab Invest. 2012 Mar;92(3):371-83. PMID: 22157722.

" Not dangerous goods.

LKT W9600 WZ-4002 25 mg 260.9 EGFR (T790M) inhibitor. 1213269-23-8 ≥98% 494.97 C25H27ClN6O3 CN1CCN(CC1)C2=CC(=C(C=C2)NC3=NC=C(C(=N3)OC4=CC=CC(=C4)NC(=O)C=C)Cl)OC Ambient -20°C "Nakagawa T, Takeuchi S, Yamada T, et al. Combined therapy with mutant-selective EGFR inhibitor and Met kinase inhibitor for overcoming erlotinib resistance in EGFR-mutant lung cancer. Mol Cancer Ther. 2012 Oct;11(10):2149-57. PMID: 22844075.

 

Sakuma Y, Yamazaki Y, Nakamura Y, et al. WZ4002, a third-generation EGFR inhibitor, can overcome anoikis resistance in EGFR-mutant lung adenocarcinomas more efficiently than Src inhibitors. Lab Invest. 2012 Mar;92(3):371-83. PMID: 22157722.

" Not dangerous goods.

LKT W9600 WZ-4002 100 mg 879.7 EGFR (T790M) inhibitor. 1213269-23-8 ≥98% 494.97 C25H27ClN6O3 CN1CCN(CC1)C2=CC(=C(C=C2)NC3=NC=C(C(=N3)OC4=CC=CC(=C4)NC(=O)C=C)Cl)OC Ambient -20°C "Nakagawa T, Takeuchi S, Yamada T, et al. Combined therapy with mutant-selective EGFR inhibitor and Met kinase inhibitor for overcoming erlotinib resistance in EGFR-mutant lung cancer. Mol Cancer Ther. 2012 Oct;11(10):2149-57. PMID: 22844075.

 

Sakuma Y, Yamazaki Y, Nakamura Y, et al. WZ4002, a third-generation EGFR inhibitor, can overcome anoikis resistance in EGFR-mutant lung adenocarcinomas more efficiently than Src inhibitors. Lab Invest. 2012 Mar;92(3):371-83. PMID: 22157722.

" Not dangerous goods.

LKT V9202 VX-702 5 mg 78.9 p38 MAPK inhibitor. VX702 479543-46-9 ≥98% 404.32 C19H12F4N4O2 C1=CC(=C(C(=C1)F)N(C2=NC(=C(C=C2)C(=O)N)C3=C(C=C(C=C3)F)F)C(=O)N)F Ambient -20°C "Skripchenko A, Awatefe H, Thompson-Montgomery D, et al. An inhibition of p38 mitogen activated protein kinase delays the platelet storage lesion. PLoS One. 2013 Aug 13;8(8):e70732. PMID: 23967093.

 

Ding C. Drug evaluation: VX-702, a MAP kinase inhibitor for rheumatoid arthritis and acute coronary syndrome. Curr Opin Investig Drugs. 2006 Nov;7(11):1020-5. PMID: 17117592.

 

Lee MR, Dominguez C. MAP kinase p38 inhibitors: clinical results and an intimate look at their interactions with p38alpha protein. Curr Med Chem. 2005;12(25):2979-94. PMID: 16378500.

" Not dangerous goods.

LKT V9202 VX-702 25 mg 200.2 p38 MAPK inhibitor. VX702 479543-46-9 ≥98% 404.32 C19H12F4N4O2 C1=CC(=C(C(=C1)F)N(C2=NC(=C(C=C2)C(=O)N)C3=C(C=C(C=C3)F)F)C(=O)N)F Ambient -20°C "Skripchenko A, Awatefe H, Thompson-Montgomery D, et al. An inhibition of p38 mitogen activated protein kinase delays the platelet storage lesion. PLoS One. 2013 Aug 13;8(8):e70732. PMID: 23967093.

 

Ding C. Drug evaluation: VX-702, a MAP kinase inhibitor for rheumatoid arthritis and acute coronary syndrome. Curr Opin Investig Drugs. 2006 Nov;7(11):1020-5. PMID: 17117592.

 

Lee MR, Dominguez C. MAP kinase p38 inhibitors: clinical results and an intimate look at their interactions with p38alpha protein. Curr Med Chem. 2005;12(25):2979-94. PMID: 16378500.

" Not dangerous goods.

LKT V9202 VX-702 100 mg 546 p38 MAPK inhibitor. VX702 479543-46-9 ≥98% 404.32 C19H12F4N4O2 C1=CC(=C(C(=C1)F)N(C2=NC(=C(C=C2)C(=O)N)C3=C(C=C(C=C3)F)F)C(=O)N)F Ambient -20°C "Skripchenko A, Awatefe H, Thompson-Montgomery D, et al. An inhibition of p38 mitogen activated protein kinase delays the platelet storage lesion. PLoS One. 2013 Aug 13;8(8):e70732. PMID: 23967093.

 

Ding C. Drug evaluation: VX-702, a MAP kinase inhibitor for rheumatoid arthritis and acute coronary syndrome. Curr Opin Investig Drugs. 2006 Nov;7(11):1020-5. PMID: 17117592.

 

Lee MR, Dominguez C. MAP kinase p38 inhibitors: clinical results and an intimate look at their interactions with p38alpha protein. Curr Med Chem. 2005;12(25):2979-94. PMID: 16378500.

" Not dangerous goods.

LKT V9201 VX-11e 1 mg 78.9 ERK2 inhibitor, potential AurKA, GSK3, CDK2, FLT3, ROCK1, JNK3 inhibitor. ERK 11e, TCS ERK 11e 896720-20-0 ≥98% 500.35 C24H20Cl2FN5O2 CC1=CN=C(N=C1C2=CNC(=C2)C(=O)NC(CO)C3=CC(=CC=C3)Cl)NC4=C(C=C(C=C4)F)Cl Ambient -20°C Aronov AM, Tang Q, Martinez-Botella G, et al. Structure-guided design of potent and selective pyrimidylpyrrole inhibitors of extracellular signal-regulated kinase (ERK) using conformational control. J Med Chem. 2009 Oct 22;52(20):6362-8. PMID: 19827834. Not dangerous goods.

LKT V9201 VX-11e 5 mg 157.7 ERK2 inhibitor, potential AurKA, GSK3, CDK2, FLT3, ROCK1, JNK3 inhibitor. ERK 11e, TCS ERK 11e 896720-20-0 ≥98% 500.35 C24H20Cl2FN5O2 CC1=CN=C(N=C1C2=CNC(=C2)C(=O)NC(CO)C3=CC(=CC=C3)Cl)NC4=C(C=C(C=C4)F)Cl Ambient -20°C Aronov AM, Tang Q, Martinez-Botella G, et al. Structure-guided design of potent and selective pyrimidylpyrrole inhibitors of extracellular signal-regulated kinase (ERK) using conformational control. J Med Chem. 2009 Oct 22;52(20):6362-8. PMID: 19827834. Not dangerous goods.

LKT V9201 VX-11e 10 mg 254.8 ERK2 inhibitor, potential AurKA, GSK3, CDK2, FLT3, ROCK1, JNK3 inhibitor. ERK 11e, TCS ERK 11e 896720-20-0 ≥98% 500.35 C24H20Cl2FN5O2 CC1=CN=C(N=C1C2=CNC(=C2)C(=O)NC(CO)C3=CC(=CC=C3)Cl)NC4=C(C=C(C=C4)F)Cl Ambient -20°C Aronov AM, Tang Q, Martinez-Botella G, et al. Structure-guided design of potent and selective pyrimidylpyrrole inhibitors of extracellular signal-regulated kinase (ERK) using conformational control. J Med Chem. 2009 Oct 22;52(20):6362-8. PMID: 19827834. Not dangerous goods.

LKT R1217 RDEA119 1 mg 78.9 MEK1/2 inhibitor. Refametinib, BAY 869766 923032-37-5 ≥98% 572.34 C19H20F3lN2O5S COC1=CC(=C(C(=C1NS(=O)(=O)C2(CC2)CC(CO)O)NC3=C(C=C(C=C3)I)F)F)F Ambient -20°C "Weekes CD, Von Hoff DD, Adjei AA, et al. Multicenter phase I trial of the mitogen-activated protein kinase 1/2 inhibitor BAY 86-9766 in patients with advanced cancer. Clin Cancer Res. 2013 Mar 1;19(5):1232-43. PMID: 23434733.

 

Liu D, Xing J, Trink B, et al. BRAF mutation-selective inhibition of thyroid cancer cells by the novel MEK inhibitor RDEA119 and genetic-potentiated synergism with the mTOR inhibitor temsirolimus. Int J Cancer. 2010 Dec 15;127(12):2965-73. PMID: 21351275.

 

Iverson C, Larson G, Lai C, et al. RDEA119/BAY 869766: a potent, selective, allosteric inhibitor of MEK1/2 for the treatment of cancer. Cancer Res. 2009 Sep 1;69(17):6839-47. PMID: 19706763.

" Not dangerous goods.

LKT R1217 RDEA119 5 mg 157.7 MEK1/2 inhibitor. Refametinib, BAY 869766 923032-37-5 ≥98% 572.34 C19H20F3lN2O5S COC1=CC(=C(C(=C1NS(=O)(=O)C2(CC2)CC(CO)O)NC3=C(C=C(C=C3)I)F)F)F Ambient -20°C "Weekes CD, Von Hoff DD, Adjei AA, et al. Multicenter phase I trial of the mitogen-activated protein kinase 1/2 inhibitor BAY 86-9766 in patients with advanced cancer. Clin Cancer Res. 2013 Mar 1;19(5):1232-43. PMID: 23434733.

 

Liu D, Xing J, Trink B, et al. BRAF mutation-selective inhibition of thyroid cancer cells by the novel MEK inhibitor RDEA119 and genetic-potentiated synergism with the mTOR inhibitor temsirolimus. Int J Cancer. 2010 Dec 15;127(12):2965-73. PMID: 21351275.

 

Iverson C, Larson G, Lai C, et al. RDEA119/BAY 869766: a potent, selective, allosteric inhibitor of MEK1/2 for the treatment of cancer. Cancer Res. 2009 Sep 1;69(17):6839-47. PMID: 19706763.

" Not dangerous goods.

LKT R1217 RDEA119 10 mg 254.8 MEK1/2 inhibitor. Refametinib, BAY 869766 923032-37-5 ≥98% 572.34 C19H20F3lN2O5S COC1=CC(=C(C(=C1NS(=O)(=O)C2(CC2)CC(CO)O)NC3=C(C=C(C=C3)I)F)F)F Ambient -20°C "Weekes CD, Von Hoff DD, Adjei AA, et al. Multicenter phase I trial of the mitogen-activated protein kinase 1/2 inhibitor BAY 86-9766 in patients with advanced cancer. Clin Cancer Res. 2013 Mar 1;19(5):1232-43. PMID: 23434733.

 

Liu D, Xing J, Trink B, et al. BRAF mutation-selective inhibition of thyroid cancer cells by the novel MEK inhibitor RDEA119 and genetic-potentiated synergism with the mTOR inhibitor temsirolimus. Int J Cancer. 2010 Dec 15;127(12):2965-73. PMID: 21351275.

 

Iverson C, Larson G, Lai C, et al. RDEA119/BAY 869766: a potent, selective, allosteric inhibitor of MEK1/2 for the treatment of cancer. Cancer Res. 2009 Sep 1;69(17):6839-47. PMID: 19706763.

" Not dangerous goods.

LKT P2002 PF-04691502 Dihydrate 1 mg 91 PI3K and mTOR inhibitor. 1013101-36-4 ≥98% 461.51 C22H27N5O4 2H2O CC1=C2C=C(C(=O)N(C2=NC(=N1)N)C3CCC(CC3)OCCO)C4=CN=C(C=C4)OC Ambient -20°C "Cirone P, Andresen CJ, Eswaraka JR, et al. Patient-derived xenografts reveal limits to PI3K/mTOR- and MEK-mediated inhibition of bladder cancer. Cancer Chemother Pharmacol. 2014 Mar;73(3):525-38. PMID: 24442130.

 

Wong CH, Loong HH, Hui CW, et al. Preclinical evaluation of the PI3K-mTOR dual inhibitor PF-04691502 as a novel therapeutic drug in nasopharyngeal carcinoma. Invest New Drugs. 2013 Dec;31(6):1399-408. PMID: 23975511.

 

Yuan J, Mehta PP, Yin MJ, et al. PF-04691502, a potent and selective oral inhibitor of PI3K and mTOR kinases with antitumor activity. Mol Cancer Ther. 2011 Nov;10(11):2189-99. PMID: 21750219.

" Not dangerous goods.

LKT P2002 PF-04691502 Dihydrate 5 mg 163.8 PI3K and mTOR inhibitor. 1013101-36-4 ≥98% 461.51 C22H27N5O4 2H2O CC1=C2C=C(C(=O)N(C2=NC(=N1)N)C3CCC(CC3)OCCO)C4=CN=C(C=C4)OC Ambient -20°C "Cirone P, Andresen CJ, Eswaraka JR, et al. Patient-derived xenografts reveal limits to PI3K/mTOR- and MEK-mediated inhibition of bladder cancer. Cancer Chemother Pharmacol. 2014 Mar;73(3):525-38. PMID: 24442130.

 

Wong CH, Loong HH, Hui CW, et al. Preclinical evaluation of the PI3K-mTOR dual inhibitor PF-04691502 as a novel therapeutic drug in nasopharyngeal carcinoma. Invest New Drugs. 2013 Dec;31(6):1399-408. PMID: 23975511.

 

Yuan J, Mehta PP, Yin MJ, et al. PF-04691502, a potent and selective oral inhibitor of PI3K and mTOR kinases with antitumor activity. Mol Cancer Ther. 2011 Nov;10(11):2189-99. PMID: 21750219.

" Not dangerous goods.

LKT P2002 PF-04691502 Dihydrate 10 mg 260.9 PI3K and mTOR inhibitor. 1013101-36-4 ≥98% 461.51 C22H27N5O4 2H2O CC1=C2C=C(C(=O)N(C2=NC(=N1)N)C3CCC(CC3)OCCO)C4=CN=C(C=C4)OC Ambient -20°C "Cirone P, Andresen CJ, Eswaraka JR, et al. Patient-derived xenografts reveal limits to PI3K/mTOR- and MEK-mediated inhibition of bladder cancer. Cancer Chemother Pharmacol. 2014 Mar;73(3):525-38. PMID: 24442130.

 

Wong CH, Loong HH, Hui CW, et al. Preclinical evaluation of the PI3K-mTOR dual inhibitor PF-04691502 as a novel therapeutic drug in nasopharyngeal carcinoma. Invest New Drugs. 2013 Dec;31(6):1399-408. PMID: 23975511.

 

Yuan J, Mehta PP, Yin MJ, et al. PF-04691502, a potent and selective oral inhibitor of PI3K and mTOR kinases with antitumor activity. Mol Cancer Ther. 2011 Nov;10(11):2189-99. PMID: 21750219.

" Not dangerous goods.

LKT M4652 MLN8237 1 mg 78.9 AurKA inhibitor. Alisertib 1028486-01-2 ≥98% 518.92 C27H20ClFN4O4 COC1=C(C(=CC=C1)F)C2=NCC3=CN=C(N=C3C4=C2C=C(C=C4)Cl)NC5=CC(=C(C=C5)C(=O)O)OC Ambient -20°C "Romain C, Paul P, Kim KW, et al. Targeting Aurora kinase-A downregulates cell proliferation and angiogenesis in neuroblastoma. J Pediatr Surg. 2014 Jan;49(1):159-65. PMID: 24439602.

 

Kelly KR, Shea TC, Goy A, et al. Phase I study of MLN8237-investigational Aurora A kinase inhibitor-in relapsed/refractory multiple myeloma, Non-Hodgkin lymphoma and chronic lymphocytic leukemia. Invest New Drugs. 2013 Dec 20. [Epub ahead of print]. PMID: 24352795.

 

Zhou N, Singh K, Mir MC, et al. The investigational Aurora kinase A inhibitor MLN8237 induces defects in cell viability and cell-cycle progression in malignant bladder cancer cells in vitro and in vivo. Clin Cancer Res. 2013 Apr 1;19(7):1717-28. PMID: 23403633.

" Not dangerous goods.

LKT M4652 MLN8237 5 mg 145.6 AurKA inhibitor. Alisertib 1028486-01-2 ≥98% 518.92 C27H20ClFN4O4 COC1=C(C(=CC=C1)F)C2=NCC3=CN=C(N=C3C4=C2C=C(C=C4)Cl)NC5=CC(=C(C=C5)C(=O)O)OC Ambient -20°C "Romain C, Paul P, Kim KW, et al. Targeting Aurora kinase-A downregulates cell proliferation and angiogenesis in neuroblastoma. J Pediatr Surg. 2014 Jan;49(1):159-65. PMID: 24439602.

 

Kelly KR, Shea TC, Goy A, et al. Phase I study of MLN8237-investigational Aurora A kinase inhibitor-in relapsed/refractory multiple myeloma, Non-Hodgkin lymphoma and chronic lymphocytic leukemia. Invest New Drugs. 2013 Dec 20. [Epub ahead of print]. PMID: 24352795.

 

Zhou N, Singh K, Mir MC, et al. The investigational Aurora kinase A inhibitor MLN8237 induces defects in cell viability and cell-cycle progression in malignant bladder cancer cells in vitro and in vivo. Clin Cancer Res. 2013 Apr 1;19(7):1717-28. PMID: 23403633.

" Not dangerous goods.

LKT M4652 MLN8237 10 mg 224.5 AurKA inhibitor. Alisertib 1028486-01-2 ≥98% 518.92 C27H20ClFN4O4 COC1=C(C(=CC=C1)F)C2=NCC3=CN=C(N=C3C4=C2C=C(C=C4)Cl)NC5=CC(=C(C=C5)C(=O)O)OC Ambient -20°C "Romain C, Paul P, Kim KW, et al. Targeting Aurora kinase-A downregulates cell proliferation and angiogenesis in neuroblastoma. J Pediatr Surg. 2014 Jan;49(1):159-65. PMID: 24439602.

 

Kelly KR, Shea TC, Goy A, et al. Phase I study of MLN8237-investigational Aurora A kinase inhibitor-in relapsed/refractory multiple myeloma, Non-Hodgkin lymphoma and chronic lymphocytic leukemia. Invest New Drugs. 2013 Dec 20. [Epub ahead of print]. PMID: 24352795.

 

Zhou N, Singh K, Mir MC, et al. The investigational Aurora kinase A inhibitor MLN8237 induces defects in cell viability and cell-cycle progression in malignant bladder cancer cells in vitro and in vivo. Clin Cancer Res. 2013 Apr 1;19(7):1717-28. PMID: 23403633.

" Not dangerous goods.

LKT G7440 GSK-1120212 5 mg 78.9 MEK1/2 inhibitor. Trametinib, JTP-74057 871700-17-3 ≥98% 615.39 C26H23FlN5O4 CC1=C2C(=C(N(C1=O)C)NC3=C(C=C(C=C3)I)F)C(=O)N(C(=O)N2C4=CC(=CC=C4)NC(=O)C)C5CC5 Ambient -20°C DMSO (10 mg/ml) "Hartsough EJ, Basile K, Aplin AE. Beneficial Effects of RAF Inhibitor in Mutant BRAF Splice Variant-expressing Melanoma. Mol Cancer Res. 2014 Feb 11. [Epub ahead of print]. PMID: 24520098.

 

Kim KB, Kefford R, Pavlick AC, et al. Phase II study of the MEK1/MEK2 inhibitor Trametinib in patients with metastatic BRAF-mutant cutaneous melanoma previously treated with or without a BRAF inhibitor. J Clin Oncol. 2013 Feb 1;31(4):482-9. PMID: 23248257.

 

Yamaguchi T, Kakefuda R, Tajima N, et al. Antitumor activities of JTP-74057 (GSK1120212), a novel MEK1/2 inhibitor, on colorectal cancer cell lines in vitro and in vivo. Int J Oncol. 2011 Jul;39(1):23-31. PMID: 21523318.

" Not dangerous goods.

LKT G7440 GSK-1120212 25 mg 145.6 MEK1/2 inhibitor. Trametinib, JTP-74057 871700-17-3 ≥98% 615.39 C26H23FlN5O4 CC1=C2C(=C(N(C1=O)C)NC3=C(C=C(C=C3)I)F)C(=O)N(C(=O)N2C4=CC(=CC=C4)NC(=O)C)C5CC5 Ambient -20°C DMSO (10 mg/ml) "Hartsough EJ, Basile K, Aplin AE. Beneficial Effects of RAF Inhibitor in Mutant BRAF Splice Variant-expressing Melanoma. Mol Cancer Res. 2014 Feb 11. [Epub ahead of print]. PMID: 24520098.

 

Kim KB, Kefford R, Pavlick AC, et al. Phase II study of the MEK1/MEK2 inhibitor Trametinib in patients with metastatic BRAF-mutant cutaneous melanoma previously treated with or without a BRAF inhibitor. J Clin Oncol. 2013 Feb 1;31(4):482-9. PMID: 23248257.

 

Yamaguchi T, Kakefuda R, Tajima N, et al. Antitumor activities of JTP-74057 (GSK1120212), a novel MEK1/2 inhibitor, on colorectal cancer cell lines in vitro and in vivo. Int J Oncol. 2011 Jul;39(1):23-31. PMID: 21523318.

" Not dangerous goods.

LKT G7440 GSK-1120212 100 mg 285.2 MEK1/2 inhibitor. Trametinib, JTP-74057 871700-17-3 ≥98% 615.39 C26H23FlN5O4 CC1=C2C(=C(N(C1=O)C)NC3=C(C=C(C=C3)I)F)C(=O)N(C(=O)N2C4=CC(=CC=C4)NC(=O)C)C5CC5 Ambient -20°C DMSO (10 mg/ml) "Hartsough EJ, Basile K, Aplin AE. Beneficial Effects of RAF Inhibitor in Mutant BRAF Splice Variant-expressing Melanoma. Mol Cancer Res. 2014 Feb 11. [Epub ahead of print]. PMID: 24520098.

 

Kim KB, Kefford R, Pavlick AC, et al. Phase II study of the MEK1/MEK2 inhibitor Trametinib in patients with metastatic BRAF-mutant cutaneous melanoma previously treated with or without a BRAF inhibitor. J Clin Oncol. 2013 Feb 1;31(4):482-9. PMID: 23248257.

 

Yamaguchi T, Kakefuda R, Tajima N, et al. Antitumor activities of JTP-74057 (GSK1120212), a novel MEK1/2 inhibitor, on colorectal cancer cell lines in vitro and in vivo. Int J Oncol. 2011 Jul;39(1):23-31. PMID: 21523318.

" Not dangerous goods.

LKT C9708 CYC-116 5 mg 78.9 AurKB/C inhibitor. 693228-63-6 ≥98% 368.46 C18H20N6OS CC1=C(SC(=N1)N)C2=NC(=NC=C2)NC3=CC=C(C=C3)N4CCOCC4 Ambient -20°C "Kamei H, Jackson RC, Zheleva D, et al. An integrated pharmacokinetic-pharmacodynamic model for an Aurora kinase inhibitor. J Pharmacokinet Pharmacodyn. 2010 Aug;37(4):407-34. PMID: 20694801.

 

Wang S, Midgley CA, Scaërou F, et al. Discovery of N-phenyl-4-(thiazol-5-yl)pyrimidin-2-amine aurora kinase inhibitors. J Med Chem. 2010 Jun 10;53(11):4367-78. PMID: 20462263.

" "UN number: 3077     Class: 9     Packing Group: III

Proper shipping name: Environmentally hazardous substance, solid, n.o.s. (CYC-116)"

LKT C9708 CYC-116 25 mg 260.9 AurKB/C inhibitor. 693228-63-6 ≥98% 368.46 C18H20N6OS CC1=C(SC(=N1)N)C2=NC(=NC=C2)NC3=CC=C(C=C3)N4CCOCC4 Ambient -20°C "Kamei H, Jackson RC, Zheleva D, et al. An integrated pharmacokinetic-pharmacodynamic model for an Aurora kinase inhibitor. J Pharmacokinet Pharmacodyn. 2010 Aug;37(4):407-34. PMID: 20694801.

 

Wang S, Midgley CA, Scaërou F, et al. Discovery of N-phenyl-4-(thiazol-5-yl)pyrimidin-2-amine aurora kinase inhibitors. J Med Chem. 2010 Jun 10;53(11):4367-78. PMID: 20462263.

" "UN number: 3077     Class: 9     Packing Group: III

Proper shipping name: Environmentally hazardous substance, solid, n.o.s. (CYC-116)"

LKT A9715 AZD-8330 1 mg 103.1 MEK 1/2 inhibitor. ARRY-704, ARRY-424704 869357-68-6 ≥98% 461.23 C16H17FlN3O4 CC1=CC(=C(N(C1=O)C)NC2=C(C=C(C=C2)I)F)C(=O)NOCCO Ambient -20°C "Cohen RB, Aamdal S, Nyakas M, et al. A phase I dose-finding, safety and tolerability study of AZD8330 in patients with advanced malignancies. Eur J Cancer. 2013 May;49(7):1521-9. PMID: 23433846.

 

Akinleye A, Furqan M, Mukhi N, et al. MEK and the inhibitors: from bench to bedside. J Hematol Oncol. 2013 Apr 12;6:27. PMID: 23587417.

" "UN number: 3077     Class: 9     Packing Group: III

Proper shipping name: Environmentally hazardous substance, solid, n.o.s. (AZD-8330)"

LKT A9715 AZD-8330 5 mg 260.9 MEK 1/2 inhibitor. ARRY-704, ARRY-424704 869357-68-6 ≥98% 461.23 C16H17FlN3O4 CC1=CC(=C(N(C1=O)C)NC2=C(C=C(C=C2)I)F)C(=O)NOCCO Ambient -20°C "Cohen RB, Aamdal S, Nyakas M, et al. A phase I dose-finding, safety and tolerability study of AZD8330 in patients with advanced malignancies. Eur J Cancer. 2013 May;49(7):1521-9. PMID: 23433846.

 

Akinleye A, Furqan M, Mukhi N, et al. MEK and the inhibitors: from bench to bedside. J Hematol Oncol. 2013 Apr 12;6:27. PMID: 23587417.

" "UN number: 3077     Class: 9     Packing Group: III

Proper shipping name: Environmentally hazardous substance, solid, n.o.s. (AZD-8330)"

LKT A9715 AZD-8330 10 mg 418.6 MEK 1/2 inhibitor. ARRY-704, ARRY-424704 869357-68-6 ≥98% 461.23 C16H17FlN3O4 CC1=CC(=C(N(C1=O)C)NC2=C(C=C(C=C2)I)F)C(=O)NOCCO Ambient -20°C "Cohen RB, Aamdal S, Nyakas M, et al. A phase I dose-finding, safety and tolerability study of AZD8330 in patients with advanced malignancies. Eur J Cancer. 2013 May;49(7):1521-9. PMID: 23433846.

 

Akinleye A, Furqan M, Mukhi N, et al. MEK and the inhibitors: from bench to bedside. J Hematol Oncol. 2013 Apr 12;6:27. PMID: 23587417.

" "UN number: 3077     Class: 9     Packing Group: III

Proper shipping name: Environmentally hazardous substance, solid, n.o.s. (AZD-8330)"

LKT A9714 AZD-1152-HQPA 1 mg 78.9 AurKA/B inhibitor. Barasertib; AZD1152 722544-51-6 ≥98% 507.56 C26H30FN7O3 CCN(CCCOC1=CC2=C(C=C1)C(=NC=N2)NC3=NNC(=C3)CC(=O)NC4=CC(=CC=C4)F)CCO Ambient -20°C "Hartsink-Segers SA, Zwaan CM, Exalto C, et al. Aurora kinases in childhood acute leukemia: the promise of aurora B as therapeutic target. Leukemia. 2013 Mar;27(3):560-8. PMID: 22940834.

 

Diaz RJ, Golbourn B, Shekarforoush M, et al. Aurora kinase B/C inhibition impairs malignant glioma growth in vivo. J Neurooncol. 2012 Jul;108(3):349-60. PMID: 22382783.

 

Boss DS, Witteveen PO, van der Sar J,et al. Clinical evaluation of AZD1152, an i.v. inhibitor of Aurora B kinase, in patients with solid malignant tumors. Ann Oncol. 2011 Feb;22(2):431-7. PMID: 20924078.

" N/A Not dangerous goods.

LKT A9714 AZD-1152-HQPA 5 mg 145.6 AurKA/B inhibitor. Barasertib; AZD1152 722544-51-6 ≥98% 507.56 C26H30FN7O3 CCN(CCCOC1=CC2=C(C=C1)C(=NC=N2)NC3=NNC(=C3)CC(=O)NC4=CC(=CC=C4)F)CCO Ambient -20°C "Hartsink-Segers SA, Zwaan CM, Exalto C, et al. Aurora kinases in childhood acute leukemia: the promise of aurora B as therapeutic target. Leukemia. 2013 Mar;27(3):560-8. PMID: 22940834.

 

Diaz RJ, Golbourn B, Shekarforoush M, et al. Aurora kinase B/C inhibition impairs malignant glioma growth in vivo. J Neurooncol. 2012 Jul;108(3):349-60. PMID: 22382783.

 

Boss DS, Witteveen PO, van der Sar J,et al. Clinical evaluation of AZD1152, an i.v. inhibitor of Aurora B kinase, in patients with solid malignant tumors. Ann Oncol. 2011 Feb;22(2):431-7. PMID: 20924078.

" N/A Not dangerous goods.

LKT A9714 AZD-1152-HQPA 10 mg 236.6 AurKA/B inhibitor. Barasertib; AZD1152 722544-51-6 ≥98% 507.56 C26H30FN7O3 CCN(CCCOC1=CC2=C(C=C1)C(=NC=N2)NC3=NNC(=C3)CC(=O)NC4=CC(=CC=C4)F)CCO Ambient -20°C "Hartsink-Segers SA, Zwaan CM, Exalto C, et al. Aurora kinases in childhood acute leukemia: the promise of aurora B as therapeutic target. Leukemia. 2013 Mar;27(3):560-8. PMID: 22940834.

 

Diaz RJ, Golbourn B, Shekarforoush M, et al. Aurora kinase B/C inhibition impairs malignant glioma growth in vivo. J Neurooncol. 2012 Jul;108(3):349-60. PMID: 22382783.

 

Boss DS, Witteveen PO, van der Sar J,et al. Clinical evaluation of AZD1152, an i.v. inhibitor of Aurora B kinase, in patients with solid malignant tumors. Ann Oncol. 2011 Feb;22(2):431-7. PMID: 20924078.

" N/A Not dangerous goods.

LKT A7203 AS-703026 5 mg 103.1 MEK1/2 inhibitor. MSC1936369B 1236699-92-5 ≥98% 431.2 C15H15FlN3O3 C1=CC(=C(C=C1I)F)NC2=C(C=CN=C2)C(=O)NCC(CO)O Ambient -20°C "Park SJ, Hong SW, Moon JH, et al. The MEK1/2 inhibitor AS703026 circumvents resistance to the BRAF inhibitor PLX4032 in human malignant melanoma cells. Am J Med Sci. 2013 Dec;346(6):494-8. PMID: 24051957.

 

Yoon J, Koo KH, Choi KY. MEK1/2 inhibitors AS703026 and AZD6244 may be potential therapies for KRAS mutated colorectal cancer that is resistant to EGFR monoclonal antibody therapy. Cancer Res. 2011 Jan 15;71(2):445-53. PMID: 21118963.

 

Kim K, Kong SY, Fulciniti M, et al. Blockade of the MEK/ERK signalling cascade by AS703026, a novel selective MEK1/2 inhibitor, induces pleiotropic anti-myeloma activity in vitro and in vivo. Br J Haematol. 2010 May;149(4):537-49. PMID: 20331454.

" Not dangerous goods.

LKT A7203 AS-703026 25 mg 194.1 MEK1/2 inhibitor. MSC1936369B 1236699-92-5 ≥98% 431.2 C15H15FlN3O3 C1=CC(=C(C=C1I)F)NC2=C(C=CN=C2)C(=O)NCC(CO)O Ambient -20°C "Park SJ, Hong SW, Moon JH, et al. The MEK1/2 inhibitor AS703026 circumvents resistance to the BRAF inhibitor PLX4032 in human malignant melanoma cells. Am J Med Sci. 2013 Dec;346(6):494-8. PMID: 24051957.

 

Yoon J, Koo KH, Choi KY. MEK1/2 inhibitors AS703026 and AZD6244 may be potential therapies for KRAS mutated colorectal cancer that is resistant to EGFR monoclonal antibody therapy. Cancer Res. 2011 Jan 15;71(2):445-53. PMID: 21118963.

 

Kim K, Kong SY, Fulciniti M, et al. Blockade of the MEK/ERK signalling cascade by AS703026, a novel selective MEK1/2 inhibitor, induces pleiotropic anti-myeloma activity in vitro and in vivo. Br J Haematol. 2010 May;149(4):537-49. PMID: 20331454.

" Not dangerous goods.

LKT H9863 Hyperforin Dicyclohexylammonium 500 µg 203.8 Stable salt form of hyperforin, a compound found in Hypericum perforatum. Hyperforin DCHA 238074-03-8 ≥97% 718.1 C35H52O4 C12H23N CC(C)C(=O)C12C(=O)C(=C(C(C1=O)(CC(C2(C)CCC=C(C)C)CC=C(C)C)CC=C(C)C)O)CC=C(C)C.C1CCC(CC1)NC2CCCCC2 Ambient -20°C "Liu JY, Liu Z, Wang DM, et al. Induction of apoptosis in K562 cells by dicyclohexylammonium salt of hyperforin through a mitochondrial-related pathway. Chem Biol Interact. 2011 Apr 25;190(2-3):91-101. PMID: 21376709. 

 

Sosa S, Pace R, Bornancin A, et al. Topical anti-inflammatory activity of extracts and compounds from Hypericum perforatum L. J Pharm Pharmacol. 2007 May;59(5):703-9. PMID: 17524236.

 

Gobbi M, Moia M, Funicello M, et al. In vitro effects of the dicyclohexylammonium salt of hyperforin on interleukin-6 release in different experimental models. Planta Med. 2004 Jul;70(7):680-2. PMID: 15303261.

 

Cervo L, Rozio M, Ekalle-Soppo CB, et al. Role of hyperforin in the antidepressant-like activity of Hypericum perforatum extracts. Psychopharmacology (Berl). 2002 Dec;164(4):423-8. PMID: 12457273. 

" "UN number: 1759     Class: 8     Packing Group: II

Proper shipping name: Corrosive solid, n.o.s. (Hyperforin dicyclohexylammonium)"

LKT H9863 Hyperforin Dicyclohexylammonium 1 mg 333.7 Stable salt form of hyperforin, a compound found in Hypericum perforatum. Hyperforin DCHA 238074-03-8 ≥97% 718.1 C35H52O4 C12H23N CC(C)C(=O)C12C(=O)C(=C(C(C1=O)(CC(C2(C)CCC=C(C)C)CC=C(C)C)CC=C(C)C)O)CC=C(C)C.C1CCC(CC1)NC2CCCCC2 Ambient -20°C "Liu JY, Liu Z, Wang DM, et al. Induction of apoptosis in K562 cells by dicyclohexylammonium salt of hyperforin through a mitochondrial-related pathway. Chem Biol Interact. 2011 Apr 25;190(2-3):91-101. PMID: 21376709. 

 

Sosa S, Pace R, Bornancin A, et al. Topical anti-inflammatory activity of extracts and compounds from Hypericum perforatum L. J Pharm Pharmacol. 2007 May;59(5):703-9. PMID: 17524236.

 

Gobbi M, Moia M, Funicello M, et al. In vitro effects of the dicyclohexylammonium salt of hyperforin on interleukin-6 release in different experimental models. Planta Med. 2004 Jul;70(7):680-2. PMID: 15303261.

 

Cervo L, Rozio M, Ekalle-Soppo CB, et al. Role of hyperforin in the antidepressant-like activity of Hypericum perforatum extracts. Psychopharmacology (Berl). 2002 Dec;164(4):423-8. PMID: 12457273. 

" "UN number: 1759     Class: 8     Packing Group: II

Proper shipping name: Corrosive solid, n.o.s. (Hyperforin dicyclohexylammonium)"

LKT I7258 Isoflurane 250 mg 54.6 "Ca2+ ATPase and ATP-sensitive K+ channel activator, GABA-A and GlyR potentiator, NMDA antagonist, L-type Ca2+, delayed rectifier K+, A-type K+ channel blocker.

" 26675-46-7 ≥98% 184.49 C3H2ClF5O C(C(F)(F)F)(OC(F)F)Cl Ambient Ambient "Shen X, Bhatt N, Xu J, et al. Effect of isoflurane on myocardial energetic and oxidative stress in cardiac muscle from zucker diabetic Fatty rat. J Pharmacol Exp Ther. 2014 Apr;349(1):21-8. PMID: 24431470.

 

Fanchaouy M, Cubano L, Maldonado H, et al. PKC independent inhibition of voltage gated calcium channels by volatile anesthetics in freshly isolated vascular myocytes from the aorta. Cell Calcium. 2013 Oct;54(4):257-65. PMID: 23948226.

 

Zhang L, Zhang J, Yang L, et al. Isoflurane and sevoflurane increase interleukin-6 levels through the nuclear factor-kappa B pathway in neuroglioma cells. Br J Anaesth. 2013 Jun;110 Suppl 1:i82-91. PMID: 23604542.

" "UN number: 3334     Class:  9     Packing Group: III

Proper shipping name:  Aviation regulated liquid, n.o.s. (Isoflurane)

Reportable Quantity (RQ):     Poison inhalation hazard:  No

"

LKT I7258 Isoflurane 1 g 151.7 "Ca2+ ATPase and ATP-sensitive K+ channel activator, GABA-A and GlyR potentiator, NMDA antagonist, L-type Ca2+, delayed rectifier K+, A-type K+ channel blocker.

" 26675-46-7 ≥98% 184.49 C3H2ClF5O C(C(F)(F)F)(OC(F)F)Cl Ambient Ambient "Shen X, Bhatt N, Xu J, et al. Effect of isoflurane on myocardial energetic and oxidative stress in cardiac muscle from zucker diabetic Fatty rat. J Pharmacol Exp Ther. 2014 Apr;349(1):21-8. PMID: 24431470.

 

Fanchaouy M, Cubano L, Maldonado H, et al. PKC independent inhibition of voltage gated calcium channels by volatile anesthetics in freshly isolated vascular myocytes from the aorta. Cell Calcium. 2013 Oct;54(4):257-65. PMID: 23948226.

 

Zhang L, Zhang J, Yang L, et al. Isoflurane and sevoflurane increase interleukin-6 levels through the nuclear factor-kappa B pathway in neuroglioma cells. Br J Anaesth. 2013 Jun;110 Suppl 1:i82-91. PMID: 23604542.

" "UN number: 3334     Class:  9     Packing Group: III

Proper shipping name:  Aviation regulated liquid, n.o.s. (Isoflurane)

Reportable Quantity (RQ):     Poison inhalation hazard:  No

"

LKT M1874 3-Methyladenine 25 mg 60.7 Nucleobase (adenine) analog; DNA polymerase inhibitor. 3-MA, NSC 66389, NSC66389 5142-23-4 ≥98% 149.15 C6H7N5 CN1C=NC(=C2C1=NC=N2)N Ambient Ambient "Ramírez C, Pham K, Franco MF, et al. Hydroquinone induces oxidative and mitochondrial damage to human retinal Müller cells (MIO-M1). Neurotoxicology. 2013 Dec;39:102-8. PMID: 23994029.

 

Kumar S, Guru SK, Pathania AS, et al. Autophagy triggered by magnolol derivative negatively regulates angiogenesis. Cell Death Dis. 2013 Oct 31;4:e889. PMID: 24176847.

 

Johnson RE, Yu SL, Prakash S, et al. A role for yeast and human translesion synthesis DNA polymerases in promoting replication through 3-methyl adenine. Mol Cell Biol. 2007 Oct;27(20):7198-205. PMID: 17698580.

" Not dangerous goods.

LKT M1874 3-Methyladenine 100 mg 163.8 Nucleobase (adenine) analog; DNA polymerase inhibitor. 3-MA, NSC 66389, NSC66389 5142-23-4 ≥98% 149.15 C6H7N5 CN1C=NC(=C2C1=NC=N2)N Ambient Ambient "Ramírez C, Pham K, Franco MF, et al. Hydroquinone induces oxidative and mitochondrial damage to human retinal Müller cells (MIO-M1). Neurotoxicology. 2013 Dec;39:102-8. PMID: 23994029.

 

Kumar S, Guru SK, Pathania AS, et al. Autophagy triggered by magnolol derivative negatively regulates angiogenesis. Cell Death Dis. 2013 Oct 31;4:e889. PMID: 24176847.

 

Johnson RE, Yu SL, Prakash S, et al. A role for yeast and human translesion synthesis DNA polymerases in promoting replication through 3-methyl adenine. Mol Cell Biol. 2007 Oct;27(20):7198-205. PMID: 17698580.

" Not dangerous goods.

LKT M1874 3-Methyladenine 500 mg 582.4 Nucleobase (adenine) analog; DNA polymerase inhibitor. 3-MA, NSC 66389, NSC66389 5142-23-4 ≥98% 149.15 C6H7N5 CN1C=NC(=C2C1=NC=N2)N Ambient Ambient "Ramírez C, Pham K, Franco MF, et al. Hydroquinone induces oxidative and mitochondrial damage to human retinal Müller cells (MIO-M1). Neurotoxicology. 2013 Dec;39:102-8. PMID: 23994029.

 

Kumar S, Guru SK, Pathania AS, et al. Autophagy triggered by magnolol derivative negatively regulates angiogenesis. Cell Death Dis. 2013 Oct 31;4:e889. PMID: 24176847.

 

Johnson RE, Yu SL, Prakash S, et al. A role for yeast and human translesion synthesis DNA polymerases in promoting replication through 3-methyl adenine. Mol Cell Biol. 2007 Oct;27(20):7198-205. PMID: 17698580.

" Not dangerous goods.

LKT C2802 CH5132799 1 mg 103.1 p110α PI3K inhibitor. 1007207-67-1 ≥98% 377.42 C15H19N7O3S CS(=O)(=O)N1CCC2=C(N=C(N=C21)N3CCOCC3)C4=CN=C(N=C4)N Ambient -20°C "Tanaka H, Yoshida M, Tanimura H, et al. The selective class I PI3K inhibitor CH5132799 targets human cancers harboring oncogenic PIK3CA mutations. Clin Cancer Res. 2011 May 15;17(10):3272-81. PMID: 21558396.

 

Ohwada J, Ebiike H, Kawada H, et al. Discovery and biological activity of a novel class I PI3K inhibitor, CH5132799. Bioorg Med Chem Lett. 2011 Mar 15;21(6):1767-72. PMID: 21316229.

" Not dangerous goods.

LKT C2802 CH5132799 5 mg 333.7 p110α PI3K inhibitor. 1007207-67-1 ≥98% 377.42 C15H19N7O3S CS(=O)(=O)N1CCC2=C(N=C(N=C21)N3CCOCC3)C4=CN=C(N=C4)N Ambient -20°C "Tanaka H, Yoshida M, Tanimura H, et al. The selective class I PI3K inhibitor CH5132799 targets human cancers harboring oncogenic PIK3CA mutations. Clin Cancer Res. 2011 May 15;17(10):3272-81. PMID: 21558396.

 

Ohwada J, Ebiike H, Kawada H, et al. Discovery and biological activity of a novel class I PI3K inhibitor, CH5132799. Bioorg Med Chem Lett. 2011 Mar 15;21(6):1767-72. PMID: 21316229.

" Not dangerous goods.

LKT C2802 CH5132799 25 mg 1031.4 p110α PI3K inhibitor. 1007207-67-1 ≥98% 377.42 C15H19N7O3S CS(=O)(=O)N1CCC2=C(N=C(N=C21)N3CCOCC3)C4=CN=C(N=C4)N Ambient -20°C "Tanaka H, Yoshida M, Tanimura H, et al. The selective class I PI3K inhibitor CH5132799 targets human cancers harboring oncogenic PIK3CA mutations. Clin Cancer Res. 2011 May 15;17(10):3272-81. PMID: 21558396.

 

Ohwada J, Ebiike H, Kawada H, et al. Discovery and biological activity of a novel class I PI3K inhibitor, CH5132799. Bioorg Med Chem Lett. 2011 Mar 15;21(6):1767-72. PMID: 21316229.

" Not dangerous goods.

LKT C8112 CUDC-907 1 mg 103.1 PI3K and HDAC inhibitor. 1339928-25-4 ≥98% 508.55 C23H24N8O4S CN(CC1=CC2=C(S1)C(=NC(=N2)C3=CN=C(C=C3)OC)N4CCOCC4)C5=NC=C(C=N5)C(=O)NO Ambient -20°C Qian C, Lai CJ, Bao R, et al. Cancer network disruption by a single molecule inhibitor targeting both histone deacetylase activity and phosphatidylinositol 3-kinase signaling. Clin Cancer Res. 2012 Aug 1;18(15):4104-13. PMID: 22693356. Not dangerous goods.

LKT C8112 CUDC-907 5 mg 333.7 PI3K and HDAC inhibitor. 1339928-25-4 ≥98% 508.55 C23H24N8O4S CN(CC1=CC2=C(S1)C(=NC(=N2)C3=CN=C(C=C3)OC)N4CCOCC4)C5=NC=C(C=N5)C(=O)NO Ambient -20°C Qian C, Lai CJ, Bao R, et al. Cancer network disruption by a single molecule inhibitor targeting both histone deacetylase activity and phosphatidylinositol 3-kinase signaling. Clin Cancer Res. 2012 Aug 1;18(15):4104-13. PMID: 22693356. Not dangerous goods.

LKT C8112 CUDC-907 25 mg 1031.4 PI3K and HDAC inhibitor. 1339928-25-4 ≥98% 508.55 C23H24N8O4S CN(CC1=CC2=C(S1)C(=NC(=N2)C3=CN=C(C=C3)OC)N4CCOCC4)C5=NC=C(C=N5)C(=O)NO Ambient -20°C Qian C, Lai CJ, Bao R, et al. Cancer network disruption by a single molecule inhibitor targeting both histone deacetylase activity and phosphatidylinositol 3-kinase signaling. Clin Cancer Res. 2012 Aug 1;18(15):4104-13. PMID: 22693356. Not dangerous goods.

LKT P1969 Perifosine 5 mg 121.4 Alkylphospholipid analog; Akt inhibitor. 157716-52-4 ≥98% 461.66 C25H52NO4P CCCCCCCCCCCCCCCCCCOP(=O)([O-])OC1CC[N+](CC1)(C)C Ambient -20°C "Gradziel CS, Wang Y, Stec B, et al. Cytotoxic amphiphiles and phosphoinositides bind to two discrete sites on the Akt1 PH domain. Biochemistry. 2014 Jan 28;53(3):462-72. PMID: 24383815.

 

Shen J, Liang L, Wang C. Perifosine inhibits lipopolysaccharide (LPS)-induced tumor necrosis factor (TNF)-α production via regulation multiple signaling pathways: new implication for Kawasaki disease (KD) treatment. Biochem Biophys Res Commun. 2013 Jul 26;437(2):250-5. PMID: 23806687.

 

Richardson PG, Eng C, Kolesar J, et al. Perifosine, an oral, anti-cancer agent and inhibitor of the Akt pathway: mechanistic actions, pharmacodynamics, pharmacokinetics, and clinical activity. Expert Opin Drug Metab Toxicol. 2012 May;8(5):623-33. PMID: 22512706.

 

Fei HR, Chen G, Wang JM, et al. Perifosine induces cell cycle arrest and apoptosis in human hepatocellular carcinoma cell lines by blockade of Akt phosphorylation. Cytotechnology. 2010 Oct;62(5):449-60. PMID: 20842425.

" Not dangerous goods.

LKT P1969 Perifosine 10 mg 182 Alkylphospholipid analog; Akt inhibitor. 157716-52-4 ≥98% 461.66 C25H52NO4P CCCCCCCCCCCCCCCCCCOP(=O)([O-])OC1CC[N+](CC1)(C)C Ambient -20°C "Gradziel CS, Wang Y, Stec B, et al. Cytotoxic amphiphiles and phosphoinositides bind to two discrete sites on the Akt1 PH domain. Biochemistry. 2014 Jan 28;53(3):462-72. PMID: 24383815.

 

Shen J, Liang L, Wang C. Perifosine inhibits lipopolysaccharide (LPS)-induced tumor necrosis factor (TNF)-α production via regulation multiple signaling pathways: new implication for Kawasaki disease (KD) treatment. Biochem Biophys Res Commun. 2013 Jul 26;437(2):250-5. PMID: 23806687.

 

Richardson PG, Eng C, Kolesar J, et al. Perifosine, an oral, anti-cancer agent and inhibitor of the Akt pathway: mechanistic actions, pharmacodynamics, pharmacokinetics, and clinical activity. Expert Opin Drug Metab Toxicol. 2012 May;8(5):623-33. PMID: 22512706.

 

Fei HR, Chen G, Wang JM, et al. Perifosine induces cell cycle arrest and apoptosis in human hepatocellular carcinoma cell lines by blockade of Akt phosphorylation. Cytotechnology. 2010 Oct;62(5):449-60. PMID: 20842425.

" Not dangerous goods.

LKT P1969 Perifosine 25 mg 418.6 Alkylphospholipid analog; Akt inhibitor. 157716-52-4 ≥98% 461.66 C25H52NO4P CCCCCCCCCCCCCCCCCCOP(=O)([O-])OC1CC[N+](CC1)(C)C Ambient -20°C "Gradziel CS, Wang Y, Stec B, et al. Cytotoxic amphiphiles and phosphoinositides bind to two discrete sites on the Akt1 PH domain. Biochemistry. 2014 Jan 28;53(3):462-72. PMID: 24383815.

 

Shen J, Liang L, Wang C. Perifosine inhibits lipopolysaccharide (LPS)-induced tumor necrosis factor (TNF)-α production via regulation multiple signaling pathways: new implication for Kawasaki disease (KD) treatment. Biochem Biophys Res Commun. 2013 Jul 26;437(2):250-5. PMID: 23806687.

 

Richardson PG, Eng C, Kolesar J, et al. Perifosine, an oral, anti-cancer agent and inhibitor of the Akt pathway: mechanistic actions, pharmacodynamics, pharmacokinetics, and clinical activity. Expert Opin Drug Metab Toxicol. 2012 May;8(5):623-33. PMID: 22512706.

 

Fei HR, Chen G, Wang JM, et al. Perifosine induces cell cycle arrest and apoptosis in human hepatocellular carcinoma cell lines by blockade of Akt phosphorylation. Cytotechnology. 2010 Oct;62(5):449-60. PMID: 20842425.

" Not dangerous goods.

LKT V7200 VS-5584 5 mg 182 PI3K inhibitor. 1246560-33-7 ≥98% 354.41 C17H22N8O CC1=NC2=C(N=C(N=C2N1C(C)C)N3CCOCC3)C4=CN=C(N=C4)N Ambient -20°C Hart S, Novotny-Diermayr V, Goh KC, et al. VS-5584, a novel and highly selective PI3K/mTOR kinase inhibitor for the treatment of cancer. Mol Cancer Ther. 2013 Feb;12(2):151-61. PMID: 23270925. Not dangerous goods.

LKT V7200 VS-5584 10 mg 333.7 PI3K inhibitor. 1246560-33-7 ≥98% 354.41 C17H22N8O CC1=NC2=C(N=C(N=C2N1C(C)C)N3CCOCC3)C4=CN=C(N=C4)N Ambient -20°C Hart S, Novotny-Diermayr V, Goh KC, et al. VS-5584, a novel and highly selective PI3K/mTOR kinase inhibitor for the treatment of cancer. Mol Cancer Ther. 2013 Feb;12(2):151-61. PMID: 23270925. Not dangerous goods.

LKT V7200 VS-5584 25 mg 728.1 PI3K inhibitor. 1246560-33-7 ≥98% 354.41 C17H22N8O CC1=NC2=C(N=C(N=C2N1C(C)C)N3CCOCC3)C4=CN=C(N=C4)N Ambient -20°C Hart S, Novotny-Diermayr V, Goh KC, et al. VS-5584, a novel and highly selective PI3K/mTOR kinase inhibitor for the treatment of cancer. Mol Cancer Ther. 2013 Feb;12(2):151-61. PMID: 23270925. Not dangerous goods.

LKT T1979 Tetrahydrocoptisine 1 mg 42.4 Alkaloid compound originally found in Corydalis; AChE inhibitor. Stylopine 4312-32-7 ≥98% 323.34 C19H17NO4 C1CN2CC3=C(CC2C4=CC5=C(C=C41)OCO5)C=CC6=C3OCO6 Ambient 4°C "Li W, Huang H, Zhang Y, et al. Anti-inflammatory effect of tetrahydrocoptisine from Corydalis impatiens is a function of possible inhibition of TNF-α, IL-6 and NO production in lipopolysaccharide-stimulated peritoneal macrophages through inhibiting NF-κB activation and MAPK pathway. Eur J Pharmacol. 2013 Sep 5;715(1-3):62-71. PMID: 23810685.

 

Li W, Huang H, Niu X, et al. Protective effect of tetrahydrocoptisine against ethanol-induced gastric ulcer in mice. Toxicol Appl Pharmacol. 2013 Oct 1;272(1):21-9. PMID: 23769714.

 

Wangchuk P, Keller PA, Pyne SG, et al. Phytochemical and biological activity studies of the Bhutanese medicinal plant Corydalis crispa. Nat Prod Commun. 2012 May;7(5):575-80. PMID: 22799079.

 

Satou T, Koga M, Matsuhashi R, et al. Assay of nematocidal activity of isoquinoline alkaloids using third-stage larvae of Strongyloides ratti and S. venezuelensis. Vet Parasitol. 2002 Mar 1;104(2):131-8. PMID: 11809332.

" Not dangerous goods.

LKT T1979 Tetrahydrocoptisine 5 mg 121.4 Alkaloid compound originally found in Corydalis; AChE inhibitor. Stylopine 4312-32-7 ≥98% 323.34 C19H17NO4 C1CN2CC3=C(CC2C4=CC5=C(C=C41)OCO5)C=CC6=C3OCO6 Ambient 4°C "Li W, Huang H, Zhang Y, et al. Anti-inflammatory effect of tetrahydrocoptisine from Corydalis impatiens is a function of possible inhibition of TNF-α, IL-6 and NO production in lipopolysaccharide-stimulated peritoneal macrophages through inhibiting NF-κB activation and MAPK pathway. Eur J Pharmacol. 2013 Sep 5;715(1-3):62-71. PMID: 23810685.

 

Li W, Huang H, Niu X, et al. Protective effect of tetrahydrocoptisine against ethanol-induced gastric ulcer in mice. Toxicol Appl Pharmacol. 2013 Oct 1;272(1):21-9. PMID: 23769714.

 

Wangchuk P, Keller PA, Pyne SG, et al. Phytochemical and biological activity studies of the Bhutanese medicinal plant Corydalis crispa. Nat Prod Commun. 2012 May;7(5):575-80. PMID: 22799079.

 

Satou T, Koga M, Matsuhashi R, et al. Assay of nematocidal activity of isoquinoline alkaloids using third-stage larvae of Strongyloides ratti and S. venezuelensis. Vet Parasitol. 2002 Mar 1;104(2):131-8. PMID: 11809332.

" Not dangerous goods.

LKT P3018 Phellodendrine 1 mg 60.7 Quaternary base alkaloid found in Phellodendron. 6873-13-8 ≥98% 342.41 C20H24NO4 C[N+]12CCC3=CC(=C(C=C3C1CC4=CC(=C(C=C4C2)OC)O)O)OC Ambient 4°C "Mori H, Fuchigami M, Inoue N, et al. Principle of the bark of Phellodendron amurense to suppress the cellular immune response: effect of phellodendrine on cellular and humoral immune responses. Planta Med. 1995 Feb;61(1):45-9. PMID: 7700991.

 

Hattori T, Furuta K, Hayashi K, et al. Studies on the antinephritic effects of plant components (6): antinephritic effects and mechanisms of phellodendrine (OB-5) on crescentic-type anti-GBM nephritis in rats (2). Jpn J Pharmacol. 1992 Nov;60(3):187-95. PMID: 1491511.

" Not dangerous goods.

LKT P3018 Phellodendrine 5 mg 242.7 Quaternary base alkaloid found in Phellodendron. 6873-13-8 ≥98% 342.41 C20H24NO4 C[N+]12CCC3=CC(=C(C=C3C1CC4=CC(=C(C=C4C2)OC)O)O)OC Ambient 4°C "Mori H, Fuchigami M, Inoue N, et al. Principle of the bark of Phellodendron amurense to suppress the cellular immune response: effect of phellodendrine on cellular and humoral immune responses. Planta Med. 1995 Feb;61(1):45-9. PMID: 7700991.

 

Hattori T, Furuta K, Hayashi K, et al. Studies on the antinephritic effects of plant components (6): antinephritic effects and mechanisms of phellodendrine (OB-5) on crescentic-type anti-GBM nephritis in rats (2). Jpn J Pharmacol. 1992 Nov;60(3):187-95. PMID: 1491511.

" Not dangerous goods.

LKT J0379 Jatrorrhizine Chloride 1 mg 58.2 Alkaloid compound originally found in Corydalis and Coptydis; AChE inhibitor. 6681-15-8 ≥95% 373.83 C20H20NO4Cl COC1=C(C2=C[N+]3=C(C=C2C=C1)C4=CC(=C(C=C4CC3)O)OC)OC.[Cl-] Ambient 4°C "Liu R, Cao Z, Pan Y, et al. Jatrorrhizine hydrochloride inhibits the proliferation and neovascularization of C8161 metastatic melanoma cells. Anticancer Drugs. 2013 Aug;24(7):667-76. PMID: 23695011.

 

Malebo HM, Wenzler T, Cal M, et al. Anti-protozoal activity of aporphine and protoberberine alkaloids from Annickia kummeriae (Engl. & Diels) Setten & Maas (Annonaceae). BMC Complement Altern Med. 2013 Feb 27;13:48. PMID: 23445637.

 

Luo T, Jiang W, Kong Y, et al. The protective effects of jatrorrhizine on β-amyloid (25-35)-induced neurotoxicity in rat cortical neurons. CNS Neurol Disord Drug Targets. 2012 Dec;11(8):1030-7. PMID: 23244426.

 

Zhang B, Cao A, Zhou J, et al. Effect of jatrorrhizine on delayed gastrointestinal transit in rat postoperative ileus. J Pharm Pharmacol. 2012 Mar;64(3):413-9. PMID: 22309273.

 

Luo T, Zhang H, Zhang WW, et al. Neuroprotective effect of Jatrorrhizine on hydrogen peroxide-induced cell injury and its potential mechanisms in PC12 cells. Neurosci Lett. 2011 Jul 12;498(3):227-31. PMID: 21605627.

 

Xiao HT, Peng J, Liang Y, et al. Acetylcholinesterase inhibitors from Corydalis yanhusuo. Nat Prod Res. 2011 Sep;25(15):1418-22. PMID: 20234973.

"

LKT J0379 Jatrorrhizine Chloride 5 mg 216 Alkaloid compound originally found in Corydalis and Coptydis; AChE inhibitor. 6681-15-8 ≥95% 373.83 C20H20NO4Cl COC1=C(C2=C[N+]3=C(C=C2C=C1)C4=CC(=C(C=C4CC3)O)OC)OC.[Cl-] Ambient 4°C "Liu R, Cao Z, Pan Y, et al. Jatrorrhizine hydrochloride inhibits the proliferation and neovascularization of C8161 metastatic melanoma cells. Anticancer Drugs. 2013 Aug;24(7):667-76. PMID: 23695011.

 

Malebo HM, Wenzler T, Cal M, et al. Anti-protozoal activity of aporphine and protoberberine alkaloids from Annickia kummeriae (Engl. & Diels) Setten & Maas (Annonaceae). BMC Complement Altern Med. 2013 Feb 27;13:48. PMID: 23445637.

 

Luo T, Jiang W, Kong Y, et al. The protective effects of jatrorrhizine on β-amyloid (25-35)-induced neurotoxicity in rat cortical neurons. CNS Neurol Disord Drug Targets. 2012 Dec;11(8):1030-7. PMID: 23244426.

 

Zhang B, Cao A, Zhou J, et al. Effect of jatrorrhizine on delayed gastrointestinal transit in rat postoperative ileus. J Pharm Pharmacol. 2012 Mar;64(3):413-9. PMID: 22309273.

 

Luo T, Zhang H, Zhang WW, et al. Neuroprotective effect of Jatrorrhizine on hydrogen peroxide-induced cell injury and its potential mechanisms in PC12 cells. Neurosci Lett. 2011 Jul 12;498(3):227-31. PMID: 21605627.

 

Xiao HT, Peng J, Liang Y, et al. Acetylcholinesterase inhibitors from Corydalis yanhusuo. Nat Prod Res. 2011 Sep;25(15):1418-22. PMID: 20234973.

"

LKT J0378 Jatrorrhizine 1 mg 58.2 Alkaloid compound originally found in Corydalis and Coptydis; AChE inhibitor. 3621-38-3 ≥98% 338.38 C20H20NO4 COC1=C(C2=C[N+]3=C(C=C2C=C1)C4=CC(=C(C=C4CC3)O)OC)OC Ambient 4°C "Liu R, Cao Z, Pan Y, et al. Jatrorrhizine hydrochloride inhibits the proliferation and neovascularization of C8161 metastatic melanoma cells. Anticancer Drugs. 2013 Aug;24(7):667-76. PMID: 23695011.

 

Malebo HM, Wenzler T, Cal M, et al. Anti-protozoal activity of aporphine and protoberberine alkaloids from Annickia kummeriae (Engl. & Diels) Setten & Maas (Annonaceae). BMC Complement Altern Med. 2013 Feb 27;13:48. PMID: 23445637.

 

Luo T, Jiang W, Kong Y, et al. The protective effects of jatrorrhizine on β-amyloid (25-35)-induced neurotoxicity in rat cortical neurons. CNS Neurol Disord Drug Targets. 2012 Dec;11(8):1030-7. PMID: 23244426.

 

Zhang B, Cao A, Zhou J, et al. Effect of jatrorrhizine on delayed gastrointestinal transit in rat postoperative ileus. J Pharm Pharmacol. 2012 Mar;64(3):413-9. PMID: 22309273.

 

Luo T, Zhang H, Zhang WW, et al. Neuroprotective effect of Jatrorrhizine on hydrogen peroxide-induced cell injury and its potential mechanisms in PC12 cells. Neurosci Lett. 2011 Jul 12;498(3):227-31. PMID: 21605627.

 

Xiao HT, Peng J, Liang Y, et al. Acetylcholinesterase inhibitors from Corydalis yanhusuo. Nat Prod Res. 2011 Sep;25(15):1418-22. PMID: 20234973.

" Not dangerous goods.

LKT J0378 Jatrorrhizine 5 mg 216 Alkaloid compound originally found in Corydalis and Coptydis; AChE inhibitor. 3621-38-3 ≥98% 338.38 C20H20NO4 COC1=C(C2=C[N+]3=C(C=C2C=C1)C4=CC(=C(C=C4CC3)O)OC)OC Ambient 4°C "Liu R, Cao Z, Pan Y, et al. Jatrorrhizine hydrochloride inhibits the proliferation and neovascularization of C8161 metastatic melanoma cells. Anticancer Drugs. 2013 Aug;24(7):667-76. PMID: 23695011.

 

Malebo HM, Wenzler T, Cal M, et al. Anti-protozoal activity of aporphine and protoberberine alkaloids from Annickia kummeriae (Engl. & Diels) Setten & Maas (Annonaceae). BMC Complement Altern Med. 2013 Feb 27;13:48. PMID: 23445637.

 

Luo T, Jiang W, Kong Y, et al. The protective effects of jatrorrhizine on β-amyloid (25-35)-induced neurotoxicity in rat cortical neurons. CNS Neurol Disord Drug Targets. 2012 Dec;11(8):1030-7. PMID: 23244426.

 

Zhang B, Cao A, Zhou J, et al. Effect of jatrorrhizine on delayed gastrointestinal transit in rat postoperative ileus. J Pharm Pharmacol. 2012 Mar;64(3):413-9. PMID: 22309273.

 

Luo T, Zhang H, Zhang WW, et al. Neuroprotective effect of Jatrorrhizine on hydrogen peroxide-induced cell injury and its potential mechanisms in PC12 cells. Neurosci Lett. 2011 Jul 12;498(3):227-31. PMID: 21605627.

 

Xiao HT, Peng J, Liang Y, et al. Acetylcholinesterase inhibitors from Corydalis yanhusuo. Nat Prod Res. 2011 Sep;25(15):1418-22. PMID: 20234973.

" Not dangerous goods.

LKT D1631 Dehydrocorydaline 1 mg 84.9 Alkaloid compound originally found in Corydalis; AChE inhibitor. 30045-16-0 ≥95% 366.43 C22H24NO4 CC1=C2C=CC(=C(C2=C[N+]3=C1C4=CC(=C(C=C4CC3)OC)OC)OC)OC Ambient 4°C "Xu Z, Chen X, Fu S, et al. Dehydrocorydaline inhibits breast cancer cells proliferation by inducing apoptosis in MCF-7 cells. Am J Chin Med. 2012;40(1):177-85. Erratum in: Am J Chin Med. 2012;40(6):1323. PMID: 22298457.

 

Ishiguro K, Ando T, Maeda O, et al. Dehydrocorydaline inhibits elevated mitochondrial membrane potential in lipopolysaccharide-stimulated macrophages. Int Immunopharmacol. 2011 Sep;11(9):1362-7. PMID: 21575743.

 

Xiao HT, Peng J, Liang Y, et al. Acetylcholinesterase inhibitors from Corydalis yanhusuo. Nat Prod Res. 2011 Sep;25(15):1418-22. PMID: 20234973.

 

Matsuda H, Tokuoka K, Wu J, et al. Inhibitory effects of dehydrocorydaline isolated from Corydalis Tuber against type I-IV allergic models. Biol Pharm Bull. 1997 Apr;20(4):431-4. PMID: 9145224.

" Not dangerous goods.

LKT D1631 Dehydrocorydaline 5 mg 333.7 Alkaloid compound originally found in Corydalis; AChE inhibitor. 30045-16-0 ≥95% 366.43 C22H24NO4 CC1=C2C=CC(=C(C2=C[N+]3=C1C4=CC(=C(C=C4CC3)OC)OC)OC)OC Ambient 4°C "Xu Z, Chen X, Fu S, et al. Dehydrocorydaline inhibits breast cancer cells proliferation by inducing apoptosis in MCF-7 cells. Am J Chin Med. 2012;40(1):177-85. Erratum in: Am J Chin Med. 2012;40(6):1323. PMID: 22298457.

 

Ishiguro K, Ando T, Maeda O, et al. Dehydrocorydaline inhibits elevated mitochondrial membrane potential in lipopolysaccharide-stimulated macrophages. Int Immunopharmacol. 2011 Sep;11(9):1362-7. PMID: 21575743.

 

Xiao HT, Peng J, Liang Y, et al. Acetylcholinesterase inhibitors from Corydalis yanhusuo. Nat Prod Res. 2011 Sep;25(15):1418-22. PMID: 20234973.

 

Matsuda H, Tokuoka K, Wu J, et al. Inhibitory effects of dehydrocorydaline isolated from Corydalis Tuber against type I-IV allergic models. Biol Pharm Bull. 1997 Apr;20(4):431-4. PMID: 9145224.

" Not dangerous goods.

LKT C5972 Corynoline 1 mg 42.4 Alkaloid compound originally found in Corydalis; AChE inhibitor. 18797-79-0 ≥98% 367.4 C21H21NO5 CC12C(CC3=CC4=C(C=C3C1N(CC5=C2C=CC6=C5OCO6)C)OCO4)O Ambient 4°C "Choi SU, Baek NI, Kim SH, et al. Cytotoxic isoquinoline alkaloids from the aerial parts of Corydalis incisa. Arch Pharm Res. 2007 Feb;30(2):151-4. PMID: 17366734.

 

Kim DK. Inhibitory effect of corynoline isolated from the aerial parts of Corydalis incisa on the acetylcholinesterase. Arch Pharm Res. 2002 Dec;25(6):817-9. PMID: 12510831.

" Not dangerous goods.

LKT C5972 Corynoline 5 mg 145.6 Alkaloid compound originally found in Corydalis; AChE inhibitor. 18797-79-0 ≥98% 367.4 C21H21NO5 CC12C(CC3=CC4=C(C=C3C1N(CC5=C2C=CC6=C5OCO6)C)OCO4)O Ambient 4°C "Choi SU, Baek NI, Kim SH, et al. Cytotoxic isoquinoline alkaloids from the aerial parts of Corydalis incisa. Arch Pharm Res. 2007 Feb;30(2):151-4. PMID: 17366734.

 

Kim DK. Inhibitory effect of corynoline isolated from the aerial parts of Corydalis incisa on the acetylcholinesterase. Arch Pharm Res. 2002 Dec;25(6):817-9. PMID: 12510831.

" Not dangerous goods.

LKT C5970 Corydaline 1 mg 103.1 Alkaloid compound found in Corydalis. 518-69-4 ≥95% 369.45 C22H27NO4 CC1C2C3=CC(=C(C=C3CCN2CC4=C1C=CC(=C4OC)OC)OC)OC Ambient 4°C "Lee TH, Son M, Kim SY. Effects of corydaline from Corydalis tuber on gastric motor function in an animal model. Biol Pharm Bull. 2010;33(6):958-62. PMID: 20522959.

 

Wang C, Wang S, Fan G, et al. Screening of antinociceptive components in Corydalis yanhusuo W.T. Wang by comprehensive two-dimensional liquid chromatography/tandem mass spectrometry. Anal Bioanal Chem. 2010 Mar;396(5):1731-40. PMID: 20101504.

 

Saito SY, Tanaka M, Matsunaga K, et al. The combination of rat mast cell and rabbit aortic smooth muscle is the simple bioassay for the screening of anti-allergic ingredient from methanolic extract of Corydalis tuber. Biol Pharm Bull. 2004 Aug;27(8):1270-4. PMID: 15305035.

 

Satou T, Koga M, Matsuhashi R, et al. Assay of nematocidal activity of isoquinoline alkaloids using third-stage larvae of Strongyloides ratti and S. venezuelensis. Vet Parasitol. 2002 Mar 1;104(2):131-8. PMID: 1180933.

" Not dangerous goods.

LKT C5970 Corydaline 5 mg 410.1 Alkaloid compound found in Corydalis. 518-69-4 ≥95% 369.45 C22H27NO4 CC1C2C3=CC(=C(C=C3CCN2CC4=C1C=CC(=C4OC)OC)OC)OC Ambient 4°C "Lee TH, Son M, Kim SY. Effects of corydaline from Corydalis tuber on gastric motor function in an animal model. Biol Pharm Bull. 2010;33(6):958-62. PMID: 20522959.

 

Wang C, Wang S, Fan G, et al. Screening of antinociceptive components in Corydalis yanhusuo W.T. Wang by comprehensive two-dimensional liquid chromatography/tandem mass spectrometry. Anal Bioanal Chem. 2010 Mar;396(5):1731-40. PMID: 20101504.

 

Saito SY, Tanaka M, Matsunaga K, et al. The combination of rat mast cell and rabbit aortic smooth muscle is the simple bioassay for the screening of anti-allergic ingredient from methanolic extract of Corydalis tuber. Biol Pharm Bull. 2004 Aug;27(8):1270-4. PMID: 15305035.

 

Satou T, Koga M, Matsuhashi R, et al. Assay of nematocidal activity of isoquinoline alkaloids using third-stage larvae of Strongyloides ratti and S. venezuelensis. Vet Parasitol. 2002 Mar 1;104(2):131-8. PMID: 1180933.

" Not dangerous goods.

LKT A4002 AK-7 5 mg 82.4 SIRT2 inhibitor. AK7 420831-40-9 ≥98% 437.35 C19H21BrN2O3S C1CCCN(CC1)S(=O)(=O)C2=CC=CC(=C2)C(=O)NC3=CC(=CC=C3)Br Ambient -20°C Chopra V, Quinti L, Kim J, et al. The sirtuin 2 inhibitor AK-7 is neuroprotective in Huntington's disease mouse models. Cell Rep. 2012 Dec 27;2(6):1492-7. PMID: 23200855. Not dangerous goods.

LKT A4002 AK-7 25 mg 333.7 SIRT2 inhibitor. AK7 420831-40-9 ≥98% 437.35 C19H21BrN2O3S C1CCCN(CC1)S(=O)(=O)C2=CC=CC(=C2)C(=O)NC3=CC(=CC=C3)Br Ambient -20°C Chopra V, Quinti L, Kim J, et al. The sirtuin 2 inhibitor AK-7 is neuroprotective in Huntington's disease mouse models. Cell Rep. 2012 Dec 27;2(6):1492-7. PMID: 23200855. Not dangerous goods.

LKT S6247 Splitomicin 5 mg 66.8 SIRT1/2 inhibitor. 5690-03-9 ≥98% 198.22 C13H10O2 C1CC(=O)OC2=C1C3=CC=CC=C3C=C2 Ambient 4°C "Hori YS, Kuno A, Hosoda R, et al. Regulation of FOXOs and p53 by SIRT1 modulators under oxidative stress. PLoS One. 2013 Sep 11;8(9):e73875. PMID: 24040102.

 

Bonezzi K, Belotti D, North BJ, et al. Inhibition of SIRT2 potentiates the anti-motility activity of taxanes: implications for antineoplastic combination therapies. Neoplasia. 2012 Sep;14(9):846-54. PMID: 23019416.

 

Liu FC, Day YJ, Liou JT, et al. Splitomicin inhibits fMLP-induced superoxide anion production in human neutrophils by activate cAMP/PKA signaling inhibition of ERK pathway. Eur J Pharmacol. 2012 Aug 5;688(1-3):68-75. PMID: 22634165.

 

Liu FC, Liao CH, Chang YW, et al. Splitomicin suppresses human platelet aggregation via inhibition of cyclic AMP phosphodiesterase and intracellular Ca++ release. Thromb Res. 2009 Jun;124(2):199-207. PMID: 19327818.

 

Kuhn AN, van Santen MA, Schwienhorst A, et al. Stalling of spliceosome assembly at distinct stages by small-molecule inhibitors of protein acetylation and deacetylation. RNA. 2009 Jan;15(1):153-75. PMID: 19029308.

" Not dangerous goods.

LKT S6247 Splitomicin 10 mg 109.2 SIRT1/2 inhibitor. 5690-03-9 ≥98% 198.22 C13H10O2 C1CC(=O)OC2=C1C3=CC=CC=C3C=C2 Ambient 4°C "Hori YS, Kuno A, Hosoda R, et al. Regulation of FOXOs and p53 by SIRT1 modulators under oxidative stress. PLoS One. 2013 Sep 11;8(9):e73875. PMID: 24040102.

 

Bonezzi K, Belotti D, North BJ, et al. Inhibition of SIRT2 potentiates the anti-motility activity of taxanes: implications for antineoplastic combination therapies. Neoplasia. 2012 Sep;14(9):846-54. PMID: 23019416.

 

Liu FC, Day YJ, Liou JT, et al. Splitomicin inhibits fMLP-induced superoxide anion production in human neutrophils by activate cAMP/PKA signaling inhibition of ERK pathway. Eur J Pharmacol. 2012 Aug 5;688(1-3):68-75. PMID: 22634165.

 

Liu FC, Liao CH, Chang YW, et al. Splitomicin suppresses human platelet aggregation via inhibition of cyclic AMP phosphodiesterase and intracellular Ca++ release. Thromb Res. 2009 Jun;124(2):199-207. PMID: 19327818.

 

Kuhn AN, van Santen MA, Schwienhorst A, et al. Stalling of spliceosome assembly at distinct stages by small-molecule inhibitors of protein acetylation and deacetylation. RNA. 2009 Jan;15(1):153-75. PMID: 19029308.

" Not dangerous goods.

LKT S6247 Splitomicin 25 mg 224.5 SIRT1/2 inhibitor. 5690-03-9 ≥98% 198.22 C13H10O2 C1CC(=O)OC2=C1C3=CC=CC=C3C=C2 Ambient 4°C "Hori YS, Kuno A, Hosoda R, et al. Regulation of FOXOs and p53 by SIRT1 modulators under oxidative stress. PLoS One. 2013 Sep 11;8(9):e73875. PMID: 24040102.

 

Bonezzi K, Belotti D, North BJ, et al. Inhibition of SIRT2 potentiates the anti-motility activity of taxanes: implications for antineoplastic combination therapies. Neoplasia. 2012 Sep;14(9):846-54. PMID: 23019416.

 

Liu FC, Day YJ, Liou JT, et al. Splitomicin inhibits fMLP-induced superoxide anion production in human neutrophils by activate cAMP/PKA signaling inhibition of ERK pathway. Eur J Pharmacol. 2012 Aug 5;688(1-3):68-75. PMID: 22634165.

 

Liu FC, Liao CH, Chang YW, et al. Splitomicin suppresses human platelet aggregation via inhibition of cyclic AMP phosphodiesterase and intracellular Ca++ release. Thromb Res. 2009 Jun;124(2):199-207. PMID: 19327818.

 

Kuhn AN, van Santen MA, Schwienhorst A, et al. Stalling of spliceosome assembly at distinct stages by small-molecule inhibitors of protein acetylation and deacetylation. RNA. 2009 Jan;15(1):153-75. PMID: 19029308.

" Not dangerous goods.

LKT A4000 AK-1 5 mg 91 SIRT2 inhibitor. SIRT2 inhibitor II 330461-64-8 ≥98% 403.45 C19H21N3O5S C1CCCN(CC1)S(=O)(=O)C2=CC=CC(=C2)C(=O)NC3=CC(=CC=C3)[N+](=O)[O-] Ambient -20°C "Cheon MG, Kim W, Choi M, et al. AK-1, a specific SIRT2 inhibitor, induces cell cycle arrest by downregulating Snail in HCT116 human colon carcinoma cells. Cancer Lett. 2015 Jan 28;356(2 Pt B):637-45. PMID: 25312940.

 

Spires-Jones TL, Fox LM, Rozkalne A, et al. Inhibition of Sirtuin 2 with Sulfobenzoic Acid Derivative AK1 is Non-Toxic and Potentially Neuroprotective in a Mouse Model of Frontotemporal Dementia. Front Pharmacol. 2012 Mar 12;3:42. PMID: 22416232." Not dangerous goods.

LKT A4000 AK-1 10 mg 145.6 SIRT2 inhibitor. SIRT2 inhibitor II 330461-64-8 ≥98% 403.45 C19H21N3O5S C1CCCN(CC1)S(=O)(=O)C2=CC=CC(=C2)C(=O)NC3=CC(=CC=C3)[N+](=O)[O-] Ambient -20°C "Cheon MG, Kim W, Choi M, et al. AK-1, a specific SIRT2 inhibitor, induces cell cycle arrest by downregulating Snail in HCT116 human colon carcinoma cells. Cancer Lett. 2015 Jan 28;356(2 Pt B):637-45. PMID: 25312940.

 

Spires-Jones TL, Fox LM, Rozkalne A, et al. Inhibition of Sirtuin 2 with Sulfobenzoic Acid Derivative AK1 is Non-Toxic and Potentially Neuroprotective in a Mouse Model of Frontotemporal Dementia. Front Pharmacol. 2012 Mar 12;3:42. PMID: 22416232." Not dangerous goods.

LKT A4000 AK-1 25 mg 273 SIRT2 inhibitor. SIRT2 inhibitor II 330461-64-8 ≥98% 403.45 C19H21N3O5S C1CCCN(CC1)S(=O)(=O)C2=CC=CC(=C2)C(=O)NC3=CC(=CC=C3)[N+](=O)[O-] Ambient -20°C "Cheon MG, Kim W, Choi M, et al. AK-1, a specific SIRT2 inhibitor, induces cell cycle arrest by downregulating Snail in HCT116 human colon carcinoma cells. Cancer Lett. 2015 Jan 28;356(2 Pt B):637-45. PMID: 25312940.

 

Spires-Jones TL, Fox LM, Rozkalne A, et al. Inhibition of Sirtuin 2 with Sulfobenzoic Acid Derivative AK1 is Non-Toxic and Potentially Neuroprotective in a Mouse Model of Frontotemporal Dementia. Front Pharmacol. 2012 Mar 12;3:42. PMID: 22416232." Not dangerous goods.

LKT E9201 EX-527 5 mg 91 SIRT1 inhibitor. Selisistat 49843-98-3 ≥98% 248.71 C13H13ClN2O C1CC(C2=C(C1)C3=C(N2)C=CC(=C3)Cl)C(=O)N Ambient -20°C "Akimova T, Xiao H, Liu Y, et al. Targeting sirtuin-1 alleviates experimental autoimmune colitis by induction of Foxp3+ T-regulatory cells. Mucosal Immunol. 2014 Feb 19. [Epub ahead of print]. PMID: 24549276.

 

Gertz M, Fischer F, Nguyen GT, et al. Ex-527 inhibits Sirtuins by exploiting their unique NAD+-dependent deacetylation mechanism. Proc Natl Acad Sci U S A. 2013 Jul 23;110(30):E2772-81. PMID: 23840057.

 

Zhou X, Fan LX, Sweeney WE Jr, et al. Sirtuin 1 inhibition delays cyst formation in autosomal-dominant polycystic kidney disease. J Clin Invest. 2013 Jul 1;123(7):3084-98. PMID: 23778143.

 

Beier UH, Wang L, Bhatti TR, et al. Sirtuin-1 targeting promotes Foxp3+ T-regulatory cell function and prolongs allograft survival. Mol Cell Biol. 2011 Mar;31(5):1022-9. PMID: 21199917.

" Not dangerous goods.

LKT E9201 EX-527 25 mg 357.9 SIRT1 inhibitor. Selisistat 49843-98-3 ≥98% 248.71 C13H13ClN2O C1CC(C2=C(C1)C3=C(N2)C=CC(=C3)Cl)C(=O)N Ambient -20°C "Akimova T, Xiao H, Liu Y, et al. Targeting sirtuin-1 alleviates experimental autoimmune colitis by induction of Foxp3+ T-regulatory cells. Mucosal Immunol. 2014 Feb 19. [Epub ahead of print]. PMID: 24549276.

 

Gertz M, Fischer F, Nguyen GT, et al. Ex-527 inhibits Sirtuins by exploiting their unique NAD+-dependent deacetylation mechanism. Proc Natl Acad Sci U S A. 2013 Jul 23;110(30):E2772-81. PMID: 23840057.

 

Zhou X, Fan LX, Sweeney WE Jr, et al. Sirtuin 1 inhibition delays cyst formation in autosomal-dominant polycystic kidney disease. J Clin Invest. 2013 Jul 1;123(7):3084-98. PMID: 23778143.

 

Beier UH, Wang L, Bhatti TR, et al. Sirtuin-1 targeting promotes Foxp3+ T-regulatory cell function and prolongs allograft survival. Mol Cell Biol. 2011 Mar;31(5):1022-9. PMID: 21199917.

" Not dangerous goods.

LKT B8277 Butein 5 mg 176 Flavonoid found in Rhus verniciflua and Butea monosperma. 487-52-5 ≥98% 272.25 C15H12O5 C1=CC(=C(C=C1C=CC(=O)C2=C(C=C(C=C2)O)O)O)O Ambient -20°C "Li Y, Ma C, Qian M, et al. Butein induces cell apoptosis and inhibition of cyclooxygenase 2 expression in A549 lung cancer cells. Mol Med Rep. 2014 Feb;9(2):763-7. PMID: 24337484.

 

Chung CH, Chang CH, Chen SS, et al. Butein Inhibits Angiogenesis of Human Endothelial Progenitor Cells via the Translation Dependent Signaling Pathway. Evid Based Complement Alternat Med. 2013;2013:943187. PMID: 23840271.

 

Lu M, Wang S, Han X, et al. Butein inhibits NF-κB activation and reduces infiltration of inflammatory cells and apoptosis after spinal cord injury in rats. Neurosci Lett. 2013 May 10;542:87-91. PMID: 23499960.

 

Szuster-Ciesielska A, Mizerska-Dudka M, Daniluk J, et al. Butein inhibits ethanol-induced activation of liver stellate cells through TGF-β, NFκB, p38, and JNK signaling pathways and inhibition of oxidative stress. J Gastroenterol. 2013 Feb;48(2):222-37. PMID: 22722906.

 

Sehrawat A, Kumar V. Butein imparts free radical scavenging, anti-oxidative and proapoptotic properties in the flower extracts of Butea monosperma. Biocell. 2012 Aug;36(2):63-71. PMID: 23185781.

 

Khan N, Adhami VM, Afaq F, et al. Butein induces apoptosis and inhibits prostate tumor growth in vitro and in vivo. Antioxid Redox Signal. 2012 Jun 1;16(11):1195-204. PMID: 22114764.

" Not dangerous goods.

LKT B8277 Butein 10 mg 240.2 Flavonoid found in Rhus verniciflua and Butea monosperma. 487-52-5 ≥98% 272.25 C15H12O5 C1=CC(=C(C=C1C=CC(=O)C2=C(C=C(C=C2)O)O)O)O Ambient -20°C "Li Y, Ma C, Qian M, et al. Butein induces cell apoptosis and inhibition of cyclooxygenase 2 expression in A549 lung cancer cells. Mol Med Rep. 2014 Feb;9(2):763-7. PMID: 24337484.

 

Chung CH, Chang CH, Chen SS, et al. Butein Inhibits Angiogenesis of Human Endothelial Progenitor Cells via the Translation Dependent Signaling Pathway. Evid Based Complement Alternat Med. 2013;2013:943187. PMID: 23840271.

 

Lu M, Wang S, Han X, et al. Butein inhibits NF-κB activation and reduces infiltration of inflammatory cells and apoptosis after spinal cord injury in rats. Neurosci Lett. 2013 May 10;542:87-91. PMID: 23499960.

 

Szuster-Ciesielska A, Mizerska-Dudka M, Daniluk J, et al. Butein inhibits ethanol-induced activation of liver stellate cells through TGF-β, NFκB, p38, and JNK signaling pathways and inhibition of oxidative stress. J Gastroenterol. 2013 Feb;48(2):222-37. PMID: 22722906.

 

Sehrawat A, Kumar V. Butein imparts free radical scavenging, anti-oxidative and proapoptotic properties in the flower extracts of Butea monosperma. Biocell. 2012 Aug;36(2):63-71. PMID: 23185781.

 

Khan N, Adhami VM, Afaq F, et al. Butein induces apoptosis and inhibits prostate tumor growth in vitro and in vivo. Antioxid Redox Signal. 2012 Jun 1;16(11):1195-204. PMID: 22114764.

" Not dangerous goods.

LKT B8277 Butein 25 mg 546 Flavonoid found in Rhus verniciflua and Butea monosperma. 487-52-5 ≥98% 272.25 C15H12O5 C1=CC(=C(C=C1C=CC(=O)C2=C(C=C(C=C2)O)O)O)O Ambient -20°C "Li Y, Ma C, Qian M, et al. Butein induces cell apoptosis and inhibition of cyclooxygenase 2 expression in A549 lung cancer cells. Mol Med Rep. 2014 Feb;9(2):763-7. PMID: 24337484.

 

Chung CH, Chang CH, Chen SS, et al. Butein Inhibits Angiogenesis of Human Endothelial Progenitor Cells via the Translation Dependent Signaling Pathway. Evid Based Complement Alternat Med. 2013;2013:943187. PMID: 23840271.

 

Lu M, Wang S, Han X, et al. Butein inhibits NF-κB activation and reduces infiltration of inflammatory cells and apoptosis after spinal cord injury in rats. Neurosci Lett. 2013 May 10;542:87-91. PMID: 23499960.

 

Szuster-Ciesielska A, Mizerska-Dudka M, Daniluk J, et al. Butein inhibits ethanol-induced activation of liver stellate cells through TGF-β, NFκB, p38, and JNK signaling pathways and inhibition of oxidative stress. J Gastroenterol. 2013 Feb;48(2):222-37. PMID: 22722906.

 

Sehrawat A, Kumar V. Butein imparts free radical scavenging, anti-oxidative and proapoptotic properties in the flower extracts of Butea monosperma. Biocell. 2012 Aug;36(2):63-71. PMID: 23185781.

 

Khan N, Adhami VM, Afaq F, et al. Butein induces apoptosis and inhibits prostate tumor growth in vitro and in vivo. Antioxid Redox Signal. 2012 Jun 1;16(11):1195-204. PMID: 22114764.

" Not dangerous goods.

LKT S7868 SRT1720 Hydrochloride 5 mg 182 SIRT 1 activator, SIRT3 inhibitor. STR-1720 HCl salt 1001645-58-4 ≥98% 506.02 C25H23N7OS HCl C1CN(CCN1)CC2=CSC3=NC(=CN23)C4=CC=CC=C4NC(=O)C5=NC6=CC=CC=C6N=C5.Cl Ambient -20°C "Mitchell SJ, Martin-Montalvo A, Mercken EM, et al. The SIRT1 Activator SRT1720 Extends Lifespan and Improves Health of Mice Fed a Standard Diet. Cell Rep. 2014 Mar 13;6(5):836-43. PMID: 24582957.

 

Cao L, Liu C, Wang F, et al. SIRT1 negatively regulates amyloid-beta-induced inflammation via the NF-κB pathway. Braz J Med Biol Res. 2013 Aug;46(8):659-69. PMID: 24036938.

 

Nguyen GT, Schaefer S, Gertz M, et al. Structures of human sirtuin 3 complexes with ADP-ribose and with carba-NAD+ and SRT1720: binding details and inhibition mechanism. Acta Crystallogr D Biol Crystallogr. 2013 Aug;69(Pt 8):1423-32. PMID: 23897466.

 

Fan H, Yang HC, You L, et al. The histone deacetylase, SIRT1, contributes to the resistance of young mice to ischemia/reperfusion-induced acute kidney injury. Kidney Int. 2013 Mar;83(3):404-13. PMID: 23302720.

 

Suzuki K, Hayashi R, Ichikawa T, et al. SRT1720, a SIRT1 activator, promotes tumor cell migration, and lung metastasis of breast cancer in mice. Oncol Rep. 2012 Jun;27(6):1726-32. PMID: 22470132.

" Not dangerous goods.

LKT S7868 SRT1720 Hydrochloride 25 mg 582.4 SIRT 1 activator, SIRT3 inhibitor. STR-1720 HCl salt 1001645-58-4 ≥98% 506.02 C25H23N7OS HCl C1CN(CCN1)CC2=CSC3=NC(=CN23)C4=CC=CC=C4NC(=O)C5=NC6=CC=CC=C6N=C5.Cl Ambient -20°C "Mitchell SJ, Martin-Montalvo A, Mercken EM, et al. The SIRT1 Activator SRT1720 Extends Lifespan and Improves Health of Mice Fed a Standard Diet. Cell Rep. 2014 Mar 13;6(5):836-43. PMID: 24582957.

 

Cao L, Liu C, Wang F, et al. SIRT1 negatively regulates amyloid-beta-induced inflammation via the NF-κB pathway. Braz J Med Biol Res. 2013 Aug;46(8):659-69. PMID: 24036938.

 

Nguyen GT, Schaefer S, Gertz M, et al. Structures of human sirtuin 3 complexes with ADP-ribose and with carba-NAD+ and SRT1720: binding details and inhibition mechanism. Acta Crystallogr D Biol Crystallogr. 2013 Aug;69(Pt 8):1423-32. PMID: 23897466.

 

Fan H, Yang HC, You L, et al. The histone deacetylase, SIRT1, contributes to the resistance of young mice to ischemia/reperfusion-induced acute kidney injury. Kidney Int. 2013 Mar;83(3):404-13. PMID: 23302720.

 

Suzuki K, Hayashi R, Ichikawa T, et al. SRT1720, a SIRT1 activator, promotes tumor cell migration, and lung metastasis of breast cancer in mice. Oncol Rep. 2012 Jun;27(6):1726-32. PMID: 22470132.

" Not dangerous goods.

LKT S7868 SRT1720 Hydrochloride 100 mg 1759.4 SIRT 1 activator, SIRT3 inhibitor. STR-1720 HCl salt 1001645-58-4 ≥98% 506.02 C25H23N7OS HCl C1CN(CCN1)CC2=CSC3=NC(=CN23)C4=CC=CC=C4NC(=O)C5=NC6=CC=CC=C6N=C5.Cl Ambient -20°C "Mitchell SJ, Martin-Montalvo A, Mercken EM, et al. The SIRT1 Activator SRT1720 Extends Lifespan and Improves Health of Mice Fed a Standard Diet. Cell Rep. 2014 Mar 13;6(5):836-43. PMID: 24582957.

 

Cao L, Liu C, Wang F, et al. SIRT1 negatively regulates amyloid-beta-induced inflammation via the NF-κB pathway. Braz J Med Biol Res. 2013 Aug;46(8):659-69. PMID: 24036938.

 

Nguyen GT, Schaefer S, Gertz M, et al. Structures of human sirtuin 3 complexes with ADP-ribose and with carba-NAD+ and SRT1720: binding details and inhibition mechanism. Acta Crystallogr D Biol Crystallogr. 2013 Aug;69(Pt 8):1423-32. PMID: 23897466.

 

Fan H, Yang HC, You L, et al. The histone deacetylase, SIRT1, contributes to the resistance of young mice to ischemia/reperfusion-induced acute kidney injury. Kidney Int. 2013 Mar;83(3):404-13. PMID: 23302720.

 

Suzuki K, Hayashi R, Ichikawa T, et al. SRT1720, a SIRT1 activator, promotes tumor cell migration, and lung metastasis of breast cancer in mice. Oncol Rep. 2012 Jun;27(6):1726-32. PMID: 22470132.

" Not dangerous goods.

LKT T1853 Tenovin-6 1 mg 151.7 SIRT1/2 inhibitor, indirect p53 activator. 1011557-82-6 ≥98% 454.63 C25H34N4O2S CC(C)(C)C1=CC=C(C=C1)C(=O)NC(=S)NC2=CC=C(C=C2)NC(=O)CCCCN(C)C Ambient -20°C "Ueno T, Endo S, Saito R, et al. The sirtuin inhibitor tenovin-6 upregulates death receptor 5 and enhances cytotoxic effects of 5-Fluorouracil and oxaliplatin in colon cancer cells. Oncol Res. 2014;21(3):155-64. PMID: 24512730.

 

MacCallum SF, Groves MJ, James J, et al. Dysregulation of autophagy in chronic lymphocytic leukemia with the small-molecule Sirtuin inhibitor Tenovin-6. Sci Rep. 2013;3:1275. PMID: 23429453.

 

Lain S, Hollick JJ, Campbell J, et al. Discovery, in vivo activity, and mechanism of action of a small-molecule p53 activator. Cancer Cell. 2008 May;13(5):454-63. PMID: 18455128.

 

Brooks CL, Gu W. p53 Activation: a case against Sir. Cancer Cell. 2008 May;13(5):377-8. PMID: 18455119.

" Not dangerous goods.

LKT T1853 Tenovin-6 5 mg 606.7 SIRT1/2 inhibitor, indirect p53 activator. 1011557-82-6 ≥98% 454.63 C25H34N4O2S CC(C)(C)C1=CC=C(C=C1)C(=O)NC(=S)NC2=CC=C(C=C2)NC(=O)CCCCN(C)C Ambient -20°C "Ueno T, Endo S, Saito R, et al. The sirtuin inhibitor tenovin-6 upregulates death receptor 5 and enhances cytotoxic effects of 5-Fluorouracil and oxaliplatin in colon cancer cells. Oncol Res. 2014;21(3):155-64. PMID: 24512730.

 

MacCallum SF, Groves MJ, James J, et al. Dysregulation of autophagy in chronic lymphocytic leukemia with the small-molecule Sirtuin inhibitor Tenovin-6. Sci Rep. 2013;3:1275. PMID: 23429453.

 

Lain S, Hollick JJ, Campbell J, et al. Discovery, in vivo activity, and mechanism of action of a small-molecule p53 activator. Cancer Cell. 2008 May;13(5):454-63. PMID: 18455128.

 

Brooks CL, Gu W. p53 Activation: a case against Sir. Cancer Cell. 2008 May;13(5):377-8. PMID: 18455119.

" Not dangerous goods.

LKT T1853 Tenovin-6 25 mg 2123.4 SIRT1/2 inhibitor, indirect p53 activator. 1011557-82-6 ≥98% 454.63 C25H34N4O2S CC(C)(C)C1=CC=C(C=C1)C(=O)NC(=S)NC2=CC=C(C=C2)NC(=O)CCCCN(C)C Ambient -20°C "Ueno T, Endo S, Saito R, et al. The sirtuin inhibitor tenovin-6 upregulates death receptor 5 and enhances cytotoxic effects of 5-Fluorouracil and oxaliplatin in colon cancer cells. Oncol Res. 2014;21(3):155-64. PMID: 24512730.

 

MacCallum SF, Groves MJ, James J, et al. Dysregulation of autophagy in chronic lymphocytic leukemia with the small-molecule Sirtuin inhibitor Tenovin-6. Sci Rep. 2013;3:1275. PMID: 23429453.

 

Lain S, Hollick JJ, Campbell J, et al. Discovery, in vivo activity, and mechanism of action of a small-molecule p53 activator. Cancer Cell. 2008 May;13(5):454-63. PMID: 18455128.

 

Brooks CL, Gu W. p53 Activation: a case against Sir. Cancer Cell. 2008 May;13(5):377-8. PMID: 18455119.

" Not dangerous goods.

LKT T1852 Tenovin-1 10 mg 72.8 SIRT1/2 inhibitor, indirect p53 activator. 380315-80-0 ≥98% 369.48 C20H23N3O2S CC(=O)NC1=CC=C(C=C1)NC(=S)NC(=O)C2=CC=C(C=C2)C(C)(C)C Ambient -20°C "Nihal M, Ahmad N, Wood GS. SIRT1 is upregulated in cutaneous T-cell lymphoma, and its inhibition induces growth arrest and apoptosis. Cell Cycle. 2014 Feb 15;13(4):632-40. PMID: 24343700.

 

Lain S, Hollick JJ, Campbell J, et al. Discovery, in vivo activity, and mechanism of action of a small-molecule p53 activator. Cancer Cell. 2008 May;13(5):454-63. PMID: 18455128.

" Not dangerous goods.

LKT T1852 Tenovin-1 25 mg 145.6 SIRT1/2 inhibitor, indirect p53 activator. 380315-80-0 ≥98% 369.48 C20H23N3O2S CC(=O)NC1=CC=C(C=C1)NC(=S)NC(=O)C2=CC=C(C=C2)C(C)(C)C Ambient -20°C "Nihal M, Ahmad N, Wood GS. SIRT1 is upregulated in cutaneous T-cell lymphoma, and its inhibition induces growth arrest and apoptosis. Cell Cycle. 2014 Feb 15;13(4):632-40. PMID: 24343700.

 

Lain S, Hollick JJ, Campbell J, et al. Discovery, in vivo activity, and mechanism of action of a small-molecule p53 activator. Cancer Cell. 2008 May;13(5):454-63. PMID: 18455128.

" Not dangerous goods.

LKT T1852 Tenovin-1 100 mg 467.1 SIRT1/2 inhibitor, indirect p53 activator. 380315-80-0 ≥98% 369.48 C20H23N3O2S CC(=O)NC1=CC=C(C=C1)NC(=S)NC(=O)C2=CC=C(C=C2)C(C)(C)C Ambient -20°C "Nihal M, Ahmad N, Wood GS. SIRT1 is upregulated in cutaneous T-cell lymphoma, and its inhibition induces growth arrest and apoptosis. Cell Cycle. 2014 Feb 15;13(4):632-40. PMID: 24343700.

 

Lain S, Hollick JJ, Campbell J, et al. Discovery, in vivo activity, and mechanism of action of a small-molecule p53 activator. Cancer Cell. 2008 May;13(5):454-63. PMID: 18455128.

" Not dangerous goods.

LKT N5655 Nonoxynol-9 10 g 33.9 Nonoxynol surfactant. α-(4-Nonylphenyl)-ω-hydroxypoly(oxy-1,2-ethane- diyl) C-Film; Encare; Intercept; Semicid; Staycept; Tergitol TP-9 26571-11-9 ≥98% 616.82 C33H60O10 CCCCCCCCCC1=CC=C(C=C1)OCCOCCOCCOCCOCCOCCOCCOCCOCCO Ambient Ambient Soluble in water, ethanol, ethylene glycol, or xylene. "Hillier SL, Moench T, Shattock R, et al. In vitro and in vivo: the story of nonoxynol 9. J Acquir Immune Defic Syndr. 2005 May 1;39(1):1-8. PMID: 15851907.

 

Maikhuri JP, Dwivedi AK, Dhar JD, et al. Mechanism of action of some acrylophenones, quinolines and dithiocarbamate as potent, non-detergent spermicidal agents. Contraception. 2003 May;67(5):403-8. PMID: 12742565.

" "UN number: 3082     Class: 9     Packing Group: III

Proper shipping name: Environmentally hazardous substance, liquid, n.o.s. (Nonoxynol-9)

Marine pollutant: Yes"

LKT B4517 Bleomycin A5 Hydrochloride 1 mg 88.3 Glycopeptide, induces DNA strand breaks. Pingyangmycin hydrochloride 55658-47-4 ≥90% 1477.02 C57H89N19O21S2 HCl CC1=C(N=C(N=C1N)C(CC(=O)N)NCC(C(=O)N)N)C(=O)NC(C(C2=CN=CN2)OC3C(C(C(C(O3)CO)O)O)OC4C(C(C(C(O4)CO)O)OC(=O)N)O)C(=O)NC(C)C(C(C)C(=O)NC(C(C)O)C(=O)NCCC5=NC(=CS5)C6=NC(=CS6)C(=O)NCCCNCCCCN)O.Cl Ambient 4°C "Li P, Li DF, Guo ZT, et al. Therapeutic mechanism of bleomycin A5 on infancy hemangioma: an experimental study. Zhonghua Kou Qiang Yi Xue Za Zhi. 2013 Jan;48(1):18-22. PMID: 23534516.

 

Yang Y, Sun M, Ma Q, et al. Bleomycin A5 sclerotherapy for cervicofacial lymphatic malformations. J Vasc Surg. 2011 Jan;53(1):150-5. PMID: 20843632.

 

Liu Y, Wu F, Zou G. Electrophoresis mobility shift assay and biosensor used in studying the interaction between bleomycin A5 and DNA. Anal Chim Acta. 2007 Sep 19;599(2):310-4. PMID: 17870295.

 

Vorobjev PE, Smith JB, Pyshnaya IA, et al. Site-specific cleavage of RNA and DNA by complementary DNA--bleomycin A5 conjugates. Bioconjug Chem. 2003 Nov-Dec;14(6):1307-13. PMID: 14624648.

" Not dangerous goods.

LKT L1982 Leupeptin Hemisulfate 5 mg 54.6 Protease inhibitor. 103476-89-7 ≥95% 475.59 C20H38N6O4 1/2H2SO4 CC(C)CC(C(=O)NC(CC(C)C)C(=O)NC(CCCN=C(N)N)C=O)NC(=O)C.CC(C)CC(C(=O)NC(CC(C)C)C(=O)NC(CCCN=C(N)N)C=O)NC(=O)C.OS(=O)(=O)O Ambient -20°C "Ganapathi TR, Sunil Kumar GB, Srinivas L, et al. Analysis of the limitations of hepatitis B surface antigen expression in soybean cell suspension cultures. Plant Cell Rep. 2007 Sep;26(9):1575-84. PMID: 17534624.

 

Morejohn LC, Bureau TE, Fosket DE. Inhibition of plant cell proteolytic activities that degrade tubulin. Cell Biol Int Rep. 1985 Sep;9(9):849-57. PMID: 2864138.

" Not dangerous goods.

LKT L1982 Leupeptin Hemisulfate 10 mg 84.9 Protease inhibitor. 103476-89-7 ≥95% 475.59 C20H38N6O4 1/2H2SO4 CC(C)CC(C(=O)NC(CC(C)C)C(=O)NC(CCCN=C(N)N)C=O)NC(=O)C.CC(C)CC(C(=O)NC(CC(C)C)C(=O)NC(CCCN=C(N)N)C=O)NC(=O)C.OS(=O)(=O)O Ambient -20°C "Ganapathi TR, Sunil Kumar GB, Srinivas L, et al. Analysis of the limitations of hepatitis B surface antigen expression in soybean cell suspension cultures. Plant Cell Rep. 2007 Sep;26(9):1575-84. PMID: 17534624.

 

Morejohn LC, Bureau TE, Fosket DE. Inhibition of plant cell proteolytic activities that degrade tubulin. Cell Biol Int Rep. 1985 Sep;9(9):849-57. PMID: 2864138.

" Not dangerous goods.

LKT L1982 Leupeptin Hemisulfate 25 mg 176 Protease inhibitor. 103476-89-7 ≥95% 475.59 C20H38N6O4 1/2H2SO4 CC(C)CC(C(=O)NC(CC(C)C)C(=O)NC(CCCN=C(N)N)C=O)NC(=O)C.CC(C)CC(C(=O)NC(CC(C)C)C(=O)NC(CCCN=C(N)N)C=O)NC(=O)C.OS(=O)(=O)O Ambient -20°C "Ganapathi TR, Sunil Kumar GB, Srinivas L, et al. Analysis of the limitations of hepatitis B surface antigen expression in soybean cell suspension cultures. Plant Cell Rep. 2007 Sep;26(9):1575-84. PMID: 17534624.

 

Morejohn LC, Bureau TE, Fosket DE. Inhibition of plant cell proteolytic activities that degrade tubulin. Cell Biol Int Rep. 1985 Sep;9(9):849-57. PMID: 2864138.

" Not dangerous goods.

LKT E0003 E64-d 1 mg 60.7 Cathepsin inhibitor. Aloxistatin 88321-09-9 ≥97% 342.43 C17H30N2O5 CCOC(=O)C1C(O1)C(=O)NC(CC(C)C)C(=O)NCCC(C)C Ambient -20°C "Hook G, Yu J, Toneff T, et al. Brain Pyroglutamate Amyloid-Beta is Produced by Cathepsin B and is Reduced by the Cysteine Protease Inhibitor E64d, Representing a Potential Alzheimer's Disease Therapeutic. J Alzheimers Dis. 2014 Mar 4. [Epub ahead of print]. PMID: 24595198.

 

Chen H, Wang J, Xiang MX, et al. Cathepsin S-mediated fibroblast trans-differentiation contributes to left ventricular remodelling after myocardial infarction. Cardiovasc Res. 2013 Oct 1;100(1):84-94. PMID: 23771947.

" Not dangerous goods.

LKT E0003 E64-d 5 mg 242.7 Cathepsin inhibitor. Aloxistatin 88321-09-9 ≥97% 342.43 C17H30N2O5 CCOC(=O)C1C(O1)C(=O)NC(CC(C)C)C(=O)NCCC(C)C Ambient -20°C "Hook G, Yu J, Toneff T, et al. Brain Pyroglutamate Amyloid-Beta is Produced by Cathepsin B and is Reduced by the Cysteine Protease Inhibitor E64d, Representing a Potential Alzheimer's Disease Therapeutic. J Alzheimers Dis. 2014 Mar 4. [Epub ahead of print]. PMID: 24595198.

 

Chen H, Wang J, Xiang MX, et al. Cathepsin S-mediated fibroblast trans-differentiation contributes to left ventricular remodelling after myocardial infarction. Cardiovasc Res. 2013 Oct 1;100(1):84-94. PMID: 23771947.

" Not dangerous goods.

LKT E0001 E64 5 mg 91 Cysteine protease inhibitor. 66701-25-5 ≥98% 357.41 C15H27N5O5 CC(C)CC(C(=O)NCCCCN=C(N)N)NC(=O)C1C(O1)C(=O)O Ambient -20°C "Quain MD, Makgopa ME, Márquez-García B, et al. Ectopic phytocystatin expression leads to enhanced drought stress tolerance in soybean (Glycine max) and Arabidopsis thaliana through effects on strigolactone pathways and can also result in improved seed traits. Plant Biotechnol J. 2014 Apr 22. [Epub ahead of print]. PMID: 24754628.

 

Lee YA, Nam YH, Min A, et al. Entamoeba histolytica-secreted cysteine proteases induce IL-8 production in human mast cells via a PAR2-independent mechanism. Parasite. 2014;21:1. PMID: 24502918.

 

Shin SP, Han SY, Han JE, et al. Expression and characterization of cathepsin L-like cysteine protease from Philasterides dicentrarchi. Parasitol Int. 2014 Apr;63(2):359-65. PMID: 24361286.

" Not dangerous goods.

LKT E0001 E64 25 mg 327.6 Cysteine protease inhibitor. 66701-25-5 ≥98% 357.41 C15H27N5O5 CC(C)CC(C(=O)NCCCCN=C(N)N)NC(=O)C1C(O1)C(=O)O Ambient -20°C "Quain MD, Makgopa ME, Márquez-García B, et al. Ectopic phytocystatin expression leads to enhanced drought stress tolerance in soybean (Glycine max) and Arabidopsis thaliana through effects on strigolactone pathways and can also result in improved seed traits. Plant Biotechnol J. 2014 Apr 22. [Epub ahead of print]. PMID: 24754628.

 

Lee YA, Nam YH, Min A, et al. Entamoeba histolytica-secreted cysteine proteases induce IL-8 production in human mast cells via a PAR2-independent mechanism. Parasite. 2014;21:1. PMID: 24502918.

 

Shin SP, Han SY, Han JE, et al. Expression and characterization of cathepsin L-like cysteine protease from Philasterides dicentrarchi. Parasitol Int. 2014 Apr;63(2):359-65. PMID: 24361286.

" Not dangerous goods.

LKT E0001 E64 100 mg 1152.7 Cysteine protease inhibitor. 66701-25-5 ≥98% 357.41 C15H27N5O5 CC(C)CC(C(=O)NCCCCN=C(N)N)NC(=O)C1C(O1)C(=O)O Ambient -20°C "Quain MD, Makgopa ME, Márquez-García B, et al. Ectopic phytocystatin expression leads to enhanced drought stress tolerance in soybean (Glycine max) and Arabidopsis thaliana through effects on strigolactone pathways and can also result in improved seed traits. Plant Biotechnol J. 2014 Apr 22. [Epub ahead of print]. PMID: 24754628.

 

Lee YA, Nam YH, Min A, et al. Entamoeba histolytica-secreted cysteine proteases induce IL-8 production in human mast cells via a PAR2-independent mechanism. Parasite. 2014;21:1. PMID: 24502918.

 

Shin SP, Han SY, Han JE, et al. Expression and characterization of cathepsin L-like cysteine protease from Philasterides dicentrarchi. Parasitol Int. 2014 Apr;63(2):359-65. PMID: 24361286.

" Not dangerous goods.

LKT I0516 I-BET151 5 mg 118.9 BRD2/3/4 inhibitor. GSK-1210151A, GSK1210151A 1300031-49-5 ≥98% 415.44 C23H21N5O3 CC1=C(C(=NO1)C)C2=C(C=C3C(=C2)N=CC4=C3N(C(=O)N4)C(C)C5=CC=CC=N5)OC Ambient -20°C "Chaidos A, Caputo V, Gouvedenou K, et al. Potent antimyeloma activity of the novel bromodomain inhibitors I-BET151 and I-BET762. Blood. 2014 Jan 30;123(5):697-705. PMID: 24335499.

 

Seal J, Lamotte Y, Donche F, et al. Identification of a novel series of BET family bromodomain inhibitors: binding mode and profile of I-BET151 (GSK1210151A). Bioorg Med Chem Lett. 2012 Apr 15;22(8):2968-72. PMID: 22437115.

" "UN number: 2811     Class:  6.1     Packing group:  III

Proper shipping name:  Toxic solid, organic, n.o.s. (I-BET 151)  Marine pollutant:  No  Poison inhalation hazard:  No"

LKT I0516 I-BET151 10 mg 174.7 BRD2/3/4 inhibitor. GSK-1210151A, GSK1210151A 1300031-49-5 ≥98% 415.44 C23H21N5O3 CC1=C(C(=NO1)C)C2=C(C=C3C(=C2)N=CC4=C3N(C(=O)N4)C(C)C5=CC=CC=N5)OC Ambient -20°C "Chaidos A, Caputo V, Gouvedenou K, et al. Potent antimyeloma activity of the novel bromodomain inhibitors I-BET151 and I-BET762. Blood. 2014 Jan 30;123(5):697-705. PMID: 24335499.

 

Seal J, Lamotte Y, Donche F, et al. Identification of a novel series of BET family bromodomain inhibitors: binding mode and profile of I-BET151 (GSK1210151A). Bioorg Med Chem Lett. 2012 Apr 15;22(8):2968-72. PMID: 22437115.

" "UN number: 2811     Class:  6.1     Packing group:  III

Proper shipping name:  Toxic solid, organic, n.o.s. (I-BET 151)  Marine pollutant:  No  Poison inhalation hazard:  No"

LKT I0516 I-BET151 25 mg 333.7 BRD2/3/4 inhibitor. GSK-1210151A, GSK1210151A 1300031-49-5 ≥98% 415.44 C23H21N5O3 CC1=C(C(=NO1)C)C2=C(C=C3C(=C2)N=CC4=C3N(C(=O)N4)C(C)C5=CC=CC=N5)OC Ambient -20°C "Chaidos A, Caputo V, Gouvedenou K, et al. Potent antimyeloma activity of the novel bromodomain inhibitors I-BET151 and I-BET762. Blood. 2014 Jan 30;123(5):697-705. PMID: 24335499.

 

Seal J, Lamotte Y, Donche F, et al. Identification of a novel series of BET family bromodomain inhibitors: binding mode and profile of I-BET151 (GSK1210151A). Bioorg Med Chem Lett. 2012 Apr 15;22(8):2968-72. PMID: 22437115.

" "UN number: 2811     Class:  6.1     Packing group:  III

Proper shipping name:  Toxic solid, organic, n.o.s. (I-BET 151)  Marine pollutant:  No  Poison inhalation hazard:  No"

LKT G7541 GSK-1904529A 1 mg 78.9 InsR and IGF-1R inhibitor. GSK1904529A 1089283-49-7 ≥98% 851.96 C44H47F2N9O5S CCC1=CC(=C(C=C1N2CCC(CC2)N3CCN(CC3)S(=O)(=O)C)OC)NC4=NC=CC(=N4)C5=C(N=C6N5C=CC=C6)C7=CC(=C(C=C7)OC)C(=O)NC8=C(C=CC=C8F)F Ambient -20°C DMSO Sabbatini P, Rowand JL, Groy A, et al. Antitumor activity of GSK1904529A, a small-molecule inhibitor of the insulin-like growth factor-I receptor tyrosine kinase. Clin Cancer Res. 2009 May 1;15(9):3058-67. PMID: 19383820. Not dangerous goods.

LKT G7541 GSK-1904529A 5 mg 276.6 InsR and IGF-1R inhibitor. GSK1904529A 1089283-49-7 ≥98% 851.96 C44H47F2N9O5S CCC1=CC(=C(C=C1N2CCC(CC2)N3CCN(CC3)S(=O)(=O)C)OC)NC4=NC=CC(=N4)C5=C(N=C6N5C=CC=C6)C7=CC(=C(C=C7)OC)C(=O)NC8=C(C=CC=C8F)F Ambient -20°C DMSO Sabbatini P, Rowand JL, Groy A, et al. Antitumor activity of GSK1904529A, a small-molecule inhibitor of the insulin-like growth factor-I receptor tyrosine kinase. Clin Cancer Res. 2009 May 1;15(9):3058-67. PMID: 19383820. Not dangerous goods.

LKT G7541 GSK-1904529A 25 mg 910 InsR and IGF-1R inhibitor. GSK1904529A 1089283-49-7 ≥98% 851.96 C44H47F2N9O5S CCC1=CC(=C(C=C1N2CCC(CC2)N3CCN(CC3)S(=O)(=O)C)OC)NC4=NC=CC(=N4)C5=C(N=C6N5C=CC=C6)C7=CC(=C(C=C7)OC)C(=O)NC8=C(C=CC=C8F)F Ambient -20°C DMSO Sabbatini P, Rowand JL, Groy A, et al. Antitumor activity of GSK1904529A, a small-molecule inhibitor of the insulin-like growth factor-I receptor tyrosine kinase. Clin Cancer Res. 2009 May 1;15(9):3058-67. PMID: 19383820. Not dangerous goods.

LKT G7540 GSK-1838705A 1 mg 60.7 ALK and IGF-1R inhibitor. GSK1838705A 1116235-49-7 ≥98% 532.57 C27H29FN8O3 Ambient -20°C Sabbatini P, Korenchuk S, Rowand JL, et al. GSK1838705A inhibits the insulin-like growth factor-1 receptor and anaplastic lymphoma kinase and shows antitumor activity in experimental models of human cancers. Mol Cancer Ther. 2009 Oct;8(10):2811-20. PMID: 19825801. Not dangerous goods.

LKT G7540 GSK-1838705A 5 mg 218.4 ALK and IGF-1R inhibitor. GSK1838705A 1116235-49-7 ≥98% 532.57 C27H29FN8O3 Ambient -20°C Sabbatini P, Korenchuk S, Rowand JL, et al. GSK1838705A inhibits the insulin-like growth factor-1 receptor and anaplastic lymphoma kinase and shows antitumor activity in experimental models of human cancers. Mol Cancer Ther. 2009 Oct;8(10):2811-20. PMID: 19825801. Not dangerous goods.

LKT G7540 GSK-1838705A 25 mg 703.7 ALK and IGF-1R inhibitor. GSK1838705A 1116235-49-7 ≥98% 532.57 C27H29FN8O3 Ambient -20°C Sabbatini P, Korenchuk S, Rowand JL, et al. GSK1838705A inhibits the insulin-like growth factor-1 receptor and anaplastic lymphoma kinase and shows antitumor activity in experimental models of human cancers. Mol Cancer Ther. 2009 Oct;8(10):2811-20. PMID: 19825801. Not dangerous goods.

LKT F5968 Foretinib 5 mg 72.8 ROS1, MET, Ron, Axl, TIE-2, VEGFR2 inhibitor. GSK-1363089, GSK1363089 849217-64-7 ≥98% 632.65 C34H34F2N4O6 COC1=CC2=C(C=CN=C2C=C1OCCCN3CCOCC3)OC4=C(C=C(C=C4)NC(=O)C5(CC5)C(=O)NC6=CC=C(C=C6)F)F Ambient -20°C Relatively insoluble in water and ethanol. Soluble in DMSO to 127 mg/mL. "Shah MA, Wainberg ZA, Catenacci DV, et al. Phase II study evaluating 2 dosing schedules of oral foretinib (GSK1363089), cMET/VEGFR2 inhibitor, in patients with metastatic gastric cancer. PLoS One. 2013;8(3):e54014. PMID: 23516391.

 

Seiwert T, Sarantopoulos J, Kallender H, et al. Phase II trial of single-agent foretinib (GSK1363089) in patients with recurrent or metastatic squamous cell carcinoma of the head and neck. Invest New Drugs. 2013 Apr;31(2):417-24. PMID: 22918720.

 

Huynh H, Ong R, Soo KC. Foretinib demonstrates anti-tumor activity and improves overall survival in preclinical models of hepatocellular carcinoma. Angiogenesis. 2012 Mar;15(1):59-70. PMID: 22187171.

" Not dangerous goods.

LKT F5968 Foretinib 10 mg 109.2 ROS1, MET, Ron, Axl, TIE-2, VEGFR2 inhibitor. GSK-1363089, GSK1363089 849217-64-7 ≥98% 632.65 C34H34F2N4O6 COC1=CC2=C(C=CN=C2C=C1OCCCN3CCOCC3)OC4=C(C=C(C=C4)NC(=O)C5(CC5)C(=O)NC6=CC=C(C=C6)F)F Ambient -20°C Relatively insoluble in water and ethanol. Soluble in DMSO to 127 mg/mL. "Shah MA, Wainberg ZA, Catenacci DV, et al. Phase II study evaluating 2 dosing schedules of oral foretinib (GSK1363089), cMET/VEGFR2 inhibitor, in patients with metastatic gastric cancer. PLoS One. 2013;8(3):e54014. PMID: 23516391.

 

Seiwert T, Sarantopoulos J, Kallender H, et al. Phase II trial of single-agent foretinib (GSK1363089) in patients with recurrent or metastatic squamous cell carcinoma of the head and neck. Invest New Drugs. 2013 Apr;31(2):417-24. PMID: 22918720.

 

Huynh H, Ong R, Soo KC. Foretinib demonstrates anti-tumor activity and improves overall survival in preclinical models of hepatocellular carcinoma. Angiogenesis. 2012 Mar;15(1):59-70. PMID: 22187171.

" Not dangerous goods.

LKT F5968 Foretinib 25 mg 212.3 ROS1, MET, Ron, Axl, TIE-2, VEGFR2 inhibitor. GSK-1363089, GSK1363089 849217-64-7 ≥98% 632.65 C34H34F2N4O6 COC1=CC2=C(C=CN=C2C=C1OCCCN3CCOCC3)OC4=C(C=C(C=C4)NC(=O)C5(CC5)C(=O)NC6=CC=C(C=C6)F)F Ambient -20°C Relatively insoluble in water and ethanol. Soluble in DMSO to 127 mg/mL. "Shah MA, Wainberg ZA, Catenacci DV, et al. Phase II study evaluating 2 dosing schedules of oral foretinib (GSK1363089), cMET/VEGFR2 inhibitor, in patients with metastatic gastric cancer. PLoS One. 2013;8(3):e54014. PMID: 23516391.

 

Seiwert T, Sarantopoulos J, Kallender H, et al. Phase II trial of single-agent foretinib (GSK1363089) in patients with recurrent or metastatic squamous cell carcinoma of the head and neck. Invest New Drugs. 2013 Apr;31(2):417-24. PMID: 22918720.

 

Huynh H, Ong R, Soo KC. Foretinib demonstrates anti-tumor activity and improves overall survival in preclinical models of hepatocellular carcinoma. Angiogenesis. 2012 Mar;15(1):59-70. PMID: 22187171.

" Not dangerous goods.

LKT B5072 BMS-754807 5 mg 151.7 InsR and IGF-1R inhibitor. BMS754807 1001350-96-4 ≥98% 463.51 C23H26FN9O CC1(CCCN1C2=NN3C=CC=C3C(=N2)NC4=NNC(=C4)C5CC5)C(=O)NC6=CN=C(C=C6)F Ambient -20°C "Awasthi N, Zhang C, Ruan W, et al. BMS-754807, a small-molecule inhibitor of insulin-like growth factor-1 receptor/insulin receptor, enhances gemcitabine response in pancreatic cancer. Mol Cancer Ther. 2012 Dec;11(12):2644-53. PMID: 23047891.

 

Hou X, Huang F, Macedo LF, et al. Dual IGF-1R/InsR inhibitor BMS-754807 synergizes with hormonal agents in treatment of estrogen-dependent breast cancer. Cancer Res. 2011 Dec 15;71(24):7597-607. PMID: 22042792.

" Not dangerous goods.

LKT B5072 BMS-754807 10 mg 218.4 InsR and IGF-1R inhibitor. BMS754807 1001350-96-4 ≥98% 463.51 C23H26FN9O CC1(CCCN1C2=NN3C=CC=C3C(=N2)NC4=NNC(=C4)C5CC5)C(=O)NC6=CN=C(C=C6)F Ambient -20°C "Awasthi N, Zhang C, Ruan W, et al. BMS-754807, a small-molecule inhibitor of insulin-like growth factor-1 receptor/insulin receptor, enhances gemcitabine response in pancreatic cancer. Mol Cancer Ther. 2012 Dec;11(12):2644-53. PMID: 23047891.

 

Hou X, Huang F, Macedo LF, et al. Dual IGF-1R/InsR inhibitor BMS-754807 synergizes with hormonal agents in treatment of estrogen-dependent breast cancer. Cancer Res. 2011 Dec 15;71(24):7597-607. PMID: 22042792.

" Not dangerous goods.

LKT B5072 BMS-754807 25 mg 424.7 InsR and IGF-1R inhibitor. BMS754807 1001350-96-4 ≥98% 463.51 C23H26FN9O CC1(CCCN1C2=NN3C=CC=C3C(=N2)NC4=NNC(=C4)C5CC5)C(=O)NC6=CN=C(C=C6)F Ambient -20°C "Awasthi N, Zhang C, Ruan W, et al. BMS-754807, a small-molecule inhibitor of insulin-like growth factor-1 receptor/insulin receptor, enhances gemcitabine response in pancreatic cancer. Mol Cancer Ther. 2012 Dec;11(12):2644-53. PMID: 23047891.

 

Hou X, Huang F, Macedo LF, et al. Dual IGF-1R/InsR inhibitor BMS-754807 synergizes with hormonal agents in treatment of estrogen-dependent breast cancer. Cancer Res. 2011 Dec 15;71(24):7597-607. PMID: 22042792.

" Not dangerous goods.

LKT A8644 AVL-292 1 mg 60.7 BTK inhibitor. CC-292 1202757-89-8 ≥98% 423.44 C22H22FN5O3 COCCOC1=CC=C(C=C1)NC2=NC=C(C(=N2)NC3=CC(=CC=C3)NC(=O)C=C)F Ambient -20°C "Burger JA. Bruton's tyrosine kinase (BTK) inhibitors in clinical trials. Curr Hematol Malig Rep. 2014 Mar;9(1):44-9. PMID: 24357428.

 

Robak T, Robak E. Tyrosine kinase inhibitors as potential drugs for B-cell lymphoid malignancies and autoimmune disorders. Expert Opin Investig Drugs. 2012 Jul;21(7):921-47. PMID: 22612424.

" Not dangerous goods.

LKT A8644 AVL-292 5 mg 218.4 BTK inhibitor. CC-292 1202757-89-8 ≥98% 423.44 C22H22FN5O3 COCCOC1=CC=C(C=C1)NC2=NC=C(C(=N2)NC3=CC(=CC=C3)NC(=O)C=C)F Ambient -20°C "Burger JA. Bruton's tyrosine kinase (BTK) inhibitors in clinical trials. Curr Hematol Malig Rep. 2014 Mar;9(1):44-9. PMID: 24357428.

 

Robak T, Robak E. Tyrosine kinase inhibitors as potential drugs for B-cell lymphoid malignancies and autoimmune disorders. Expert Opin Investig Drugs. 2012 Jul;21(7):921-47. PMID: 22612424.

" Not dangerous goods.

LKT A8644 AVL-292 25 mg 728.1 BTK inhibitor. CC-292 1202757-89-8 ≥98% 423.44 C22H22FN5O3 COCCOC1=CC=C(C=C1)NC2=NC=C(C(=N2)NC3=CC(=CC=C3)NC(=O)C=C)F Ambient -20°C "Burger JA. Bruton's tyrosine kinase (BTK) inhibitors in clinical trials. Curr Hematol Malig Rep. 2014 Mar;9(1):44-9. PMID: 24357428.

 

Robak T, Robak E. Tyrosine kinase inhibitors as potential drugs for B-cell lymphoid malignancies and autoimmune disorders. Expert Opin Investig Drugs. 2012 Jul;21(7):921-47. PMID: 22612424.

" Not dangerous goods.

LKT Z5852 Zonampanel 5 mg 224.5 AMPA antagonist. (2,3-Dioxo-7-(1H-imidazol-1-yl)-6-nitro-1,2,3,4- tetrahydro-1-quinoxalinyl)acetic acid monohydrate YM872, HY-15072 210245-80-0 ≥88% 331.24 C13H9N5O6 C1=CN(C=N1)C2=C(C=C3C(=C2)N(C(=O)C(=O)N3)CC(=O)O)[N+](=O)[O-] Ambient Ambient "Ferro JM, Dávalos A. Other neuroprotective therapies on trial in acute stroke. Cerebrovasc Dis. 2006;21 Suppl 2:127-30. PMID: 16651823.

 

Terai K, Suzuki M, Sasamata M, et al. Effect of AMPA receptor antagonist YM872 on cerebral hematoma size and neurological recovery in the intracerebral hemorrhage rat model. Eur J Pharmacol. 2003 Apr 25;467(1-3):95-101. PMID: 12706461.

"

LKT Z5852 Zonampanel 25 mg 667.4 AMPA antagonist. (2,3-Dioxo-7-(1H-imidazol-1-yl)-6-nitro-1,2,3,4- tetrahydro-1-quinoxalinyl)acetic acid monohydrate YM872, HY-15072 210245-80-0 ≥88% 331.24 C13H9N5O6 C1=CN(C=N1)C2=C(C=C3C(=C2)N(C(=O)C(=O)N3)CC(=O)O)[N+](=O)[O-] Ambient Ambient "Ferro JM, Dávalos A. Other neuroprotective therapies on trial in acute stroke. Cerebrovasc Dis. 2006;21 Suppl 2:127-30. PMID: 16651823.

 

Terai K, Suzuki M, Sasamata M, et al. Effect of AMPA receptor antagonist YM872 on cerebral hematoma size and neurological recovery in the intracerebral hemorrhage rat model. Eur J Pharmacol. 2003 Apr 25;467(1-3):95-101. PMID: 12706461.

"

LKT Z5852 Zonampanel 100 mg 2426.8 AMPA antagonist. (2,3-Dioxo-7-(1H-imidazol-1-yl)-6-nitro-1,2,3,4- tetrahydro-1-quinoxalinyl)acetic acid monohydrate YM872, HY-15072 210245-80-0 ≥88% 331.24 C13H9N5O6 C1=CN(C=N1)C2=C(C=C3C(=C2)N(C(=O)C(=O)N3)CC(=O)O)[N+](=O)[O-] Ambient Ambient "Ferro JM, Dávalos A. Other neuroprotective therapies on trial in acute stroke. Cerebrovasc Dis. 2006;21 Suppl 2:127-30. PMID: 16651823.

 

Terai K, Suzuki M, Sasamata M, et al. Effect of AMPA receptor antagonist YM872 on cerebral hematoma size and neurological recovery in the intracerebral hemorrhage rat model. Eur J Pharmacol. 2003 Apr 25;467(1-3):95-101. PMID: 12706461.

"

LKT F4532 Flibanserin 5 mg 58.2 5-HT1A agonist, 5-HT2A antagonist. 167933-07-5 ≥98% 390.4 C20H21F3N4O C1CN(CCN1CCN2C3=CC=CC=C3NC2=O)C4=CC=C(C=C4)C(F)(F)F Ambient Ambient "Gelez H, Clement P, Compagnie S, et al. Brain neuronal activation induced by flibanserin treatment in female rats. Psychopharmacology (Berl). 2013 Dec;230(4):639-52. PMID: 23857113.

 

Strecker K, Adamaszek M, Ohm S, et al. The 5-HT1A-receptor agonist flibanserin reduces drug-induced dyskinesia in RGS9-deficient mice. J Neural Transm. 2012 Nov;119(11):1351-9. PMID: 22569849.

 

Stahl SM, Sommer B, Allers KA. Multifunctional pharmacology of flibanserin: possible mechanism of therapeutic action in hypoactive sexual desire disorder. J Sex Med. 2011 Jan;8(1):15-27. PMID: 20840530.

" "UN number: 2811     Class:  6.1     Packing group:  III

Proper shipping name:  Toxic solids, organic, n.o.s. (Flibanserin)

Reportable Quantity     Poison Inhalation Hazard:  No"

LKT F4532 Flibanserin 25 mg 200.2 5-HT1A agonist, 5-HT2A antagonist. 167933-07-5 ≥98% 390.4 C20H21F3N4O C1CN(CCN1CCN2C3=CC=CC=C3NC2=O)C4=CC=C(C=C4)C(F)(F)F Ambient Ambient "Gelez H, Clement P, Compagnie S, et al. Brain neuronal activation induced by flibanserin treatment in female rats. Psychopharmacology (Berl). 2013 Dec;230(4):639-52. PMID: 23857113.

 

Strecker K, Adamaszek M, Ohm S, et al. The 5-HT1A-receptor agonist flibanserin reduces drug-induced dyskinesia in RGS9-deficient mice. J Neural Transm. 2012 Nov;119(11):1351-9. PMID: 22569849.

 

Stahl SM, Sommer B, Allers KA. Multifunctional pharmacology of flibanserin: possible mechanism of therapeutic action in hypoactive sexual desire disorder. J Sex Med. 2011 Jan;8(1):15-27. PMID: 20840530.

" "UN number: 2811     Class:  6.1     Packing group:  III

Proper shipping name:  Toxic solids, organic, n.o.s. (Flibanserin)

Reportable Quantity     Poison Inhalation Hazard:  No"

LKT F4532 Flibanserin 100 mg 449 5-HT1A agonist, 5-HT2A antagonist. 167933-07-5 ≥98% 390.4 C20H21F3N4O C1CN(CCN1CCN2C3=CC=CC=C3NC2=O)C4=CC=C(C=C4)C(F)(F)F Ambient Ambient "Gelez H, Clement P, Compagnie S, et al. Brain neuronal activation induced by flibanserin treatment in female rats. Psychopharmacology (Berl). 2013 Dec;230(4):639-52. PMID: 23857113.

 

Strecker K, Adamaszek M, Ohm S, et al. The 5-HT1A-receptor agonist flibanserin reduces drug-induced dyskinesia in RGS9-deficient mice. J Neural Transm. 2012 Nov;119(11):1351-9. PMID: 22569849.

 

Stahl SM, Sommer B, Allers KA. Multifunctional pharmacology of flibanserin: possible mechanism of therapeutic action in hypoactive sexual desire disorder. J Sex Med. 2011 Jan;8(1):15-27. PMID: 20840530.

" "UN number: 2811     Class:  6.1     Packing group:  III

Proper shipping name:  Toxic solids, organic, n.o.s. (Flibanserin)

Reportable Quantity     Poison Inhalation Hazard:  No"

LKT B1955 Benztropine Mesylate 1 g 46.1 DAT inhibitor. 132-17-2 ≥98% 403.53 C21H25NO  CH4O3S CN1C2CCC1CC(C2)OC(C3=CC=CC=C3)C4=CC=CC=C4.CS(=O)(=O)O Ambient Ambient "Ukairo OT, Bondi CD, Newman AH, et al. Recognition of benztropine by the dopamine transporter (DAT) differs from that of the classical dopamine uptake inhibitors cocaine, methylphenidate, and mazindol as a function of a DAT transmembrane 1 aspartic acid residue. J Pharmacol Exp Ther. 2005 Aug;314(2):575-83. PMID: 15879005.

 

Wieczorek WJ, Kruk ZL. A quantitative comparison on the effects of benztropine, cocaine and nomifensine on electrically evoked dopamine overflow and rate of re-uptake in the caudate putamen and nucleus accumbens in the rat brain slice. Brain Res. 1994  19;657(1-2):42-50. PMID: 7820642.

" Not dangerous goods.

LKT B1955 Benztropine Mesylate 5 g 182 DAT inhibitor. 132-17-2 ≥98% 403.53 C21H25NO  CH4O3S CN1C2CCC1CC(C2)OC(C3=CC=CC=C3)C4=CC=CC=C4.CS(=O)(=O)O Ambient Ambient "Ukairo OT, Bondi CD, Newman AH, et al. Recognition of benztropine by the dopamine transporter (DAT) differs from that of the classical dopamine uptake inhibitors cocaine, methylphenidate, and mazindol as a function of a DAT transmembrane 1 aspartic acid residue. J Pharmacol Exp Ther. 2005 Aug;314(2):575-83. PMID: 15879005.

 

Wieczorek WJ, Kruk ZL. A quantitative comparison on the effects of benztropine, cocaine and nomifensine on electrically evoked dopamine overflow and rate of re-uptake in the caudate putamen and nucleus accumbens in the rat brain slice. Brain Res. 1994  19;657(1-2):42-50. PMID: 7820642.

" Not dangerous goods.

LKT B1955 Benztropine Mesylate 25 g 455.1 DAT inhibitor. 132-17-2 ≥98% 403.53 C21H25NO  CH4O3S CN1C2CCC1CC(C2)OC(C3=CC=CC=C3)C4=CC=CC=C4.CS(=O)(=O)O Ambient Ambient "Ukairo OT, Bondi CD, Newman AH, et al. Recognition of benztropine by the dopamine transporter (DAT) differs from that of the classical dopamine uptake inhibitors cocaine, methylphenidate, and mazindol as a function of a DAT transmembrane 1 aspartic acid residue. J Pharmacol Exp Ther. 2005 Aug;314(2):575-83. PMID: 15879005.

 

Wieczorek WJ, Kruk ZL. A quantitative comparison on the effects of benztropine, cocaine and nomifensine on electrically evoked dopamine overflow and rate of re-uptake in the caudate putamen and nucleus accumbens in the rat brain slice. Brain Res. 1994  19;657(1-2):42-50. PMID: 7820642.

" Not dangerous goods.

LKT A7868 Atropine 1 g 36.4 Tropane alkaloid found in plants in the Solanaceae family; mAChR antagonist. 51-55-8 ≥98% 289.37 C17H23NO3 CN1C2CCC1CC(C2)OC(=O)C(CO)C3=CC=CC=C3 Ambient Ambient "Ghelardini C, Malmberg-Aiello P, Giotti A, et al. Investigation into atropine-induced antinociception. Br J Pharmacol. 1990 Sep;101(1):49-54. PMID: 2282466.

 

Alberts P, Ogren VR. Interaction of forskolin with the effect of atropine on [3H]acetylcholine secretion in guinea-pig ileum myenteric plexus. J Physiol. 1988 Jan;395:441-53. PMID: 2457681.

 

Berti F, Folco GC, Giachetti A, et al. Atropine inhibits thromboxane A2 generation in isolated lungs of the guinea-pig. Br J Pharmacol. 1980 Mar;68(3):467-72. PMID: 7052339.

" "UN number: 1544     Class: 6.1     Packing group: II

Proper shipping name: Alkaloids, solid, n.o.s. (atropine)

Marine pollutant: no     Poison inhalation hazard: yes"

LKT A7868 Atropine 5 g 72.8 Tropane alkaloid found in plants in the Solanaceae family; mAChR antagonist. 51-55-8 ≥98% 289.37 C17H23NO3 CN1C2CCC1CC(C2)OC(=O)C(CO)C3=CC=CC=C3 Ambient Ambient "Ghelardini C, Malmberg-Aiello P, Giotti A, et al. Investigation into atropine-induced antinociception. Br J Pharmacol. 1990 Sep;101(1):49-54. PMID: 2282466.

 

Alberts P, Ogren VR. Interaction of forskolin with the effect of atropine on [3H]acetylcholine secretion in guinea-pig ileum myenteric plexus. J Physiol. 1988 Jan;395:441-53. PMID: 2457681.

 

Berti F, Folco GC, Giachetti A, et al. Atropine inhibits thromboxane A2 generation in isolated lungs of the guinea-pig. Br J Pharmacol. 1980 Mar;68(3):467-72. PMID: 7052339.

" "UN number: 1544     Class: 6.1     Packing group: II

Proper shipping name: Alkaloids, solid, n.o.s. (atropine)

Marine pollutant: no     Poison inhalation hazard: yes"

LKT A7868 Atropine 25 g 297.3 Tropane alkaloid found in plants in the Solanaceae family; mAChR antagonist. 51-55-8 ≥98% 289.37 C17H23NO3 CN1C2CCC1CC(C2)OC(=O)C(CO)C3=CC=CC=C3 Ambient Ambient "Ghelardini C, Malmberg-Aiello P, Giotti A, et al. Investigation into atropine-induced antinociception. Br J Pharmacol. 1990 Sep;101(1):49-54. PMID: 2282466.

 

Alberts P, Ogren VR. Interaction of forskolin with the effect of atropine on [3H]acetylcholine secretion in guinea-pig ileum myenteric plexus. J Physiol. 1988 Jan;395:441-53. PMID: 2457681.

 

Berti F, Folco GC, Giachetti A, et al. Atropine inhibits thromboxane A2 generation in isolated lungs of the guinea-pig. Br J Pharmacol. 1980 Mar;68(3):467-72. PMID: 7052339.

" "UN number: 1544     Class: 6.1     Packing group: II

Proper shipping name: Alkaloids, solid, n.o.s. (atropine)

Marine pollutant: no     Poison inhalation hazard: yes"

LKT A7868 Atropine 100 g 788.7 Tropane alkaloid found in plants in the Solanaceae family; mAChR antagonist. 51-55-8 ≥98% 289.37 C17H23NO3 CN1C2CCC1CC(C2)OC(=O)C(CO)C3=CC=CC=C3 Ambient Ambient "Ghelardini C, Malmberg-Aiello P, Giotti A, et al. Investigation into atropine-induced antinociception. Br J Pharmacol. 1990 Sep;101(1):49-54. PMID: 2282466.

 

Alberts P, Ogren VR. Interaction of forskolin with the effect of atropine on [3H]acetylcholine secretion in guinea-pig ileum myenteric plexus. J Physiol. 1988 Jan;395:441-53. PMID: 2457681.

 

Berti F, Folco GC, Giachetti A, et al. Atropine inhibits thromboxane A2 generation in isolated lungs of the guinea-pig. Br J Pharmacol. 1980 Mar;68(3):467-72. PMID: 7052339.

" "UN number: 1544     Class: 6.1     Packing group: II

Proper shipping name: Alkaloids, solid, n.o.s. (atropine)

Marine pollutant: no     Poison inhalation hazard: yes"

LKT P0110 (R)-P7C3-OMe 5 mg 118.9 Methoxy aminopropyl carbazole, neuroprotective. O-methoxy-P7C3, P7C3-OMe 1325481-43-2 ≥98% 504.21 C22H20Br2N2O2 Ambient 4°C "Walker AK, Rivera PD, Wang Q, et al. The P7C3 class of neuroprotective compounds exerts antidepressant efficacy in mice by increasing hippocampal neurogenesis. Mol Psychiatry. 2014 Apr 22. [Epub ahead of print]. PMID: 24751964.

 

De Jesús-Cortés H, Xu P, Drawbridge J, et al. Neuroprotective efficacy of aminopropyl carbazoles in a mouse model of Parkinson disease. Proc Natl Acad Sci U S A. 2012 Oct 16;109(42):17010-5. PMID: 23027934.

 

Tesla R, Wolf HP, Xu P, et al. Neuroprotective efficacy of aminopropyl carbazoles in a mouse model of amyotrophic lateral sclerosis. Proc Natl Acad Sci U S A. 2012 Oct 16;109(42):17016-21. PMID: 23027932.

" Not dangerous goods.

LKT P0110 (R)-P7C3-OMe 25 mg 467.1 Methoxy aminopropyl carbazole, neuroprotective. O-methoxy-P7C3, P7C3-OMe 1325481-43-2 ≥98% 504.21 C22H20Br2N2O2 Ambient 4°C "Walker AK, Rivera PD, Wang Q, et al. The P7C3 class of neuroprotective compounds exerts antidepressant efficacy in mice by increasing hippocampal neurogenesis. Mol Psychiatry. 2014 Apr 22. [Epub ahead of print]. PMID: 24751964.

 

De Jesús-Cortés H, Xu P, Drawbridge J, et al. Neuroprotective efficacy of aminopropyl carbazoles in a mouse model of Parkinson disease. Proc Natl Acad Sci U S A. 2012 Oct 16;109(42):17010-5. PMID: 23027934.

 

Tesla R, Wolf HP, Xu P, et al. Neuroprotective efficacy of aminopropyl carbazoles in a mouse model of amyotrophic lateral sclerosis. Proc Natl Acad Sci U S A. 2012 Oct 16;109(42):17016-21. PMID: 23027932.

" Not dangerous goods.

LKT P0109 P7C3A20 5 mg 118.9 Fluorinated aminopropyl carbazole, neuroprotective. 1235481-90-9 ≥94% 506.21 C22H19Br2FN2O Ambient "Walker AK, Rivera PD, Wang Q, et al. The P7C3 class of neuroprotective compounds exerts antidepressant efficacy in mice by increasing hippocampal neurogenesis. Mol Psychiatry. 2014 Apr 22. [Epub ahead of print]. PMID: 24751964.

 

Blaya MO, Bramlett HM, Naidoo J, et al. Neuroprotective efficacy of a proneurogenic compound after traumatic brain injury. J Neurotrauma. 2014 Mar 1;31(5):476-86. PMID: 24070637.

 

De Jesús-Cortés H, Xu P, Drawbridge J, et al. Neuroprotective efficacy of aminopropyl carbazoles in a mouse model of Parkinson disease. Proc Natl Acad Sci U S A. 2012 Oct 16;109(42):17010-5. PMID: 23027934.

 

Tesla R, Wolf HP, Xu P, et al. Neuroprotective efficacy of aminopropyl carbazoles in a mouse model of amyotrophic lateral sclerosis. Proc Natl Acad Sci U S A. 2012 Oct 16;109(42):17016-21. PMID: 23027932.

" Not dangerous goods.

LKT P0109 P7C3A20 25 mg 467.1 Fluorinated aminopropyl carbazole, neuroprotective. 1235481-90-9 ≥94% 506.21 C22H19Br2FN2O Ambient "Walker AK, Rivera PD, Wang Q, et al. The P7C3 class of neuroprotective compounds exerts antidepressant efficacy in mice by increasing hippocampal neurogenesis. Mol Psychiatry. 2014 Apr 22. [Epub ahead of print]. PMID: 24751964.

 

Blaya MO, Bramlett HM, Naidoo J, et al. Neuroprotective efficacy of a proneurogenic compound after traumatic brain injury. J Neurotrauma. 2014 Mar 1;31(5):476-86. PMID: 24070637.

 

De Jesús-Cortés H, Xu P, Drawbridge J, et al. Neuroprotective efficacy of aminopropyl carbazoles in a mouse model of Parkinson disease. Proc Natl Acad Sci U S A. 2012 Oct 16;109(42):17010-5. PMID: 23027934.

 

Tesla R, Wolf HP, Xu P, et al. Neuroprotective efficacy of aminopropyl carbazoles in a mouse model of amyotrophic lateral sclerosis. Proc Natl Acad Sci U S A. 2012 Oct 16;109(42):17016-21. PMID: 23027932.

" Not dangerous goods.

LKT M2400 MG-132 5 mg 91 Proteasome inhibitor. MG-132 133407-82-6 ≥98% 475.62 C26H41N3O5 CC(C)CC(C=O)NC(=O)C(CC(C)C)NC(=O)C(CC(C)C)NC(=O)OCC1=CC=CC=C1 Ambient -20°C "Zhu B, Jin Y, Han L, et al. Proteasome inhibitor inhibits proliferation and induces apoptosis in renal interstitial fibroblasts. Pharmacol Rep. 2013;65(5):1357-65. PMID: 24399732.

 

Ma BM, Liu ZH, Liang ZK, et al. The proteasome inhibitor MG132 attenuates skeletal muscle atrophy in a rat model of chronic obstructive pulmonary disease. Zhonghua Jie He He Hu Xi Za Zhi. 2013 Jun;36(6):441-6. PMID: 24103208.

 

Quan R, Huang Z, Yue Z, et al. Effects of a proteasome inhibitor on the NF-κB signalling pathway in experimental osteoarthritis. Scand J Rheumatol. 2013;42(5):400-7. PMID: 23826657.

" Not dangerous goods.

LKT M2400 MG-132 25 mg 345.8 Proteasome inhibitor. MG-132 133407-82-6 ≥98% 475.62 C26H41N3O5 CC(C)CC(C=O)NC(=O)C(CC(C)C)NC(=O)C(CC(C)C)NC(=O)OCC1=CC=CC=C1 Ambient -20°C "Zhu B, Jin Y, Han L, et al. Proteasome inhibitor inhibits proliferation and induces apoptosis in renal interstitial fibroblasts. Pharmacol Rep. 2013;65(5):1357-65. PMID: 24399732.

 

Ma BM, Liu ZH, Liang ZK, et al. The proteasome inhibitor MG132 attenuates skeletal muscle atrophy in a rat model of chronic obstructive pulmonary disease. Zhonghua Jie He He Hu Xi Za Zhi. 2013 Jun;36(6):441-6. PMID: 24103208.

 

Quan R, Huang Z, Yue Z, et al. Effects of a proteasome inhibitor on the NF-κB signalling pathway in experimental osteoarthritis. Scand J Rheumatol. 2013;42(5):400-7. PMID: 23826657.

" Not dangerous goods.

LKT A4646 ALLN 5 mg 91 Calpain I/II inhibitor. Calpain inhibitor 1, Ac-LLnL-CHO, MG-101, N-Acetyl-Leu-Leu-Norleu-al, N-Acetyl-L-leucyl-L-leucyl-L-norleucinal 110044-82-1 ≥98% 383.53 C20H37N3O4 CCCCC(C=O)NC(=O)C(CC(C)C)NC(=O)C(CC(C)C)NC(=O)C Ambient -20°C "Kaneko Y, Murphy CR, Day ML. Calpain 2 activity increases at the time of implantation in rat uterine luminal epithelial cells and administration of calpain inhibitor significantly reduces implantation sites. Histochem Cell Biol. 2014 Apr;141(4):423-30. PMID: 24271063.

 

Chatterjee C, Sparks DL. Hepatic Lipase Release is Inhibited by a Purinergic Induction of Autophagy. Cell Physiol Biochem. 2014 Mar 28;33(4):883-894. PMID: 24713587.

 

Ariyadi B, Isobe N, Yoshimura Y. Toll-like receptor signaling for the induction of mucin expression by lipopolysaccharide in the hen vagina. Poult Sci. 2014 Mar;93(3):673-9. PMID: 24604861.

 

Li SZ, Zhang HH, Zhang JN, et al. ALLN hinders HCT116 tumor growth through Bax-dependent apoptosis. Biochem Biophys Res Commun. 2013 Jul 26;437(2):325-30. PMID: 23831472.

" Not dangerous goods.

LKT A4646 ALLN 25 mg 333.7 Calpain I/II inhibitor. Calpain inhibitor 1, Ac-LLnL-CHO, MG-101, N-Acetyl-Leu-Leu-Norleu-al, N-Acetyl-L-leucyl-L-leucyl-L-norleucinal 110044-82-1 ≥98% 383.53 C20H37N3O4 CCCCC(C=O)NC(=O)C(CC(C)C)NC(=O)C(CC(C)C)NC(=O)C Ambient -20°C "Kaneko Y, Murphy CR, Day ML. Calpain 2 activity increases at the time of implantation in rat uterine luminal epithelial cells and administration of calpain inhibitor significantly reduces implantation sites. Histochem Cell Biol. 2014 Apr;141(4):423-30. PMID: 24271063.

 

Chatterjee C, Sparks DL. Hepatic Lipase Release is Inhibited by a Purinergic Induction of Autophagy. Cell Physiol Biochem. 2014 Mar 28;33(4):883-894. PMID: 24713587.

 

Ariyadi B, Isobe N, Yoshimura Y. Toll-like receptor signaling for the induction of mucin expression by lipopolysaccharide in the hen vagina. Poult Sci. 2014 Mar;93(3):673-9. PMID: 24604861.

 

Li SZ, Zhang HH, Zhang JN, et al. ALLN hinders HCT116 tumor growth through Bax-dependent apoptosis. Biochem Biophys Res Commun. 2013 Jul 26;437(2):325-30. PMID: 23831472.

" Not dangerous goods.

LKT A1607 AEBSF Hydrochloride 25 mg 42.4 Serine protease substrate/inhibitor. 4-(2-Aminoethyl)benzenesulfonyl fluoride hydrochloride, Pefabloc 30827-99-7 ≥98% 239.69 C8H10FNO2S HCl C1=CC(=CC=C1CCN)S(=O)(=O)F.Cl Ambient -20°C "Monnappa AK, Dwidar M, Seo JK, et al. Bdellovibrio bacteriovorus inhibits Staphylococcus aureus biofilm formation and invasion into human epithelial cells. Sci Rep. 2014 Jan 22;4:3811. PMID: 24448451.

 

Wang R, Liu S, Wang J, et al. Purification, characterization and identification of a senescence related serine protease in dark-induced senescent wheat leaves. Phytochemistry. 2013 Nov;95:118-26. PMID: 23910959.

" "UN number: 3261     Class: 8     Packing Group: II

Proper shipping name: Corrosive solid, acidic, organic, n.o.s. (AEBSF hydrochloride)"

LKT A1607 AEBSF Hydrochloride 100 mg 121.4 Serine protease substrate/inhibitor. 4-(2-Aminoethyl)benzenesulfonyl fluoride hydrochloride, Pefabloc 30827-99-7 ≥98% 239.69 C8H10FNO2S HCl C1=CC(=CC=C1CCN)S(=O)(=O)F.Cl Ambient -20°C "Monnappa AK, Dwidar M, Seo JK, et al. Bdellovibrio bacteriovorus inhibits Staphylococcus aureus biofilm formation and invasion into human epithelial cells. Sci Rep. 2014 Jan 22;4:3811. PMID: 24448451.

 

Wang R, Liu S, Wang J, et al. Purification, characterization and identification of a senescence related serine protease in dark-induced senescent wheat leaves. Phytochemistry. 2013 Nov;95:118-26. PMID: 23910959.

" "UN number: 3261     Class: 8     Packing Group: II

Proper shipping name: Corrosive solid, acidic, organic, n.o.s. (AEBSF hydrochloride)"

LKT A1607 AEBSF Hydrochloride 500 mg 479.3 Serine protease substrate/inhibitor. 4-(2-Aminoethyl)benzenesulfonyl fluoride hydrochloride, Pefabloc 30827-99-7 ≥98% 239.69 C8H10FNO2S HCl C1=CC(=CC=C1CCN)S(=O)(=O)F.Cl Ambient -20°C "Monnappa AK, Dwidar M, Seo JK, et al. Bdellovibrio bacteriovorus inhibits Staphylococcus aureus biofilm formation and invasion into human epithelial cells. Sci Rep. 2014 Jan 22;4:3811. PMID: 24448451.

 

Wang R, Liu S, Wang J, et al. Purification, characterization and identification of a senescence related serine protease in dark-induced senescent wheat leaves. Phytochemistry. 2013 Nov;95:118-26. PMID: 23910959.

" "UN number: 3261     Class: 8     Packing Group: II

Proper shipping name: Corrosive solid, acidic, organic, n.o.s. (AEBSF hydrochloride)"

LKT T8006 Tubastatin A Hydrochloride 5 mg 177.1 HDAC6/10 inhibitor. Tubastatin A HCl 1310693-92-5 ≥98% 371.86 C20H21N3O2  HCl CN1CCC2=C(C1)C3=CC=CC=C3N2CC4=CC=C(C=C4)C(=O)NO.Cl Ambient -20°C "Zhang D, Wu CT, Qi X, et al. Activation of histone deacetylase-6 induces contractile dysfunction through derailment of α-tubulin proteostasis in experimental and human atrial fibrillation. Circulation. 2014 Jan 21;129(3):346-58. PMID: 24146251.

 

Gradilone SA, Radtke BN, Bogert PS, et al. HDAC6 inhibition restores ciliary expression and decreases tumor growth. Cancer Res. 2013 Apr 1;73(7):2259-70. PMID: 23370327.

" Not dangerous goods.

LKT T8006 Tubastatin A Hydrochloride 10 mg 283.9 HDAC6/10 inhibitor. Tubastatin A HCl 1310693-92-5 ≥98% 371.86 C20H21N3O2  HCl CN1CCC2=C(C1)C3=CC=CC=C3N2CC4=CC=C(C=C4)C(=O)NO.Cl Ambient -20°C "Zhang D, Wu CT, Qi X, et al. Activation of histone deacetylase-6 induces contractile dysfunction through derailment of α-tubulin proteostasis in experimental and human atrial fibrillation. Circulation. 2014 Jan 21;129(3):346-58. PMID: 24146251.

 

Gradilone SA, Radtke BN, Bogert PS, et al. HDAC6 inhibition restores ciliary expression and decreases tumor growth. Cancer Res. 2013 Apr 1;73(7):2259-70. PMID: 23370327.

" Not dangerous goods.

LKT Z0944 ZCL-278 5 mg 118.9 Cdc42 inhibitor. ZCL278 587841-73-4 ≥98% 584.89 C21H19BrClN5O4S2 CC1=CC(=NC(=N1)NS(=O)(=O)C2=CC=C(C=C2)NC(=S)NC(=O)COC3=C(C=C(C=C3)Br)Cl)C Ambient Friesland A, Zhao Y, Chen YH, et al. Small molecule targeting Cdc42-intersectin interaction disrupts Golgi organization and suppresses cell motility. Proc Natl Acad Sci U S A. 2013 Jan 22;110(4):1261-6. PMID: 23284167. Not dangerous goods.

LKT Z0944 ZCL-278 10 mg 189.3 Cdc42 inhibitor. ZCL278 587841-73-4 ≥98% 584.89 C21H19BrClN5O4S2 CC1=CC(=NC(=N1)NS(=O)(=O)C2=CC=C(C=C2)NC(=S)NC(=O)COC3=C(C=C(C=C3)Br)Cl)C Ambient Friesland A, Zhao Y, Chen YH, et al. Small molecule targeting Cdc42-intersectin interaction disrupts Golgi organization and suppresses cell motility. Proc Natl Acad Sci U S A. 2013 Jan 22;110(4):1261-6. PMID: 23284167. Not dangerous goods.

LKT Y4800 YM-155 5 mg 98.3 Survivin inhibitor. YM155, Sepantronium bromide 781661-94-7 ≥98% 443.29 C20H19N4O3Br CC1=[N+](C2=C(N1CCOC)C(=O)C3=CC=CC=C3C2=O)CC4=NC=CN=C4.[Br-] Ambient -20°C "Liang H, Zhang L, Xu R, et al. Silencing of survivin using YM155 induces apoptosis and chemosensitization in neuroblastomas cells. Eur Rev Med Pharmacol Sci. 2013 Nov;17(21):2909-15. PMID: 24254560.

 

Feng W, Yoshida A, Ueda T. YM155 induces caspase-8 dependent apoptosis through downregulation of survivin and Mcl-1 in human leukemia cells. Biochem Biophys Res Commun. 2013 May 24;435(1):52-7. PMID: 23618862.

 

Tolcher AW, Quinn DI, Ferrari A, et al. A phase II study of YM155, a novel small-molecule suppressor of survivin, in castration-resistant taxane-pretreated prostate cancer. Ann Oncol. 2012 Apr;23(4):968-73. PMID: 21859898.

" Not dangerous goods.

LKT Y4800 YM-155 10 mg 157.7 Survivin inhibitor. YM155, Sepantronium bromide 781661-94-7 ≥98% 443.29 C20H19N4O3Br CC1=[N+](C2=C(N1CCOC)C(=O)C3=CC=CC=C3C2=O)CC4=NC=CN=C4.[Br-] Ambient -20°C "Liang H, Zhang L, Xu R, et al. Silencing of survivin using YM155 induces apoptosis and chemosensitization in neuroblastomas cells. Eur Rev Med Pharmacol Sci. 2013 Nov;17(21):2909-15. PMID: 24254560.

 

Feng W, Yoshida A, Ueda T. YM155 induces caspase-8 dependent apoptosis through downregulation of survivin and Mcl-1 in human leukemia cells. Biochem Biophys Res Commun. 2013 May 24;435(1):52-7. PMID: 23618862.

 

Tolcher AW, Quinn DI, Ferrari A, et al. A phase II study of YM155, a novel small-molecule suppressor of survivin, in castration-resistant taxane-pretreated prostate cancer. Ann Oncol. 2012 Apr;23(4):968-73. PMID: 21859898.

" Not dangerous goods.

LKT T3584 Tivantinib 5 mg 197.7 MET and GSK-3α/β inhibitor. ARQ-197 1000873-98-2 ≥98% 369.42 C23H19N3O2 C1CC2=CC=CC3=C2N(C1)C=C3C4C(C(=O)NC4=O)C5=CNC6=CC=CC=C65 Ambient -20°C "Remsing Rix LL, Kuenzi BM, Luo Y, et al. GSK3 alpha and beta are new functionally relevant targets of tivantinib in lung cancer cells. ACS Chem Biol. 2014 Feb 21;9(2):353-8. PMID: 24215125.

 

Rimassa L, Personeni N, Simonelli M, et al. Tivantinib: a new promising mesenchymal-epithelial transition factor inhibitor in the treatment of hepatocellular carcinoma. Future Oncol. 2013 Feb;9(2):153-65. PMID: 23414466.

 

Bagai R, Fan W, Ma PC. ARQ-197, an oral small-molecule inhibitor of c-Met for the treatment of solid tumors. IDrugs. 2010 Jun;13(6):404-14. PMID: 20506063.

" Not dangerous goods.

LKT T3584 Tivantinib 10 mg 315.5 MET and GSK-3α/β inhibitor. ARQ-197 1000873-98-2 ≥98% 369.42 C23H19N3O2 C1CC2=CC=CC3=C2N(C1)C=C3C4C(C(=O)NC4=O)C5=CNC6=CC=CC=C65 Ambient -20°C "Remsing Rix LL, Kuenzi BM, Luo Y, et al. GSK3 alpha and beta are new functionally relevant targets of tivantinib in lung cancer cells. ACS Chem Biol. 2014 Feb 21;9(2):353-8. PMID: 24215125.

 

Rimassa L, Personeni N, Simonelli M, et al. Tivantinib: a new promising mesenchymal-epithelial transition factor inhibitor in the treatment of hepatocellular carcinoma. Future Oncol. 2013 Feb;9(2):153-65. PMID: 23414466.

 

Bagai R, Fan W, Ma PC. ARQ-197, an oral small-molecule inhibitor of c-Met for the treatment of solid tumors. IDrugs. 2010 Jun;13(6):404-14. PMID: 20506063.

" Not dangerous goods.

LKT T3132 Thiazovivin 5 mg 197.7 ROCK inhibitor. 1226056-71-8 ≥98% 311.36 C15H13N5OS C1=CC=C(C=C1)CNC(=O)C2=CSC(=N2)NC3=NC=NC=C3 Ambient -20°C "Wang F, Scoville D, He XC, et al. Isolation and characterization of intestinal stem cells based on surface marker combinations and colony-formation assay. Gastroenterology. 2013 Aug;145(2):383-95.e1-21. PMID: 23644405.

 

Groß B, Sgodda M, Rasche M, et al. Improved generation of patient-specific induced pluripotent stem cells using a chemically-defined and matrigel-based approach. Curr Mol Med. 2013 Jun;13(5):765-76. PMID: 23642058.

 

Zhu J, Pang D, Zhou Y, et al. Direct conversion of porcine embryonic fibroblasts into adipocytes by chemical molecules. Cell Reprogram. 2012 Apr;14(2):99-105. PMID: 22372576.

" Not dangerous goods.

LKT T3132 Thiazovivin 10 mg 315.5 ROCK inhibitor. 1226056-71-8 ≥98% 311.36 C15H13N5OS C1=CC=C(C=C1)CNC(=O)C2=CSC(=N2)NC3=NC=NC=C3 Ambient -20°C "Wang F, Scoville D, He XC, et al. Isolation and characterization of intestinal stem cells based on surface marker combinations and colony-formation assay. Gastroenterology. 2013 Aug;145(2):383-95.e1-21. PMID: 23644405.

 

Groß B, Sgodda M, Rasche M, et al. Improved generation of patient-specific induced pluripotent stem cells using a chemically-defined and matrigel-based approach. Curr Mol Med. 2013 Jun;13(5):765-76. PMID: 23642058.

 

Zhu J, Pang D, Zhou Y, et al. Direct conversion of porcine embryonic fibroblasts into adipocytes by chemical molecules. Cell Reprogram. 2012 Apr;14(2):99-105. PMID: 22372576.

" Not dangerous goods.

LKT S2792 SGX-523 1 mg 70.4 MET inhibitor. SGX523 1022150-57-7 ≥98% 359.41 C18H13N7S CN1C=C(C=N1)C2=NN3C(=NN=C3SC4=CC5=C(C=C4)N=CC=C5)C=C2 Ambient -20°C "Zhang YW, Staal B, Essenburg C, et al. Strengthening context-dependent anticancer effects on non-small cell lung carcinoma by inhibition of both MET and EGFR. Mol Cancer Ther. 2013 Aug;12(8):1429-41. PMID: 23720767.

 

Zhang YW, Staal B, Essenburg C, et al. MET kinase inhibitor SGX523 synergizes with epidermal growth factor receptor inhibitor erlotinib in a hepatocyte growth factor-dependent fashion to suppress carcinoma growth. Cancer Res. 2010 Sep 1;70(17):6880-90. Erratum in: Cancer Res. 2011 Apr 1;71(7):2804.  PMID: 20643778.

 

Buchanan SG, Hendle J, Lee PS, et al. SGX523 is an exquisitely selective, ATP-competitive inhibitor of the MET receptor tyrosine kinase with antitumor activity in vivo. Mol Cancer Ther. 2009 Dec;8(12):3181-90. PMID: 19934279.

" Not dangerous goods.

LKT S2792 SGX-523 5 mg 245.2 MET inhibitor. SGX523 1022150-57-7 ≥98% 359.41 C18H13N7S CN1C=C(C=N1)C2=NN3C(=NN=C3SC4=CC5=C(C=C4)N=CC=C5)C=C2 Ambient -20°C "Zhang YW, Staal B, Essenburg C, et al. Strengthening context-dependent anticancer effects on non-small cell lung carcinoma by inhibition of both MET and EGFR. Mol Cancer Ther. 2013 Aug;12(8):1429-41. PMID: 23720767.

 

Zhang YW, Staal B, Essenburg C, et al. MET kinase inhibitor SGX523 synergizes with epidermal growth factor receptor inhibitor erlotinib in a hepatocyte growth factor-dependent fashion to suppress carcinoma growth. Cancer Res. 2010 Sep 1;70(17):6880-90. Erratum in: Cancer Res. 2011 Apr 1;71(7):2804.  PMID: 20643778.

 

Buchanan SG, Hendle J, Lee PS, et al. SGX523 is an exquisitely selective, ATP-competitive inhibitor of the MET receptor tyrosine kinase with antitumor activity in vivo. Mol Cancer Ther. 2009 Dec;8(12):3181-90. PMID: 19934279.

" Not dangerous goods.

LKT S0500 SB-203580 5 mg 54.6 p38 MAPK inhibitor. SB203580 152121-47-6 ≥98% 377.43 C21H16FN3OS CS(=O)C1=CC=C(C=C1)C2=NC(=C(N2)C3=CC=NC=C3)C4=CC=C(C=C4)F Ambient -20°C "Kühnöl C, Herbarth M, Föll J, et al. CD137 stimulation and p38 MAPK inhibition improve reactivity in an in vitro model of glioblastoma immunotherapy. Cancer Immunol Immunother. 2013 Dec;62(12):1797-809. PMID: 24129764.

 

Chen HH, Zhou XL, Shi YL, et al. Roles of p38 MAPK and JNK in TGF-β1-induced human alveolar epithelial to mesenchymal transition. Arch Med Res. 2013 Feb;44(2):93-8. PMID: 23376055.

 

Morales MG, Vazquez Y, Acuña MJ, et al. Angiotensin II-induced pro-fibrotic effects require p38MAPK activity and transforming growth factor beta 1 expression in skeletal muscle cells. Int J Biochem Cell Biol. 2012 Nov;44(11):1993-2002. PMID: 22964022.

" Not dangerous goods.

LKT S0500 SB-203580 25 mg 189.3 p38 MAPK inhibitor. SB203580 152121-47-6 ≥98% 377.43 C21H16FN3OS CS(=O)C1=CC=C(C=C1)C2=NC(=C(N2)C3=CC=NC=C3)C4=CC=C(C=C4)F Ambient -20°C "Kühnöl C, Herbarth M, Föll J, et al. CD137 stimulation and p38 MAPK inhibition improve reactivity in an in vitro model of glioblastoma immunotherapy. Cancer Immunol Immunother. 2013 Dec;62(12):1797-809. PMID: 24129764.

 

Chen HH, Zhou XL, Shi YL, et al. Roles of p38 MAPK and JNK in TGF-β1-induced human alveolar epithelial to mesenchymal transition. Arch Med Res. 2013 Feb;44(2):93-8. PMID: 23376055.

 

Morales MG, Vazquez Y, Acuña MJ, et al. Angiotensin II-induced pro-fibrotic effects require p38MAPK activity and transforming growth factor beta 1 expression in skeletal muscle cells. Int J Biochem Cell Biol. 2012 Nov;44(11):1993-2002. PMID: 22964022.

" Not dangerous goods.

LKT R4132 RKI-1447 1 mg 69.2 ROCK1/2 inhibitor. RKI1447 1342278-01-6 ≥98% 326.37 C16H14N4O2S C1=CC(=CC(=C1)O)CNC(=O)NC2=NC(=CS2)C3=CC=NC=C3 Ambient -20°C Patel RA, Forinash KD, Pireddu R, et al. RKI-1447 is a potent inhibitor of the Rho-associated ROCK kinases with anti-invasive and antitumor activities in breast cancer. Cancer Res. 2012 Oct 1;72(19):5025-34. PMID: 22846914. Not dangerous goods.

LKT R4132 RKI-1447 5 mg 236.6 ROCK1/2 inhibitor. RKI1447 1342278-01-6 ≥98% 326.37 C16H14N4O2S C1=CC(=CC(=C1)O)CNC(=O)NC2=NC(=CS2)C3=CC=NC=C3 Ambient -20°C Patel RA, Forinash KD, Pireddu R, et al. RKI-1447 is a potent inhibitor of the Rho-associated ROCK kinases with anti-invasive and antitumor activities in breast cancer. Cancer Res. 2012 Oct 1;72(19):5025-34. PMID: 22846914. Not dangerous goods.

LKT R3476 RITA 5 mg 148.1 p53 activator. Reactivation of p53 and induction of tumor cell apoptosis 213261-59-7 ≥98% 292.37 C14H12O3S2 C1=C(SC(=C1)C2=CC=C(O2)C3=CC=C(S3)CO)CO Ambient -20°C "Burmakin M, Shi Y, Hedström E, et al. Dual targeting of wild-type and mutant p53 by small molecule RITA results in the inhibition of N-Myc and key survival oncogenes and kills neuroblastoma cells in vivo and in vitro. Clin Cancer Res. 2013 Sep 15;19(18):5092-103. PMID: 23864164.

 

Henze J, Mühlenberg T, Simon S, et al. p53 modulation as a therapeutic strategy in gastrointestinal stromal tumors. PLoS One. 2012;7(5):e37776. PMID: 22662219.

 

Zhao CY, Szekely L, Bao W, et al. Rescue of p53 function by small-molecule RITA in cervical carcinoma by blocking E6-mediated degradation. Cancer Res. 2010 Apr 15;70(8):3372-81. PMID: 20395210.

 

Yang J, Ahmed A, Poon E, et al. Small-molecule activation of p53 blocks hypoxia-inducible factor 1alpha and vascular endothelial growth factor expression in vivo and leads to tumor cell apoptosis in normoxia and hypoxia. Mol Cell Biol. 2009 Apr;29(8):2243-53. PMID: 19223463.

" Not dangerous goods.

LKT R3476 RITA 10 mg 236.6 p53 activator. Reactivation of p53 and induction of tumor cell apoptosis 213261-59-7 ≥98% 292.37 C14H12O3S2 C1=C(SC(=C1)C2=CC=C(O2)C3=CC=C(S3)CO)CO Ambient -20°C "Burmakin M, Shi Y, Hedström E, et al. Dual targeting of wild-type and mutant p53 by small molecule RITA results in the inhibition of N-Myc and key survival oncogenes and kills neuroblastoma cells in vivo and in vitro. Clin Cancer Res. 2013 Sep 15;19(18):5092-103. PMID: 23864164.

 

Henze J, Mühlenberg T, Simon S, et al. p53 modulation as a therapeutic strategy in gastrointestinal stromal tumors. PLoS One. 2012;7(5):e37776. PMID: 22662219.

 

Zhao CY, Szekely L, Bao W, et al. Rescue of p53 function by small-molecule RITA in cervical carcinoma by blocking E6-mediated degradation. Cancer Res. 2010 Apr 15;70(8):3372-81. PMID: 20395210.

 

Yang J, Ahmed A, Poon E, et al. Small-molecule activation of p53 blocks hypoxia-inducible factor 1alpha and vascular endothelial growth factor expression in vivo and leads to tumor cell apoptosis in normoxia and hypoxia. Mol Cell Biol. 2009 Apr;29(8):2243-53. PMID: 19223463.

" Not dangerous goods.

LKT P3076 PHT-427 5 mg 49.8 PDK1 and Akt inhibitor. PHT427 1191951-57-1 ≥98% 409.61 C20H31N3O2S2 CCCCCCCCCCCCC1=CC=C(C=C1)S(=O)(=O)NC2=NN=CS2 Ambient -20°C Meuillet EJ, Zuohe S, Lemos R, et al. Molecular pharmacology and antitumor activity of PHT-427, a novel Akt/phosphatidylinositide-dependent protein kinase 1 pleckstrin homology domain inhibitor. Mol Cancer Ther. 2010 Mar;9(3):706-17. PMID: 20197390. Not dangerous goods.

LKT P3076 PHT-427 10 mg 78.9 PDK1 and Akt inhibitor. PHT427 1191951-57-1 ≥98% 409.61 C20H31N3O2S2 CCCCCCCCCCCCC1=CC=C(C=C1)S(=O)(=O)NC2=NN=CS2 Ambient -20°C Meuillet EJ, Zuohe S, Lemos R, et al. Molecular pharmacology and antitumor activity of PHT-427, a novel Akt/phosphatidylinositide-dependent protein kinase 1 pleckstrin homology domain inhibitor. Mol Cancer Ther. 2010 Mar;9(3):706-17. PMID: 20197390. Not dangerous goods.

LKT P2133 PFI-1 5 mg 118.9 Acyl-lysine (Kac) mimetic; BRD2/4 inhibitor. PF-06405761 1403764-72-6 ≥98% 347.39 C16H17N3O4S CN1CC2=C(C=CC(=C2)NS(=O)(=O)C3=CC=CC=C3OC)NC1=O Ambient -20°C "Khan YM, Kirkham P, Barnes PJ, et al. Brd4 Is Essential for IL-1β-Induced Inflammation in Human Airway Epithelial Cells. PLoS One. 2014 Apr 23;9(4):e95051. PMID: 24759736.

 

Picaud S, Da Costa D, Thanasopoulou A, et al. PFI-1, a highly selective protein interaction inhibitor, targeting BET Bromodomains. Cancer Res. 2013 Jun 1;73(11):3336-46. PMID: 23576556.

" Not dangerous goods.

LKT P2133 PFI-1 10 mg 189.3 Acyl-lysine (Kac) mimetic; BRD2/4 inhibitor. PF-06405761 1403764-72-6 ≥98% 347.39 C16H17N3O4S CN1CC2=C(C=CC(=C2)NS(=O)(=O)C3=CC=CC=C3OC)NC1=O Ambient -20°C "Khan YM, Kirkham P, Barnes PJ, et al. Brd4 Is Essential for IL-1β-Induced Inflammation in Human Airway Epithelial Cells. PLoS One. 2014 Apr 23;9(4):e95051. PMID: 24759736.

 

Picaud S, Da Costa D, Thanasopoulou A, et al. PFI-1, a highly selective protein interaction inhibitor, targeting BET Bromodomains. Cancer Res. 2013 Jun 1;73(11):3336-46. PMID: 23576556.

" Not dangerous goods.

LKT N8277 Nutlin-3 1 mg 41.3 Imidzoline derivative; MDM2 inhibitor. Nutlin3 548472-68-0 ≥98% 581.49 C30H30Cl2N4O4 CC(C)OC1=C(C=CC(=C1)OC)C2=NC(C(N2C(=O)N3CCNC(=O)C3)C4=CC=C(C=C4)Cl)C5=CC=C(C=C5)Cl Ambient -20°C "Shi X, Liu J, Ren L, et al. Nutlin-3 downregulates p53 phosphorylation on serine(392) and induces apoptosis in hepatocellular carcinoma cells. BMB Rep. 2014 Apr;47(4):221-6. PMID: 24286312.

 

Choe YJ, Lee SY, Ko KW, et al. Nutlin-3 induces HO-1 expression by activating JNK in a transcription-independent manner of p53. Int J Oncol. 2014 Mar;44(3):761-8. PMID: 24366007.

 

Wu Y, Fu Y, Zheng L, et al. Nutlin-3 inhibits epithelial-mesenchymal transition by interfering with canonical transforming growth factor-β1-Smad-Snail/Slug axis. Cancer Lett. 2014 Jan 1;342(1):82-91. PMID: 24001610.

 

Secchiero P, Toffoli B, Melloni E, et al. The MDM2 inhibitor Nutlin-3 attenuates streptozotocin-induced diabetes mellitus and increases serum level of IL-12p40. Acta Diabetol. 2013 Dec;50(6):899-906. PMID: 23615706.

 

Tisato V, Norcio A, Voltan R, et al. MDM2 non-genotoxic inhibitors as innovative therapeutic approaches for the treatment of pediatric malignancies. Curr Med Chem. 2013;20(17):2226-36. PMID: 23458617.

" Not dangerous goods.

LKT N8277 Nutlin-3 5 mg 142 Imidzoline derivative; MDM2 inhibitor. Nutlin3 548472-68-0 ≥98% 581.49 C30H30Cl2N4O4 CC(C)OC1=C(C=CC(=C1)OC)C2=NC(C(N2C(=O)N3CCNC(=O)C3)C4=CC=C(C=C4)Cl)C5=CC=C(C=C5)Cl Ambient -20°C "Shi X, Liu J, Ren L, et al. Nutlin-3 downregulates p53 phosphorylation on serine(392) and induces apoptosis in hepatocellular carcinoma cells. BMB Rep. 2014 Apr;47(4):221-6. PMID: 24286312.

 

Choe YJ, Lee SY, Ko KW, et al. Nutlin-3 induces HO-1 expression by activating JNK in a transcription-independent manner of p53. Int J Oncol. 2014 Mar;44(3):761-8. PMID: 24366007.

 

Wu Y, Fu Y, Zheng L, et al. Nutlin-3 inhibits epithelial-mesenchymal transition by interfering with canonical transforming growth factor-β1-Smad-Snail/Slug axis. Cancer Lett. 2014 Jan 1;342(1):82-91. PMID: 24001610.

 

Secchiero P, Toffoli B, Melloni E, et al. The MDM2 inhibitor Nutlin-3 attenuates streptozotocin-induced diabetes mellitus and increases serum level of IL-12p40. Acta Diabetol. 2013 Dec;50(6):899-906. PMID: 23615706.

 

Tisato V, Norcio A, Voltan R, et al. MDM2 non-genotoxic inhibitors as innovative therapeutic approaches for the treatment of pediatric malignancies. Curr Med Chem. 2013;20(17):2226-36. PMID: 23458617.

" Not dangerous goods.

LKT N7209 NSC-207895 1 mg 69.2 Benzofuroxan derivative; MDMX inhibitor. Benzofurazan, 7-(4-methyl-1-piperazinyl)-4-nitro-, 1-oxide NSC207895 58131-57-0 ≥98% 279.25 C11H13N5O4 CN1CCN(CC1)C2=CC=C(C3=NO[N+](=C23)[O-])[N+](=O)[O-] Ambient -20°C Wang H, Ma X, Ren S, et al. A small-molecule inhibitor of MDMX activates p53 and induces apoptosis. Mol Cancer Ther. 2011 Jan;10(1):69-79. PMID: 21075910. Not dangerous goods.

LKT N7209 NSC-207895 5 mg 236.6 Benzofuroxan derivative; MDMX inhibitor. Benzofurazan, 7-(4-methyl-1-piperazinyl)-4-nitro-, 1-oxide NSC207895 58131-57-0 ≥98% 279.25 C11H13N5O4 CN1CCN(CC1)C2=CC=C(C3=NO[N+](=C23)[O-])[N+](=O)[O-] Ambient -20°C Wang H, Ma X, Ren S, et al. A small-molecule inhibitor of MDMX activates p53 and induces apoptosis. Mol Cancer Ther. 2011 Jan;10(1):69-79. PMID: 21075910. Not dangerous goods.

LKT M4004 MK-2461 1 mg 82.4 MET, FGFR, PDGFR inhibitor. MK2461 917879-39-1 ≥98% 495.55 C24H25N5N5S CN1C=C(C=N1)C2=CN=C3C=CC4=C(C=C(C=C4)NS(=O)(=O)N(C)CC5COCCO5)C(=O)C3=C2 Ambient -20°C "Katz JD, Jewell JP, Guerin DJ, et al. Discovery of a 5H-benzo[4,5]cyclohepta[1,2-b]pyridin-5-one (MK-2461) inhibitor of c-Met kinase for the treatment of cancer. J Med Chem. 2011 Jun 23;54(12):4092-108. PMID: 21608528.

 

Pan BS, Chan GK, Chenard M, et al. MK-2461, a novel multitargeted kinase inhibitor, preferentially inhibits the activated c-Met receptor. Cancer Res. 2010 Feb 15;70(4):1524-33. PMID: 20145145.

" Not dangerous goods.

LKT M4004 MK-2461 5 mg 283.9 MET, FGFR, PDGFR inhibitor. MK2461 917879-39-1 ≥98% 495.55 C24H25N5N5S CN1C=C(C=N1)C2=CN=C3C=CC4=C(C=C(C=C4)NS(=O)(=O)N(C)CC5COCCO5)C(=O)C3=C2 Ambient -20°C "Katz JD, Jewell JP, Guerin DJ, et al. Discovery of a 5H-benzo[4,5]cyclohepta[1,2-b]pyridin-5-one (MK-2461) inhibitor of c-Met kinase for the treatment of cancer. J Med Chem. 2011 Jun 23;54(12):4092-108. PMID: 21608528.

 

Pan BS, Chan GK, Chenard M, et al. MK-2461, a novel multitargeted kinase inhibitor, preferentially inhibits the activated c-Met receptor. Cancer Res. 2010 Feb 15;70(4):1524-33. PMID: 20145145.

" Not dangerous goods.

LKT L2540 LGK-974 1 mg 160.2 PORCN inhibitor. LGK974 1243244-14-5 ≥98% 396.44 C23H20N6O CC1=C(N=CC(=C1)CC(=O)NC2=NC=C(C=C2)C3=NC=CN=C3)C4=CC(=NC=C4)C Ambient -20°C "Liu J, Pan S, Hsieh MH, et al. Targeting Wnt-driven cancer through the inhibition of Porcupine by LGK974. Proc Natl Acad Sci U S A. 2013 Dec 10;110(50):20224-9. PMID: 24277854.

 

Jiang X, Hao HX, Growney JD, et al. Inactivating mutations of RNF43 confer Wnt dependency in pancreatic ductal adenocarcinoma. Proc Natl Acad Sci U S A. 2013 Jul 30;110(31):12649-54. PMID: 23847203.

" Not dangerous goods.

LKT L2540 LGK-974 5 mg 552.1 PORCN inhibitor. LGK974 1243244-14-5 ≥98% 396.44 C23H20N6O CC1=C(N=CC(=C1)CC(=O)NC2=NC=C(C=C2)C3=NC=CN=C3)C4=CC(=NC=C4)C Ambient -20°C "Liu J, Pan S, Hsieh MH, et al. Targeting Wnt-driven cancer through the inhibition of Porcupine by LGK974. Proc Natl Acad Sci U S A. 2013 Dec 10;110(50):20224-9. PMID: 24277854.

 

Jiang X, Hao HX, Growney JD, et al. Inactivating mutations of RNF43 confer Wnt dependency in pancreatic ductal adenocarcinoma. Proc Natl Acad Sci U S A. 2013 Jul 30;110(31):12649-54. PMID: 23847203.

" Not dangerous goods.

LKT K9600 KY-02111 5 mg 148.1 Wnt signaling inhibitor. KY-02111 1118807-13-8 ≥98% 376.86 C18H17ClN2O3S COC1=C(C=C(C=C1)CCC(=O)NC2=NC3=C(S2)C=C(C=C3)Cl)OC Ambient Minami I, Yamada K, Otsuji TG, et al. A small molecule that promotes cardiac differentiation of human pluripotent stem cells under defined, cytokine- and xeno-free conditions. Cell Rep. 2012 Nov 29;2(5):1448-60. PMID: 23103164. Not dangerous goods.

LKT K9600 KY-02111 10 mg 236.6 Wnt signaling inhibitor. KY-02111 1118807-13-8 ≥98% 376.86 C18H17ClN2O3S COC1=C(C=C(C=C1)CCC(=O)NC2=NC3=C(S2)C=C(C=C3)Cl)OC Ambient Minami I, Yamada K, Otsuji TG, et al. A small molecule that promotes cardiac differentiation of human pluripotent stem cells under defined, cytokine- and xeno-free conditions. Cell Rep. 2012 Nov 29;2(5):1448-60. PMID: 23103164. Not dangerous goods.

LKT I9060 IWP-2 5 mg 148.1 PORCN inhibitor. IWP2 686770-61-6 ≥98% 466.6 C22H18N4O2S3 CC1=CC2=C(C=C1)N=C(S2)NC(=O)CSC3=NC4=C(C(=O)N3C5=CC=CC=C5)SCC4 Ambient -20°C "Frewer KA, Sanders AJ, Owen S, et al. A role for WISP2 in colorectal cancer cell invasion and motility. Cancer Genomics Proteomics. 2013 Jul-Aug;10(4):187-96. PMID: 23893926.

 

Mo ML, Li MR, Chen Z, et al. Inhibition of the Wnt palmitoyltransferase porcupine suppresses cell growth and downregulates the Wnt/β-catenin pathway in gastric cancer. Oncol Lett. 2013 May;5(5):1719-1723. PMID: 23761839.

" Not dangerous goods.

LKT I9060 IWP-2 10 mg 236.6 PORCN inhibitor. IWP2 686770-61-6 ≥98% 466.6 C22H18N4O2S3 CC1=CC2=C(C=C1)N=C(S2)NC(=O)CSC3=NC4=C(C(=O)N3C5=CC=CC=C5)SCC4 Ambient -20°C "Frewer KA, Sanders AJ, Owen S, et al. A role for WISP2 in colorectal cancer cell invasion and motility. Cancer Genomics Proteomics. 2013 Jul-Aug;10(4):187-96. PMID: 23893926.

 

Mo ML, Li MR, Chen Z, et al. Inhibition of the Wnt palmitoyltransferase porcupine suppresses cell growth and downregulates the Wnt/β-catenin pathway in gastric cancer. Oncol Lett. 2013 May;5(5):1719-1723. PMID: 23761839.

" Not dangerous goods.

LKT G7443 GSK-429286A 1 mg 69.2 ROCK1/2 inhibitor, potential RSK and p70S6K inhibitor. GSK429286A 864082-47-3 ≥98% 432.37 C21H16F4N4O2 CC1=C(C(CC(=O)N1)C2=CC=C(C=C2)C(F)(F)F)C(=O)NC3=C(C=C4C(=C3)C=NN4)F Ambient -20°C "Nichols RJ, Dzamko N, Hutti JE, et al. Substrate specificity and inhibitors of LRRK2, a protein kinase mutated in Parkinson's disease. Biochem J. 2009 Oct 23;424(1):47-60. PMID: 19740074.

 

Goodman KB, Cui H, Dowdell SE, et al. Development of dihydropyridone indazole amides as selective Rho-kinase inhibitors. J Med Chem. 2007 Jan 11;50(1):6-9. PMID: 17201405.

" "UN number: 2811     Class: 6.1     Packing Group: III

Proper shipping name: Toxic solid, organic, n.o.s. (GSK429286A)"

LKT G7443 GSK-429286A 5 mg 236.6 ROCK1/2 inhibitor, potential RSK and p70S6K inhibitor. GSK429286A 864082-47-3 ≥98% 432.37 C21H16F4N4O2 CC1=C(C(CC(=O)N1)C2=CC=C(C=C2)C(F)(F)F)C(=O)NC3=C(C=C4C(=C3)C=NN4)F Ambient -20°C "Nichols RJ, Dzamko N, Hutti JE, et al. Substrate specificity and inhibitors of LRRK2, a protein kinase mutated in Parkinson's disease. Biochem J. 2009 Oct 23;424(1):47-60. PMID: 19740074.

 

Goodman KB, Cui H, Dowdell SE, et al. Development of dihydropyridone indazole amides as selective Rho-kinase inhibitors. J Med Chem. 2007 Jan 11;50(1):6-9. PMID: 17201405.

" "UN number: 2811     Class: 6.1     Packing Group: III

Proper shipping name: Toxic solid, organic, n.o.s. (GSK429286A)"

LKT G1310 GDC-0349 1 mg 100.7 mTOR inhibitor. GDC0349 1207360-89-1 ≥98% 452.55 C24H32N6O3 CCNC(=O)NC1=CC=C(C=C1)C2=NC3=C(CCN(C3)C4COC4)C(=N2)N5CCOCC5C Ambient -20°C Pei Z, Blackwood E, Liu L, et al. Discovery and Biological Profiling of Potent and Selective mTOR Inhibito GDC-0349. ACS Med Chem Lett. 2012 Nov 29;4(1):103-7. PMID: 24900569. "UN number: 3077     Class: 9     Packing Group: III

Proper shipping name: Environmentally hazardous substance, solid, n.o.s. (GDC-0349)"

LKT G1310 GDC-0349 5 mg 347 mTOR inhibitor. GDC0349 1207360-89-1 ≥98% 452.55 C24H32N6O3 CCNC(=O)NC1=CC=C(C=C1)C2=NC3=C(CCN(C3)C4COC4)C(=N2)N5CCOCC5C Ambient -20°C Pei Z, Blackwood E, Liu L, et al. Discovery and Biological Profiling of Potent and Selective mTOR Inhibitr GDC-0349. ACS Med Chem Lett. 2012 Nov 29;4(1):103-7. PMID: 24900569. "UN number: 3077     Class: 9     Packing Group: III

Proper shipping name: Environmentally hazardous substance, solid, n.o.s. (GDC-0349)"

LKT C0800 C59 1 mg 118.9 PORCN inhibitor. Wnt-C59 1243243-89-1 ≥98% 379.45 C25H21N3O CC1=NC=CC(=C1)C2=CC=C(C=C2)CC(=O)NC3=CC=C(C=C3)C4=CN=CC=C4 Ambient -20°C Proffitt KD, Madan B, Ke Z, et al. Pharmacological inhibition of the Wnt acyltransferase PORCN prevents growth of WNT-driven mammary cancer. Cancer Res. 2013 Jan 15;73(2):502-7. PMID: 23188502. Not dangerous goods.

LKT C0800 C59 5 mg 410.1 PORCN inhibitor. Wnt-C59 1243243-89-1 ≥98% 379.45 C25H21N3O CC1=NC=CC(=C1)C2=CC=C(C=C2)CC(=O)NC3=CC=C(C=C3)C4=CN=CC=C4 Ambient -20°C Proffitt KD, Madan B, Ke Z, et al. Pharmacological inhibition of the Wnt acyltransferase PORCN prevents growth of WNT-driven mammary cancer. Cancer Res. 2013 Jan 15;73(2):502-7. PMID: 23188502. Not dangerous goods.

LKT B9200 BX-795 5 mg 118.9 PDK1 inhibitor. BX795 702675-74-9 ≥98% 591.47 C23H26IN7O2S C1CCN(C1)C(=O)NC2=CC=CC(=C2)NC3=NC=C(C(=N3)NCCCNC(=O)C4=CC=CS4)I Ambient -20°C Feldman RI, Wu JM, Polokoff MA, et al. Novel small molecule inhibitors of 3-phosphoinositide-dependent kinase-1. J Biol Chem. 2005 May 20;280(20):19867-74. PMID: 15772071. Not dangerous goods.

LKT B9200 BX-795 10 mg 189.3 PDK1 inhibitor. BX795 702675-74-9 ≥98% 591.47 C23H26IN7O2S C1CCN(C1)C(=O)NC2=CC=CC(=C2)NC3=NC=C(C(=N3)NCCCNC(=O)C4=CC=CS4)I Ambient -20°C Feldman RI, Wu JM, Polokoff MA, et al. Novel small molecule inhibitors of 3-phosphoinositide-dependent kinase-1. J Biol Chem. 2005 May 20;280(20):19867-74. PMID: 15772071. Not dangerous goods.

LKT B6959 Bromosporine 1 mg 114 BRD2/4/9 and CECR2 inhibitor. "N-[6-(3-Methanesulfonamido-4-methylphenyl)-3-methyl-[1,2,4]triazolo[4,3-b]pyridazin-8-yl]carbamate

" ≥98% 404.44 C17H20N6O4S CCOC(=O)NC1=CC(=NN2C1=NN=C2C)C3=CC(=C(C=C3)C)NS(=O)(=O)C Ambient -20°C Not dangerous goods.

LKT B6959 Bromosporine 5 mg 394.4 BRD2/4/9 and CECR2 inhibitor. "N-[6-(3-Methanesulfonamido-4-methylphenyl)-3-methyl-[1,2,4]triazolo[4,3-b]pyridazin-8-yl]carbamate

" ≥98% 404.44 C17H20N6O4S CCOC(=O)NC1=CC(=NN2C1=NN=C2C)C3=CC(=C(C=C3)C)NS(=O)(=O)C Ambient -20°C Not dangerous goods.

LKT B4974 BMS-777607 1 mg 51 MET and Ron inhibitor. BMS777607 1196681-44-3 ≥98% 512.89 C25H19ClF2N4O4 CCOC1=C(C(=O)N(C=C1)C2=CC=C(C=C2)F)C(=O)NC3=CC(=C(C=C3)OC4=C(C(=NC=C4)N)Cl)F Ambient -20°C "Sharma S, Zeng JY, Zhuang CM, et al. Small-molecule inhibitor BMS-777607 induces breast cancer cell polyploidy with increased resistance to cytotoxic chemotherapy agents. Mol Cancer Ther. 2013 May;12(5):725-36. PMID: 23468529.

 

Dai Y, Bae K, Pampo C, et al. Impact of the small molecule Met inhibitor BMS-777607 on the metastatic process in a rodent tumor model with constitutive c-Met activation. Clin Exp Metastasis. 2012 Mar;29(3):253-61. PMID: 22286523.

" Not dangerous goods.

LKT B4974 BMS-777607 5 mg 173.5 MET and Ron inhibitor. BMS777607 1196681-44-3 ≥98% 512.89 C25H19ClF2N4O4 CCOC1=C(C(=O)N(C=C1)C2=CC=C(C=C2)F)C(=O)NC3=CC(=C(C=C3)OC4=C(C(=NC=C4)N)Cl)F Ambient -20°C "Sharma S, Zeng JY, Zhuang CM, et al. Small-molecule inhibitor BMS-777607 induces breast cancer cell polyploidy with increased resistance to cytotoxic chemotherapy agents. Mol Cancer Ther. 2013 May;12(5):725-36. PMID: 23468529.

 

Dai Y, Bae K, Pampo C, et al. Impact of the small molecule Met inhibitor BMS-777607 on the metastatic process in a rodent tumor model with constitutive c-Met activation. Clin Exp Metastasis. 2012 Mar;29(3):253-61. PMID: 22286523.

" Not dangerous goods.

LKT A4926 AMG-458 1 mg 91 c-MET inhibitor. AMG458 913376-83-7 ≥98% 539.58 C30H29N5O5 CC1=C(C(=O)N(N1CC(C)(C)O)C2=CC=CC=C2)C(=O)NC3=NC=C(C=C3)OC4=C5C=CC(=CC5=NC=C4)OC Ambient -20°C "Li B, Torossian A, Sun Y, et al. Higher levels of c-Met expression and phosphorylation identify cell lines with increased sensitivity to AMG-458, a novel selective c-Met inhibitor with radiosensitizing effects. Int J Radiat Oncol Biol Phys. 2012 Nov 15;84(4):e525-31. PMID: 22836051.

 

Liu L, Siegmund A, Xi N, et al. Discovery of a potent, selective, and orally bioavailable c-Met inhibitor: 1-(2-hydroxy-2-methylpropyl)-N-(5-(7-methoxyquinolin-4-yloxy)pyridin-2-yl)-5-methyl-3-oxo-2-phenyl-2,3-dihydro-1H-pyrazole-4-carboxamide (AMG 458). J Med Chem. 2008 Jul 10;51(13):3688-91. PMID: 18553959.

" Not dangerous goods.

LKT A4926 AMG-458 5 mg 315.5 c-MET inhibitor. AMG458 913376-83-7 ≥98% 539.58 C30H29N5O5 CC1=C(C(=O)N(N1CC(C)(C)O)C2=CC=CC=C2)C(=O)NC3=NC=C(C=C3)OC4=C5C=CC(=CC5=NC=C4)OC Ambient -20°C "Li B, Torossian A, Sun Y, et al. Higher levels of c-Met expression and phosphorylation identify cell lines with increased sensitivity to AMG-458, a novel selective c-Met inhibitor with radiosensitizing effects. Int J Radiat Oncol Biol Phys. 2012 Nov 15;84(4):e525-31. PMID: 22836051.

 

Liu L, Siegmund A, Xi N, et al. Discovery of a potent, selective, and orally bioavailable c-Met inhibitor: 1-(2-hydroxy-2-methylpropyl)-N-(5-(7-methoxyquinolin-4-yloxy)pyridin-2-yl)-5-methyl-3-oxo-2-phenyl-2,3-dihydro-1H-pyrazole-4-carboxamide (AMG 458). J Med Chem. 2008 Jul 10;51(13):3688-91. PMID: 18553959.

" Not dangerous goods.

LKT A4924 AMG-208 1 mg 69.2 c-MET and Ron inhibitor. AMG208 1002304-34-8 ≥98% 383.4 C22H17N5O2 COC1=CC2=NC=CC(=C2C=C1)OCC3=NN=C4N3N=C(C=C4)C5=CC=CC=C5 Ambient -20°C "Liu X, Newton RC, Scherle PA. Developing c-MET pathway inhibitors for cancer therapy: progress and challenges. Trends Mol Med. 2010 Jan;16(1):37-45. PMID: 20031486.

 

Albrecht BK, Harmange JC, Bauer D, et al. Discovery and optimization of triazolopyridazines as potent and selective inhibitors of the c-Met kinase. J Med Chem. 2008 May 22;51(10):2879-82. PMID: 18426196.

" Not dangerous goods.

LKT A4924 AMG-208 5 mg 236.6 c-MET and Ron inhibitor. AMG208 1002304-34-8 ≥98% 383.4 C22H17N5O2 COC1=CC2=NC=CC(=C2C=C1)OCC3=NN=C4N3N=C(C=C4)C5=CC=CC=C5 Ambient -20°C "Liu X, Newton RC, Scherle PA. Developing c-MET pathway inhibitors for cancer therapy: progress and challenges. Trends Mol Med. 2010 Jan;16(1):37-45. PMID: 20031486.

 

Albrecht BK, Harmange JC, Bauer D, et al. Discovery and optimization of triazolopyridazines as potent and selective inhibitors of the c-Met kinase. J Med Chem. 2008 May 22;51(10):2879-82. PMID: 18426196.

" Not dangerous goods.

LKT A2400 AG-1024 1 mg 46.1 Tyrphostin; IGF-1R inhibitor. AG1024 (tyrphostin) 65678-07-1 ≥98% 305.17 C14H13BrN2O CC(C)(C)C1=C(C(=CC(=C1)C=C(C#N)C#N)Br)O Ambient -20°C "Yao WF, Liu JW, Sheng GL, et al. Blockade of IGF-IR exerts anticancer effects in hepatocellular carcinoma. Mol Med Rep. 2011 Jul-Aug;4(4):719-22. PMID: 21567089.

 

Chakraborty AK, Welsh A, Digiovanna MP. Co-targeting the insulin-like growth factor I receptor enhances growth-inhibitory and pro-apoptotic effects of anti-estrogens in human breast cancer cell lines. Breast Cancer Res Treat. 2010 Apr;120(2):327-35. PMID: 19337828.

" Not dangerous goods.

LKT A2400 AG-1024 5 mg 157.7 Tyrphostin; IGF-1R inhibitor. AG1024 (tyrphostin) 65678-07-1 ≥98% 305.17 C14H13BrN2O CC(C)(C)C1=C(C(=CC(=C1)C=C(C#N)C#N)Br)O Ambient -20°C "Yao WF, Liu JW, Sheng GL, et al. Blockade of IGF-IR exerts anticancer effects in hepatocellular carcinoma. Mol Med Rep. 2011 Jul-Aug;4(4):719-22. PMID: 21567089.

 

Chakraborty AK, Welsh A, Digiovanna MP. Co-targeting the insulin-like growth factor I receptor enhances growth-inhibitory and pro-apoptotic effects of anti-estrogens in human breast cancer cell lines. Breast Cancer Res Treat. 2010 Apr;120(2):327-35. PMID: 19337828.

" Not dangerous goods.

LKT B5870 Borrelidin 1 mg 200.2 Macrolide; threonyl-tRNA synthetase/ligase inhibitor. 7184-60-3 ≥99% 489.64 C28H43NO6 CC1CC(CC(C(C(=CC=CCC(OC(=O)CC(C(C1)C)O)C2CCCC2C(=O)O)C#N)O)C)C Ambient 4°C Methanol, DMSO (10 mg/mL) "Kalidas S, Cestari I, Monnerat S, et al. Genetic validation of aminoacyl-tRNA synthetases as drug targets in Trypanosoma brucei. Eukaryot Cell. 2014 Apr;13(4):504-16. PMID: 24562907.

 

Azcárate IG, Marín-García P, Camacho N, et al. Insights into the preclinical treatment of blood-stage malaria by the antibiotic borrelidin. Br J Pharmacol. 2013 Jun;169(3):645-58. PMID: 23488671.

 

Gao YM, Wang XJ, Zhang J, et al. Borrelidin, a potent antifungal agent: insight into the antifungal mechanism against Phytophthora sojae. J Agric Food Chem. 2012 Oct 3;60(39):9874-81. PMID: 22967236.

 

Habibi D, Ogloff N, Jalili RB, et al. Borrelidin, a small molecule nitrile-containing macrolide inhibitor of threonyl-tRNA synthetase, is a potent inducer of apoptosis in acute lymphoblastic leukemia. Invest New Drugs. 2012 Aug;30(4):1361-70. PMID: 21678129.

 

Otoguro K, Ui H, Ishiyama A, et al. In vitro and in vivo antimalarial activities of a non-glycosidic 18-membered macrolide antibiotic, borrelidin, against drug-resistant strains of Plasmodia. J Antibiot (Tokyo). 2003 Aug;56(8):727-9. PMID: 14563165.

" Not dangerous goods.

LKT B5870 Borrelidin 5 mg 788.7 Macrolide; threonyl-tRNA synthetase/ligase inhibitor. 7184-60-3 ≥99% 489.64 C28H43NO6 CC1CC(CC(C(C(=CC=CCC(OC(=O)CC(C(C1)C)O)C2CCCC2C(=O)O)C#N)O)C)C Ambient 4°C Methanol, DMSO (10 mg/mL) "Kalidas S, Cestari I, Monnerat S, et al. Genetic validation of aminoacyl-tRNA synthetases as drug targets in Trypanosoma brucei. Eukaryot Cell. 2014 Apr;13(4):504-16. PMID: 24562907.

 

Azcárate IG, Marín-García P, Camacho N, et al. Insights into the preclinical treatment of blood-stage malaria by the antibiotic borrelidin. Br J Pharmacol. 2013 Jun;169(3):645-58. PMID: 23488671.

 

Gao YM, Wang XJ, Zhang J, et al. Borrelidin, a potent antifungal agent: insight into the antifungal mechanism against Phytophthora sojae. J Agric Food Chem. 2012 Oct 3;60(39):9874-81. PMID: 22967236.

 

Habibi D, Ogloff N, Jalili RB, et al. Borrelidin, a small molecule nitrile-containing macrolide inhibitor of threonyl-tRNA synthetase, is a potent inducer of apoptosis in acute lymphoblastic leukemia. Invest New Drugs. 2012 Aug;30(4):1361-70. PMID: 21678129.

 

Otoguro K, Ui H, Ishiyama A, et al. In vitro and in vivo antimalarial activities of a non-glycosidic 18-membered macrolide antibiotic, borrelidin, against drug-resistant strains of Plasmodia. J Antibiot (Tokyo). 2003 Aug;56(8):727-9. PMID: 14563165.

" Not dangerous goods.

LKT B8071 3-tert-Butyl-4-Hydroxyanisole 5 g 109.7 BHA derivative, antioxidative food and cosmetics additive. 3-(1,1-Di-methylethyl)4-methoxyphenol 3-BHA 121-00-6 ≥99% 180.25 C11H16O2 CC(C)(C)C1=C(C=CC(=C1)OC)O Ambient Ambient Insoluble in water.  Soluble in ethanol, acetone, or DMSO. "Hwang GH, Jeon YJ, Han HJ, et al. Protective effect of butylated hydroxylanisole against hydrogen peroxide-induced apoptosis in primary cultured mouse hepatocytes. J Vet Sci. 2014 Oct 8. [Epub ahead of print]. PMID: 25293491.

 

Okubo T, Yokoyama Y, Kano K, et al. Molecular mechanism of cell death induced by the antioxidant tert-butylhydroxyanisole in human monocytic leukemia U937 cells. Biol Pharm Bull. 2004 Mar;27(3):295-302. PMID: 14993791.

 

Prochaska HJ, Fernandes CL. Elevation of serum phase II enzymes by anticarcinogenic enzyme inducers: markers for a chemoprotected state? Carcinogenesis. 1993 Dec;14(12):2441-5. PMID: 8269610.

 

Matsuoka A, Matsui M, Miyata N, et al. Mutagenicity of 3-tert-butyl-4-hydroxyanisole (BHA) and its metabolites in short-term tests in vitro. Mutat Res. 1990 Jun;241(2):125-32. PMID: 2345551.

" Xi Not dangerous goods.

LKT C1879 Cetrorelix Acetate    50 mg 1444 Peptide, GnRH analog;GnRH agonist. 130143-01-0 ≥95% 1431.06 C70H92N17O14 CC(C)CC(C(=O)NC(CCCN=C(N)N)C(=O)N1CCCC1C(=O)NC(C)C(=O)N)NC(=O)C(CCCNC(=O)N)NC(=O)C(CC2=CC=C(C=C2)O)NC(=O)C(CO)NC(=O)C(CC3=CN=CC=C3)NC(=O)C(CC4=CC=C(C=C4)Cl)NC(=O)C(CC5=CC6=CC=CC=C6C=C5)NC(=O)C Ambient -20°C "Rick FG, Schally AV, Block NL, et al. LHRH antagonist Cetrorelix reduces prostate size and gene expression of proinflammatory cytokines and growth factors in a rat model of benign prostatic hyperplasia. Prostate. 2011 May 15;71(7):736-47. PMID: 20945403.

 

Zhao XJ, Huang YH, Yu YC, et al. GnRH antagonist cetrorelix inhibits mitochondria-dependent apoptosis triggered by chemotherapy in granulosa cells of rats. Gynecol Oncol. 2010 Jul;118(1):69-75. PMID: 20417958.

 

Reissmann T, Felberbaum R, Diedrich K, et al. Development and applications of luteinizing hormone-releasing hormone antagonists in the treatment of infertility: an overview. Hum Reprod. 1995 Aug;10(8):1974-81. PMID: 8567825.

" Not dangerous goods.

LKT C1879 Cetrorelix Acetate    100 mg 1965.7 Peptide, GnRH analog;GnRH agonist. 130143-01-0 ≥95% 1431.06 C70H92N17O14 CC(C)CC(C(=O)NC(CCCN=C(N)N)C(=O)N1CCCC1C(=O)NC(C)C(=O)N)NC(=O)C(CCCNC(=O)N)NC(=O)C(CC2=CC=C(C=C2)O)NC(=O)C(CO)NC(=O)C(CC3=CN=CC=C3)NC(=O)C(CC4=CC=C(C=C4)Cl)NC(=O)C(CC5=CC6=CC=CC=C6C=C5)NC(=O)C Ambient -20°C "Rick FG, Schally AV, Block NL, et al. LHRH antagonist Cetrorelix reduces prostate size and gene expression of proinflammatory cytokines and growth factors in a rat model of benign prostatic hyperplasia. Prostate. 2011 May 15;71(7):736-47. PMID: 20945403.

 

Zhao XJ, Huang YH, Yu YC, et al. GnRH antagonist cetrorelix inhibits mitochondria-dependent apoptosis triggered by chemotherapy in granulosa cells of rats. Gynecol Oncol. 2010 Jul;118(1):69-75. PMID: 20417958.

 

Reissmann T, Felberbaum R, Diedrich K, et al. Development and applications of luteinizing hormone-releasing hormone antagonists in the treatment of infertility: an overview. Hum Reprod. 1995 Aug;10(8):1974-81. PMID: 8567825.

" Not dangerous goods.

LKT V0144 n-Valeric Acid 10 ml 48.5 GHB/GABA analog found in Valeriana officinalis; potential HDAC inhibitor. Pentanoic acid 109-52-4 ≥99% 102.13 C5H10O2 CCCCC(=O)O Ambient Ambient "Huang HM, Ou HC, Chen HL, et al. Protective effect of alpha-keto-beta-methyl-n-valeric acid on BV-2 microglia under hypoxia or oxidative stress. Ann N Y Acad Sci. 2005 May;1042:272-8. PMID: 15965072.

 

Huang HM, Zhang H, Ou HC, et al. alpha-keto-beta-methyl-n-valeric acid diminishes reactive oxygen species and alters endoplasmic reticulum Ca(2+) stores. Free Radic Biol Med. 2004 Dec 1;37(11):1779-89. PMID: 15528037.

 

Midtvedt AC, Midtvedt T. Production of short chain fatty acids by the intestinal microflora during the first 2 years of human life. J Pediatr Gastroenterol Nutr. 1992 Nov;15(4):395-403. PMID: 1469519.

" "UN number: 3265     Class:  8     Packing group:  II

Proper shipping name:  Corrosive liquid, acidic, organic, n.o.s. (Valeric acid)

Reportable Quantity (RQ):        Poison Inhalation Hazard:  No"

LKT V0144 n-Valeric Acid 50 ml 60.7 GHB/GABA analog found in Valeriana officinalis; potential HDAC inhibitor. Pentanoic acid 109-52-4 ≥99% 102.13 C5H10O2 CCCCC(=O)O Ambient Ambient "Huang HM, Ou HC, Chen HL, et al. Protective effect of alpha-keto-beta-methyl-n-valeric acid on BV-2 microglia under hypoxia or oxidative stress. Ann N Y Acad Sci. 2005 May;1042:272-8. PMID: 15965072.

 

Huang HM, Zhang H, Ou HC, et al. alpha-keto-beta-methyl-n-valeric acid diminishes reactive oxygen species and alters endoplasmic reticulum Ca(2+) stores. Free Radic Biol Med. 2004 Dec 1;37(11):1779-89. PMID: 15528037.

 

Midtvedt AC, Midtvedt T. Production of short chain fatty acids by the intestinal microflora during the first 2 years of human life. J Pediatr Gastroenterol Nutr. 1992 Nov;15(4):395-403. PMID: 1469519.

" "UN number: 3265     Class:  8     Packing group:  II

Proper shipping name:  Corrosive liquid, acidic, organic, n.o.s. (Valeric acid)

Reportable Quantity (RQ):        Poison Inhalation Hazard:  No"

LKT V0144 n-Valeric Acid 100 ml 78.9 GHB/GABA analog found in Valeriana officinalis; potential HDAC inhibitor. Pentanoic acid 109-52-4 ≥99% 102.13 C5H10O2 CCCCC(=O)O Ambient Ambient "Huang HM, Ou HC, Chen HL, et al. Protective effect of alpha-keto-beta-methyl-n-valeric acid on BV-2 microglia under hypoxia or oxidative stress. Ann N Y Acad Sci. 2005 May;1042:272-8. PMID: 15965072.

 

Huang HM, Zhang H, Ou HC, et al. alpha-keto-beta-methyl-n-valeric acid diminishes reactive oxygen species and alters endoplasmic reticulum Ca(2+) stores. Free Radic Biol Med. 2004 Dec 1;37(11):1779-89. PMID: 15528037.

 

Midtvedt AC, Midtvedt T. Production of short chain fatty acids by the intestinal microflora during the first 2 years of human life. J Pediatr Gastroenterol Nutr. 1992 Nov;15(4):395-403. PMID: 1469519.

" "UN number: 3265     Class:  8     Packing group:  II

Proper shipping name:  Corrosive liquid, acidic, organic, n.o.s. (Valeric acid)

Reportable Quantity (RQ):        Poison Inhalation Hazard:  No"

LKT M1579 Methazolamide 250 mg 78.9 Carbonic anhydrase inhibitor. 554-57-4 ≥98% 236.27 C5H8N4O3S2 CC(=O)N=C1N(N=C(S1)S(=O)(=O)N)C Ambient Ambient "Syrjänen L, Parkkila S, Scozzafava A, et al.  Sulfonamide inhibition studies of the β carbonic anhydrase from Drosophila melanogaster. Bioorg Med Chem Lett. 2014 Jul 1;24(13):2797-801. PMID: 24852120.

 

Konstantopoulos N, Molero JC, McGee SL, et al. Methazolamide is a new hepatic insulin sensitizer that lowers blood glucose in vivo. Diabetes. 2012 Aug;61(8):2146-54. PMID: 22586591.

 

Friedman Z, Allen RC, Raph SM. Topical acetazolamide and methazolamide delivered by contact lenses. Arch Ophthalmol. 1985 Jul;103(7):963-6. PMID: 3860197.

 

Torchiana ML, Lotti VJ, Stone CA. The anticonvulsant effect of carbonic anhydrase inhibitors in mice--a noradrenergic mechanism of action. Eur J Pharmacol. 1973 Mar;21(3):343-9. PMID: 4145319.

" Not dangerous goods.

LKT M1579 Methazolamide 1 g 157.7 Carbonic anhydrase inhibitor. 554-57-4 ≥98% 236.27 C5H8N4O3S2 CC(=O)N=C1N(N=C(S1)S(=O)(=O)N)C Ambient Ambient "Syrjänen L, Parkkila S, Scozzafava A, et al.  Sulfonamide inhibition studies of the β carbonic anhydrase from Drosophila melanogaster. Bioorg Med Chem Lett. 2014 Jul 1;24(13):2797-801. PMID: 24852120.

 

Konstantopoulos N, Molero JC, McGee SL, et al. Methazolamide is a new hepatic insulin sensitizer that lowers blood glucose in vivo. Diabetes. 2012 Aug;61(8):2146-54. PMID: 22586591.

 

Friedman Z, Allen RC, Raph SM. Topical acetazolamide and methazolamide delivered by contact lenses. Arch Ophthalmol. 1985 Jul;103(7):963-6. PMID: 3860197.

 

Torchiana ML, Lotti VJ, Stone CA. The anticonvulsant effect of carbonic anhydrase inhibitors in mice--a noradrenergic mechanism of action. Eur J Pharmacol. 1973 Mar;21(3):343-9. PMID: 4145319.

" Not dangerous goods.

LKT T6931 Triclosan 1 g 42.4 Diarylether; bacterial ENR binder, fatty acid synthesis inhibitor. 3380-34-5 ≥98% 289.54 C12H7Cl3O2 C1=CC(=C(C=C1Cl)O)OC2=C(C=C(C=C2)Cl)Cl Ambient 4°C "Wallet MA, Calderon Nl, Alonso TR, et al. Triclosan alters antimicrobial and inflammatory responses of epithelial cells. Oral Dis. 2013 Apr;19(3):296-302. PMID: 24079913.

 

Twanabasu BR, Smith CM, Stevens KJ, et al. Triclosan inhibits arbuscular mycorrhizal colonization in three wetland plants. Sci Total Environ. 2013 Mar 1;447:450-7. PMID: 23410867.

 

Russell AD. Whither triclosan? J Antimicrob Chemother. 2004 May;53(5):693-5. PMID: 15073159.

" "UN number: 3077     Class: 9     Packing Group: III

Proper shipping name: Environmentally hazardous substance, solid, n.o.s (Triclosan)"

LKT T6931 Triclosan 5 g 133.5 Diarylether; bacterial ENR binder, fatty acid synthesis inhibitor. 3380-34-5 ≥98% 289.54 C12H7Cl3O2 C1=CC(=C(C=C1Cl)O)OC2=C(C=C(C=C2)Cl)Cl Ambient 4°C "Wallet MA, Calderon Nl, Alonso TR, et al. Triclosan alters antimicrobial and inflammatory responses of epithelial cells. Oral Dis. 2013 Apr;19(3):296-302. PMID: 24079913.

 

Twanabasu BR, Smith CM, Stevens KJ, et al. Triclosan inhibits arbuscular mycorrhizal colonization in three wetland plants. Sci Total Environ. 2013 Mar 1;447:450-7. PMID: 23410867.

 

Russell AD. Whither triclosan? J Antimicrob Chemother. 2004 May;53(5):693-5. PMID: 15073159.

" "UN number: 3077     Class: 9     Packing Group: III

Proper shipping name: Environmentally hazardous substance, solid, n.o.s (Triclosan)"

LKT T6931 Triclosan 25 g 303.3 Diarylether; bacterial ENR binder, fatty acid synthesis inhibitor. 3380-34-5 ≥98% 289.54 C12H7Cl3O2 C1=CC(=C(C=C1Cl)O)OC2=C(C=C(C=C2)Cl)Cl Ambient 4°C "Wallet MA, Calderon Nl, Alonso TR, et al. Triclosan alters antimicrobial and inflammatory responses of epithelial cells. Oral Dis. 2013 Apr;19(3):296-302. PMID: 24079913.

 

Twanabasu BR, Smith CM, Stevens KJ, et al. Triclosan inhibits arbuscular mycorrhizal colonization in three wetland plants. Sci Total Environ. 2013 Mar 1;447:450-7. PMID: 23410867.

 

Russell AD. Whither triclosan? J Antimicrob Chemother. 2004 May;53(5):693-5. PMID: 15073159.

" "UN number: 3077     Class: 9     Packing Group: III

Proper shipping name: Environmentally hazardous substance, solid, n.o.s (Triclosan)"

LKT C6957 Croton Oil 100 mL 231 Mixture found in Croton, used to induce inflammation; carcinogen. Croton resin; Oleum tiglii 8001-28-3 Ambient Ambient Insoluble in water. Soluble in chloroform, ether, oils, or glacial acetic acid. Slightly soluble in alcohol. "Boukhatem MN, Ferhat MA, Kameli A, et al. Lemon grass (Cymbopogon citratus) essential oil as a potent anti-inflammatory and antifungal drugs. Libyan J Med. 2014 Sep 19;9:25431. PMID: 25242268.

 

Liju VB, Jeena K, Kuttan R. Chemopreventive activity of turmeric essential oil and possible mechanisms of action. Asian Pac J Cancer Prev. 2014;15(16):6575-80. PMID: 25169490.

 

Vongsombath C, Pålsson K, Björk L, et al. Mosquito (Diptera: Culicidae) repellency field tests of essential oils from plants traditionally used in Laos. J Med Entomol. 2012 Nov;49(6):1398-404. PMID: 23270168.

 

Alviano WS, Mendonça-Filho RR, Alviano DS, et al. Antimicrobial activity of Croton cajucara Benth linalool-rich essential oil on artificial biofilms and planktonic microorganisms. Oral Microbiol Immunol. 2005 Apr;20(2):101-5. PMID: 15720570.

" None Not dangerous goods.

LKT C6957 Croton Oil 500 mL 703.5 Mixture found in Croton, used to induce inflammation; carcinogen. Croton resin; Oleum tiglii 8001-28-3 Ambient Ambient Insoluble in water. Soluble in chloroform, ether, oils, or glacial acetic acid. Slightly soluble in alcohol. "Boukhatem MN, Ferhat MA, Kameli A, et al. Lemon grass (Cymbopogon citratus) essential oil as a potent anti-inflammatory and antifungal drugs. Libyan J Med. 2014 Sep 19;9:25431. PMID: 25242268.

 

Liju VB, Jeena K, Kuttan R. Chemopreventive activity of turmeric essential oil and possible mechanisms of action. Asian Pac J Cancer Prev. 2014;15(16):6575-80. PMID: 25169490.

 

Vongsombath C, Pålsson K, Björk L, et al. Mosquito (Diptera: Culicidae) repellency field tests of essential oils from plants traditionally used in Laos. J Med Entomol. 2012 Nov;49(6):1398-404. PMID: 23270168.

 

Alviano WS, Mendonça-Filho RR, Alviano DS, et al. Antimicrobial activity of Croton cajucara Benth linalool-rich essential oil on artificial biofilms and planktonic microorganisms. Oral Microbiol Immunol. 2005 Apr;20(2):101-5. PMID: 15720570.

" None Not dangerous goods.

LKT C6957 Croton Oil 1 L 1018.5 Mixture found in Croton, used to induce inflammation; carcinogen. Croton resin; Oleum tiglii 8001-28-3 Ambient Ambient Insoluble in water. Soluble in chloroform, ether, oils, or glacial acetic acid. Slightly soluble in alcohol. "Boukhatem MN, Ferhat MA, Kameli A, et al. Lemon grass (Cymbopogon citratus) essential oil as a potent anti-inflammatory and antifungal drugs. Libyan J Med. 2014 Sep 19;9:25431. PMID: 25242268.

 

Liju VB, Jeena K, Kuttan R. Chemopreventive activity of turmeric essential oil and possible mechanisms of action. Asian Pac J Cancer Prev. 2014;15(16):6575-80. PMID: 25169490.

 

Vongsombath C, Pålsson K, Björk L, et al. Mosquito (Diptera: Culicidae) repellency field tests of essential oils from plants traditionally used in Laos. J Med Entomol. 2012 Nov;49(6):1398-404. PMID: 23270168.

 

Alviano WS, Mendonça-Filho RR, Alviano DS, et al. Antimicrobial activity of Croton cajucara Benth linalool-rich essential oil on artificial biofilms and planktonic microorganisms. Oral Microbiol Immunol. 2005 Apr;20(2):101-5. PMID: 15720570.

" None Not dangerous goods.

LKT E7858 Etoricoxib 25 mg 78.9 NSAID; COX-2 inhibitor. 202409-33-4 ≥98% 358.84 C18H15CLN2O2S CC1=NC=C(C=C1)C2=NC=C(C=C2C3=CC=C(C=C3)S(=O)(=O)C)Cl Ambient Ambient "Nadda N, Vaish V, Setia S, et al. Angiostatic role of the selective cyclooxygenase-2 inhibitor etoricoxib (MK0663) in experimental lung cancer. Biomed Pharmacother. 2012 Sep;66(6):474-83. PMID: 22681911.

 

Sharma P, Kaur J, Sanyal SN. Effect of etoricoxib, a cyclooxygenase-2 selective inhibitor on aberrant crypt formation and apoptosis in 1,2 dimethyl hydrazine induced colon carcinogenesis in rat model. Nutr Hosp. 2010 Jan-Feb;25(1):39-48. PMID: 20204254.

 

Kanwar SS, Vaiphei K, Nehru B, et al. Antioxidative effects of nonsteroidal anti-inflammatory drugs during the initiation stages of experimental colon carcinogenesis in rats. J Environ Pathol Toxicol Oncol. 2008;27(2):89-100. PMID: 18540845.

" "UN number: 2811     Class:  6.1     Packing group:  II

Proper shipping name:  Toxic solids, organic, n.o.s.  (Etoricoxib)

Reportable Quantity (RQ):  No     Marine pollutant:  No     Poison inhalation hazard:  No"

LKT E7858 Etoricoxib 100 mg 273 NSAID; COX-2 inhibitor. 202409-33-4 ≥98% 358.84 C18H15CLN2O2S CC1=NC=C(C=C1)C2=NC=C(C=C2C3=CC=C(C=C3)S(=O)(=O)C)Cl Ambient Ambient "Nadda N, Vaish V, Setia S, et al. Angiostatic role of the selective cyclooxygenase-2 inhibitor etoricoxib (MK0663) in experimental lung cancer. Biomed Pharmacother. 2012 Sep;66(6):474-83. PMID: 22681911.

 

Sharma P, Kaur J, Sanyal SN. Effect of etoricoxib, a cyclooxygenase-2 selective inhibitor on aberrant crypt formation and apoptosis in 1,2 dimethyl hydrazine induced colon carcinogenesis in rat model. Nutr Hosp. 2010 Jan-Feb;25(1):39-48. PMID: 20204254.

 

Kanwar SS, Vaiphei K, Nehru B, et al. Antioxidative effects of nonsteroidal anti-inflammatory drugs during the initiation stages of experimental colon carcinogenesis in rats. J Environ Pathol Toxicol Oncol. 2008;27(2):89-100. PMID: 18540845.

" "UN number: 2811     Class:  6.1     Packing group:  II

Proper shipping name:  Toxic solids, organic, n.o.s.  (Etoricoxib)

Reportable Quantity (RQ):  No     Marine pollutant:  No     Poison inhalation hazard:  No"

LKT P0369 Parecoxib Sodium 25 mg 118.9 NSAID; COX-2 inhibitor. 198470-85-8 ≥98% 392.4 C19H18N2O4S Na CCC(=O)[N-]S(=O)(=O)C1=CC=C(C=C1)C2=C(ON=C2C3=CC=CC=C3)C.[Na+] Ambient Ambient "Zhou GB, Li HY, Ji JQ, et al. Analgesic effect of COX inhibitors and its mechanism in a rat model of neuropathic pain. Nan Fang Yi Ke Da Xue Xue Bao. 2011 Oct;31(10):1764-6. PMID: 22027786.

 

Koppert W, Wehrfritz A, Körber N, et al. The cyclooxygenase isozyme inhibitors parecoxib and paracetamol reduce central hyperalgesia in humans. Pain. 2004 Mar;108(1-2):148-53. PMID: 15109518.

" Not dangerous goods.

LKT P0369 Parecoxib Sodium 100 mg 333.7 NSAID; COX-2 inhibitor. 198470-85-8 ≥98% 392.4 C19H18N2O4S Na CCC(=O)[N-]S(=O)(=O)C1=CC=C(C=C1)C2=C(ON=C2C3=CC=CC=C3)C.[Na+] Ambient Ambient "Zhou GB, Li HY, Ji JQ, et al. Analgesic effect of COX inhibitors and its mechanism in a rat model of neuropathic pain. Nan Fang Yi Ke Da Xue Xue Bao. 2011 Oct;31(10):1764-6. PMID: 22027786.

 

Koppert W, Wehrfritz A, Körber N, et al. The cyclooxygenase isozyme inhibitors parecoxib and paracetamol reduce central hyperalgesia in humans. Pain. 2004 Mar;108(1-2):148-53. PMID: 15109518.

" Not dangerous goods.

LKT D1995 Dexrazoxane Hydrochloride 5 mg 58.2 Iron chelator. 149003-01-0 ≥98% 304.73 C11H16N4O4 HCl CC(CN1CC(=O)NC(=O)C1)N2CC(=O)NC(=O)C2.Cl Ambient Ambient "Doroshow JH. Dexrazoxane for the prevention of cardiac toxicity and treatment of extravasation injury from the anthracycline antibiotics. Curr Pharm Biotechnol. 2012 Aug;13(10):1949-56. PMID: 22352729.

 

Zhou L, Sung RY, Li K, et al. Cardioprotective effect of dexrazoxane in a rat model of myocardial infarction: anti-apoptosis and promoting angiogenesis. Int J Cardiol. 2011 Oct 20;152(2):196-201. PMID: 20692056.

 

Jones RL. Utility of dexrazoxane for the reduction of anthracycline-induced cardiotoxicity. Expert Rev Cardiovasc Ther. 2008 Nov;6(10):1311-7. PMID: 19018683.

 

Loyevsky M, Sacci JB Jr, Boehme P, et al. Plasmodium falciparum and Plasmodium yoelii: effect of the iron chelation prodrug dexrazoxane on in vitro cultures. Exp Parasitol. 1999 Feb;91(2):105-14. PMID: 9990337.

" Not dangerous goods.

LKT D1995 Dexrazoxane Hydrochloride 25 mg 182 Iron chelator. 149003-01-0 ≥98% 304.73 C11H16N4O4 HCl CC(CN1CC(=O)NC(=O)C1)N2CC(=O)NC(=O)C2.Cl Ambient Ambient "Doroshow JH. Dexrazoxane for the prevention of cardiac toxicity and treatment of extravasation injury from the anthracycline antibiotics. Curr Pharm Biotechnol. 2012 Aug;13(10):1949-56. PMID: 22352729.

 

Zhou L, Sung RY, Li K, et al. Cardioprotective effect of dexrazoxane in a rat model of myocardial infarction: anti-apoptosis and promoting angiogenesis. Int J Cardiol. 2011 Oct 20;152(2):196-201. PMID: 20692056.

 

Jones RL. Utility of dexrazoxane for the reduction of anthracycline-induced cardiotoxicity. Expert Rev Cardiovasc Ther. 2008 Nov;6(10):1311-7. PMID: 19018683.

 

Loyevsky M, Sacci JB Jr, Boehme P, et al. Plasmodium falciparum and Plasmodium yoelii: effect of the iron chelation prodrug dexrazoxane on in vitro cultures. Exp Parasitol. 1999 Feb;91(2):105-14. PMID: 9990337.

" Not dangerous goods.

LKT D1995 Dexrazoxane Hydrochloride 100 mg 546 Iron chelator. 149003-01-0 ≥98% 304.73 C11H16N4O4 HCl CC(CN1CC(=O)NC(=O)C1)N2CC(=O)NC(=O)C2.Cl Ambient Ambient "Doroshow JH. Dexrazoxane for the prevention of cardiac toxicity and treatment of extravasation injury from the anthracycline antibiotics. Curr Pharm Biotechnol. 2012 Aug;13(10):1949-56. PMID: 22352729.

 

Zhou L, Sung RY, Li K, et al. Cardioprotective effect of dexrazoxane in a rat model of myocardial infarction: anti-apoptosis and promoting angiogenesis. Int J Cardiol. 2011 Oct 20;152(2):196-201. PMID: 20692056.

 

Jones RL. Utility of dexrazoxane for the reduction of anthracycline-induced cardiotoxicity. Expert Rev Cardiovasc Ther. 2008 Nov;6(10):1311-7. PMID: 19018683.

 

Loyevsky M, Sacci JB Jr, Boehme P, et al. Plasmodium falciparum and Plasmodium yoelii: effect of the iron chelation prodrug dexrazoxane on in vitro cultures. Exp Parasitol. 1999 Feb;91(2):105-14. PMID: 9990337.

" Not dangerous goods.

LKT D1994 Dexrazoxane 5 mg 58.2 Iron chelator. 24584-09-6 ≥98% 268.27 C11H6N4O4 CC(CN1CC(=O)NC(=O)C1)N2CC(=O)NC(=O)C2 Ambient Ambient "Doroshow JH. Dexrazoxane for the prevention of cardiac toxicity and treatment of extravasation injury from the anthracycline antibiotics. Curr Pharm Biotechnol. 2012 Aug;13(10):1949-56. PMID: 22352729.

 

Zhou L, Sung RY, Li K, et al. Cardioprotective effect of dexrazoxane in a rat model of myocardial infarction: anti-apoptosis and promoting angiogenesis. Int J Cardiol. 2011 Oct 20;152(2):196-201. PMID: 20692056.

 

Jones RL. Utility of dexrazoxane for the reduction of anthracycline-induced cardiotoxicity. Expert Rev Cardiovasc Ther. 2008 Nov;6(10):1311-7. PMID: 19018683.

 

Loyevsky M, Sacci JB Jr, Boehme P, et al. Plasmodium falciparum and Plasmodium yoelii: effect of the iron chelation prodrug dexrazoxane on in vitro cultures. Exp Parasitol. 1999 Feb;91(2):105-14. PMID: 9990337.

" Not dangerous goods.

LKT D1994 Dexrazoxane 25 mg 182 Iron chelator. 24584-09-6 ≥98% 268.27 C11H6N4O4 CC(CN1CC(=O)NC(=O)C1)N2CC(=O)NC(=O)C2 Ambient Ambient "Doroshow JH. Dexrazoxane for the prevention of cardiac toxicity and treatment of extravasation injury from the anthracycline antibiotics. Curr Pharm Biotechnol. 2012 Aug;13(10):1949-56. PMID: 22352729.

 

Zhou L, Sung RY, Li K, et al. Cardioprotective effect of dexrazoxane in a rat model of myocardial infarction: anti-apoptosis and promoting angiogenesis. Int J Cardiol. 2011 Oct 20;152(2):196-201. PMID: 20692056.

 

Jones RL. Utility of dexrazoxane for the reduction of anthracycline-induced cardiotoxicity. Expert Rev Cardiovasc Ther. 2008 Nov;6(10):1311-7. PMID: 19018683.

 

Loyevsky M, Sacci JB Jr, Boehme P, et al. Plasmodium falciparum and Plasmodium yoelii: effect of the iron chelation prodrug dexrazoxane on in vitro cultures. Exp Parasitol. 1999 Feb;91(2):105-14. PMID: 9990337.

" Not dangerous goods.

LKT D1994 Dexrazoxane 100 mg 546 Iron chelator. 24584-09-6 ≥98% 268.27 C11H6N4O4 CC(CN1CC(=O)NC(=O)C1)N2CC(=O)NC(=O)C2 Ambient Ambient "Doroshow JH. Dexrazoxane for the prevention of cardiac toxicity and treatment of extravasation injury from the anthracycline antibiotics. Curr Pharm Biotechnol. 2012 Aug;13(10):1949-56. PMID: 22352729.

 

Zhou L, Sung RY, Li K, et al. Cardioprotective effect of dexrazoxane in a rat model of myocardial infarction: anti-apoptosis and promoting angiogenesis. Int J Cardiol. 2011 Oct 20;152(2):196-201. PMID: 20692056.

 

Jones RL. Utility of dexrazoxane for the reduction of anthracycline-induced cardiotoxicity. Expert Rev Cardiovasc Ther. 2008 Nov;6(10):1311-7. PMID: 19018683.

 

Loyevsky M, Sacci JB Jr, Boehme P, et al. Plasmodium falciparum and Plasmodium yoelii: effect of the iron chelation prodrug dexrazoxane on in vitro cultures. Exp Parasitol. 1999 Feb;91(2):105-14. PMID: 9990337.

" Not dangerous goods.

LKT S2957 Shogaol 5 mg 357.9 Phenol found in Zingiber; PPARγ agonist, 5-HT3 antagonist. 6-Shogaol 555-66-8 ≥98% 276.37 C17H24O3 CCCCCC=CC(=O)CCC1=CC(=C(C=C1)O)OC Ambient -20°C "Kim SM, Kim C, Bae H, et al. 6-Shogaol exerts anti-proliferative and pro-apoptotic effects through the modulation of STAT3 and MAPKs signaling pathways. Mol Carcinog. 2014 Jun 24. [Epub ahead of print]. PMID: 24962868.

 

Tan BS, Kang O, Mai CW, et al. 6-Shogaol inhibits breast and colon cancer cell proliferation through activation of peroxisomal proliferator activated receptor γ (PPARγ). Cancer Lett. 2013 Aug 9;336(1):127-39. PMID: 23612072.

 

Liao YR, Leu YL, Chan YY, et al. Anti-platelet aggregation and vasorelaxing effects of the constituents of the rhizomes of Zingiber officinale. Molecules. 2012 Jul 26;17(8):8928-37. PMID: 22836212.

 

Weng CJ, Chou CP, Ho CT, et al. Molecular mechanism inhibiting human hepatocarcinoma cell invasion by 6-shogaol and 6-gingerol. Mol Nutr Food Res. 2012 Aug;56(8):1304-14. PMID: 22714996.

 

Haniadka R, Rajeev AG, Palatty PL, et al. Zingiber officinale (ginger) as an anti-emetic in cancer chemotherapy: a review. J Altern Complement Med. 2012 May;18(5):440-4. PMID: 22540971.

 

Wang Z, Hasegawa J, Wang X, et al. Protective Effects of Ginger against Aspirin-Induced Gastric Ulcers in Rats. Yonago Acta Med. 2011 Mar;54(1):11-9. PMID: 24031124.

 

Wu H, Hsieh MC, Lo CY, et al. 6-Shogaol is more effective than 6-gingerol and curcumin in inhibiting 12-O-tetradecanoylphorbol 13-acetate-induced tumor promotion in mice. Mol Nutr Food Res. 2010 Sep;54(9):1296-306. PMID: 20336681.

 

Onogi T, Minami M, Kuraishi Y, et al. Capsaicin-like effect of (6)-shogaol on substance P-containing primary afferents of rats: a possible mechanism of its analgesic action. Neuropharmacology. 1992 Nov;31(11):1165-9. PMID: 1282221.

" Not dangerous goods.

LKT S2957 Shogaol 10 mg 515.7 Phenol found in Zingiber; PPARγ agonist, 5-HT3 antagonist. 6-Shogaol 555-66-8 ≥98% 276.37 C17H24O3 CCCCCC=CC(=O)CCC1=CC(=C(C=C1)O)OC Ambient -20°C "Kim SM, Kim C, Bae H, et al. 6-Shogaol exerts anti-proliferative and pro-apoptotic effects through the modulation of STAT3 and MAPKs signaling pathways. Mol Carcinog. 2014 Jun 24. [Epub ahead of print]. PMID: 24962868.

 

Tan BS, Kang O, Mai CW, et al. 6-Shogaol inhibits breast and colon cancer cell proliferation through activation of peroxisomal proliferator activated receptor γ (PPARγ). Cancer Lett. 2013 Aug 9;336(1):127-39. PMID: 23612072.

 

Liao YR, Leu YL, Chan YY, et al. Anti-platelet aggregation and vasorelaxing effects of the constituents of the rhizomes of Zingiber officinale. Molecules. 2012 Jul 26;17(8):8928-37. PMID: 22836212.

 

Weng CJ, Chou CP, Ho CT, et al. Molecular mechanism inhibiting human hepatocarcinoma cell invasion by 6-shogaol and 6-gingerol. Mol Nutr Food Res. 2012 Aug;56(8):1304-14. PMID: 22714996.

 

Haniadka R, Rajeev AG, Palatty PL, et al. Zingiber officinale (ginger) as an anti-emetic in cancer chemotherapy: a review. J Altern Complement Med. 2012 May;18(5):440-4. PMID: 22540971.

 

Wang Z, Hasegawa J, Wang X, et al. Protective Effects of Ginger against Aspirin-Induced Gastric Ulcers in Rats. Yonago Acta Med. 2011 Mar;54(1):11-9. PMID: 24031124.

 

Wu H, Hsieh MC, Lo CY, et al. 6-Shogaol is more effective than 6-gingerol and curcumin in inhibiting 12-O-tetradecanoylphorbol 13-acetate-induced tumor promotion in mice. Mol Nutr Food Res. 2010 Sep;54(9):1296-306. PMID: 20336681.

 

Onogi T, Minami M, Kuraishi Y, et al. Capsaicin-like effect of (6)-shogaol on substance P-containing primary afferents of rats: a possible mechanism of its analgesic action. Neuropharmacology. 1992 Nov;31(11):1165-9. PMID: 1282221.

" Not dangerous goods.

LKT D1869 Deracoxib 10 mg 97 NSAID; COX-2 inhibitor. 169590-41-4 ≥98% 397.37 C17H14F3N3O3S COC1=C(C=C(C=C1)C2=CC(=NN2C3=CC=C(C=C3)S(=O)(=O)N)C(F)F)F Ambient Ambient "Ustün Alkan F, Ustüner O, et al. The effects of piroxicam and deracoxib on canine mammary tumour cell line. ScientificWorldJournal. 2012;2012:976740. PMID: 23251109.

 

Bienhoff SE, Smith ES, Roycroft LM, et al. Efficacy and safety of deracoxib for control of postoperative pain and inflammation associated with soft tissue surgery in dogs. Vet Surg. 2012 Apr;41(3):336-44. PMID: 22225463.

 

McMillan SK, Boria P, Moore GE, et al. Antitumor effects of deracoxib treatment in 26 dogs with transitional cell carcinoma of the urinary bladder. J Am Vet Med Assoc. 2011 Oct 15;239(8):1084-9. PMID: 21985349.

 

Blois SL, Allen DG, Wood RD, et al. Effects of aspirin, carprofen, deracoxib, and meloxicam on platelet function and systemic prostaglandin concentrations in healthy dogs. Am J Vet Res. 2010 Mar;71(3):349-58. PMID: 20187838.

" Not dangerous goods.

LKT D1869 Deracoxib 25 mg 176 NSAID; COX-2 inhibitor. 169590-41-4 ≥98% 397.37 C17H14F3N3O3S COC1=C(C=C(C=C1)C2=CC(=NN2C3=CC=C(C=C3)S(=O)(=O)N)C(F)F)F Ambient Ambient "Ustün Alkan F, Ustüner O, et al. The effects of piroxicam and deracoxib on canine mammary tumour cell line. ScientificWorldJournal. 2012;2012:976740. PMID: 23251109.

 

Bienhoff SE, Smith ES, Roycroft LM, et al. Efficacy and safety of deracoxib for control of postoperative pain and inflammation associated with soft tissue surgery in dogs. Vet Surg. 2012 Apr;41(3):336-44. PMID: 22225463.

 

McMillan SK, Boria P, Moore GE, et al. Antitumor effects of deracoxib treatment in 26 dogs with transitional cell carcinoma of the urinary bladder. J Am Vet Med Assoc. 2011 Oct 15;239(8):1084-9. PMID: 21985349.

 

Blois SL, Allen DG, Wood RD, et al. Effects of aspirin, carprofen, deracoxib, and meloxicam on platelet function and systemic prostaglandin concentrations in healthy dogs. Am J Vet Res. 2010 Mar;71(3):349-58. PMID: 20187838.

" Not dangerous goods.

LKT D1869 Deracoxib 100 mg 527.8 NSAID; COX-2 inhibitor. 169590-41-4 ≥98% 397.37 C17H14F3N3O3S COC1=C(C=C(C=C1)C2=CC(=NN2C3=CC=C(C=C3)S(=O)(=O)N)C(F)F)F Ambient Ambient "Ustün Alkan F, Ustüner O, et al. The effects of piroxicam and deracoxib on canine mammary tumour cell line. ScientificWorldJournal. 2012;2012:976740. PMID: 23251109.

 

Bienhoff SE, Smith ES, Roycroft LM, et al. Efficacy and safety of deracoxib for control of postoperative pain and inflammation associated with soft tissue surgery in dogs. Vet Surg. 2012 Apr;41(3):336-44. PMID: 22225463.

 

McMillan SK, Boria P, Moore GE, et al. Antitumor effects of deracoxib treatment in 26 dogs with transitional cell carcinoma of the urinary bladder. J Am Vet Med Assoc. 2011 Oct 15;239(8):1084-9. PMID: 21985349.

 

Blois SL, Allen DG, Wood RD, et al. Effects of aspirin, carprofen, deracoxib, and meloxicam on platelet function and systemic prostaglandin concentrations in healthy dogs. Am J Vet Res. 2010 Mar;71(3):349-58. PMID: 20187838.

" Not dangerous goods.

LKT R1724 Regadenoson 5 mg 151.7 Adenosine A2A agonist. 313348-27-5 ≥98% 390.35 C15H18N8O5 CNC(=O)C1=CN(N=C1)C2=NC3=C(C(=N2)N)N=CN3C4C(C(C(O4)CO)O)O Ambient Ambient "Palani G, Ananthasubramaniam K. Regadenoson: review of its established role in myocardial perfusion imaging and emerging applications. Cardiol Rev. 2013 Jan-Feb;21(1):42-8. PMID: 22643345.

 

Cerqueira MD. The future of pharmacologic stress: selective A2A adenosine receptor agonists. Am J Cardiol. 2004 Jul 22;94(2A):33D-40D; discussion 40D-42D. PMID: 15261132.

" Not dangerous goods.

LKT R1724 Regadenoson 25 mg 515.7 Adenosine A2A agonist. 313348-27-5 ≥98% 390.35 C15H18N8O5 CNC(=O)C1=CN(N=C1)C2=NC3=C(C(=N2)N)N=CN3C4C(C(C(O4)CO)O)O Ambient Ambient "Palani G, Ananthasubramaniam K. Regadenoson: review of its established role in myocardial perfusion imaging and emerging applications. Cardiol Rev. 2013 Jan-Feb;21(1):42-8. PMID: 22643345.

 

Cerqueira MD. The future of pharmacologic stress: selective A2A adenosine receptor agonists. Am J Cardiol. 2004 Jul 22;94(2A):33D-40D; discussion 40D-42D. PMID: 15261132.

" Not dangerous goods.

LKT R1724 Regadenoson 100 mg 1456 Adenosine A2A agonist. 313348-27-5 ≥98% 390.35 C15H18N8O5 CNC(=O)C1=CN(N=C1)C2=NC3=C(C(=N2)N)N=CN3C4C(C(C(O4)CO)O)O Ambient Ambient "Palani G, Ananthasubramaniam K. Regadenoson: review of its established role in myocardial perfusion imaging and emerging applications. Cardiol Rev. 2013 Jan-Feb;21(1):42-8. PMID: 22643345.

 

Cerqueira MD. The future of pharmacologic stress: selective A2A adenosine receptor agonists. Am J Cardiol. 2004 Jul 22;94(2A):33D-40D; discussion 40D-42D. PMID: 15261132.

" Not dangerous goods.

LKT G3254 10-Gingerol 5 mg 200.2 Phenol found in Zingiber; 5-HT3 antagonist. 23513-15-7 ≥99% 350.49 C21H34O4 CCCCCCCCCC(CC(=O)CCC1=CC(=C(C=C1)O)OC)O Avoid exposure to oxygen and direct sun light Ambient -20°C "Almada da Silva J, Becceneri AB, Sanches Mutti H, et al. Purification and differential biological effects of ginger-derived substances on normal and tumor cell lines. J Chromatogr B Analyt Technol Biomed Life Sci. 2012 Aug 15;903:157-62. PMID: 22858304.

 

Dugasani S, Pichika MR, Nadarajah VD, et al. Comparative antioxidant and anti-inflammatory effects of [6]-gingerol, [8]-gingerol, [10]-gingerol and [6]-shogaol. J Ethnopharmacol. 2010 Feb 3;127(2):515-20. PMID: 19833188.

 

Park M, Bae J, Lee DS. Antibacterial activity of [10]-gingerol and [12]-gingerol isolated from ginger rhizome against periodontal bacteria. Phytother Res. 2008 Nov;22(11):1446-9. PMID: 18814211.

 

Abdel-Aziz H, Windeck T, Ploch M, et al. Mode of action of gingerols and shogaols on 5-HT3 receptors: binding studies, cation uptake by the receptor channel and contraction of isolated guinea-pig ileum. Eur J Pharmacol. 2006 Jan 13;530(1-2):136-43. PMID: 16364290.

" Not dangerous goods.

LKT G3254 10-Gingerol 25 mg 606.7 Phenol found in Zingiber; 5-HT3 antagonist. 23513-15-7 ≥99% 350.49 C21H34O4 CCCCCCCCCC(CC(=O)CCC1=CC(=C(C=C1)O)OC)O Avoid exposure to oxygen and direct sun light Ambient -20°C "Almada da Silva J, Becceneri AB, Sanches Mutti H, et al. Purification and differential biological effects of ginger-derived substances on normal and tumor cell lines. J Chromatogr B Analyt Technol Biomed Life Sci. 2012 Aug 15;903:157-62. PMID: 22858304.

 

Dugasani S, Pichika MR, Nadarajah VD, et al. Comparative antioxidant and anti-inflammatory effects of [6]-gingerol, [8]-gingerol, [10]-gingerol and [6]-shogaol. J Ethnopharmacol. 2010 Feb 3;127(2):515-20. PMID: 19833188.

 

Park M, Bae J, Lee DS. Antibacterial activity of [10]-gingerol and [12]-gingerol isolated from ginger rhizome against periodontal bacteria. Phytother Res. 2008 Nov;22(11):1446-9. PMID: 18814211.

 

Abdel-Aziz H, Windeck T, Ploch M, et al. Mode of action of gingerols and shogaols on 5-HT3 receptors: binding studies, cation uptake by the receptor channel and contraction of isolated guinea-pig ileum. Eur J Pharmacol. 2006 Jan 13;530(1-2):136-43. PMID: 16364290.

" Not dangerous goods.

LKT G3253 8-Gingerol 5 mg 176 Phenol found in Zingiber; 5-HT3 antagonist. 23513-08-8 ≥99% 322.44 C19H30O4 CCCCCCCC(CC(=O)CCC1=CC(=C(C=C1)O)OC)O Ambient -20°C "Townsend EA, Siviski ME, Zhang Y, et al. Effects of ginger and its constituents on airway smooth muscle relaxation and calcium regulation. Am J Respir Cell Mol Biol. 2013 Feb;48(2):157-63. PMID: 23065130.

 

Li Y, Tran VH, Duke CC, et al. Gingerols of Zingiber officinale enhance glucose uptake by increasing cell surface GLUT4 in cultured L6 myotubes. Planta Med. 2012 Sep;78(14):1549-55. PMID: 22828920.

 

Almada da Silva J, Becceneri AB, Sanches Mutti H, et al. Purification and differential biological effects of ginger-derived substances on normal and tumor cell lines. J Chromatogr B Analyt Technol Biomed Life Sci. 2012 Aug 15;903:157-62. PMID: 22858304.

 

Lu J, Guan S, Shen X, et al. Immunosuppressive activity of 8-gingerol on immune responses in mice. Molecules. 2011 Mar 22;16(3):2636-45. PMID: 21441866.

 

Dugasani S, Pichika MR, Nadarajah VD, et al. Comparative antioxidant and anti-inflammatory effects of [6]-gingerol, [8]-gingerol, [10]-gingerol and [6]-shogaol. J Ethnopharmacol. 2010 Feb 3;127(2):515-20. PMID: 19833188.

 

Abdel-Aziz H, Windeck T, Ploch M, et al. Mode of action of gingerols and shogaols on 5-HT3 receptors: binding studies, cation uptake by the receptor channel and contraction of isolated guinea-pig ileum. Eur J Pharmacol. 2006 Jan 13;530(1-2):136-43. PMID: 16364290.

 

Kobayashi M, Ishida Y, Shoji N, et al. Cardiotonic action of [8]-gingerol, an activator of the Ca++-pumping adenosine triphosphatase of sarcoplasmic reticulum, in guinea pig atrial muscle. J Pharmacol Exp Ther. 1988 Aug;246(2):667-73. PMID: 2457078.

" Not dangerous goods.

LKT G3253 8-Gingerol 25 mg 588.5 Phenol found in Zingiber; 5-HT3 antagonist. 23513-08-8 ≥99% 322.44 C19H30O4 CCCCCCCC(CC(=O)CCC1=CC(=C(C=C1)O)OC)O Ambient -20°C "Townsend EA, Siviski ME, Zhang Y, et al. Effects of ginger and its constituents on airway smooth muscle relaxation and calcium regulation. Am J Respir Cell Mol Biol. 2013 Feb;48(2):157-63. PMID: 23065130.

 

Li Y, Tran VH, Duke CC, et al. Gingerols of Zingiber officinale enhance glucose uptake by increasing cell surface GLUT4 in cultured L6 myotubes. Planta Med. 2012 Sep;78(14):1549-55. PMID: 22828920.

 

Almada da Silva J, Becceneri AB, Sanches Mutti H, et al. Purification and differential biological effects of ginger-derived substances on normal and tumor cell lines. J Chromatogr B Analyt Technol Biomed Life Sci. 2012 Aug 15;903:157-62. PMID: 22858304.

 

Lu J, Guan S, Shen X, et al. Immunosuppressive activity of 8-gingerol on immune responses in mice. Molecules. 2011 Mar 22;16(3):2636-45. PMID: 21441866.

 

Dugasani S, Pichika MR, Nadarajah VD, et al. Comparative antioxidant and anti-inflammatory effects of [6]-gingerol, [8]-gingerol, [10]-gingerol and [6]-shogaol. J Ethnopharmacol. 2010 Feb 3;127(2):515-20. PMID: 19833188.

 

Abdel-Aziz H, Windeck T, Ploch M, et al. Mode of action of gingerols and shogaols on 5-HT3 receptors: binding studies, cation uptake by the receptor channel and contraction of isolated guinea-pig ileum. Eur J Pharmacol. 2006 Jan 13;530(1-2):136-43. PMID: 16364290.

 

Kobayashi M, Ishida Y, Shoji N, et al. Cardiotonic action of [8]-gingerol, an activator of the Ca++-pumping adenosine triphosphatase of sarcoplasmic reticulum, in guinea pig atrial muscle. J Pharmacol Exp Ther. 1988 Aug;246(2):667-73. PMID: 2457078.

" Not dangerous goods.

LKT M0113 Madecassoside 25 mg 91 Triterpenoid found in Centella. 34540-22-2 ≥90% 975.12 C48H78O20 CC1CCC2(CCC3(C(=CCC4C3(CC(C5C4(CC(C(C5(C)CO)O)O)C)O)C)C2C1C)C)C(=O)OC6C(C(C(C(O6)COC7C(C(C(C(O7)CO)OC8C(C(C(C(O8)C)O)O)O)O)O)O)O)O Ambient Ambient "Luo Y, Yang YP, Liu J, et al. Neuroprotective effects of madecassoside against focal cerebral ischemia reperfusion injury in rats. Brain Res. 2014 May 27;1565:37-47. PMID: 24735651.

 

Du B, Zhang Z, Li N. Madecassoside prevents Aβ(25-35)-induced inflammatory responses and autophagy in neuronal cells through the class III PI3K/Beclin-1/Bcl-2 pathway. Int Immunopharmacol. 2014 May;20(1):221-8. PMID: 24631516.

 

Lu GX, Bian DF, Ji Y, et al. Madecassoside Ameliorates Bleomycin-Induced Pulmonary Fibrosis in Mice by Downregulating Collagen Deposition. Phytother Res. 2014 Jan 23. [Epub ahead of print]. PMID: 24458872.

 

Bian GX, Li GG, Yang Y, et al. Madecassoside reduces ischemia-reperfusion injury on regional ischemia induced heart infarction in rat. Biol Pharm Bull. 2008 Mar;31(3):458-63. PMID: 18310910.

" Not dangerous goods.

LKT M0113 Madecassoside 100 mg 200.2 Triterpenoid found in Centella. 34540-22-2 ≥90% 975.12 C48H78O20 CC1CCC2(CCC3(C(=CCC4C3(CC(C5C4(CC(C(C5(C)CO)O)O)C)O)C)C2C1C)C)C(=O)OC6C(C(C(C(O6)COC7C(C(C(C(O7)CO)OC8C(C(C(C(O8)C)O)O)O)O)O)O)O)O Ambient Ambient "Luo Y, Yang YP, Liu J, et al. Neuroprotective effects of madecassoside against focal cerebral ischemia reperfusion injury in rats. Brain Res. 2014 May 27;1565:37-47. PMID: 24735651.

 

Du B, Zhang Z, Li N. Madecassoside prevents Aβ(25-35)-induced inflammatory responses and autophagy in neuronal cells through the class III PI3K/Beclin-1/Bcl-2 pathway. Int Immunopharmacol. 2014 May;20(1):221-8. PMID: 24631516.

 

Lu GX, Bian DF, Ji Y, et al. Madecassoside Ameliorates Bleomycin-Induced Pulmonary Fibrosis in Mice by Downregulating Collagen Deposition. Phytother Res. 2014 Jan 23. [Epub ahead of print]. PMID: 24458872.

 

Bian GX, Li GG, Yang Y, et al. Madecassoside reduces ischemia-reperfusion injury on regional ischemia induced heart infarction in rat. Biol Pharm Bull. 2008 Mar;31(3):458-63. PMID: 18310910.

" Not dangerous goods.

LKT M0113 Madecassoside 250 mg 364 Triterpenoid found in Centella. 34540-22-2 ≥90% 975.12 C48H78O20 CC1CCC2(CCC3(C(=CCC4C3(CC(C5C4(CC(C(C5(C)CO)O)O)C)O)C)C2C1C)C)C(=O)OC6C(C(C(C(O6)COC7C(C(C(C(O7)CO)OC8C(C(C(C(O8)C)O)O)O)O)O)O)O)O Ambient Ambient "Luo Y, Yang YP, Liu J, et al. Neuroprotective effects of madecassoside against focal cerebral ischemia reperfusion injury in rats. Brain Res. 2014 May 27;1565:37-47. PMID: 24735651.

 

Du B, Zhang Z, Li N. Madecassoside prevents Aβ(25-35)-induced inflammatory responses and autophagy in neuronal cells through the class III PI3K/Beclin-1/Bcl-2 pathway. Int Immunopharmacol. 2014 May;20(1):221-8. PMID: 24631516.

 

Lu GX, Bian DF, Ji Y, et al. Madecassoside Ameliorates Bleomycin-Induced Pulmonary Fibrosis in Mice by Downregulating Collagen Deposition. Phytother Res. 2014 Jan 23. [Epub ahead of print]. PMID: 24458872.

 

Bian GX, Li GG, Yang Y, et al. Madecassoside reduces ischemia-reperfusion injury on regional ischemia induced heart infarction in rat. Biol Pharm Bull. 2008 Mar;31(3):458-63. PMID: 18310910.

" Not dangerous goods.

LKT M0113 Madecassoside 1 g 1092 Triterpenoid found in Centella. 34540-22-2 ≥90% 975.12 C48H78O20 CC1CCC2(CCC3(C(=CCC4C3(CC(C5C4(CC(C(C5(C)CO)O)O)C)O)C)C2C1C)C)C(=O)OC6C(C(C(C(O6)COC7C(C(C(C(O7)CO)OC8C(C(C(C(O8)C)O)O)O)O)O)O)O)O Ambient Ambient "Luo Y, Yang YP, Liu J, et al. Neuroprotective effects of madecassoside against focal cerebral ischemia reperfusion injury in rats. Brain Res. 2014 May 27;1565:37-47. PMID: 24735651.

 

Du B, Zhang Z, Li N. Madecassoside prevents Aβ(25-35)-induced inflammatory responses and autophagy in neuronal cells through the class III PI3K/Beclin-1/Bcl-2 pathway. Int Immunopharmacol. 2014 May;20(1):221-8. PMID: 24631516.

 

Lu GX, Bian DF, Ji Y, et al. Madecassoside Ameliorates Bleomycin-Induced Pulmonary Fibrosis in Mice by Downregulating Collagen Deposition. Phytother Res. 2014 Jan 23. [Epub ahead of print]. PMID: 24458872.

 

Bian GX, Li GG, Yang Y, et al. Madecassoside reduces ischemia-reperfusion injury on regional ischemia induced heart infarction in rat. Biol Pharm Bull. 2008 Mar;31(3):458-63. PMID: 18310910.

" Not dangerous goods.

LKT N3476 Nitisinone 10 mg 42.4 Nitrobenzene; HPPD inhibitor. NTBC; orfadin 104206-65-7 ≥98% 329.23 C14H10F3NO5 C1CC(=O)C(C(=O)C1)C(=O)C2=C(C=C(C=C2)C(F)(F)F)[N+](=O)[O-] Ambient 4°C "McKiernan PJ. Nitisinone in the treatment of hereditary tyrosinaemia type 1. Drugs. 2006;66(6):743-50. PMID: 16706549.

 

Kavana M, Moran GR. Interaction of (4-hydroxyphenyl)pyruvate dioxygenase with the specific inhibitor 2-[2-nitro-4-(trifluoromethyl)benzoyl]-1,3-cyclohexanedione. Biochemistry. 2003 Sep 2;42(34):10238-45. PMID: 12939152.

 

Phornphutkul C, Introne WJ, Perry MB, et al. Natural history of alkaptonuria. N Engl J Med. 2002 Dec 26;347(26):2111-21. PMID: 12501223." Not dangerous goods.

LKT N3476 Nitisinone 50 mg 163.8 Nitrobenzene; HPPD inhibitor. NTBC; orfadin 104206-65-7 ≥98% 329.23 C14H10F3NO5 C1CC(=O)C(C(=O)C1)C(=O)C2=C(C=C(C=C2)C(F)(F)F)[N+](=O)[O-] Ambient 4°C "McKiernan PJ. Nitisinone in the treatment of hereditary tyrosinaemia type 1. Drugs. 2006;66(6):743-50. PMID: 16706549.

 

Kavana M, Moran GR. Interaction of (4-hydroxyphenyl)pyruvate dioxygenase with the specific inhibitor 2-[2-nitro-4-(trifluoromethyl)benzoyl]-1,3-cyclohexanedione. Biochemistry. 2003 Sep 2;42(34):10238-45. PMID: 12939152.

 

Phornphutkul C, Introne WJ, Perry MB, et al. Natural history of alkaptonuria. N Engl J Med. 2002 Dec 26;347(26):2111-21. PMID: 12501223." Not dangerous goods.

LKT N3476 Nitisinone 250 mg 546 Nitrobenzene; HPPD inhibitor. NTBC; orfadin 104206-65-7 ≥98% 329.23 C14H10F3NO5 C1CC(=O)C(C(=O)C1)C(=O)C2=C(C=C(C=C2)C(F)(F)F)[N+](=O)[O-] Ambient 4°C "McKiernan PJ. Nitisinone in the treatment of hereditary tyrosinaemia type 1. Drugs. 2006;66(6):743-50. PMID: 16706549.

 

Kavana M, Moran GR. Interaction of (4-hydroxyphenyl)pyruvate dioxygenase with the specific inhibitor 2-[2-nitro-4-(trifluoromethyl)benzoyl]-1,3-cyclohexanedione. Biochemistry. 2003 Sep 2;42(34):10238-45. PMID: 12939152.

 

Phornphutkul C, Introne WJ, Perry MB, et al. Natural history of alkaptonuria. N Engl J Med. 2002 Dec 26;347(26):2111-21. PMID: 12501223." Not dangerous goods.

LKT C1876 Cetirizine Dihydrochloride 1 g 33.9 Histamine H1 antagonist. 2-[2-[4-[(4-chlorophenyl)-phenyl-methyl]piperazin-1-yl]ethoxy]acetic acid 83881-52-1 ≥99% 461.82 C21H25ClN2O3 2HCl C1CN(CCN1CCOCC(=O)O)C(C2=CC=CC=C2)C3=CC=C(C=C3)Cl.Cl.Cl Ambient Ambient Soluble in water & Methanol "Namazi MR. Cetirizine and allopurinol as novel weapons against cellular autoimmune disorders. Int Immunopharmacol. 2004 Mar;4(3):349-53. PMID: 15037212.

 

Bruno G, Andreozzi P, Magrini L, et al. Serum tryptase in allergic rhinitis: effect of cetirizine treatment. Int J Immunopathol Pharmacol. 2001 Sep-Dec;14(3):147-152. PMID: 12604015.

 

Slater JW, Zechnich AD, Haxby DG. Second-generation antihistamines: a comparative review. Drugs. 1999 Jan;57(1):31-47. PMID: 9951950.

" Xn Not Dangerous Goods

LKT L9610 Lycorine Hydrochloride 10 mg 54.6 Alkaloid found in plants in the Amaryllidaceae family; protein synthesis inhibitor, potential peptidyltransferase and HDAC inhibitor. Lycorine HCl 2188-68-3 ≥98% 323.77 C16H17NO4 HCl C1CN2CC3=CC4=C(C=C3C5C2C1=CC(C5O)O)OCO4.Cl Ambient 4°C "Shen JW, Ruan Y, Ren W, et al. Lycorine: a potential broad-spectrum agent against crop pathogenic fungi. J Microbiol Biotechnol. 2014 Mar 28;24(3):354-8. PMID: 24346469.

 

Li L, Dai HJ, Ye M, et al. Lycorine induces cell-cycle arrest in the G0/G1 phase in K562 cells via HDAC inhibition. Cancer Cell Int. 2012 Nov 23;12(1):49. PMID: 23176676.

 

Giordani RB, Vieira Pde B, Weizenmann M, et al. Lycorine induces cell death in the amitochondriate parasite, Trichomonas vaginalis, via an alternative non-apoptotic death pathway. Phytochemistry. 2011 May;72(7):645-50. PMID: 21324496.

 

Yui S, Mikami M, Mimaki Y, et al. Inhibition effect of Amaryllidaceae alkaloids, lycorine and lycoricidinol on macrophage TNF-alpha production. Yakugaku Zasshi. 2001 Feb;121(2):167-71. PMID: 11218731.

 

Kukhanova M, Victorova L, Krayevsky A. Peptidyltransferase center of ribosomes. On the mechanism of action of alkaloid lycorine. FEBS Lett. 1983 Aug 22;160(1-2):129-33. PMID: 6350039.

" "UN number: 2811     Class:  6.1     Packing group:  III

Proper shipping name:  Toxic solids, organic, n.o.s. (Lycorine hydrochloride)  Reportable Quantity (RQ):  No.  Marine pollutant:  No.  Poison inhalation hazard:  No."

LKT L9610 Lycorine Hydrochloride 25 mg 103.1 Alkaloid found in plants in the Amaryllidaceae family; protein synthesis inhibitor, potential peptidyltransferase and HDAC inhibitor. Lycorine HCl 2188-68-3 ≥98% 323.77 C16H17NO4 HCl C1CN2CC3=CC4=C(C=C3C5C2C1=CC(C5O)O)OCO4.Cl Ambient 4°C "Shen JW, Ruan Y, Ren W, et al. Lycorine: a potential broad-spectrum agent against crop pathogenic fungi. J Microbiol Biotechnol. 2014 Mar 28;24(3):354-8. PMID: 24346469.

 

Li L, Dai HJ, Ye M, et al. Lycorine induces cell-cycle arrest in the G0/G1 phase in K562 cells via HDAC inhibition. Cancer Cell Int. 2012 Nov 23;12(1):49. PMID: 23176676.

 

Giordani RB, Vieira Pde B, Weizenmann M, et al. Lycorine induces cell death in the amitochondriate parasite, Trichomonas vaginalis, via an alternative non-apoptotic death pathway. Phytochemistry. 2011 May;72(7):645-50. PMID: 21324496.

 

Yui S, Mikami M, Mimaki Y, et al. Inhibition effect of Amaryllidaceae alkaloids, lycorine and lycoricidinol on macrophage TNF-alpha production. Yakugaku Zasshi. 2001 Feb;121(2):167-71. PMID: 11218731.

 

Kukhanova M, Victorova L, Krayevsky A. Peptidyltransferase center of ribosomes. On the mechanism of action of alkaloid lycorine. FEBS Lett. 1983 Aug 22;160(1-2):129-33. PMID: 6350039.

" "UN number: 2811     Class:  6.1     Packing group:  III

Proper shipping name:  Toxic solids, organic, n.o.s. (Lycorine hydrochloride)  Reportable Quantity (RQ):  No.  Marine pollutant:  No.  Poison inhalation hazard:  No."

LKT L9610 Lycorine Hydrochloride 100 mg 303.3 Alkaloid found in plants in the Amaryllidaceae family; protein synthesis inhibitor, potential peptidyltransferase and HDAC inhibitor. Lycorine HCl 2188-68-3 ≥98% 323.77 C16H17NO4 HCl C1CN2CC3=CC4=C(C=C3C5C2C1=CC(C5O)O)OCO4.Cl Ambient 4°C "Shen JW, Ruan Y, Ren W, et al. Lycorine: a potential broad-spectrum agent against crop pathogenic fungi. J Microbiol Biotechnol. 2014 Mar 28;24(3):354-8. PMID: 24346469.

 

Li L, Dai HJ, Ye M, et al. Lycorine induces cell-cycle arrest in the G0/G1 phase in K562 cells via HDAC inhibition. Cancer Cell Int. 2012 Nov 23;12(1):49. PMID: 23176676.

 

Giordani RB, Vieira Pde B, Weizenmann M, et al. Lycorine induces cell death in the amitochondriate parasite, Trichomonas vaginalis, via an alternative non-apoptotic death pathway. Phytochemistry. 2011 May;72(7):645-50. PMID: 21324496.

 

Yui S, Mikami M, Mimaki Y, et al. Inhibition effect of Amaryllidaceae alkaloids, lycorine and lycoricidinol on macrophage TNF-alpha production. Yakugaku Zasshi. 2001 Feb;121(2):167-71. PMID: 11218731.

 

Kukhanova M, Victorova L, Krayevsky A. Peptidyltransferase center of ribosomes. On the mechanism of action of alkaloid lycorine. FEBS Lett. 1983 Aug 22;160(1-2):129-33. PMID: 6350039.

" "UN number: 2811     Class:  6.1     Packing group:  III

Proper shipping name:  Toxic solids, organic, n.o.s. (Lycorine hydrochloride)  Reportable Quantity (RQ):  No.  Marine pollutant:  No.  Poison inhalation hazard:  No."

LKT M3411 [D-Asp3, (E)-Dhb7]-Microcystin-RR 100 µg 570.3 Cyclic heptapeptide produced by Microcystis; PP1/2A inhibitor, potential GSK-3β activator. 202120-08-9 ≥95% 1038.2 C49H75N13O12 CC=C1C(=O)NC(C(=O)NC(C(=O)NC(CC(=O)NC(C(=O)NC(C(C(=O)NC(CCC(=O)N1)C(=O)O)C)C=CC(=CC(C)C(CC2=CC=CC=C2)OC)C)CCCN=C(N)N)C(=O)O)CCCN=C(N)N)C Blue Ice -20°C "Pavagadhi S, Natera S, Roessner U, et al. Insights into Lipidomic Perturbations in Zebrafish Tissues upon Exposure to Microcystin-LR and Microcystin-RR. Environ Sci Technol. 2013 Dec 17;47(24):14376-84. PMID: 24152164.

 

Zhao S, Xie P, Li G, et al. The proteomic study on cellular responses of the testes of zebrafish (Danio rerio) exposed to microcystin-RR. Proteomics. 2012 Jan;12(2):300-12. PMID: 22140076.

 

Huang P, Zheng Q, Xu LH. The apoptotic effect of oral administration of microcystin-RR on mice liver. Environ Toxicol. 2011 Oct;26(5):443-52. PMID: 20196164.

" "UN number: 3462     Class:  6.1     Packing group:  I

Proper shipping name:  Toxins, extracted from living sources, solid, n.o.s. ([D-Asp3, (E)-Dhb7]-Microcystin-RR)"

LKT Z0252 Zanamivir 5 mg 78.9 Neuraminidase inhibitor. 5-acetamido- 4-guanidino- 6-(1,2,3-trihydroxypropyl)- 5,6-dihydro- 4H-pyran- 2-carboxylic acid 139110-80-8 ≥98% 332.31 C12H20N4O7 CC(=O)NC1C(C=C(OC1C(C(CO)O)O)C(=O)O)N=C(N)N Ambient Ambient "Kim JH, Resende R, Wennekes T, et al. Mechanism-based covalent neuraminidase inhibitors with broad-spectrum influenza antiviral activity. Science. 2013 Apr 5;340(6128):71-5. PMID: 23429702.

 

Leyssen P, De Clercq E, Neyts J. Molecular strategies to inhibit the replication of RNA viruses. Antiviral Res. 2008 Apr;78(1):9-25. PMID: 18313769.

" Not dangerous goods.

LKT F1768 Ferintoic Acid A 100 µg 364 Hexapeptide found in Microcystis. 176327-91-6 ≥95% 867 C46H58N8O9 CC1C(=O)NC(C(=O)NCCCCC(C(=O)NC(C(=O)NC(C(=O)N1C)CCC2=CC=C(C=C2)O)C(C)C)NC(=O)NC(CC3=CNC4=CC=CC=C43)C(=O)O)CC5=CC=CC=C5 Blue Ice -20°C Williams DE, Craig M, Holmes CFB, et al. Ferintoic Acids A and B, New Cyclic Hexapeptides from the Freshwater Cyanobacterium Microcystis aeruginosa. J Nat Prod. 1996;59(6): 570-575.

LKT T6930 Triclosan Methyl Ether 25 mg 110.1 Diarylether; bacterial ENR binder, fatty acid synthesis inhibitor. 2,4,4′-Trichloro-2′-methoxydiphenyl ether 5-Chloro-2-(2,4-dichlorophenoxy)anisole, Methyl triclosan 4640-01-1 ≥99% 303.57 C13H9Cl3O2 COC1=C(C=CC(=C1)Cl)OC2=C(C=C(C=C2)Cl)Cl Ambient 4°C "Wallet MA, Calderon Nl, Alonso TR, et al. Triclosan alters antimicrobial and inflammatory responses of epithelial cells. Oral Dis. 2013 Apr;19(3):296-302. PMID: 24079913.

 

Twanabasu BR, Smith CM, Stevens KJ, et al. Triclosan inhibits arbuscular mycorrhizal colonization in three wetland plants. Sci Total Environ. 2013 Mar 1;447:450-7. PMID: 23410867.

 

Russell AD. Whither triclosan? J Antimicrob Chemother. 2004 May;53(5):693-5. PMID: 15073159.

" "UN number: 3082     Class: 9     Packing Group: III

Proper shipping name: Environmentally hazardous substance, liquid, n.o.s. (Triclosan methyl ether)"

LKT T6930 Triclosan Methyl Ether 50 mg 168.5 Diarylether; bacterial ENR binder, fatty acid synthesis inhibitor. 2,4,4′-Trichloro-2′-methoxydiphenyl ether 5-Chloro-2-(2,4-dichlorophenoxy)anisole, Methyl triclosan 4640-01-1 ≥99% 303.57 C13H9Cl3O2 COC1=C(C=CC(=C1)Cl)OC2=C(C=C(C=C2)Cl)Cl Ambient 4°C "Wallet MA, Calderon Nl, Alonso TR, et al. Triclosan alters antimicrobial and inflammatory responses of epithelial cells. Oral Dis. 2013 Apr;19(3):296-302. PMID: 24079913.

 

Twanabasu BR, Smith CM, Stevens KJ, et al. Triclosan inhibits arbuscular mycorrhizal colonization in three wetland plants. Sci Total Environ. 2013 Mar 1;447:450-7. PMID: 23410867.

 

Russell AD. Whither triclosan? J Antimicrob Chemother. 2004 May;53(5):693-5. PMID: 15073159.

" "UN number: 3082     Class: 9     Packing Group: III

Proper shipping name: Environmentally hazardous substance, liquid, n.o.s. (Triclosan methyl ether)"

LKT S0245 Salmeterol 10 mg 101.1 β2-adrenergic agonist. 89365-50-4 ≥98% 415.57 C25H37NO4 C1=CC=C(C=C1)CCCCOCCCCCCNCC(C2=CC(=C(C=C2)O)CO)O Ambient Ambient "Lambers C, Qi Y, Eleni P, et al. Extracellular matrix composition is modified by β2-agonists through cAMP in COPD. Biochem Pharmacol. 2014 Oct 1;91(3):400-8. PMID: 25107701.

 

Coleman RA. On the mechanism of the persistent action of salmeterol: what is the current position? Br J Pharmacol. 2009 Sep;158(1):180-2. PMID: 19719780.

" Not dangerous goods.

LKT S0245 Salmeterol 25 mg 215.7 β2-adrenergic agonist. 89365-50-4 ≥98% 415.57 C25H37NO4 C1=CC=C(C=C1)CCCCOCCCCCCNCC(C2=CC(=C(C=C2)O)CO)O Ambient Ambient "Lambers C, Qi Y, Eleni P, et al. Extracellular matrix composition is modified by β2-agonists through cAMP in COPD. Biochem Pharmacol. 2014 Oct 1;91(3):400-8. PMID: 25107701.

 

Coleman RA. On the mechanism of the persistent action of salmeterol: what is the current position? Br J Pharmacol. 2009 Sep;158(1):180-2. PMID: 19719780.

" Not dangerous goods.

LKT S0245 Salmeterol 50 mg 410.1 β2-adrenergic agonist. 89365-50-4 ≥98% 415.57 C25H37NO4 C1=CC=C(C=C1)CCCCOCCCCCCNCC(C2=CC(=C(C=C2)O)CO)O Ambient Ambient "Lambers C, Qi Y, Eleni P, et al. Extracellular matrix composition is modified by β2-agonists through cAMP in COPD. Biochem Pharmacol. 2014 Oct 1;91(3):400-8. PMID: 25107701.

 

Coleman RA. On the mechanism of the persistent action of salmeterol: what is the current position? Br J Pharmacol. 2009 Sep;158(1):180-2. PMID: 19719780.

" Not dangerous goods.

LKT A0402 Abacavir Sulfate 5 mg 39.4 Nucleoside (guanosine) analog; RT, guanylyl cyclase, telomerase inhibitor. Abacavir hemisulfate 188062-50-2 ≥98% 670.75 C14H18N6O 1/2H2O4S C1CC1NC2=NC(=NC3=C2N=CN3C4CC(C=C4)CO)N.OS(=O)(=O)O Ambient Ambient "Leeansyah E, Cameron PU, Solomon A, et al. Inhibition of telomerase activity by human immunodeficiency virus (HIV) nucleos(t)ide reverse transcriptase inhibitors: a potential factor contributing to HIV-associated accelerated aging. J Infect Dis. 2013 Apr;207(7):1157-65. PMID: 23303810.

 

Baum PD, Sullam PM, Stoddart CA, et al. Abacavir increases platelet reactivity via competitive inhibition of soluble guanylyl cyclase. AIDS. 2011 Nov 28;25(18):2243-8. PMID: 21941165.

 

Ribera E, Tuset M, Martín M, et al. Characteristics of antiretroviral drugs. Enferm Infecc Microbiol Clin. 2011 May;29(5):362-91. PMID: 21531048.

" Not dangerous goods.

LKT A0402 Abacavir Sulfate 10 mg 76.4 Nucleoside (guanosine) analog; RT, guanylyl cyclase, telomerase inhibitor. Abacavir hemisulfate 188062-50-2 ≥98% 670.75 C14H18N6O 1/2H2O4S C1CC1NC2=NC(=NC3=C2N=CN3C4CC(C=C4)CO)N.OS(=O)(=O)O Ambient Ambient "Leeansyah E, Cameron PU, Solomon A, et al. Inhibition of telomerase activity by human immunodeficiency virus (HIV) nucleos(t)ide reverse transcriptase inhibitors: a potential factor contributing to HIV-associated accelerated aging. J Infect Dis. 2013 Apr;207(7):1157-65. PMID: 23303810.

 

Baum PD, Sullam PM, Stoddart CA, et al. Abacavir increases platelet reactivity via competitive inhibition of soluble guanylyl cyclase. AIDS. 2011 Nov 28;25(18):2243-8. PMID: 21941165.

 

Ribera E, Tuset M, Martín M, et al. Characteristics of antiretroviral drugs. Enferm Infecc Microbiol Clin. 2011 May;29(5):362-91. PMID: 21531048.

" Not dangerous goods.

LKT A0402 Abacavir Sulfate 25 mg 177.6 Nucleoside (guanosine) analog; RT, guanylyl cyclase, telomerase inhibitor. Abacavir hemisulfate 188062-50-2 ≥98% 670.75 C14H18N6O 1/2H2O4S C1CC1NC2=NC(=NC3=C2N=CN3C4CC(C=C4)CO)N.OS(=O)(=O)O Ambient Ambient "Leeansyah E, Cameron PU, Solomon A, et al. Inhibition of telomerase activity by human immunodeficiency virus (HIV) nucleos(t)ide reverse transcriptase inhibitors: a potential factor contributing to HIV-associated accelerated aging. J Infect Dis. 2013 Apr;207(7):1157-65. PMID: 23303810.

 

Baum PD, Sullam PM, Stoddart CA, et al. Abacavir increases platelet reactivity via competitive inhibition of soluble guanylyl cyclase. AIDS. 2011 Nov 28;25(18):2243-8. PMID: 21941165.

 

Ribera E, Tuset M, Martín M, et al. Characteristics of antiretroviral drugs. Enferm Infecc Microbiol Clin. 2011 May;29(5):362-91. PMID: 21531048.

" Not dangerous goods.

LKT A0402 Abacavir Sulfate 50 mg 297.8 Nucleoside (guanosine) analog; RT, guanylyl cyclase, telomerase inhibitor. Abacavir hemisulfate 188062-50-2 ≥98% 670.75 C14H18N6O 1/2H2O4S C1CC1NC2=NC(=NC3=C2N=CN3C4CC(C=C4)CO)N.OS(=O)(=O)O Ambient Ambient "Leeansyah E, Cameron PU, Solomon A, et al. Inhibition of telomerase activity by human immunodeficiency virus (HIV) nucleos(t)ide reverse transcriptase inhibitors: a potential factor contributing to HIV-associated accelerated aging. J Infect Dis. 2013 Apr;207(7):1157-65. PMID: 23303810.

 

Baum PD, Sullam PM, Stoddart CA, et al. Abacavir increases platelet reactivity via competitive inhibition of soluble guanylyl cyclase. AIDS. 2011 Nov 28;25(18):2243-8. PMID: 21941165.

 

Ribera E, Tuset M, Martín M, et al. Characteristics of antiretroviral drugs. Enferm Infecc Microbiol Clin. 2011 May;29(5):362-91. PMID: 21531048.

" Not dangerous goods.

LKT E4785 Elvitegravir 10 mg 224.7 Integrase inhibitor. 697761-98-1 ≥98% 447.88 C23H23ClFNO5 CC(C)C(CO)N1C=C(C(=O)C2=CC(=C(C=C21)OC)CC3=C(C(=CC=C3)Cl)F)C(=O)O Ambient Ambient "Reviriego C. Elvitegravir for the treatment of HIV infection. Drugs Today (Barc). 2014 Mar;50(3):209-17. PMID: 24696866.

 

Shimura K, Kodama E, Sakagami Y, et al. Broad antiretroviral activity and resistance profile of the novel human immunodeficiency virus integrase inhibitor elvitegravir (JTK-303/GS-9137). J Virol. 2008 Jan;82(2):764-74. PMID: 17977962.

" Not dangerous goods.

LKT E4785 Elvitegravir 25 mg 443.8 Integrase inhibitor. 697761-98-1 ≥98% 447.88 C23H23ClFNO5 CC(C)C(CO)N1C=C(C(=O)C2=CC(=C(C=C21)OC)CC3=C(C(=CC=C3)Cl)F)C(=O)O Ambient Ambient "Reviriego C. Elvitegravir for the treatment of HIV infection. Drugs Today (Barc). 2014 Mar;50(3):209-17. PMID: 24696866.

 

Shimura K, Kodama E, Sakagami Y, et al. Broad antiretroviral activity and resistance profile of the novel human immunodeficiency virus integrase inhibitor elvitegravir (JTK-303/GS-9137). J Virol. 2008 Jan;82(2):764-74. PMID: 17977962.

" Not dangerous goods.

LKT E4785 Elvitegravir 50 mg 814.6 Integrase inhibitor. 697761-98-1 ≥98% 447.88 C23H23ClFNO5 CC(C)C(CO)N1C=C(C(=O)C2=CC(=C(C=C21)OC)CC3=C(C(=CC=C3)Cl)F)C(=O)O Ambient Ambient "Reviriego C. Elvitegravir for the treatment of HIV infection. Drugs Today (Barc). 2014 Mar;50(3):209-17. PMID: 24696866.

 

Shimura K, Kodama E, Sakagami Y, et al. Broad antiretroviral activity and resistance profile of the novel human immunodeficiency virus integrase inhibitor elvitegravir (JTK-303/GS-9137). J Virol. 2008 Jan;82(2):764-74. PMID: 17977962.

" Not dangerous goods.

LKT S5722 Sofosbuvir 10 mg 280.9 Viral RNA polymerase inhibitor. 1190307-88-0 ≥98% 529.45 C22H29FN3O9P CC(C)OC(=O)C(C)NP(=O)(OCC1C(C(C(O1)N2C=CC(=O)NC2=O)(C)F)O)OC3=CC=CC=C3 Ambient Ambient "Murakami C, Melda Urekli H, Atta MG. Antiviral medications for the treatment of hepatitis B and C infection and their effects on kidney function. Minerva Gastroenterol Dietol. 2014 Sep;60(3):177-89. PMID: 25027705.

 

Fung A, Jin Z, Dyatkina N, et al. Efficiency of incorporation and chain termination determines the inhibition potency of 2'-modified nucleotide analogs against hepatitis C virus polymerase. Antimicrob Agents Chemother. 2014 Jul;58(7):3636-45. PMID: 24733478.

 

Murakami E, Tolstykh T, Bao H, et al. Mechanism of activation of PSI-7851 and its diastereoisomer PSI-7977. J Biol Chem. 2010 Nov 5;285(45):34337-47. PMID: 20801890.

" Not dangerous goods.

LKT S5722 Sofosbuvir 25 mg 533.7 Viral RNA polymerase inhibitor. 1190307-88-0 ≥98% 529.45 C22H29FN3O9P CC(C)OC(=O)C(C)NP(=O)(OCC1C(C(C(O1)N2C=CC(=O)NC2=O)(C)F)O)OC3=CC=CC=C3 Ambient Ambient "Murakami C, Melda Urekli H, Atta MG. Antiviral medications for the treatment of hepatitis B and C infection and their effects on kidney function. Minerva Gastroenterol Dietol. 2014 Sep;60(3):177-89. PMID: 25027705.

 

Fung A, Jin Z, Dyatkina N, et al. Efficiency of incorporation and chain termination determines the inhibition potency of 2'-modified nucleotide analogs against hepatitis C virus polymerase. Antimicrob Agents Chemother. 2014 Jul;58(7):3636-45. PMID: 24733478.

 

Murakami E, Tolstykh T, Bao H, et al. Mechanism of activation of PSI-7851 and its diastereoisomer PSI-7977. J Biol Chem. 2010 Nov 5;285(45):34337-47. PMID: 20801890.

" Not dangerous goods.

LKT S5722 Sofosbuvir 50 mg 842.6 Viral RNA polymerase inhibitor. 1190307-88-0 ≥98% 529.45 C22H29FN3O9P CC(C)OC(=O)C(C)NP(=O)(OCC1C(C(C(O1)N2C=CC(=O)NC2=O)(C)F)O)OC3=CC=CC=C3 Ambient Ambient "Murakami C, Melda Urekli H, Atta MG. Antiviral medications for the treatment of hepatitis B and C infection and their effects on kidney function. Minerva Gastroenterol Dietol. 2014 Sep;60(3):177-89. PMID: 25027705.

 

Fung A, Jin Z, Dyatkina N, et al. Efficiency of incorporation and chain termination determines the inhibition potency of 2'-modified nucleotide analogs against hepatitis C virus polymerase. Antimicrob Agents Chemother. 2014 Jul;58(7):3636-45. PMID: 24733478.

 

Murakami E, Tolstykh T, Bao H, et al. Mechanism of activation of PSI-7851 and its diastereoisomer PSI-7977. J Biol Chem. 2010 Nov 5;285(45):34337-47. PMID: 20801890.

" Not dangerous goods.

LKT E5178 Emtricitabine 10 mg 134.8 Nucleoside (cytidine) analog; RT and telomerase inhibitor. 143491-57-0 ≥98% 247.25 C8H10FN3O3S C1C(OC(S1)CO)N2C=C(C(=NC2=O)N)F Ambient 4°C "Kulkarni R, Hluhanich R, McColl DM, et al. The combined anti-HIV-1 activities of emtricitabine and tenofovir plus the integrase inhibitor elvitegravir or raltegravir show high levels of synergy in vitro. Antimicrob Agents Chemother. 2014 Oct;58(10):6145-50. PMID: 25092710.

 

Arribas JR, Eron J. Advances in antiretroviral therapy. Curr Opin HIV AIDS. 2013 Jul;8(4):341-9. PMID: 23666392.

 

Leeansyah E, Cameron PU, Solomon A, et al. Inhibition of telomerase activity by human immunodeficiency virus (HIV) nucleos(t)ide reverse transcriptase inhibitors: a potential factor contributing to HIV-associated accelerated aging. J Infect Dis. 2013 Apr;207(7):1157-65. PMID: 23303810.

" Not dangerous goods.

LKT E5178 Emtricitabine 25 mg 280.9 Nucleoside (cytidine) analog; RT and telomerase inhibitor. 143491-57-0 ≥98% 247.25 C8H10FN3O3S C1C(OC(S1)CO)N2C=C(C(=NC2=O)N)F Ambient 4°C "Kulkarni R, Hluhanich R, McColl DM, et al. The combined anti-HIV-1 activities of emtricitabine and tenofovir plus the integrase inhibitor elvitegravir or raltegravir show high levels of synergy in vitro. Antimicrob Agents Chemother. 2014 Oct;58(10):6145-50. PMID: 25092710.

 

Arribas JR, Eron J. Advances in antiretroviral therapy. Curr Opin HIV AIDS. 2013 Jul;8(4):341-9. PMID: 23666392.

 

Leeansyah E, Cameron PU, Solomon A, et al. Inhibition of telomerase activity by human immunodeficiency virus (HIV) nucleos(t)ide reverse transcriptase inhibitors: a potential factor contributing to HIV-associated accelerated aging. J Infect Dis. 2013 Apr;207(7):1157-65. PMID: 23303810.

" Not dangerous goods.

LKT E5178 Emtricitabine 50 mg 421.4 Nucleoside (cytidine) analog; RT and telomerase inhibitor. 143491-57-0 ≥98% 247.25 C8H10FN3O3S C1C(OC(S1)CO)N2C=C(C(=NC2=O)N)F Ambient 4°C "Kulkarni R, Hluhanich R, McColl DM, et al. The combined anti-HIV-1 activities of emtricitabine and tenofovir plus the integrase inhibitor elvitegravir or raltegravir show high levels of synergy in vitro. Antimicrob Agents Chemother. 2014 Oct;58(10):6145-50. PMID: 25092710.

 

Arribas JR, Eron J. Advances in antiretroviral therapy. Curr Opin HIV AIDS. 2013 Jul;8(4):341-9. PMID: 23666392.

 

Leeansyah E, Cameron PU, Solomon A, et al. Inhibition of telomerase activity by human immunodeficiency virus (HIV) nucleos(t)ide reverse transcriptase inhibitors: a potential factor contributing to HIV-associated accelerated aging. J Infect Dis. 2013 Apr;207(7):1157-65. PMID: 23303810.

" Not dangerous goods.

LKT A6269 Apremilast 5 mg 303.3 PDE4 inhibitor. 608141-41-9 ≥98% 459.51 C23H25NO7S CCOC1=C(C=CC(=C1)C(CS(=O)(=O)C)N2C(=O)C3=C(C2=O)C(=CC=C3)NC(=O)C)OC Ambient Ambient "Schafer PH, Parton A, Capone L, et al. Apremilast is a selective PDE4 inhibitor with regulatory effects on innate immunity. Cell Signal. 2014 Sep;26(9):2016-29. PMID: 24882690.

 

Schafer P. Apremilast mechanism of action and application to psoriasis and psoriatic arthritis. Biochem Pharmacol. 2012 Jun 15;83(12):1583-90. PMID: 22257911.

" Not dangerous goods.

LKT A6269 Apremilast 25 mg 970.7 PDE4 inhibitor. 608141-41-9 ≥98% 459.51 C23H25NO7S CCOC1=C(C=CC(=C1)C(CS(=O)(=O)C)N2C(=O)C3=C(C2=O)C(=CC=C3)NC(=O)C)OC Ambient Ambient "Schafer PH, Parton A, Capone L, et al. Apremilast is a selective PDE4 inhibitor with regulatory effects on innate immunity. Cell Signal. 2014 Sep;26(9):2016-29. PMID: 24882690.

 

Schafer P. Apremilast mechanism of action and application to psoriasis and psoriatic arthritis. Biochem Pharmacol. 2012 Jun 15;83(12):1583-90. PMID: 22257911.

" Not dangerous goods.

LKT A0401 Abacavir 10 mg 76.4 Nucleoside (guanosine) analog; RT, guanylyl cyclase, telomerase inhibitor. 136470-78-5 ≥98% 286.33 C14H18N6O C1CC1NC2=NC(=NC3=C2N=CN3C4CC(C=C4)CO)N Ambient Ambient "Leeansyah E, Cameron PU, Solomon A, et al. Inhibition of telomerase activity by human immunodeficiency virus (HIV) nucleos(t)ide reverse transcriptase inhibitors: a potential factor contributing to HIV-associated accelerated aging. J Infect Dis. 2013 Apr;207(7):1157-65. PMID: 23303810.

 

Baum PD, Sullam PM, Stoddart CA, et al. Abacavir increases platelet reactivity via competitive inhibition of soluble guanylyl cyclase. AIDS. 2011 Nov 28;25(18):2243-8. PMID: 21941165.

 

Ribera E, Tuset M, Martín M, et al. Characteristics of antiretroviral drugs. Enferm Infecc Microbiol Clin. 2011 May;29(5):362-91. PMID: 21531048.

" Not dangerous goods.

LKT A0401 Abacavir 25 mg 177.6 Nucleoside (guanosine) analog; RT, guanylyl cyclase, telomerase inhibitor. 136470-78-5 ≥98% 286.33 C14H18N6O C1CC1NC2=NC(=NC3=C2N=CN3C4CC(C=C4)CO)N Ambient Ambient "Leeansyah E, Cameron PU, Solomon A, et al. Inhibition of telomerase activity by human immunodeficiency virus (HIV) nucleos(t)ide reverse transcriptase inhibitors: a potential factor contributing to HIV-associated accelerated aging. J Infect Dis. 2013 Apr;207(7):1157-65. PMID: 23303810.

 

Baum PD, Sullam PM, Stoddart CA, et al. Abacavir increases platelet reactivity via competitive inhibition of soluble guanylyl cyclase. AIDS. 2011 Nov 28;25(18):2243-8. PMID: 21941165.

 

Ribera E, Tuset M, Martín M, et al. Characteristics of antiretroviral drugs. Enferm Infecc Microbiol Clin. 2011 May;29(5):362-91. PMID: 21531048.

" Not dangerous goods.

LKT A0401 Abacavir 50 mg 297.8 Nucleoside (guanosine) analog; RT, guanylyl cyclase, telomerase inhibitor. 136470-78-5 ≥98% 286.33 C14H18N6O C1CC1NC2=NC(=NC3=C2N=CN3C4CC(C=C4)CO)N Ambient Ambient "Leeansyah E, Cameron PU, Solomon A, et al. Inhibition of telomerase activity by human immunodeficiency virus (HIV) nucleos(t)ide reverse transcriptase inhibitors: a potential factor contributing to HIV-associated accelerated aging. J Infect Dis. 2013 Apr;207(7):1157-65. PMID: 23303810.

 

Baum PD, Sullam PM, Stoddart CA, et al. Abacavir increases platelet reactivity via competitive inhibition of soluble guanylyl cyclase. AIDS. 2011 Nov 28;25(18):2243-8. PMID: 21941165.

 

Ribera E, Tuset M, Martín M, et al. Characteristics of antiretroviral drugs. Enferm Infecc Microbiol Clin. 2011 May;29(5):362-91. PMID: 21531048.

" Not dangerous goods.

LKT D3448 Dimethyl Fumarate 25 g 26.8 Fumaric acid methyl ester; nAChR agonist, indirect Nrf2 activator. BG-12 624-49-7 ≥98% 144.13 C6H8O4 COC(=O)C=CC(=O)OC Ambient Ambient "Fox RJ, Miller DH, Phillips JT, et al. Placebo-controlled phase 3 study of oral BG-12 or glatiramer in multiple sclerosis. N Engl J Med. 2012 Sep 20;367(12):1087-97. Erratum in: N Engl J Med. 2012 Oct 25;367(17):1673. PMID: 22992072.

 

Scannevin RH, Chollate S, Jung MY, et al. Fumarates promote cytoprotection of central nervous system cells against oxidative stress via the nuclear factor (erythroid-derived 2)-like 2 pathway. J Pharmacol Exp Ther. 2012 Apr;341(1):274-84. PMID: 22267202.

 

Lehmann JC, Listopad JJ, Rentzsch CU, et al. Dimethylfumarate induces immunosuppression via glutathione depletion and subsequent induction of heme oxygenase 1. J Invest Dermatol. 2007 Apr;127(4):835-45. PMID: 17235328.

 

Held KD, Epp ER, Clark EP, et al. Effect of dimethyl fumarate on the radiation sensitivity of mammalian cells in vitro. Radiat Res. 1988 Sep;115(3):495-502. PMID: 3174933.

" Not dangerous goods.

LKT D3448 Dimethyl Fumarate 100 g 72.8 Fumaric acid methyl ester; nAChR agonist, indirect Nrf2 activator. BG-12 624-49-7 ≥98% 144.13 C6H8O4 COC(=O)C=CC(=O)OC Ambient Ambient "Fox RJ, Miller DH, Phillips JT, et al. Placebo-controlled phase 3 study of oral BG-12 or glatiramer in multiple sclerosis. N Engl J Med. 2012 Sep 20;367(12):1087-97. Erratum in: N Engl J Med. 2012 Oct 25;367(17):1673. PMID: 22992072.

 

Scannevin RH, Chollate S, Jung MY, et al. Fumarates promote cytoprotection of central nervous system cells against oxidative stress via the nuclear factor (erythroid-derived 2)-like 2 pathway. J Pharmacol Exp Ther. 2012 Apr;341(1):274-84. PMID: 22267202.

 

Lehmann JC, Listopad JJ, Rentzsch CU, et al. Dimethylfumarate induces immunosuppression via glutathione depletion and subsequent induction of heme oxygenase 1. J Invest Dermatol. 2007 Apr;127(4):835-45. PMID: 17235328.

 

Held KD, Epp ER, Clark EP, et al. Effect of dimethyl fumarate on the radiation sensitivity of mammalian cells in vitro. Radiat Res. 1988 Sep;115(3):495-502. PMID: 3174933.

" Not dangerous goods.

LKT E2003 Efavirenz 10 mg 109.2 Non-nucleoside RT inhibitor. 154598-52-4 ≥98% 315.67 C14H9ClF3NO2 C1CC1C#CC2(C3=C(C=CC(=C3)Cl)NC(=O)O2)C(F)(F)F Ambient Ambient -80°, c=0.5 CHCl3 "Schauer GD, Huber KD, Leuba SH, et al. Mechanism of allosteric inhibition of HIV-1 reverse transcriptase revealed by single-molecule and ensemble fluorescence. Nucleic Acids Res. 2015 Feb 1;42(18):11687-96. PMID: 25232099.

 

Purnell PR, Fox HS. Efavirenz induces neuronal autophagy and mitochondrial alterations. J Pharmacol Exp Ther. 2014 Nov;351(2):250-8. PMID: 25161171.

 

Hecht M, Harrer T, Büttner M, et al. Cytotoxic effect of efavirenz is selective against cancer cells and associated with the cannabinoid system. AIDS. 2013 Aug 24;27(13):2031-40. PMID: 23612009.

" "UN number: 3077     Class: 9     Packing Group: III

Proper shipping name: Environmentally hazardous substance, solid, n.o.s. (Efavirenz)"

LKT E2003 Efavirenz 25 mg 242.7 Non-nucleoside RT inhibitor. 154598-52-4 ≥98% 315.67 C14H9ClF3NO2 C1CC1C#CC2(C3=C(C=CC(=C3)Cl)NC(=O)O2)C(F)(F)F Ambient Ambient -80°, c=0.5 CHCl3 "Schauer GD, Huber KD, Leuba SH, et al. Mechanism of allosteric inhibition of HIV-1 reverse transcriptase revealed by single-molecule and ensemble fluorescence. Nucleic Acids Res. 2015 Feb 1;42(18):11687-96. PMID: 25232099.

 

Purnell PR, Fox HS. Efavirenz induces neuronal autophagy and mitochondrial alterations. J Pharmacol Exp Ther. 2014 Nov;351(2):250-8. PMID: 25161171.

 

Hecht M, Harrer T, Büttner M, et al. Cytotoxic effect of efavirenz is selective against cancer cells and associated with the cannabinoid system. AIDS. 2013 Aug 24;27(13):2031-40. PMID: 23612009.

" "UN number: 3077     Class: 9     Packing Group: III

Proper shipping name: Environmentally hazardous substance, solid, n.o.s. (Efavirenz)"

LKT E2003 Efavirenz 50 mg 424.7 Non-nucleoside RT inhibitor. 154598-52-4 ≥98% 315.67 C14H9ClF3NO2 C1CC1C#CC2(C3=C(C=CC(=C3)Cl)NC(=O)O2)C(F)(F)F Ambient Ambient -80°, c=0.5 CHCl3 "Schauer GD, Huber KD, Leuba SH, et al. Mechanism of allosteric inhibition of HIV-1 reverse transcriptase revealed by single-molecule and ensemble fluorescence. Nucleic Acids Res. 2015 Feb 1;42(18):11687-96. PMID: 25232099.

 

Purnell PR, Fox HS. Efavirenz induces neuronal autophagy and mitochondrial alterations. J Pharmacol Exp Ther. 2014 Nov;351(2):250-8. PMID: 25161171.

 

Hecht M, Harrer T, Büttner M, et al. Cytotoxic effect of efavirenz is selective against cancer cells and associated with the cannabinoid system. AIDS. 2013 Aug 24;27(13):2031-40. PMID: 23612009.

" "UN number: 3077     Class: 9     Packing Group: III

Proper shipping name: Environmentally hazardous substance, solid, n.o.s. (Efavirenz)"

LKT F1769 Methoxy Ferintoic Acid A 50 µg 521.7 Hexapeptide found in Microcystis. ≥95% 881.03 C47H60N8O9 Blue Ice -20°C Williams DE, Craig M, Holmes CFB, et al. Ferintoic Acids A and B, New Cyclic Hexapeptides from the Freshwater Cyanobacterium Microcystis aeruginosa. J Nat Prod. 1996;59(6): 570-575.

LKT R1777 9-cis-Retinoic Acid 100 mg 980 Vitamin A derivative; RAR and RXR agonist. (2E,4E,6Z,8E)-3,7-Dimethyl-9-(2,6,6-trimethylcyclohex-1-enyl) nona-2,4,6,8-tetraenoic Acid 9-cis-Tretinoin; Panrexin, Alitretinoin 5300-03-8 ≥98% 300.44 C20H28O2 CC1=C(C(CCC1)(C)C)C=CC(=CC=CC(=CC(=O)O)C)C Blue Ice -80°C Soluble in DMSO and ethanol. "Shan PR, Xu WW, Huang ZQ, et al. Protective role of retinoid X receptor in H9c2 cardiomyocytes from hypoxia/reoxygenation injury in rats. World J Emerg Med. 2014;5(2):122-7. PMID: 25215161.

 

Reiner DJ, Yu SJ, Shen H, et al. 9-Cis retinoic acid protects against methamphetamine-induced neurotoxicity in nigrostriatal dopamine neurons. Neurotox Res. 2014 Apr;25(3):248-61. PMID: 23884514.

 

Szabó DR, Baghy K, Szabó PM, et al. Antitumoral effects of 9-cis retinoic acid in adrenocortical cancer. Cell Mol Life Sci. 2014 Mar;71(5):917-32. PMID: 23807211.

 

Sagara C, Takahashi K, Kagechika H, et al. Molecular mechanism of 9-cis-retinoic acid inhibition of adipogenesis in 3T3-L1 cells. Biochem Biophys Res Commun. 2013 Mar 29;433(1):102-7. PMID: 23485459.

 

Yin LH, Shen H, Diaz-Ruiz O, et al. Early post-treatment with 9-cis retinoic acid reduces neurodegeneration of dopaminergic neurons in a rat model of Parkinson's disease. BMC Neurosci. 2012 Oct 6;13:120. PMID: 23040108.

 

Choi I, Lee S, Kyoung Chung H, et al. 9-cis retinoic acid promotes lymphangiogenesis and enhances lymphatic vessel regeneration: therapeutic implications of 9-cis retinoic acid for secondary lymphedema. Circulation. 2012 Feb 21;125(7):872-82. PMID: 22275501.

 

Kolseth IB, Agren J, Sundvold-Gjerstad V, et al. 9-cis retinoic acid inhibits inflammatory responses of adherent monocytes and increases their ability to induce classical monocyte migration. J Innate Immun. 2012;4(2):176-86. PMID: 22213773." Xi, Repr. Not dangerous goods.

LKT A7208 Ascomycin 25 mg 134.8 FK506 analog; calcineurin inhibitor. 104987-12-4 ≥98% 792.01 C43H69NO12 CCC1C=C(CC(CC(C2C(CC(C(O2)(C(=O)C(=O)N3CCCCC3C(=O)OC(C(C(CC1=O)O)C)C(=CC4CCC(C(C4)OC)O)C)O)C)OC)OC)C)C Ambient 4°C Soluble in DMSO "Liu F, Wang YQ, Meng L, et al. FK506-binding protein 12 ligands: a patent review. Expert Opin Ther Pat. 2013 Nov;23(11):1435-49. PMID: 23957229.

 

Sierra-Paredes G, Sierra-Marcuño G. Ascomycin and FK506: pharmacology and therapeutic potential as anticonvulsants and neuroprotectants. CNS Neurosci Ther. 2008 Spring;14(1):36-46. PMID: 18482098.

 

Pahl A, Keller U. FK-506-binding proteins from streptomycetes producing immunosuppressive macrolactones of the FK-506 type. J Bacteriol. 1992 Sep;174(18):5888-94. PMID: 1381710." Xn Not dangerous goods.

LKT A7208 Ascomycin 100 mg 241.6 FK506 analog; calcineurin inhibitor. 104987-12-4 ≥98% 792.01 C43H69NO12 CCC1C=C(CC(CC(C2C(CC(C(O2)(C(=O)C(=O)N3CCCCC3C(=O)OC(C(C(CC1=O)O)C)C(=CC4CCC(C(C4)OC)O)C)O)C)OC)OC)C)C Ambient 4°C Soluble in DMSO "Liu F, Wang YQ, Meng L, et al. FK506-binding protein 12 ligands: a patent review. Expert Opin Ther Pat. 2013 Nov;23(11):1435-49. PMID: 23957229.

 

Sierra-Paredes G, Sierra-Marcuño G. Ascomycin and FK506: pharmacology and therapeutic potential as anticonvulsants and neuroprotectants. CNS Neurosci Ther. 2008 Spring;14(1):36-46. PMID: 18482098.

 

Pahl A, Keller U. FK-506-binding proteins from streptomycetes producing immunosuppressive macrolactones of the FK-506 type. J Bacteriol. 1992 Sep;174(18):5888-94. PMID: 1381710." Xn Not dangerous goods.

LKT C1644 Celecoxib 100 mg 78.9 NSAID; COX-2 inhibitor. 4-[5-(4-Methylphenyl)-3-(trifluoromethyl)-1H- pyrazol-1-yl]benzenesulfonamide SC-58635; Celebrex 169590-42-5 ≥98% 381.37 C17H14F3N3O2S CC1=CC=C(C=C1)C2=CC(=NN2C3=CC=C(C=C3)S(=O)(=O)N)C(F)(F)F Ambient Ambient Insoluble in water. Soluble in DMSO (200 mg/mL), ethanol (100 mg/mL). "Shao D, Kan M, Qiao P, et al. Celecoxib induces apoptosis via a mitochondria dependent pathway in the H22 mouse hepatoma cell line. Mol Med Rep. 2014 Oct;10(4):2093-8. PMID: 25109418.

 

Annamanedi M, Kalle AM. Celecoxib sensitizes Staphylococcus aureus to antibiotics in macrophages by modulating SIRT1. PLoS One. 2014 Jun 20;9(6):e99285. PMID: 24950067.

 

Li WW, Long GX, Liu DB, et al. Cyclooxygenase-2 inhibitor celecoxib suppresses invasion and migration of nasopharyngeal carcinoma cell lines through a decrease in matrix metalloproteinase-2 and -9 activity. Pharmazie. 2014 Feb;69(2):132-7. PMID: 24640603.

 

Shi S, Klotz U. Clinical use and pharmacological properties of selective COX-2 inhibitors. Eur J Clin Pharmacol. 2008 Mar;64(3):233-52. PMID: 17999057.

 

Subbaramaiah K, Howe LR, Bhardwaj P, et al. Obesity is associated with inflammation and elevated aromatase expression in the mouse mammary gland. Cancer Prev Res (Phila). 2011 Mar;4(3):329-346. PMID: 21372033." Not dangerous goods.

LKT M3377 Mitomycin C 25 mg 273 Alkaloid produced by Streptomyces, DNA cross-linker; thioredoxin reductase inhibitor. [1aS-(1aα,8β,8aα,8bα)]-6-Amino-8-[[aminocarbonyl)oxy]methyl]-1,1a,2,8,8a,8b-hexahydro-8a-methoxy-5- methylazirino[2',3':3,4]pyrrolo[1,2-a]indole-4,7-dione MMC; Ametycine; Mitocin-C; Mutamycin 50-07-7 ≥98% 334.33 C15H18N4O5 CC1=C(C(=O)C2=C(C1=O)N3CC4C(C3(C2COC(=O)N)OC)N4)N Ambient -20°C Soluble in water (25 oC - 0.9 mg/mL), acetone, methanol, or ethanol (1 mg/mL), DMSO (15 mg/mL) "Liu L, Wang F, Zheng Y, et al. Pretreatment of transfused donor splenocytes and allografts with mitomycin C attenuates acute rejection in heart transplantation in mice. Transplant Proc. 2014 May;46(4):1169-74. PMID: 24815153.

 

Paz MM, Zhang X, Lu J, et al. A new mechanism of action for the anticancer drug mitomycin C: mechanism-based inhibition of thioredoxin reductase. Chem Res Toxicol. 2012 Jul 16;25(7):1502-11. PMID: 22694104.

 

Kang YH, Lee KA, Kim JH, et al. Mitomycin C modulates DNA-double strand break repair genes in cervical carcinoma cells. Amino Acids. 2010 Nov;39(5):1291-8. PMID: 20352460.

 

Tomasz M. Mitomycin C: small, fast and deadly (but very selective). Chem Biol. 1995 Sep;2(9):575-9. PMID: 9383461." T, Carc. "UN number: 2811     Class: 6.1    Packing Group: II

Proper shipping name: Toxic solid, organic, n.o.s. (Mitomycin C)"

LKT T8269 (S)-ar-Turmerone 1 mg 84.3 Sesquiterpene found in Curcuma. 532-65-0 ≥97% 216.32 C15H20O "Cc1ccc(cc1)C(C)CC(=O)C=C(C)C

" Ambient 4°C Hexane, Petrol ether, Ethanol "Oh S, Han AR, Park HR, et al. Suppression of Inflammatory cytokine production by ar-Turmerone isolated from Curcuma phaeocaulis. Chem Biodivers. 2014 Jul;11(7):1034-41. PMID: 25044589.

 

Orellana-Paucar AM, Afrikanova T, Thomas J, et al. Insights from zebrafish and mouse models on the activity and safety of ar-turmerone as a potential drug candidate for the treatment of epilepsy. PLoS One. 2013 Dec 13;8(12):e81634. PMID: 24349101.

 

Jankasem M, Wuthi-Udomlert M, Gritsanapan W. Antidermatophytic Properties of Ar-Turmerone, Turmeric Oil, and Curcuma longa Preparations. ISRN Dermatol. 2013 Aug 26;2013:250597. PMID: 24066236.

 

Sun M, Ma WN, Guo Y, et al. Simultaneous screening of four epidermal growth factor receptor antagonists from Curcuma longa via cell membrane chromatography online coupled with HPLC-MS. J Sep Sci. 2013 Jul;36(13):2096-103. PMID: 23640922.

 

Kim D, Suh Y, Lee H, et al. Immune activation and antitumor response of ar-turmerone on P388D1 lymphoblast cell implanted tumors. Int J Mol Med. 2013 Feb;31(2):386-92. PMID: 23229920.

 

Park SY, Kim YH, Kim Y, et al. Aromatic-turmerone attenuates invasion and expression of MMP-9 and COX-2 through inhibition of NF-κB activation in TPA-induced breast cancer cells. J Cell Biochem. 2012 Dec;113(12):3653-62. PMID: 22740037.

" "UN number: 3082     Class: 9     Packing Group: III

Proper shipping name: Environmentally hazardous substance, liquid, n.o.s. ((S)-ar-Turmerone)"

LKT T8269 (S)-ar-Turmerone 5 mg 320.3 Sesquiterpene found in Curcuma. 532-65-0 ≥97% 216.32 C15H20O "Cc1ccc(cc1)C(C)CC(=O)C=C(C)C

" Ambient 4°C Hexane, Petrol ether, Ethanol "Oh S, Han AR, Park HR, et al. Suppression of Inflammatory cytokine production by ar-Turmerone isolated from Curcuma phaeocaulis. Chem Biodivers. 2014 Jul;11(7):1034-41. PMID: 25044589.

 

Orellana-Paucar AM, Afrikanova T, Thomas J, et al. Insights from zebrafish and mouse models on the activity and safety of ar-turmerone as a potential drug candidate for the treatment of epilepsy. PLoS One. 2013 Dec 13;8(12):e81634. PMID: 24349101.

 

Jankasem M, Wuthi-Udomlert M, Gritsanapan W. Antidermatophytic Properties of Ar-Turmerone, Turmeric Oil, and Curcuma longa Preparations. ISRN Dermatol. 2013 Aug 26;2013:250597. PMID: 24066236.

 

Sun M, Ma WN, Guo Y, et al. Simultaneous screening of four epidermal growth factor receptor antagonists from Curcuma longa via cell membrane chromatography online coupled with HPLC-MS. J Sep Sci. 2013 Jul;36(13):2096-103. PMID: 23640922.

 

Kim D, Suh Y, Lee H, et al. Immune activation and antitumor response of ar-turmerone on P388D1 lymphoblast cell implanted tumors. Int J Mol Med. 2013 Feb;31(2):386-92. PMID: 23229920.

 

Park SY, Kim YH, Kim Y, et al. Aromatic-turmerone attenuates invasion and expression of MMP-9 and COX-2 through inhibition of NF-κB activation in TPA-induced breast cancer cells. J Cell Biochem. 2012 Dec;113(12):3653-62. PMID: 22740037.

" "UN number: 3082     Class: 9     Packing Group: III

Proper shipping name: Environmentally hazardous substance, liquid, n.o.s. ((S)-ar-Turmerone)"

LKT T8269 (S)-ar-Turmerone 10 mg 561.8 Sesquiterpene found in Curcuma. 532-65-0 ≥97% 216.32 C15H20O "Cc1ccc(cc1)C(C)CC(=O)C=C(C)C

" Ambient 4°C Hexane, Petrol ether, Ethanol "Oh S, Han AR, Park HR, et al. Suppression of Inflammatory cytokine production by ar-Turmerone isolated from Curcuma phaeocaulis. Chem Biodivers. 2014 Jul;11(7):1034-41. PMID: 25044589.

 

Orellana-Paucar AM, Afrikanova T, Thomas J, et al. Insights from zebrafish and mouse models on the activity and safety of ar-turmerone as a potential drug candidate for the treatment of epilepsy. PLoS One. 2013 Dec 13;8(12):e81634. PMID: 24349101.

 

Jankasem M, Wuthi-Udomlert M, Gritsanapan W. Antidermatophytic Properties of Ar-Turmerone, Turmeric Oil, and Curcuma longa Preparations. ISRN Dermatol. 2013 Aug 26;2013:250597. PMID: 24066236.

 

Sun M, Ma WN, Guo Y, et al. Simultaneous screening of four epidermal growth factor receptor antagonists from Curcuma longa via cell membrane chromatography online coupled with HPLC-MS. J Sep Sci. 2013 Jul;36(13):2096-103. PMID: 23640922.

 

Kim D, Suh Y, Lee H, et al. Immune activation and antitumor response of ar-turmerone on P388D1 lymphoblast cell implanted tumors. Int J Mol Med. 2013 Feb;31(2):386-92. PMID: 23229920.

 

Park SY, Kim YH, Kim Y, et al. Aromatic-turmerone attenuates invasion and expression of MMP-9 and COX-2 through inhibition of NF-κB activation in TPA-induced breast cancer cells. J Cell Biochem. 2012 Dec;113(12):3653-62. PMID: 22740037.

" "UN number: 3082     Class: 9     Packing Group: III

Proper shipping name: Environmentally hazardous substance, liquid, n.o.s. ((S)-ar-Turmerone)"

LKT A5353 Annexin V-FITC Apoptosis Detection Kit 100 Tests 369.6 Apoptosis measuring kit. Ambient

LKT F4535 FLICA® 660 Caspase 3/7 Assay Kit 25-50 Tests 322.5 Caspases 3/7 activity measuring kit. Ambient 4°C

LKT F4534 FLICA® 660 Caspase 1 Assay Kit 25-50 Tests 322.5 Caspase 1 activity measuring kit. Ambient 4°C

LKT F4533 FLICA® 660 Poly Caspase Assay Kit 25-50 Tests 322.5 Caspase activity measuring kit. Ambient 4°C

LKT M3381 MitoPT®  TMRM Mitochondrial Depolarization Assay Kit 500 Tests 393.2 Mitochondrial depolarization measuring kit. Ambient 4°C

LKT M3380 MitoPT®  TMRE Mitochondrial Depolarization Assay Kit 500 Tests 393.2 Mitochondrial depolarization measuring kit. Ambient 4°C

LKT S7184 SR-VAD-OPH in vitro Apoptosis Detection Reagent 4 vial Pack 803.4 Apoptosis measuring kit. Ambient 4°C

LKT F0121 FAM-DEVD-OPH in vitro Apoptosis Detection Reagent 4 vial Pack 803.4 Apoptosis measuring kit. Ambient 4°C

LKT F0120 FAM-VAD-OPH II in vitro Apoptosis Detection Reagent 4 vial Pack 803.4 Apoptosis measuring kit. Ambient 4°C

LKT F0119 FAM-VAD-OPH I in vitro Apoptosis Detection Reagent 4 vial Pack 803.4 Apoptosis measuring kit. Ambient 4°C

LKT F0118 Fam-Phe-DAP Green FLISP AssayTM Kit 25 Tests 275.3 Serine protease activity measuring kit. Ambient 4°C

LKT F0118 Fam-Phe-DAP Green FLISP AssayTM Kit 100 Tests 769.7 Serine protease activity measuring kit. Ambient 4°C

LKT C9781 Basic Cytotoxicity Test Assay Kit 125 tests 320.3 Cytotoxicity measuring kit. Ambient

LKT C9781 Basic Cytotoxicity Test Assay Kit 250 tests 550.5 Cytotoxicity measuring kit. Ambient

LKT V3326 Virginiamycin S1 1 mg 106.8 Macrolide antibiotic; peptidyl transferase inhibitor, protein translation inhibitor. "Virginiamycin factor S; Staphylomycin S; N-((3-Hydroxy-2-pyridinyl)carbonyl)-L-threonyl-D-alpha-

aminobutyryl-L-prolyl-N-methyl-L-phenylalanyl-4-oxo-L-

pipecoloyl-L-2-phenylglycine rho-lactone; 

N-(3-Hydroxypicolinoyl)-L-threonyl-D-alpha-aminobutyryl-L-

prolyl-N-methyl-L-phenylalanyl-4-oxo-L-pipecoloyl-L-2-

phenylglycine rho-lactone " 23152-29-6 ≥99% 823.89 C43H49N7O10 CCC1C(=O)N2CCCC2C(=O)N(C(C(=O)N3CCC(=O)CC3C(=O)NC(C(=O)OC(C(C(=O)N1)NC(=O)C4=C(C=CC=N4)O)C)C5=CC=CC=C5)CC6=CC=CC=C6)C Ambient -20°C Soluble in ethanol, methanol, DMSO, Dichloromethane, DMF, and sparingly, in water. "Compart DM, Carlson AM, Crawford GI, et al. Presence and biological activity of antibiotics used in fuel ethanol and corn co-product production. J Anim Sci. 2013 May;91(5):2395-404. PMID: 23463564.

 

Qiu Y, Yang F, Liu Z, et al. Determination of virginiamycin M1 and S1 residues in livestock and poultry products by liquid chromatography-tandem mass spectrometry. Se Pu. 2012 May;30(5):463-7. PMID: 22934408.

 

Champney WS, Tober CL. Specific inhibition of 50S ribosomal subunit formation in Staphylococcus aureus cells by 16-membered macrolide, lincosamide, and streptogramin B antibiotics. Curr Microbiol. 2000 Aug;41(2):126-35. PMID: 10856379.

 

Prikrylová V, Samoukina GV, Kandybin NV, et al. Pesticidal activity of virginiamycins S1 and M1. Folia Microbiol (Praha). 1992;37(5):386-8. PMID: 1493906.

" Not dangerous goods.

LKT V3326 Virginiamycin S1 5 mg 421.4 Macrolide antibiotic; peptidyl transferase inhibitor, protein translation inhibitor. "Virginiamycin factor S; Staphylomycin S; N-((3-Hydroxy-2-pyridinyl)carbonyl)-L-threonyl-D-alpha-

aminobutyryl-L-prolyl-N-methyl-L-phenylalanyl-4-oxo-L-

pipecoloyl-L-2-phenylglycine rho-lactone; 

N-(3-Hydroxypicolinoyl)-L-threonyl-D-alpha-aminobutyryl-L-

prolyl-N-methyl-L-phenylalanyl-4-oxo-L-pipecoloyl-L-2-

phenylglycine rho-lactone " 23152-29-6 ≥99% 823.89 C43H49N7O10 CCC1C(=O)N2CCCC2C(=O)N(C(C(=O)N3CCC(=O)CC3C(=O)NC(C(=O)OC(C(C(=O)N1)NC(=O)C4=C(C=CC=N4)O)C)C5=CC=CC=C5)CC6=CC=CC=C6)C Ambient -20°C Soluble in ethanol, methanol, DMSO, Dichloromethane, DMF, and sparingly, in water. "Compart DM, Carlson AM, Crawford GI, et al. Presence and biological activity of antibiotics used in fuel ethanol and corn co-product production. J Anim Sci. 2013 May;91(5):2395-404. PMID: 23463564.

 

Qiu Y, Yang F, Liu Z, et al. Determination of virginiamycin M1 and S1 residues in livestock and poultry products by liquid chromatography-tandem mass spectrometry. Se Pu. 2012 May;30(5):463-7. PMID: 22934408.

 

Champney WS, Tober CL. Specific inhibition of 50S ribosomal subunit formation in Staphylococcus aureus cells by 16-membered macrolide, lincosamide, and streptogramin B antibiotics. Curr Microbiol. 2000 Aug;41(2):126-35. PMID: 10856379.

 

Prikrylová V, Samoukina GV, Kandybin NV, et al. Pesticidal activity of virginiamycins S1 and M1. Folia Microbiol (Praha). 1992;37(5):386-8. PMID: 1493906.

" Not dangerous goods.

LKT V3325 Virginiamycin M1 1 mg 106.8 Macrolide antibiotic; peptidyl transferase inhibitor, protein translation inhibitor. Mikamycin A; Staphilomycin; Ostreogrycin A; Virginiamycin M1; Pristinamycin IIA 21411-53-0 ≥97% 525.59 C28H35N3O7 CC1C=CC(=O)NCC=CC(=CC(CC(=O)CC2=NC(=CO2)C(=O)N3CCC=C3C(=O)OC1C(C)C)O)C Ambient -20°C Soluble in ethanol (3-4%) , methanol (3-4%), DMSO, Dichloromethane, DMF, and sparingly, in water. "Compart DM, Carlson AM, Crawford GI, et al. Presence and biological activity of antibiotics used in fuel ethanol and corn co-product production. J Anim Sci. 2013 May;91(5):2395-404. PMID: 23463564.

 

Qiu Y, Yang F, Liu Z, et al. Determination of virginiamycin M1 and S1 residues in livestock and poultry products by liquid chromatography-tandem mass spectrometry. Se Pu. 2012 May;30(5):463-7. PMID: 22934408.

 

Champney WS, Tober CL. Specific inhibition of 50S ribosomal subunit formation in Staphylococcus aureus cells by 16-membered macrolide, lincosamide, and streptogramin B antibiotics. Curr Microbiol. 2000 Aug;41(2):126-35. PMID: 10856379.

 

Prikrylová V, Samoukina GV, Kandybin NV, et al. Pesticidal activity of virginiamycins S1 and M1. Folia Microbiol (Praha). 1992;37(5):386-8. PMID: 1493906.

" Not dangerous goods.

LKT V3325 Virginiamycin M1 5 mg 421.4 Macrolide antibiotic; peptidyl transferase inhibitor, protein translation inhibitor. Mikamycin A; Staphilomycin; Ostreogrycin A; Virginiamycin M1; Pristinamycin IIA 21411-53-0 ≥97% 525.59 C28H35N3O7 CC1C=CC(=O)NCC=CC(=CC(CC(=O)CC2=NC(=CO2)C(=O)N3CCC=C3C(=O)OC1C(C)C)O)C Ambient -20°C Soluble in ethanol (3-4%) , methanol (3-4%), DMSO, Dichloromethane, DMF, and sparingly, in water. "Compart DM, Carlson AM, Crawford GI, et al. Presence and biological activity of antibiotics used in fuel ethanol and corn co-product production. J Anim Sci. 2013 May;91(5):2395-404. PMID: 23463564.

 

Qiu Y, Yang F, Liu Z, et al. Determination of virginiamycin M1 and S1 residues in livestock and poultry products by liquid chromatography-tandem mass spectrometry. Se Pu. 2012 May;30(5):463-7. PMID: 22934408.

 

Champney WS, Tober CL. Specific inhibition of 50S ribosomal subunit formation in Staphylococcus aureus cells by 16-membered macrolide, lincosamide, and streptogramin B antibiotics. Curr Microbiol. 2000 Aug;41(2):126-35. PMID: 10856379.

 

Prikrylová V, Samoukina GV, Kandybin NV, et al. Pesticidal activity of virginiamycins S1 and M1. Folia Microbiol (Praha). 1992;37(5):386-8. PMID: 1493906.

" Not dangerous goods.

LKT A2244 Aflatoxicol 1 mg 488.8 Mycotoxin, metabolite of aflatoxin B1 produced by species of Aspergillus; DNA synthesis inhibitor, carcinogen. 29611-03-8 ≥98% 314.29 C17H14O6 COC1=C2C3=C(C(CC3)O)C(=O)OC2=C4C5C=COC5OC4=C1 Ambient 4°C "Karabulut S, Paytakov G, Leszczynski J. Reduction of aflatoxin B1 to aflatoxicol: a comprehensive DFT study provides clues to its toxicity. J Sci Food Agric. 2014 Dec;94(15):3134-40. PMID: 24652695.

 

Cortés G, Carvajal M, Méndez-Ramírez I, et al. Identification and quantification of aflatoxins and aflatoxicol from poultry feed and their recovery in poultry litter. Poult Sci. 2010 May;89(5):993-1001. PMID: 20371852.

 

Bailey GS, Loveland PM, Pereira C, et al. Quantitative carcinogenesis and dosimetry in rainbow trout for aflatoxin B1 and aflatoxicol, two aflatoxins that form the same DNA adduct. Mutat Res. 1994 Aug;313(1):25-38. PMID: 7519308.

" "UN number: 2811     Class: 6.1     Packing Group: II

Proper shipping name: Toxic solid, organic, n.o.s. (Aflatoxicol)"

LKT A2244 Aflatoxicol 5 mg 1966.1 Mycotoxin, metabolite of aflatoxin B1 produced by species of Aspergillus; DNA synthesis inhibitor, carcinogen. 29611-03-8 ≥98% 314.29 C17H14O6 COC1=C2C3=C(C(CC3)O)C(=O)OC2=C4C5C=COC5OC4=C1 Ambient 4°C "Karabulut S, Paytakov G, Leszczynski J. Reduction of aflatoxin B1 to aflatoxicol: a comprehensive DFT study provides clues to its toxicity. J Sci Food Agric. 2014 Dec;94(15):3134-40. PMID: 24652695.

 

Cortés G, Carvajal M, Méndez-Ramírez I, et al. Identification and quantification of aflatoxins and aflatoxicol from poultry feed and their recovery in poultry litter. Poult Sci. 2010 May;89(5):993-1001. PMID: 20371852.

 

Bailey GS, Loveland PM, Pereira C, et al. Quantitative carcinogenesis and dosimetry in rainbow trout for aflatoxin B1 and aflatoxicol, two aflatoxins that form the same DNA adduct. Mutat Res. 1994 Aug;313(1):25-38. PMID: 7519308.

" "UN number: 2811     Class: 6.1     Packing Group: II

Proper shipping name: Toxic solid, organic, n.o.s. (Aflatoxicol)"

LKT D5747 Dolasetron Mesylate Hydrate 10 mg 56.2 5-HT3 antagonist. ≥98% 420.48 C19H20N2O3 CH4O3S xH2O CS(=O)(=O)O.C1C2CC3CC(CC1N3CC2=O)OC(=O)C4=CNC5=CC=CC=C54.O Ambient 4°C "Roberts SM, Bezinover DS, Janicki PK. Reappraisal of the role of dolasetron in prevention and treatment of nausea and vomiting associated with surgery or chemotherapy. Cancer Manag Res. 2012;4:67-73. PMID: 22427733.

 

Vergne-Salle P, Dufauret-Lombard C, Bonnet C, et al. A randomised, double-blind, placebo-controlled trial of dolasetron, a 5-hydroxytryptamine 3 receptor antagonist, in patients with fibromyalgia. Eur J Pain. 2011 May;15(5):509-14. PMID: 21036635.

" Not dangerous goods.

LKT D5747 Dolasetron Mesylate Hydrate 50 mg 222.5 5-HT3 antagonist. ≥98% 420.48 C19H20N2O3 CH4O3S xH2O CS(=O)(=O)O.C1C2CC3CC(CC1N3CC2=O)OC(=O)C4=CNC5=CC=CC=C54.O Ambient 4°C "Roberts SM, Bezinover DS, Janicki PK. Reappraisal of the role of dolasetron in prevention and treatment of nausea and vomiting associated with surgery or chemotherapy. Cancer Manag Res. 2012;4:67-73. PMID: 22427733.

 

Vergne-Salle P, Dufauret-Lombard C, Bonnet C, et al. A randomised, double-blind, placebo-controlled trial of dolasetron, a 5-hydroxytryptamine 3 receptor antagonist, in patients with fibromyalgia. Eur J Pain. 2011 May;15(5):509-14. PMID: 21036635.

" Not dangerous goods.

LKT R0161 Rapamycin 100 mg 505.6 Macrolide originally produced by Streptomyces; mTOR inhibitor. Sirolimus; Rapamune; AY-22989 53123-88-9 ≥98% 914.17 C51H79NO13 CC1CCC2CC(C(=CC=CC=CC(CC(C(=O)C(C(C(=CC(C(=O)CC(OC(=O)C3CCCCN3C(=O)C(=O)C1(O2)O)C(C)CC4CCC(C(C4)OC)O)C)C)O)OC)C)C)C)OC Protect from light. Hygroscopic. Ambient 4°C Soluble in ether, chloroform, acetone, methanol, DMF, DMSO (20 mg/mL), and ethanol (up to 2 mM). Sparingly soluble in hexane and petr ether.  Insoluble in water. "Klintmalm GB, Nashan B. The Role of mTOR Inhibitors in Liver Transplantation: Reviewing the Evidence. J Transplant. 2014;2014:845438. PMID: 24719752.

 

Tian J, Wang Y, Zhou X, et al. Rapamycin slows IgA nephropathy progression in the rat. Am J Nephrol. 2014;39(3):218-29. PMID: 24603476.

 

Xu X, Wan X, Geng J, et al. Rapamycin regulates connective tissue growth factor expression of lung epithelial cells via phosphoinositide 3-kinase. Exp Biol Med (Maywood). 2013 Sep;238(9):1082-94. PMID: 23986222.

" Xi Not dangerous goods.

LKT I5753 Ionomycin Calcium 10 mg 185.4 Polyether Ca2+ ionophore. ATCC 31005 56092-82-1 ≥98% 747.07 C41H70O9 Ca CC(CCC(=O)[O-])CC(C)CC(C)C(=O)C=C(C(C)CC(C)CC=CC(C)C(C(C)C(CC1CCC(O1)(C)C2CCC(O2)(C)C(C)O)O)O)[O-].[Ca+2] Protect from light. Ambient 4°C "Soluble in ethanol to 100mM,  DMSO to 25mM.

5mg/ml in methanol  " "Müller MS, Obel LF, Waagepetersen HS, et al. Complex actions of ionomycin in cultured cerebellar astrocytes affecting both calcium-induced calcium release and store-operated calcium entry. Neurochem Res. 2013 Jun;38(6):1260-5. PMID: 23519933.

 

Dedkova EN, Sigova AA, Zinchenko VP. Mechanism of action of calcium ionophores on intact cells: ionophore-resistant cells. Membr Cell Biol. 2000;13(3):357-68. PMID: 10768486

 

Reynolds JE, Eastman A. Intracellular calcium stores are not required for Bcl-2-mediated protection from apoptosis. J Biol Chem. 1996 Nov 1;271(44):27739-43. PMID: 8910367.

 

Mason MJ, Grinstein S. Ionomycin activates electrogenic Ca2+ influx in rat thymic lymphocytes. Biochem J. 1993 Nov 15;296 ( Pt 1):33-9. PMID: 8250855.

" Xn Not dangerous goods.

LKT I5752 Ionomycin, Free Acid 10 mg 256.7 Polyether Ca2+ ionophore. 56092-81-0 ≥98%, TLC, HPLC 709 C41H72O9 CC(CCC(=O)O)CC(C)CC(C)C(=O)C=C(C(C)CC(C)CC=CC(C)C(C(C)C(CC1CCC(O1)(C)C2CCC(O2)(C)C(C)O)O)O)O Ambient 4°C Soluble in DMSO (10 mg/mL), ethanol (10 mg/mL).  Insoluble in water. "Müller MS, Obel LF, Waagepetersen HS, et al. Complex actions of ionomycin in cultured cerebellar astrocytes affecting both calcium-induced calcium release and store-operated calcium entry. Neurochem Res. 2013 Jun;38(6):1260-5. PMID: 23519933.

 

Dedkova EN, Sigova AA, Zinchenko VP. Mechanism of action of calcium ionophores on intact cells: ionophore-resistant cells. Membr Cell Biol. 2000;13(3):357-68. PMID: 10768486

 

Reynolds JE, Eastman A. Intracellular calcium stores are not required for Bcl-2-mediated protection from apoptosis. J Biol Chem. 1996 Nov 1;271(44):27739-43. PMID: 8910367.

 

Mason MJ, Grinstein S. Ionomycin activates electrogenic Ca2+ influx in rat thymic lymphocytes. Biochem J. 1993 Nov 15;296 ( Pt 1):33-9. PMID: 8250855.

" Xn Not dangerous goods.

LKT D3329 7,8-Dihydroxyflavone Hydrate 25 mg 39.4 TrkB agonist. 38183-03-8 ≥98% 254.24 C15H10O4 xH2O c1ccc(cc1)c2cc(=O)c3ccc(c(c3o2)O)O Ambient Ambient "Chan CB, Tse MC, Liu X, et al. Activation of Muscular TrkB by its Small Molecular Agonist 7,8-Dihydroxyflavone Sex-Dependently Regulates Energy Metabolism in Diet-Induced Obese Mice. 2015 Mar 19;22(3):355-68. PMID: 25754472.

 

Sconce MD, Churchill MJ, Moore C, et al. Intervention with 7,8-dihydroxyflavone blocks further striatal terminal loss and restores motor deficits in a progressive mouse model of Parkinson's disease. Neuroscience. 2015 Apr 2;290:454-71. PMID: 25655214.

 

Lee RH, Shin JC, Kim KH, et al. Apoptotic effects of 7,8-dihydroxyflavone in human oral squamous cancer cells through suppression of Sp1. Oncol Rep. 2015 Feb;33(2):631-8. PMID: 25434704.

 

Wu CH, Hung TH, Chen CC, et al. Post-injury treatment with 7,8-dihydroxyflavone, a TrkB receptor agonist, protects against experimental traumatic brain injury via PI3K/Akt signaling. PLoS One. 2014 Nov 21;9(11):e113397. PMID: 25415296.

 

Yang YJ, Li YK, Wang W, et al. Small-molecule TrkB agonist 7,8-dihydroxyflavone reverses cognitive and synaptic plasticity deficits in a rat model of schizophrenia. Pharmacol Biochem Behav. 2014 Jul;122:30-6. PMID: 24662915.

 

Korkmaz OT, Aytan N, Carreras I, et al. 7,8-Dihydroxyflavone improves motor performance and enhances lower motor neuronal survival in a mouse model of amyotrophic lateral sclerosis. Neurosci Lett. 2014 Apr 30;566:286-91. PMID: 24637017.

 

Park HY, Park C, Hwang HJ, et al. 7,8-Dihydroxyflavone attenuates the release of pro-inflammatory mediators and cytokines in lipopolysaccharide-stimulated BV2 microglial cells through the suppression of the NF-κB and MAPK signaling pathways. Int J Mol Med. 2014 Apr;33(4):1027-34. PMID: 24535427.

 

Ryu MJ, Kang KA, Piao MJ, et al. 7,8-Dihydroxyflavone protects human keratinocytes against oxidative stress-induced cell damage via the ERK and PI3K/Akt-mediated Nrf2/HO-1 signaling pathways. Int J Mol Med. 2014 Apr;33(4):964-70. PMID: 24503931.

 

Castello NA, Nguyen MH, Tran JD, et al. 7,8-Dihydroxyflavone, a small molecule TrkB agonist, improves spatial memory and increases thin spine density in a mouse model of Alzheimer disease-like neuronal loss. PLoS One. 2014 Mar 10;9(3):e91453. PMID: 24614170.

" Not dangerous goods.

LKT D3329 7,8-Dihydroxyflavone Hydrate 100 mg 56.2 TrkB agonist. 38183-03-8 ≥98% 254.24 C15H10O4 xH2O c1ccc(cc1)c2cc(=O)c3ccc(c(c3o2)O)O Ambient Ambient "Chan CB, Tse MC, Liu X, et al. Activation of Muscular TrkB by its Small Molecular Agonist 7,8-Dihydroxyflavone Sex-Dependently Regulates Energy Metabolism in Diet-Induced Obese Mice. 2015 Mar 19;22(3):355-68. PMID: 25754472.

 

Sconce MD, Churchill MJ, Moore C, et al. Intervention with 7,8-dihydroxyflavone blocks further striatal terminal loss and restores motor deficits in a progressive mouse model of Parkinson's disease. Neuroscience. 2015 Apr 2;290:454-71. PMID: 25655214.

 

Lee RH, Shin JC, Kim KH, et al. Apoptotic effects of 7,8-dihydroxyflavone in human oral squamous cancer cells through suppression of Sp1. Oncol Rep. 2015 Feb;33(2):631-8. PMID: 25434704.

 

Wu CH, Hung TH, Chen CC, et al. Post-injury treatment with 7,8-dihydroxyflavone, a TrkB receptor agonist, protects against experimental traumatic brain injury via PI3K/Akt signaling. PLoS One. 2014 Nov 21;9(11):e113397. PMID: 25415296.

 

Yang YJ, Li YK, Wang W, et al. Small-molecule TrkB agonist 7,8-dihydroxyflavone reverses cognitive and synaptic plasticity deficits in a rat model of schizophrenia. Pharmacol Biochem Behav. 2014 Jul;122:30-6. PMID: 24662915.

 

Korkmaz OT, Aytan N, Carreras I, et al. 7,8-Dihydroxyflavone improves motor performance and enhances lower motor neuronal survival in a mouse model of amyotrophic lateral sclerosis. Neurosci Lett. 2014 Apr 30;566:286-91. PMID: 24637017.

 

Park HY, Park C, Hwang HJ, et al. 7,8-Dihydroxyflavone attenuates the release of pro-inflammatory mediators and cytokines in lipopolysaccharide-stimulated BV2 microglial cells through the suppression of the NF-κB and MAPK signaling pathways. Int J Mol Med. 2014 Apr;33(4):1027-34. PMID: 24535427.

 

Ryu MJ, Kang KA, Piao MJ, et al. 7,8-Dihydroxyflavone protects human keratinocytes against oxidative stress-induced cell damage via the ERK and PI3K/Akt-mediated Nrf2/HO-1 signaling pathways. Int J Mol Med. 2014 Apr;33(4):964-70. PMID: 24503931.

 

Castello NA, Nguyen MH, Tran JD, et al. 7,8-Dihydroxyflavone, a small molecule TrkB agonist, improves spatial memory and increases thin spine density in a mouse model of Alzheimer disease-like neuronal loss. PLoS One. 2014 Mar 10;9(3):e91453. PMID: 24614170.

" Not dangerous goods.

LKT D3329 7,8-Dihydroxyflavone Hydrate 500 mg 179.8 TrkB agonist. 38183-03-8 ≥98% 254.24 C15H10O4 xH2O c1ccc(cc1)c2cc(=O)c3ccc(c(c3o2)O)O Ambient Ambient "Chan CB, Tse MC, Liu X, et al. Activation of Muscular TrkB by its Small Molecular Agonist 7,8-Dihydroxyflavone Sex-Dependently Regulates Energy Metabolism in Diet-Induced Obese Mice. 2015 Mar 19;22(3):355-68. PMID: 25754472.

 

Sconce MD, Churchill MJ, Moore C, et al. Intervention with 7,8-dihydroxyflavone blocks further striatal terminal loss and restores motor deficits in a progressive mouse model of Parkinson's disease. Neuroscience. 2015 Apr 2;290:454-71. PMID: 25655214.

 

Lee RH, Shin JC, Kim KH, et al. Apoptotic effects of 7,8-dihydroxyflavone in human oral squamous cancer cells through suppression of Sp1. Oncol Rep. 2015 Feb;33(2):631-8. PMID: 25434704.

 

Wu CH, Hung TH, Chen CC, et al. Post-injury treatment with 7,8-dihydroxyflavone, a TrkB receptor agonist, protects against experimental traumatic brain injury via PI3K/Akt signaling. PLoS One. 2014 Nov 21;9(11):e113397. PMID: 25415296.

 

Yang YJ, Li YK, Wang W, et al. Small-molecule TrkB agonist 7,8-dihydroxyflavone reverses cognitive and synaptic plasticity deficits in a rat model of schizophrenia. Pharmacol Biochem Behav. 2014 Jul;122:30-6. PMID: 24662915.

 

Korkmaz OT, Aytan N, Carreras I, et al. 7,8-Dihydroxyflavone improves motor performance and enhances lower motor neuronal survival in a mouse model of amyotrophic lateral sclerosis. Neurosci Lett. 2014 Apr 30;566:286-91. PMID: 24637017.

 

Park HY, Park C, Hwang HJ, et al. 7,8-Dihydroxyflavone attenuates the release of pro-inflammatory mediators and cytokines in lipopolysaccharide-stimulated BV2 microglial cells through the suppression of the NF-κB and MAPK signaling pathways. Int J Mol Med. 2014 Apr;33(4):1027-34. PMID: 24535427.

 

Ryu MJ, Kang KA, Piao MJ, et al. 7,8-Dihydroxyflavone protects human keratinocytes against oxidative stress-induced cell damage via the ERK and PI3K/Akt-mediated Nrf2/HO-1 signaling pathways. Int J Mol Med. 2014 Apr;33(4):964-70. PMID: 24503931.

 

Castello NA, Nguyen MH, Tran JD, et al. 7,8-Dihydroxyflavone, a small molecule TrkB agonist, improves spatial memory and increases thin spine density in a mouse model of Alzheimer disease-like neuronal loss. PLoS One. 2014 Mar 10;9(3):e91453. PMID: 24614170.

" Not dangerous goods.

LKT X4424 XL-765 5 mg 166.3 PI3K and mTOR inhibitor. XL765, Voxtalisib, SAR245409 934493-76-2 ≥98% 270.29 C13H14N6O "CCn1c2c(cc(c1=O)c3ccn[nH]3)c(nc(n2)N)C

" Ambient -20°C "Papadopoulos KP, Egile C, Ruiz-Soto R, et al. Efficacy, safety, pharmacokinetics and pharmacodynamics of SAR245409 (voxtalisib, XL765), an orally administered phosphoinositide 3-kinase/mammalian target of rapamycin inhibitor: a phase 1 expansion cohort in patients with relapsed or refractory lymphoma. Leuk Lymphoma. 2014 Nov 19:1-8. [Epub ahead of print] PMID: 25300944.

 

Yu P, Laird AD, Du X, et al. Characterization of the activity of the PI3K/mTOR inhibitor XL765 (SAR245409) in tumor models with diverse genetic alterations affecting the PI3K pathway. Mol Cancer Ther. 2014 May;13(5):1078-91. PMID: 24634413.

 

Papadopoulos KP, Tabernero J, Markman B, et al. Phase I safety, pharmacokinetic, and pharmacodynamic study of SAR245409 (XL765), a novel, orally administered PI3K/mTOR inhibitor in patients with advanced solid tumors. Clin Cancer Res. 2014 May 1;20(9):2445-56. PMID: 24583798.

" Not dangerous goods.

LKT X4424 XL-765 10 mg 269.6 PI3K and mTOR inhibitor. XL765, Voxtalisib, SAR245409 934493-76-2 ≥98% 270.29 C13H14N6O "CCn1c2c(cc(c1=O)c3ccn[nH]3)c(nc(n2)N)C

" Ambient -20°C "Papadopoulos KP, Egile C, Ruiz-Soto R, et al. Efficacy, safety, pharmacokinetics and pharmacodynamics of SAR245409 (voxtalisib, XL765), an orally administered phosphoinositide 3-kinase/mammalian target of rapamycin inhibitor: a phase 1 expansion cohort in patients with relapsed or refractory lymphoma. Leuk Lymphoma. 2014 Nov 19:1-8. [Epub ahead of print] PMID: 25300944.

 

Yu P, Laird AD, Du X, et al. Characterization of the activity of the PI3K/mTOR inhibitor XL765 (SAR245409) in tumor models with diverse genetic alterations affecting the PI3K pathway. Mol Cancer Ther. 2014 May;13(5):1078-91. PMID: 24634413.

 

Papadopoulos KP, Tabernero J, Markman B, et al. Phase I safety, pharmacokinetic, and pharmacodynamic study of SAR245409 (XL765), a novel, orally administered PI3K/mTOR inhibitor in patients with advanced solid tumors. Clin Cancer Res. 2014 May 1;20(9):2445-56. PMID: 24583798.

" Not dangerous goods.

LKT V9228 VX-765 5 mg 163 NLRP3 inhibitor. VX765 273404-37-8 ≥98% 509 C24H33ClN4O6 "CCOC1C(CC(=O)O1)NC(=O)C2CCCN2C(=O)C(C(C)(C)C)NC(=O)c3ccc(c(c3)Cl)N

" Ambient -20°C "Zhang Y, Liu L, Liu YZ, et al. NLRP3 Inflammasome Mediates Chronic Mild Stress-induced Depression in Mice via Neuroinflammation. Int J Neuropsychopharmacol. 2015 Jan 20. [Epub ahead of print]. PMID: 25603858.

 

Kaminski RM, Rogawski MA, Klitgaard H. The potential of antiseizure drugs and agents that act on novel molecular targets as antiepileptogenic treatments. Neurotherapeutics. 2014 Apr;11(2):385-400. PMID: 24671870.

 

Noe FM, Polascheck N, Frigerio F, et al. Pharmacological blockade of IL-1β/IL-1 receptor type 1 axis during epileptogenesis provides neuroprotection in two rat models of temporal lobe epilepsy. Neurobiol Dis. 2013 Nov;59:183-93. PMID: 23938763.

 

Maroso M, Balosso S, Ravizza T, et al. Interleukin-1β biosynthesis inhibition reduces acute seizures and drug resistant chronic epileptic activity in mice. Neurotherapeutics. 2011 Apr;8(2):304-15. PMID: 21431948.

" Not dangerous goods.

LKT V9228 VX-765 10 mg 252.8 NLRP3 inhibitor. VX765 273404-37-8 ≥98% 509 C24H33ClN4O6 "CCOC1C(CC(=O)O1)NC(=O)C2CCCN2C(=O)C(C(C)(C)C)NC(=O)c3ccc(c(c3)Cl)N

" Ambient -20°C "Zhang Y, Liu L, Liu YZ, et al. NLRP3 Inflammasome Mediates Chronic Mild Stress-induced Depression in Mice via Neuroinflammation. Int J Neuropsychopharmacol. 2015 Jan 20. [Epub ahead of print]. PMID: 25603858.

 

Kaminski RM, Rogawski MA, Klitgaard H. The potential of antiseizure drugs and agents that act on novel molecular targets as antiepileptogenic treatments. Neurotherapeutics. 2014 Apr;11(2):385-400. PMID: 24671870.

 

Noe FM, Polascheck N, Frigerio F, et al. Pharmacological blockade of IL-1β/IL-1 receptor type 1 axis during epileptogenesis provides neuroprotection in two rat models of temporal lobe epilepsy. Neurobiol Dis. 2013 Nov;59:183-93. PMID: 23938763.

 

Maroso M, Balosso S, Ravizza T, et al. Interleukin-1β biosynthesis inhibition reduces acute seizures and drug resistant chronic epileptic activity in mice. Neurotherapeutics. 2011 Apr;8(2):304-15. PMID: 21431948.

" Not dangerous goods.

LKT V1600 VE-821 5 mg 146.1 ATR inhibitor. VE821 1232410-49-9 ≥98% 368.41 C18H16N4O3S Ambient -20°C "Flynn RL, Cox KE, Jeitany M, et al. Alternative lengthening of telomeres renders cancer cells hypersensitive to ATR inhibitors. Science. 2015 Jan 16;347(6219):273-7. PMID: 25593184.

 

Vávrová J, Zárybnická L, Lukášová E, et al. Inhibition of ATR kinase with the selective inhibitor VE-821 results in radiosensitization of cells of promyelocytic leukaemia (HL-60). Radiat Environ Biophys. 2013 Nov;52(4):471-9. PMID: 23934411.

 

Prevo R, Fokas E, Reaper PM, et al. The novel ATR inhibitor VE-821 increases sensitivity of pancreatic cancer cells to radiation and chemotherapy. Cancer Biol Ther. 2012 Sep;13(11):1072-81. PMID: 22825331.

 

Reaper PM, Griffiths MR, Long JM, et al. Selective killing of ATM- or p53-deficient cancer cells through inhibition of ATR. Nat Chem Biol. 2011 Apr 13;7(7):428-30. PMID: 21490603.

" Not dangerous goods.

LKT V1600 VE-821 10 mg 224.7 ATR inhibitor. VE821 1232410-49-9 ≥98% 368.41 C18H16N4O3S Ambient -20°C "Flynn RL, Cox KE, Jeitany M, et al. Alternative lengthening of telomeres renders cancer cells hypersensitive to ATR inhibitors. Science. 2015 Jan 16;347(6219):273-7. PMID: 25593184.

 

Vávrová J, Zárybnická L, Lukášová E, et al. Inhibition of ATR kinase with the selective inhibitor VE-821 results in radiosensitization of cells of promyelocytic leukaemia (HL-60). Radiat Environ Biophys. 2013 Nov;52(4):471-9. PMID: 23934411.

 

Prevo R, Fokas E, Reaper PM, et al. The novel ATR inhibitor VE-821 increases sensitivity of pancreatic cancer cells to radiation and chemotherapy. Cancer Biol Ther. 2012 Sep;13(11):1072-81. PMID: 22825331.

 

Reaper PM, Griffiths MR, Long JM, et al. Selective killing of ATM- or p53-deficient cancer cells through inhibition of ATR. Nat Chem Biol. 2011 Apr 13;7(7):428-30. PMID: 21490603.

" Not dangerous goods.

LKT T4800 TM3-0089 Sodium Monohydrate 5 mg 157.3 CRTH2 inhibitor. CAY10471 ≥98% 456.46 C21H20FN2O4S  Na H2O Ambient -20°C "Xue L, Fergusson J, Salimi M, et al. Prostaglandin D2 and leukotriene E4 synergize to stimulate diverse TH2 functions and TH2 cell/neutrophil crosstalk. J Allergy Clin Immunol. 2014 Oct 19. [Epub ahead of print]. PMID: 25441644.

 

Schröder R, Xue L, Konya V, et al. PGH1, the precursor for the anti-inflammatory prostaglandins of the 1-series, is a potent activator of the pro-inflammatory receptor CRTH2/DP2. PLoS One. 2012;7(3):e33329. PMID: 22442685.

 

Uller L, Mathiesen JM, Alenmyr L, et al. Antagonism of the prostaglandin D2 receptor CRTH2 attenuates asthma pathology in mouse eosinophilic airway inflammation. Respir Res. 2007 Feb 28;8:16. PMID: 17328802.

" Not dangerous goods.

LKT T4800 TM3-0089 Sodium Monohydrate 10 mg 241.6 CRTH2 inhibitor. CAY10471 ≥98% 456.46 C21H20FN2O4S  Na H2O Ambient -20°C "Xue L, Fergusson J, Salimi M, et al. Prostaglandin D2 and leukotriene E4 synergize to stimulate diverse TH2 functions and TH2 cell/neutrophil crosstalk. J Allergy Clin Immunol. 2014 Oct 19. [Epub ahead of print]. PMID: 25441644.

 

Schröder R, Xue L, Konya V, et al. PGH1, the precursor for the anti-inflammatory prostaglandins of the 1-series, is a potent activator of the pro-inflammatory receptor CRTH2/DP2. PLoS One. 2012;7(3):e33329. PMID: 22442685.

 

Uller L, Mathiesen JM, Alenmyr L, et al. Antagonism of the prostaglandin D2 receptor CRTH2 attenuates asthma pathology in mouse eosinophilic airway inflammation. Respir Res. 2007 Feb 28;8:16. PMID: 17328802.

" Not dangerous goods.

LKT T2404 TG101348 5 mg 129.3 JAK2 inhibitor. SAR302503, Fedratinib 936091-26-8 ≥98% 524.68 C27H36N6O3S "Cc1cnc(nc1Nc2cccc(c2)S(=O)(=O)NC(C)(C)C)Nc3ccc(cc3)OCCN4CCCC4

" Ambient -20°C "Zheng Y, Wang Z, Deng L, et al. Modulation of STAT3 and STAT5 activity rectifies the imbalance of Th17 and Treg cells in patients with acute coronary syndrome. Clin Immunol. 2015 Jan 5;157(1):65-77. PMID: 25572535.

 

Hao Y, Chapuy B, Monti S, et al. Selective JAK2 inhibition specifically decreases Hodgkin lymphoma and mediastinal large B-cell lymphoma growth in vitro and in vivo. Clin Cancer Res. 2014 May 15;20(10):2674-83. PMID: 24610827.

 

Zhang M, Xu CR, Shamiyeh E, et al. A randomized, placebo-controlled study of the pharmacokinetics, pharmacodynamics, and tolerability of the oral JAK2 inhibitor fedratinib (SAR302503) in healthy volunteers. J Clin Pharmacol. 2014 Apr;54(4):415-21. PMID: 24165976.

 

Wernig G, Kharas MG, Okabe R, et al. Efficacy of TG101348, a selective JAK2 inhibitor, in treatment of a murine model of JAK2V617F-induced polycythemia vera. Cancer Cell. 2008 Apr;13(4):311-20. PMID: 18394554.

" Not dangerous goods.

LKT T2404 TG101348 10 mg 196.7 JAK2 inhibitor. SAR302503, Fedratinib 936091-26-8 ≥98% 524.68 C27H36N6O3S "Cc1cnc(nc1Nc2cccc(c2)S(=O)(=O)NC(C)(C)C)Nc3ccc(cc3)OCCN4CCCC4

" Ambient -20°C "Zheng Y, Wang Z, Deng L, et al. Modulation of STAT3 and STAT5 activity rectifies the imbalance of Th17 and Treg cells in patients with acute coronary syndrome. Clin Immunol. 2015 Jan 5;157(1):65-77. PMID: 25572535.

 

Hao Y, Chapuy B, Monti S, et al. Selective JAK2 inhibition specifically decreases Hodgkin lymphoma and mediastinal large B-cell lymphoma growth in vitro and in vivo. Clin Cancer Res. 2014 May 15;20(10):2674-83. PMID: 24610827.

 

Zhang M, Xu CR, Shamiyeh E, et al. A randomized, placebo-controlled study of the pharmacokinetics, pharmacodynamics, and tolerability of the oral JAK2 inhibitor fedratinib (SAR302503) in healthy volunteers. J Clin Pharmacol. 2014 Apr;54(4):415-21. PMID: 24165976.

 

Wernig G, Kharas MG, Okabe R, et al. Efficacy of TG101348, a selective JAK2 inhibitor, in treatment of a murine model of JAK2V617F-induced polycythemia vera. Cancer Cell. 2008 Apr;13(4):311-20. PMID: 18394554.

" Not dangerous goods.

LKT T0140 TAK-632 5 mg 129.3 RAF inhibitor. TAK632 1228591-30-7 ≥98% 554.52 C27H18F4N4O3S Ambient "Nakamura A, Arita T, Tsuchiya S, et al. Antitumor activity of the selective pan-RAF inhibitor TAK-632 in BRAF inhibitor-resistant melanoma. Cancer Res. 2013 Dec 1;73(23):7043-55. PMID: 24121489.

 

Okaniwa M, Hirose M, Arita T, et al. Discovery of a selective kinase inhibitor (TAK-632) targeting pan-RAF inhibition: design, synthesis, and biological evaluation of C-7-substituted 1,3-benzothiazole derivatives. J Med Chem. 2013 Aug 22;56(16):6478-94. PMID: 23906342.

" Not dangerous goods.

LKT T0140 TAK-632 10 mg 196.7 RAF inhibitor. TAK632 1228591-30-7 ≥98% 554.52 C27H18F4N4O3S Ambient "Nakamura A, Arita T, Tsuchiya S, et al. Antitumor activity of the selective pan-RAF inhibitor TAK-632 in BRAF inhibitor-resistant melanoma. Cancer Res. 2013 Dec 1;73(23):7043-55. PMID: 24121489.

 

Okaniwa M, Hirose M, Arita T, et al. Discovery of a selective kinase inhibitor (TAK-632) targeting pan-RAF inhibition: design, synthesis, and biological evaluation of C-7-substituted 1,3-benzothiazole derivatives. J Med Chem. 2013 Aug 22;56(16):6478-94. PMID: 23906342.

" Not dangerous goods.

LKT S7618 StemRegenin 1 Hydrochloride 5 mg 73.1 AhR antagonist. SR1 ≥98% 458.7 C24H23N5OS 0.7HCl 0.2H2O Ambient -20°C "Thordardottir S, Hangalapura BN, Hutten T, et al. The aryl hydrocarbon receptor antagonist StemRegenin 1 promotes human plasmacytoid and myeloid dendritic cell development from CD34+ hematopoietic progenitor cells. Stem CelLSev. 2014 May 1;23(9):955-67. PMID: 24325394.

 

Gori JL, Chandrasekaran D, Kowalski JP, et al. Efficient generation, purification, and expansion of CD34(+) hematopoietic progenitor cells from nonhuman primate-induced pluripotent stem cells. Blood. 2012 Sep 27;120(13):e35-44. PMID: 22898598.

 

Boitano AE, Wang J, Romeo R, et al. Aryl hydrocarbon receptor antagonists promote the expansion of human hematopoietic stem cells. Science. 2010 Sep 10;329(5997):1345-8. Erratum in: Science. 2011 May 6;332(6030):664.  PMID: 20688981.

" Not dangerous goods.

LKT S7618 StemRegenin 1 Hydrochloride 25 mg 264.1 AhR antagonist. SR1 ≥98% 458.7 C24H23N5OS 0.7HCl 0.2H2O Ambient -20°C "Thordardottir S, Hangalapura BN, Hutten T, et al. The aryl hydrocarbon receptor antagonist StemRegenin 1 promotes human plasmacytoid and myeloid dendritic cell development from CD34+ hematopoietic progenitor cells. Stem CelLSev. 2014 May 1;23(9):955-67. PMID: 24325394.

 

Gori JL, Chandrasekaran D, Kowalski JP, et al. Efficient generation, purification, and expansion of CD34(+) hematopoietic progenitor cells from nonhuman primate-induced pluripotent stem cells. Blood. 2012 Sep 27;120(13):e35-44. PMID: 22898598.

 

Boitano AE, Wang J, Romeo R, et al. Aryl hydrocarbon receptor antagonists promote the expansion of human hematopoietic stem cells. Science. 2010 Sep 10;329(5997):1345-8. Erratum in: Science. 2011 May 6;332(6030):664.  PMID: 20688981.

" Not dangerous goods.

LKT S7618 StemRegenin 1 Hydrochloride 50 mg 410.1 AhR antagonist. SR1 ≥98% 458.7 C24H23N5OS 0.7HCl 0.2H2O Ambient -20°C "Thordardottir S, Hangalapura BN, Hutten T, et al. The aryl hydrocarbon receptor antagonist StemRegenin 1 promotes human plasmacytoid and myeloid dendritic cell development from CD34+ hematopoietic progenitor cells. Stem CelLSev. 2014 May 1;23(9):955-67. PMID: 24325394.

 

Gori JL, Chandrasekaran D, Kowalski JP, et al. Efficient generation, purification, and expansion of CD34(+) hematopoietic progenitor cells from nonhuman primate-induced pluripotent stem cells. Blood. 2012 Sep 27;120(13):e35-44. PMID: 22898598.

 

Boitano AE, Wang J, Romeo R, et al. Aryl hydrocarbon receptor antagonists promote the expansion of human hematopoietic stem cells. Science. 2010 Sep 10;329(5997):1345-8. Erratum in: Science. 2011 May 6;332(6030):664.  PMID: 20688981.

" Not dangerous goods.

LKT S3352 Sinefungin 1 mg 92.1 S-adenosylmethionine nucleoside analog; methyltransferase inhibitor. 58944-73-3 ≥95% 381.39 C15H23N7O5 C1=NC2=C(C(=N1)N)N=CN2C3C(C(C(O3)CC(CCC(C(=O)O)N)N)O)O Ambient 4°C "Yadav MK, Park SW, Chae SW, et al. Sinefungin, a natural nucleoside analogue of S-adenosylmethionine, inhibits Streptococcus pneumoniae biofilm growth. Biomed Res Int. 2014;2014:156987. PMID: 25050323.

 

Devkota K, Lohse B, Liu Q, et al. Analogues of the Natural Product Sinefungin as Inhibitors of EHMT1 and EHMT2. ACS Med Chem Lett. 2014 Jan 31;5(4):293-7. PMID: 24900829.

 

Niitsuma M, Hashida J, Iwatsuki M, et al. Sinefungin VA and dehydrosinefungin V, new antitrypanosomal antibiotics produced by Streptomyces sp. K05-0178. J Antibiot (Tokyo). 2010 Nov;63(11):673-9. PMID: 20859291.

 

Bachrach U, Schnur LF, El-On J, et al. Inhibitory activity of sinefungin and SIBA (5'-deoxy-5'-S-isobutylthio-adenosine) on the growth of promastigotes and amastigotes of different species of Leishmania. FEBS Lett. 1980 Dec 1;121(2):287-91. PMID: 6970144." Not dangerous goods.

LKT S3352 Sinefungin 5 mg 320.3 S-adenosylmethionine nucleoside analog; methyltransferase inhibitor. 58944-73-3 ≥95% 381.39 C15H23N7O5 C1=NC2=C(C(=N1)N)N=CN2C3C(C(C(O3)CC(CCC(C(=O)O)N)N)O)O Ambient 4°C "Yadav MK, Park SW, Chae SW, et al. Sinefungin, a natural nucleoside analogue of S-adenosylmethionine, inhibits Streptococcus pneumoniae biofilm growth. Biomed Res Int. 2014;2014:156987. PMID: 25050323.

 

Devkota K, Lohse B, Liu Q, et al. Analogues of the Natural Product Sinefungin as Inhibitors of EHMT1 and EHMT2. ACS Med Chem Lett. 2014 Jan 31;5(4):293-7. PMID: 24900829.

 

Niitsuma M, Hashida J, Iwatsuki M, et al. Sinefungin VA and dehydrosinefungin V, new antitrypanosomal antibiotics produced by Streptomyces sp. K05-0178. J Antibiot (Tokyo). 2010 Nov;63(11):673-9. PMID: 20859291.

 

Bachrach U, Schnur LF, El-On J, et al. Inhibitory activity of sinefungin and SIBA (5'-deoxy-5'-S-isobutylthio-adenosine) on the growth of promastigotes and amastigotes of different species of Leishmania. FEBS Lett. 1980 Dec 1;121(2):287-91. PMID: 6970144." Not dangerous goods.

LKT A2420 A-769662 5 mg 87.7 AMPK activator. 844499-71-4 ≥98% 360.39 C20H12N2O3S C1=CC=C(C(=C1)C2=CC=C(C=C2)C3=CSC4=C3C(=C(C(=O)N4)C#N)O)O Ambient -20°C "Kim J, Shin J, Ha J. Screening methods for AMP-activated protein kinase modulators: a patent review. Expert Opin Ther Pat. 2015 Mar;25(3):261-77. PMID: 25535089.

 

Choudhury Y, Yang Z, Ahmad I, et al. AMP-activated protein kinase (AMPK) as a potential therapeutic target independent of PI3K/Akt signaling in prostate cancer. Oncoscience. 2014 Jun 4;1(6):446-56. PMID: 25594043.

 

Zhu Y, Zhou J, Ao R, et al. A-769662 protects osteoblasts from hydrogen dioxide-induced apoptosis through activating of AMP-activated protein kinase (AMPK). Int J Mol Sci. 2014 Jun 23;15(6):11190-203. PMID: 24960362.

 

Liu Y, Oh SJ, Chang KH, et al. Antiplatelet effect of AMP-activated protein kinase activator and its potentiation by the phosphodiesterase inhibitor dipyridamole. Biochem Pharmacol. 2013 Oct 1;86(7):914-25. PMID: 23876340.

" Not dangerous goods.

LKT A2420 A-769662 10 mg 134.8 AMPK activator. 844499-71-4 ≥98% 360.39 C20H12N2O3S C1=CC=C(C(=C1)C2=CC=C(C=C2)C3=CSC4=C3C(=C(C(=O)N4)C#N)O)O Ambient -20°C "Kim J, Shin J, Ha J. Screening methods for AMP-activated protein kinase modulators: a patent review. Expert Opin Ther Pat. 2015 Mar;25(3):261-77. PMID: 25535089.

 

Choudhury Y, Yang Z, Ahmad I, et al. AMP-activated protein kinase (AMPK) as a potential therapeutic target independent of PI3K/Akt signaling in prostate cancer. Oncoscience. 2014 Jun 4;1(6):446-56. PMID: 25594043.

 

Zhu Y, Zhou J, Ao R, et al. A-769662 protects osteoblasts from hydrogen dioxide-induced apoptosis through activating of AMP-activated protein kinase (AMPK). Int J Mol Sci. 2014 Jun 23;15(6):11190-203. PMID: 24960362.

 

Liu Y, Oh SJ, Chang KH, et al. Antiplatelet effect of AMP-activated protein kinase activator and its potentiation by the phosphodiesterase inhibitor dipyridamole. Biochem Pharmacol. 2013 Oct 1;86(7):914-25. PMID: 23876340.

" Not dangerous goods.

LKT A0778 ABT-737 5 mg 134.8 BH3 mimetic; Bcl-2, Bxl-xl, Bcl-w inhibitor. ABT737 852808-04-9 ≥98% 813.43 C42H45ClN6O5S2 CN(C)CCC(CSC1=CC=CC=C1)NC2=C(C=C(C=C2)S(=O)(=O)NC(=O)C3=CC=C(C=C3)N4CCN(CC4)CC5=CC=CC=C5C6=CC=C(C=C6)Cl)[N+](=O)[O-] Ambient -20°C "Lieber J, Armeanu-Ebinger S, Fuchs J. The Role of BH3-Mimetic Drugs in the Treatment of Pediatric Hepatoblastoma. Int J Mol Sci. 2015 Feb 16;16(2):4190-4208. PMID: 25690034.

 

Baev DV, Krawczyk J, O’Dwyer M, et al. The BH3-mimetic ABT-737 effectively kills acute myeloid leukemia initiating cells. Leuk Res Rep. 2014 Sep 1;3(2):79-82. PMID: 25379408.

 

Gyulkhandanyan AV, Mutlu A, Allen DJ, et al. BH3-mimetic ABT-737 induces strong mitochondrial membrane depolarization in platelets but only weakly stimulates apoptotic morphological changes, platelet shrinkage and microparticle formation. Thromb Res. 2014 Jan;133(1):73-9. PMID: 24268298.

 

Beurlet S, Omidvar N, Gorombei P, et al. BCL-2 inhibition with ABT-737 prolongs survival in an NRAS/BCL-2 mouse model of AML by targeting primitive LSK and progenitor cells. Blood. 2013 Oct 17;122(16):2864-76. PMID: 23943652.

" Not dangerous goods.

LKT A0778 ABT-737 10 mg 213.5 BH3 mimetic; Bcl-2, Bxl-xl, Bcl-w inhibitor. ABT737 852808-04-9 ≥98% 813.43 C42H45ClN6O5S2 CN(C)CCC(CSC1=CC=CC=C1)NC2=C(C=C(C=C2)S(=O)(=O)NC(=O)C3=CC=C(C=C3)N4CCN(CC4)CC5=CC=CC=C5C6=CC=C(C=C6)Cl)[N+](=O)[O-] Ambient -20°C "Lieber J, Armeanu-Ebinger S, Fuchs J. The Role of BH3-Mimetic Drugs in the Treatment of Pediatric Hepatoblastoma. Int J Mol Sci. 2015 Feb 16;16(2):4190-4208. PMID: 25690034.

 

Baev DV, Krawczyk J, O’Dwyer M, et al. The BH3-mimetic ABT-737 effectively kills acute myeloid leukemia initiating cells. Leuk Res Rep. 2014 Sep 1;3(2):79-82. PMID: 25379408.

 

Gyulkhandanyan AV, Mutlu A, Allen DJ, et al. BH3-mimetic ABT-737 induces strong mitochondrial membrane depolarization in platelets but only weakly stimulates apoptotic morphological changes, platelet shrinkage and microparticle formation. Thromb Res. 2014 Jan;133(1):73-9. PMID: 24268298.

 

Beurlet S, Omidvar N, Gorombei P, et al. BCL-2 inhibition with ABT-737 prolongs survival in an NRAS/BCL-2 mouse model of AML by targeting primitive LSK and progenitor cells. Blood. 2013 Oct 17;122(16):2864-76. PMID: 23943652.

" Not dangerous goods.

LKT A3080 AHU-377 Tris Salt 5 mg 269.6 LBQ657 prodrug; neprilysin inhibitor. AHU377, Sacubitril 149709-62-6 ≥99% 532.63 C24H29NO5  C4H11NO3 CCOC(=O)C(C)CC(CC1=CC=C(C=C1)C2=CC=CC=C2)NC(=O)CCC(=O)O Ambient -20°C "Vardeny O, Miller R, Solomon SD. Combined neprilysin and renin-angiotensin system inhibition for the treatment of heart failure. JACC Heart Fail. 2014 Dec;2(6):663-70. PMID: 25306450.

 

Monge M, Lorthioir A, Bobrie G, et al. New drug therapies interfering with the renin-angiotensin-aldosterone system for resistant hypertension. J Renin Angiotensin Aldosterone Syst. 2013 Dec;14(4):285-9. PMID: 24222656.

 

Ruilope LM, Dukat A, Böhm M, et al. Blood-pressure reduction with LCZ696, a novel dual-acting inhibitor of the angiotensin II receptor and neprilysin: a randomised, double-blind, placebo-controlled, active comparator study. Lancet. 2010 Apr 10;375(9722):1255-66. PMID: 20236700.

" "UN number: 2811     Class: 6.1     Packing Group: III

Proper shipping name: Toxic solid, organic, n.o.s. (AHU-377 tris salt)"

LKT A3080 AHU-377 Tris Salt 10 mg 432.6 LBQ657 prodrug; neprilysin inhibitor. AHU377, Sacubitril 149709-62-6 ≥99% 532.63 C24H29NO5  C4H11NO3 CCOC(=O)C(C)CC(CC1=CC=C(C=C1)C2=CC=CC=C2)NC(=O)CCC(=O)O Ambient -20°C "Vardeny O, Miller R, Solomon SD. Combined neprilysin and renin-angiotensin system inhibition for the treatment of heart failure. JACC Heart Fail. 2014 Dec;2(6):663-70. PMID: 25306450.

 

Monge M, Lorthioir A, Bobrie G, et al. New drug therapies interfering with the renin-angiotensin-aldosterone system for resistant hypertension. J Renin Angiotensin Aldosterone Syst. 2013 Dec;14(4):285-9. PMID: 24222656.

 

Ruilope LM, Dukat A, Böhm M, et al. Blood-pressure reduction with LCZ696, a novel dual-acting inhibitor of the angiotensin II receptor and neprilysin: a randomised, double-blind, placebo-controlled, active comparator study. Lancet. 2010 Apr 10;375(9722):1255-66. PMID: 20236700.

" "UN number: 2811     Class: 6.1     Packing Group: III

Proper shipping name: Toxic solid, organic, n.o.s. (AHU-377 tris salt)"

LKT A9812 AZD-1480 5 mg 132.6 JAK1/2 inhibitor. AZD-1480 935666-88-9 ≥98% 348.77 C14H14ClFN8 CC1=CC(=NN1)NC2=NC(=NC=C2Cl)NC(C)C3=NC=C(C=N3)F Ambient -20°C "Jiang X, Kanda T, Nakamoto S, et al. The JAK2 inhibitor AZD1480 inhibits hepatitis A virus replication in Huh7 cells. Biochem Biophys Res Commun. 2015 Feb 19. [Epub ahead of print]. PMID: 25704089.

 

Gritsina G, Xiao F, O'Brien SW, et al. Targeted blockade of JAK/STAT3 signaling inhibits ovarian carcinoma growth. Mol Cancer Ther. 2015 Feb 2. [Epub ahead of print]. PMID: 25646015.

 

Suryani S, Bracken LS, Harvey RC, et al. Evaluation of the In Vitro and In Vivo Efficacy of the JAK Inhibitor AZD1480 against JAK-Mutated Acute Lymphoblastic Leukemia. Mol Cancer Ther. 2015 Feb;14(2):364-74. PMID: 25504635.

 

Houghton PJ, Kurmasheva RT, Lyalin D, et al. Initial solid tumor testing (stage 1) of AZD1480, an inhibitor of Janus kinases 1 and 2 by the pediatric preclinical testing program. Pediatr Blood Cancer. 2014 Nov;61(11):1972-9. PMID: 25131802.

 

Gu L, Talati P, Vogiatzi P, et al. Pharmacologic suppression of JAK1/2 by JAK1/2 inhibitor AZD1480 potently inhibits IL-6-induced experimental prostate cancer metastases formation. Mol Cancer Ther. 2014 May;13(5):1246-58. PMID: 24577942.

 

Liu Y, Holdbrooks AT, De Sarno P, et al. Therapeutic efficacy of suppressing the Jak/STAT pathway in multiple models of experimental autoimmune encephalomyelitis. J Immunol. 2014 Jan 1;192(1):59-72. PMID: 24323580.

" Not dangerous goods.

LKT A9812 AZD-1480 10 mg 207.9 JAK1/2 inhibitor. AZD-1480 935666-88-9 ≥98% 348.77 C14H14ClFN8 CC1=CC(=NN1)NC2=NC(=NC=C2Cl)NC(C)C3=NC=C(C=N3)F Ambient -20°C "Jiang X, Kanda T, Nakamoto S, et al. The JAK2 inhibitor AZD1480 inhibits hepatitis A virus replication in Huh7 cells. Biochem Biophys Res Commun. 2015 Feb 19. [Epub ahead of print]. PMID: 25704089.

 

Gritsina G, Xiao F, O'Brien SW, et al. Targeted blockade of JAK/STAT3 signaling inhibits ovarian carcinoma growth. Mol Cancer Ther. 2015 Feb 2. [Epub ahead of print]. PMID: 25646015.

 

Suryani S, Bracken LS, Harvey RC, et al. Evaluation of the In Vitro and In Vivo Efficacy of the JAK Inhibitor AZD1480 against JAK-Mutated Acute Lymphoblastic Leukemia. Mol Cancer Ther. 2015 Feb;14(2):364-74. PMID: 25504635.

 

Houghton PJ, Kurmasheva RT, Lyalin D, et al. Initial solid tumor testing (stage 1) of AZD1480, an inhibitor of Janus kinases 1 and 2 by the pediatric preclinical testing program. Pediatr Blood Cancer. 2014 Nov;61(11):1972-9. PMID: 25131802.

 

Gu L, Talati P, Vogiatzi P, et al. Pharmacologic suppression of JAK1/2 by JAK1/2 inhibitor AZD1480 potently inhibits IL-6-induced experimental prostate cancer metastases formation. Mol Cancer Ther. 2014 May;13(5):1246-58. PMID: 24577942.

 

Liu Y, Holdbrooks AT, De Sarno P, et al. Therapeutic efficacy of suppressing the Jak/STAT pathway in multiple models of experimental autoimmune encephalomyelitis. J Immunol. 2014 Jan 1;192(1):59-72. PMID: 24323580.

" Not dangerous goods.

LKT A9814 AZD-4547 5 mg 76.4 FGFR inhibitor. AZD-4547 1035270-39-3 ≥98% 463.57 C26H33N5O3 CC1CN(CC(N1)C)C2=CC=C(C=C2)C(=O)NC3=NNC(=C3)CCC4=CC(=CC(=C4)OC)OC Ambient -20°C "Liu L, Ye TH, Han YP, et al. Reductions in myeloid-derived suppressor cells and lung metastases using AZD4547 treatment of a metastatic murine breast tumor model. Cell Physiol Biochem. 2014;33(3):633-45. PMID: 24642893.

 

Zhang J, Zhang L, Su X, et al. Translating the therapeutic potential of AZD4547 in FGFR1-amplified non-small cell lung cancer through the use of patient-derived tumor xenograft models. Clin Cancer Res. 2012 Dec 15;18(24):6658-67. Erratum in: Clin Cancer Res. 2013 Jul 1;19(13):3714. Schöttle, Jakob [added]. PMID: 23082000.

 

Gavine PR, Mooney L, Kilgour E, et al. AZD4547: an orally bioavailable, potent, and selective inhibitor of the fibroblast growth factor receptor tyrosine kinase family. Cancer Res. 2012 Apr 15;72(8):2045-56. PMID: 22369928.

" Not dangerous goods.

LKT A9814 AZD-4547 10 mg 118 FGFR inhibitor. AZD-4547 1035270-39-3 ≥98% 463.57 C26H33N5O3 CC1CN(CC(N1)C)C2=CC=C(C=C2)C(=O)NC3=NNC(=C3)CCC4=CC(=CC(=C4)OC)OC Ambient -20°C "Liu L, Ye TH, Han YP, et al. Reductions in myeloid-derived suppressor cells and lung metastases using AZD4547 treatment of a metastatic murine breast tumor model. Cell Physiol Biochem. 2014;33(3):633-45. PMID: 24642893.

 

Zhang J, Zhang L, Su X, et al. Translating the therapeutic potential of AZD4547 in FGFR1-amplified non-small cell lung cancer through the use of patient-derived tumor xenograft models. Clin Cancer Res. 2012 Dec 15;18(24):6658-67. Erratum in: Clin Cancer Res. 2013 Jul 1;19(13):3714. Schöttle, Jakob [added]. PMID: 23082000.

 

Gavine PR, Mooney L, Kilgour E, et al. AZD4547: an orally bioavailable, potent, and selective inhibitor of the fibroblast growth factor receptor tyrosine kinase family. Cancer Res. 2012 Apr 15;72(8):2045-56. PMID: 22369928.

" Not dangerous goods.

LKT A9912 AZD-7762 Hydrochloride 5 mg 118 CHK1 inhibitor. AZD-7762 HCl 860352-01-8 ≥98% 398.88 C17H19FN4O2S HCl C1CC(CNC1)NC(=O)C2=C(C=C(S2)C3=CC(=CC=C3)F)NC(=O)N Ambient -20°C "Bryant C, Rawlinson R, Massey AJ. Chk1 inhibition as a novel therapeutic strategy for treating triple-negative breast and ovarian cancers. BMC Cancer. 2014 Aug 7;14:570. PMID: 25104095.

 

Sausville E, Lorusso P, Carducci M, et al. Phase I dose-escalation study of AZD7762, a checkpoint kinase inhibitor, in combination with gemcitabine in US patients with advanced solid tumors. Cancer Chemother Pharmacol. 2014 Mar;73(3):539-49. PMID: 24448638.

 

Ma CX, Cai S, Li S, et al. Targeting Chk1 in p53-deficient triple-negative breast cancer is therapeutically beneficial in human-in-mouse tumor models. J Clin Invest. 2012 Apr;122(4):1541-52. Erratum in: J Clin Invest. 2012 Jul 2;122(7):2702.  PMID: 22446188.

" Not dangerous goods.

LKT A9912 AZD-7762 Hydrochloride 10 mg 185.4 CHK1 inhibitor. AZD-7762 HCl 860352-01-8 ≥98% 398.88 C17H19FN4O2S HCl C1CC(CNC1)NC(=O)C2=C(C=C(S2)C3=CC(=CC=C3)F)NC(=O)N Ambient -20°C "Bryant C, Rawlinson R, Massey AJ. Chk1 inhibition as a novel therapeutic strategy for treating triple-negative breast and ovarian cancers. BMC Cancer. 2014 Aug 7;14:570. PMID: 25104095.

 

Sausville E, Lorusso P, Carducci M, et al. Phase I dose-escalation study of AZD7762, a checkpoint kinase inhibitor, in combination with gemcitabine in US patients with advanced solid tumors. Cancer Chemother Pharmacol. 2014 Mar;73(3):539-49. PMID: 24448638.

 

Ma CX, Cai S, Li S, et al. Targeting Chk1 in p53-deficient triple-negative breast cancer is therapeutically beneficial in human-in-mouse tumor models. J Clin Invest. 2012 Apr;122(4):1541-52. Erratum in: J Clin Invest. 2012 Jul 2;122(7):2702.  PMID: 22446188.

" Not dangerous goods.

LKT A9914 AZD-8055 5 mg 50.6 mTOR inhibitor. AZD-8055 1009298-09-2 ≥98% 465.55 C25H31N5O4 CC1COCCN1C2=NC(=NC3=C2C=CC(=N3)C4=CC(=C(C=C4)OC)CO)N5CCOCC5C Ambient -20°C "Limon JJ, So L, Jellbauer S, et al. mTOR kinase inhibitors promote antibody class switching via mTORC2 inhibition. Proc Natl Acad Sci U S A. 2014 Nov 25;111(47):E5076-85. PMID: 25385646.

 

Luchman HA, Stechishin OD, Nguyen SA, et al. Dual mTORC1/2 blockade inhibits glioblastoma brain tumor initiating cells in vitro and in vivo and synergizes with temozolomide to increase orthotopic xenograft survival. Clin Cancer Res. 2014 Nov 15;20(22):5756-67. PMID: 25316808.

 

Rosborough BR, Raïch-Regué D, Liu Q, et al. Adenosine triphosphate-competitive mTOR inhibitors: a new class of immunosuppressive agents that inhibit allograft rejection. Am J Transplant. 2014 Sep;14(9):2173-80. PMID: 25307040.

" Not dangerous goods.

LKT A9914 AZD-8055 25 mg 163 mTOR inhibitor. AZD-8055 1009298-09-2 ≥98% 465.55 C25H31N5O4 CC1COCCN1C2=NC(=NC3=C2C=CC(=N3)C4=CC(=C(C=C4)OC)CO)N5CCOCC5C Ambient -20°C "Limon JJ, So L, Jellbauer S, et al. mTOR kinase inhibitors promote antibody class switching via mTORC2 inhibition. Proc Natl Acad Sci U S A. 2014 Nov 25;111(47):E5076-85. PMID: 25385646.

 

Luchman HA, Stechishin OD, Nguyen SA, et al. Dual mTORC1/2 blockade inhibits glioblastoma brain tumor initiating cells in vitro and in vivo and synergizes with temozolomide to increase orthotopic xenograft survival. Clin Cancer Res. 2014 Nov 15;20(22):5756-67. PMID: 25316808.

 

Rosborough BR, Raïch-Regué D, Liu Q, et al. Adenosine triphosphate-competitive mTOR inhibitors: a new class of immunosuppressive agents that inhibit allograft rejection. Am J Transplant. 2014 Sep;14(9):2173-80. PMID: 25307040.

" Not dangerous goods.

LKT A9914 AZD-8055 50 mg 252.8 mTOR inhibitor. AZD-8055 1009298-09-2 ≥98% 465.55 C25H31N5O4 CC1COCCN1C2=NC(=NC3=C2C=CC(=N3)C4=CC(=C(C=C4)OC)CO)N5CCOCC5C Ambient -20°C "Limon JJ, So L, Jellbauer S, et al. mTOR kinase inhibitors promote antibody class switching via mTORC2 inhibition. Proc Natl Acad Sci U S A. 2014 Nov 25;111(47):E5076-85. PMID: 25385646.

 

Luchman HA, Stechishin OD, Nguyen SA, et al. Dual mTORC1/2 blockade inhibits glioblastoma brain tumor initiating cells in vitro and in vivo and synergizes with temozolomide to increase orthotopic xenograft survival. Clin Cancer Res. 2014 Nov 15;20(22):5756-67. PMID: 25316808.

 

Rosborough BR, Raïch-Regué D, Liu Q, et al. Adenosine triphosphate-competitive mTOR inhibitors: a new class of immunosuppressive agents that inhibit allograft rejection. Am J Transplant. 2014 Sep;14(9):2173-80. PMID: 25307040.

" Not dangerous goods.

LKT B1746 Belinostat 5 mg 84.3 HDAC inhibitor. PXD101 414864-00-9 ≥98% 318.35 C15H14N2O4S C1=CC=C(C=C1)NS(=O)(=O)C2=CC=CC(=C2)C=CC(=O)NO Ambient -20°C "Campbell GR, Bruckman RS, Chu YL, et al. Autophagy Induction by Histone Deacetylase Inhibitors Inhibits HIV Type 1. J Biol Chem. 2015 Feb 20;290(8):5028-40. PMID: 25540204.

 

Foss F, Advani R, Duvic M, et al. A Phase II trial of Belinostat (PXD101) in patients with relapsed or refractory peripheral or cutaneous T-cell lymphoma. Br J Haematol. 2014 Nov 17. [Epub ahead of print].

 PMID: 25404094.

 

Kirschbaum MH, Foon KA, Frankel P, et al. A phase 2 study of belinostat (PXD101) in patients with relapsed or refractory acute myeloid leukemia or patients over the age of 60 with newly diagnosed acute myeloid leukemia: a California Cancer Consortium Study. Leuk Lymphoma. 2014 Oct;55(10):2301-4. PMID: 24369094.

 

Wang B, Wang XB, Chen LY, et al. Belinostat-induced apoptosis and growth inhibition in pancreatic cancer cells involve activation of TAK1-AMPK signaling axis. Biochem Biophys Res Commun. 2013 Jul 19;437(1):1-6. PMID: 23743198.

" Not dangerous goods.

LKT B1746 Belinostat 10 mg 129.3 HDAC inhibitor. PXD101 414864-00-9 ≥98% 318.35 C15H14N2O4S C1=CC=C(C=C1)NS(=O)(=O)C2=CC=CC(=C2)C=CC(=O)NO Ambient -20°C "Campbell GR, Bruckman RS, Chu YL, et al. Autophagy Induction by Histone Deacetylase Inhibitors Inhibits HIV Type 1. J Biol Chem. 2015 Feb 20;290(8):5028-40. PMID: 25540204.

 

Foss F, Advani R, Duvic M, et al. A Phase II trial of Belinostat (PXD101) in patients with relapsed or refractory peripheral or cutaneous T-cell lymphoma. Br J Haematol. 2014 Nov 17. [Epub ahead of print].

 PMID: 25404094.

 

Kirschbaum MH, Foon KA, Frankel P, et al. A phase 2 study of belinostat (PXD101) in patients with relapsed or refractory acute myeloid leukemia or patients over the age of 60 with newly diagnosed acute myeloid leukemia: a California Cancer Consortium Study. Leuk Lymphoma. 2014 Oct;55(10):2301-4. PMID: 24369094.

 

Wang B, Wang XB, Chen LY, et al. Belinostat-induced apoptosis and growth inhibition in pancreatic cancer cells involve activation of TAK1-AMPK signaling axis. Biochem Biophys Res Commun. 2013 Jul 19;437(1):1-6. PMID: 23743198.

" Not dangerous goods.

LKT B3200 BI-2536 5 mg 177.6 PLK1 inhibitor. BI2536 755038-02-9 ≥98% 521.65 C28H39N7O3 CCC1C(=O)N(C2=CN=C(N=C2N1C3CCCC3)NC4=C(C=C(C=C4)C(=O)NC5CCN(CC5)C)OC)C Ambient -20°C "Colnaghi R, Wheatley SP. Liaisons between survivin and Plk1 during cell division and cell death. J Biol Chem. 2010 Jul 16;285(29):22592-604. PMID: 20427271.

 

Zhang J, Yang PL, Gray NS. Targeting cancer with small molecule kinase inhibitors. Nature Reviews Cancer. 2009 Jan;9:28-39. 

" Not dangerous goods.

LKT B3200 BI-2536 10 mg 275.3 PLK1 inhibitor. BI2536 755038-02-9 ≥98% 521.65 C28H39N7O3 CCC1C(=O)N(C2=CN=C(N=C2N1C3CCCC3)NC4=C(C=C(C=C4)C(=O)NC5CCN(CC5)C)OC)C Ambient -20°C "Colnaghi R, Wheatley SP. Liaisons between survivin and Plk1 during cell division and cell death. J Biol Chem. 2010 Jul 16;285(29):22592-604. PMID: 20427271.

 

Zhang J, Yang PL, Gray NS. Targeting cancer with small molecule kinase inhibitors. Nature Reviews Cancer. 2009 Jan;9:28-39. 

" Not dangerous goods.

LKT B3300 BI-6727 5 mg 177.6 PLK1 inhibitor. BI6727, Volasertib 755038-65-4 ≥99% 618.81 C34H50N8O3 CCC1C(=O)N(C2=CN=C(N=C2N1C(C)C)NC3=C(C=C(C=C3)C(=O)NC4CCC(CC4)N5CCN(CC5)CC6CC6)OC)C Ambient -20°C "Münch C, Dragoi D, Frey AV, et al. Therapeutic polo-like kinase 1 inhibition results in mitotic arrest and subsequent cell death of blasts in the bone marrow of AML patients and has similar effects in non-neoplastic cell lines. Leuk Res. 2015 Jan 28. [Epub ahead of print]. PMID: 25697066.

 

Gjertsen BT, Schöffski P. Discovery and development of the Polo-like kinase inhibitor volasertib in cancer therapy. Leukemia. 2015 Jan;29(1):11-9. PMID: 25027517.

 

Lin CC, Su WC, Yen CJ, et al. A phase I study of two dosing schedules of volasertib (BI 6727), an intravenous polo-like kinase inhibitor, in patients with advanced solid malignancies. Br J Cancer. 2014 May 13;110(10):2434-40. PMID: 24755882.

" Not dangerous goods.

LKT B3300 BI-6727 10 mg 275.3 PLK1 inhibitor. BI6727, Volasertib 755038-65-4 ≥99% 618.81 C34H50N8O3 CCC1C(=O)N(C2=CN=C(N=C2N1C(C)C)NC3=C(C=C(C=C3)C(=O)NC4CCC(CC4)N5CCN(CC5)CC6CC6)OC)C Ambient -20°C "Münch C, Dragoi D, Frey AV, et al. Therapeutic polo-like kinase 1 inhibition results in mitotic arrest and subsequent cell death of blasts in the bone marrow of AML patients and has similar effects in non-neoplastic cell lines. Leuk Res. 2015 Jan 28. [Epub ahead of print]. PMID: 25697066.

 

Gjertsen BT, Schöffski P. Discovery and development of the Polo-like kinase inhibitor volasertib in cancer therapy. Leukemia. 2015 Jan;29(1):11-9. PMID: 25027517.

 

Lin CC, Su WC, Yen CJ, et al. A phase I study of two dosing schedules of volasertib (BI 6727), an intravenous polo-like kinase inhibitor, in patients with advanced solid malignancies. Br J Cancer. 2014 May 13;110(10):2434-40. PMID: 24755882.

" Not dangerous goods.

LKT B5074 BMS-599626 5 mg 275.3 EGFR, VEGFR inhibitor. BMS599626, AC480 714971-09-2 ≥98% 530.55 C27H27FN8O3 CC1=C2C(=NC=NN2C=C1NC(=O)OCC3COCCN3)NC4=CC5=C(C=C4)N(N=C5)CC6=CC(=CC=C6)F Ambient -20°C "Soria JC, Cortes J, Massard C, et al. Phase I safety, pharmacokinetic and pharmacodynamic trial of BMS-599626 (AC480), an oral pan-HER receptor tyrosine kinase inhibitor, in patients with advanced solid tumors. Ann Oncol. 2012 Feb;23(2):463-71. PMID: 21576284.

 

Torres MA, Raju U, Molkentine D, et al. AC480, formerly BMS-599626, a pan Her inhibitor, enhances radiosensitivity and radioresponse of head and neck squamous cell carcinoma cells in vitro and in vivo. Invest New Drugs. 2011 Aug;29(4):554-61. PMID: 20119866.

" Not dangerous goods.

LKT B5074 BMS-599626 10 mg 432.6 EGFR, VEGFR inhibitor. BMS599626, AC480 714971-09-2 ≥98% 530.55 C27H27FN8O3 CC1=C2C(=NC=NN2C=C1NC(=O)OCC3COCCN3)NC4=CC5=C(C=C4)N(N=C5)CC6=CC(=CC=C6)F Ambient -20°C "Soria JC, Cortes J, Massard C, et al. Phase I safety, pharmacokinetic and pharmacodynamic trial of BMS-599626 (AC480), an oral pan-HER receptor tyrosine kinase inhibitor, in patients with advanced solid tumors. Ann Oncol. 2012 Feb;23(2):463-71. PMID: 21576284.

 

Torres MA, Raju U, Molkentine D, et al. AC480, formerly BMS-599626, a pan Her inhibitor, enhances radiosensitivity and radioresponse of head and neck squamous cell carcinoma cells in vitro and in vivo. Invest New Drugs. 2011 Aug;29(4):554-61. PMID: 20119866.

" Not dangerous goods.

LKT C2900 CH5424802 5 mg 155.1 ALK inhibitor. CH 5424802, Alectinib 1256580-46-7 ≥99% 482.62 C30H34N4O2 CCC1=C(C=C2C(=C1)C(=O)C3=C(C2(C)C)NC4=C3C=CC(=C4)C#N)N5CCC(CC5)N6CCOCC6 Ambient -20°C "Santarpia M, Altavilla G, Rosell R. Alectinib: a selective, next-generation ALK inhibitor for treatment of ALK-rearranged non-small-cell lung cancer. Expert Rev Respir Med. 2015 Feb 5:1-14. [Epub ahead of print]. PMID: 25652176.

 

Kodama T, Hasegawa M, Takanashi K, et al. Antitumor activity of the selective ALK inhibitor alectinib in models of intracranial metastases. Cancer Chemother Pharmacol. 2014 Nov;74(5):1023-8. PMID: 25205428.

 

Kodama T, Tsukaguchi T, Yoshida M, et al. Selective ALK inhibitor alectinib with potent antitumor activity in models of crizotinib resistance. Cancer Lett. 2014 Sep 1;351(2):215-21. PMID: 24887559.

 

Rossi A, Maione P, Sacco PC, et al. ALK inhibitors and advanced non-small cell lung cancer (review). Int J Oncol. 2014 Aug;45(2):499-508. PMID: 24889366.

" Not dangerous goods.

LKT C2900 CH5424802 10 mg 241.6 ALK inhibitor. CH 5424802, Alectinib 1256580-46-7 ≥99% 482.62 C30H34N4O2 CCC1=C(C=C2C(=C1)C(=O)C3=C(C2(C)C)NC4=C3C=CC(=C4)C#N)N5CCC(CC5)N6CCOCC6 Ambient -20°C "Santarpia M, Altavilla G, Rosell R. Alectinib: a selective, next-generation ALK inhibitor for treatment of ALK-rearranged non-small-cell lung cancer. Expert Rev Respir Med. 2015 Feb 5:1-14. [Epub ahead of print]. PMID: 25652176.

 

Kodama T, Hasegawa M, Takanashi K, et al. Antitumor activity of the selective ALK inhibitor alectinib in models of intracranial metastases. Cancer Chemother Pharmacol. 2014 Nov;74(5):1023-8. PMID: 25205428.

 

Kodama T, Tsukaguchi T, Yoshida M, et al. Selective ALK inhibitor alectinib with potent antitumor activity in models of crizotinib resistance. Cancer Lett. 2014 Sep 1;351(2):215-21. PMID: 24887559.

 

Rossi A, Maione P, Sacco PC, et al. ALK inhibitors and advanced non-small cell lung cancer (review). Int J Oncol. 2014 Aug;45(2):499-508. PMID: 24889366.

" Not dangerous goods.

LKT C6818 Crenolanib 5 mg 151.7 FLT3, PDGFR inhibitor. CP-868596 670220-88-9 ≥98% 443.54 C26H29N5O2 CC1(COC1)COC2=CC3=C(C=C2)N(C=N3)C4=NC5=C(C=CC=C5N6CCC(CC6)N)C=C4 Ambient -20°C "Wang P, Song L, Ge H, et al. Crenolanib, a PDGFR inhibitor, suppresses lung cancer cell proliferation and inhibits tumor growth in vivo. Onco Targets Ther. 2014 Sep 26;7:1761-8. PMID: 25328409.

 

Smith CC, Lasater EA, Lin KC, et al. Crenolanib is a selective type I pan-FLT3 inhibitor. Proc Natl Acad Sci U S A. 2014 Apr 8;111(14):5319-24. PMID: 24623852.

 

Zimmerman EI, Turner DC, Buaboonnam J, et al. Crenolanib is active against models of drug-resistant FLT3-ITD-positive acute myeloid leukemia. Blood. 2013 Nov 21;122(22):3607-15. PMID: 24046014.

" Not dangerous goods.

LKT C6818 Crenolanib 10 mg 235.9 FLT3, PDGFR inhibitor. CP-868596 670220-88-9 ≥98% 443.54 C26H29N5O2 CC1(COC1)COC2=CC3=C(C=C2)N(C=N3)C4=NC5=C(C=CC=C5N6CCC(CC6)N)C=C4 Ambient -20°C "Wang P, Song L, Ge H, et al. Crenolanib, a PDGFR inhibitor, suppresses lung cancer cell proliferation and inhibits tumor growth in vivo. Onco Targets Ther. 2014 Sep 26;7:1761-8. PMID: 25328409.

 

Smith CC, Lasater EA, Lin KC, et al. Crenolanib is a selective type I pan-FLT3 inhibitor. Proc Natl Acad Sci U S A. 2014 Apr 8;111(14):5319-24. PMID: 24623852.

 

Zimmerman EI, Turner DC, Buaboonnam J, et al. Crenolanib is active against models of drug-resistant FLT3-ITD-positive acute myeloid leukemia. Blood. 2013 Nov 21;122(22):3607-15. PMID: 24046014.

" Not dangerous goods.

LKT C9876 CYT-387 5 mg 118 JAK2 inhibitor. CYT387, CYT11387, Momelotinib 1056634-68-4 ≥99% 414.46 C23H22N6O2 C1COCCN1C2=CC=C(C=C2)NC3=NC=CC(=N3)C4=CC=C(C=C4)C(=O)NCC#N Ambient -20°C "Abubaker K, Luwor RB, Zhu H, et al. Inhibition of the JAK2/STAT3 pathway in ovarian cancer results in the loss of cancer stem cell-like characteristics and a reduced tumor burden. BMC Cancer. 2014 May 6;14:317. PMID: 24886434.

 

Geyer HL, Tibes R, Mesa RA. JAK2 inhibitors and their impact in myeloproliferative neoplasms. Hematology. 2012 Apr;17 Suppl 1:S129-32. PMID: 22507800.

 

Monaghan KA, Khong T, Burns CJ, et al. The novel JAK inhibitor CYT387 suppresses multiple signalling pathways, prevents proliferation and induces apoptosis in phenotypically diverse myeloma cells. Leukemia. 2011 Dec;25(12):1891-9. PMID: 21788946.

" Not dangerous goods.

LKT C9876 CYT-387 10 mg 185.4 JAK2 inhibitor. CYT387, CYT11387, Momelotinib 1056634-68-4 ≥99% 414.46 C23H22N6O2 C1COCCN1C2=CC=C(C=C2)NC3=NC=CC(=N3)C4=CC=C(C=C4)C(=O)NCC#N Ambient -20°C "Abubaker K, Luwor RB, Zhu H, et al. Inhibition of the JAK2/STAT3 pathway in ovarian cancer results in the loss of cancer stem cell-like characteristics and a reduced tumor burden. BMC Cancer. 2014 May 6;14:317. PMID: 24886434.

 

Geyer HL, Tibes R, Mesa RA. JAK2 inhibitors and their impact in myeloproliferative neoplasms. Hematology. 2012 Apr;17 Suppl 1:S129-32. PMID: 22507800.

 

Monaghan KA, Khong T, Burns CJ, et al. The novel JAK inhibitor CYT387 suppresses multiple signalling pathways, prevents proliferation and induces apoptosis in phenotypically diverse myeloma cells. Leukemia. 2011 Dec;25(12):1891-9. PMID: 21788946.

" Not dangerous goods.

LKT D0808 DCC-2036 5 mg 202.2 Abl inhibitor. DCC2036, Rebastinib 1020172-07-9 ≥98% 553.59 C30H28FN7O3 CC(C)(C)C1=NN(C(=C1)NC(=O)NC2=C(C=C(C=C2)OC3=CC(=NC=C3)C(=O)NC)F)C4=CC5=C(C=C4)N=CC=C5 Ambient -20°C "Shen Y, Shi X, Pan J. The conformational control inhibitor of tyrosine kinases DCC-2036 is effective for imatinib-resistant cells expressing T674I FIP1L1-PDGFRα. PLoS One. 2013 Aug 29;8(8):e73059. PMID: 24009732.

 

Eide CA, Adrian LT, Tyner JW, et al. The ABL switch control inhibitor DCC-2036 is active against the chronic myeloid leukemia mutant BCR-ABLT315I and exhibits a narrow resistance profile. Cancer Res. 2011 May 1;71(9):3189-95. PMID: 21505103.

" "UN number: 3077     Class: 9     Packing Group: III

Proper shipping name: Environmentally hazardous substance, solid, n.o.s. (DCC-2036)"

LKT D0808 DCC-2036 10 mg 320.3 Abl inhibitor. DCC2036, Rebastinib 1020172-07-9 ≥98% 553.59 C30H28FN7O3 CC(C)(C)C1=NN(C(=C1)NC(=O)NC2=C(C=C(C=C2)OC3=CC(=NC=C3)C(=O)NC)F)C4=CC5=C(C=C4)N=CC=C5 Ambient -20°C "Shen Y, Shi X, Pan J. The conformational control inhibitor of tyrosine kinases DCC-2036 is effective for imatinib-resistant cells expressing T674I FIP1L1-PDGFRα. PLoS One. 2013 Aug 29;8(8):e73059. PMID: 24009732.

 

Eide CA, Adrian LT, Tyner JW, et al. The ABL switch control inhibitor DCC-2036 is active against the chronic myeloid leukemia mutant BCR-ABLT315I and exhibits a narrow resistance profile. Cancer Res. 2011 May 1;71(9):3189-95. PMID: 21505103.

" "UN number: 3077     Class: 9     Packing Group: III

Proper shipping name: Environmentally hazardous substance, solid, n.o.s. (DCC-2036)"

LKT D1722 Defactinib 5 mg 76.4 FAK inhibitor. VS-6063, PF-04554878 1073154-85-4 ≥98% 510.49 C20H21F3N8O3S CNC(=O)C1=CC=C(C=C1)NC2=NC=C(C(=N2)NCC3=NC=CN=C3N(C)S(=O)(=O)C)C(F)(F)F Ambient -20°C "Lee BY, Timpson P, Horvath LG, et al. FAK signaling in human cancer as a target for therapeutics. Pharmacol Ther. 2015 Feb;146C:132-149. PMID: 25316657.

 

Kang Y, Hu W, Ivan C, et al. Role of focal adhesion kinase in regulating YB-1-mediated paclitaxel resistance in ovarian cancer. J Natl Cancer Inst. 2013 Oct 2;105(19):1485-95. PMID: 24062525.

" Not dangerous goods.

LKT D1722 Defactinib 25 mg 275.3 FAK inhibitor. VS-6063, PF-04554878 1073154-85-4 ≥98% 510.49 C20H21F3N8O3S CNC(=O)C1=CC=C(C=C1)NC2=NC=C(C(=N2)NCC3=NC=CN=C3N(C)S(=O)(=O)C)C(F)(F)F Ambient -20°C "Lee BY, Timpson P, Horvath LG, et al. FAK signaling in human cancer as a target for therapeutics. Pharmacol Ther. 2015 Feb;146C:132-149. PMID: 25316657.

 

Kang Y, Hu W, Ivan C, et al. Role of focal adhesion kinase in regulating YB-1-mediated paclitaxel resistance in ovarian cancer. J Natl Cancer Inst. 2013 Oct 2;105(19):1485-95. PMID: 24062525.

" Not dangerous goods.

LKT D1722 Defactinib 100 mg 617.9 FAK inhibitor. VS-6063, PF-04554878 1073154-85-4 ≥98% 510.49 C20H21F3N8O3S CNC(=O)C1=CC=C(C=C1)NC2=NC=C(C(=N2)NCC3=NC=CN=C3N(C)S(=O)(=O)C)C(F)(F)F Ambient -20°C "Lee BY, Timpson P, Horvath LG, et al. FAK signaling in human cancer as a target for therapeutics. Pharmacol Ther. 2015 Feb;146C:132-149. PMID: 25316657.

 

Kang Y, Hu W, Ivan C, et al. Role of focal adhesion kinase in regulating YB-1-mediated paclitaxel resistance in ovarian cancer. J Natl Cancer Inst. 2013 Oct 2;105(19):1485-95. PMID: 24062525.

" Not dangerous goods.

LKT D1746 Deltarasin Hydrochloride Trihydrate 5 mg 140.5 PDEδ inhibitor. 1440898-82-7 ≥98% 778.1 C40H37N5O  3.3HCl  3H2O C1CNCCC1C(COC2=CC=C(C=C2)C3=NC4=CC=CC=C4N3CC5=CC=CC=C5)N6C7=CC=CC=C7N=C6C8=CC=CC=C8.Cl Ambient -20°C "Zimmermann G, Schultz-Fademrecht C, Küchler P, et al. Structure guided design and kinetic analysis of highly potent benzimidazole inhibitors targeting the PDEδ prenyl binding site. J Med Chem. 2014 Jun 26;57(12):5435-48. PMID: 24884780.

 

Zimmermann G, Papke B, Ismail S, et al. Small molecule inhibition of the KRAS-PDEδ interaction impairs oncogenic KRAS signalling. Nature. 2013 May 30;497(7451):638-42. PMID: 23698361.

" Not dangerous goods.

LKT D1746 Deltarasin Hydrochloride Trihydrate 10 mg 219.1 PDEδ inhibitor. 1440898-82-7 ≥98% 778.1 C40H37N5O  3.3HCl  3H2O C1CNCCC1C(COC2=CC=C(C=C2)C3=NC4=CC=CC=C4N3CC5=CC=CC=C5)N6C7=CC=CC=C7N=C6C8=CC=CC=C8.Cl Ambient -20°C "Zimmermann G, Schultz-Fademrecht C, Küchler P, et al. Structure guided design and kinetic analysis of highly potent benzimidazole inhibitors targeting the PDEδ prenyl binding site. J Med Chem. 2014 Jun 26;57(12):5435-48. PMID: 24884780.

 

Zimmermann G, Papke B, Ismail S, et al. Small molecule inhibition of the KRAS-PDEδ interaction impairs oncogenic KRAS signalling. Nature. 2013 May 30;497(7451):638-42. PMID: 23698361.

" Not dangerous goods.

LKT D3349 Dimebon Dihydrochloride 5 mg 106.8 AMPK activator, L-type Ca2+ channel and NMDA, histamine H1/2, α-adrenergic, 5-HT2C/5A/6 receptor antagonist. Dimebon 2HCl, Latrepirdine 97657-92-6 ≥98% 392.37 C21H25N3 HCl CC1=CC2=C(C=C1)N(C3=C2CN(CC3)C)CCC4=CN=C(C=C4)C.Cl.Cl Ambient -20°C "Coughlan KS, Mitchem MR, Hogg MC, et al. ""Preconditioning"" with latrepirdine, an adenosine 5'-monophosphate-activated protein kinase activator, delays amyotrophic lateral sclerosis progression in SOD1(G93A) mice. Neurobiol Aging. 2015 Feb;36(2):1140-50. PMID: 25443289.

 

Shevtsova EF, Vinogradova DV, Kireeva EG, et al. Dimebon attenuates the Aβ-induced mitochondrial permeabilization. Curr Alzheimer Res. 2014;11(5):422-9. PMID: 24801220.

 

Weisová P, Alvarez SP, Kilbride SM, et al. Latrepirdine is a potent activator of AMP-activated protein kinase and reduces neuronal excitability. Transl Psychiatry. 2013 Oct 22;3:e317. PMID: 24150226.

 

Steele JW, Gandy S. Latrepirdine (Dimebon®), a potential Alzheimer therapeutic, regulates autophagy and neuropathology in an Alzheimer mouse model. Autophagy. 2013 Apr;9(4):617-8. PMID: 23380933.

 

Wu J, Li Q, Bezprozvanny I. Evaluation of Dimebon in cellular model of Huntington's disease. Mol Neurodegener. 2008 Oct 21;3:15. PMID: 18939977.

 

Grigorev VV, Dranyi OA, Bachurin SO. Comparative study of action mechanisms of dimebon and memantine on AMPA- and NMDA-subtypes glutamate receptors in rat cerebral neurons. Bull Exp Biol Med. 2003 Nov;136(5):474-7. PMID: 14968164.

" Not dangerous goods.

LKT D3349 Dimebon Dihydrochloride 10 mg 163 AMPK activator, L-type Ca2+ channel and NMDA, histamine H1/2, α-adrenergic, 5-HT2C/5A/6 receptor antagonist. Dimebon 2HCl, Latrepirdine 97657-92-6 ≥98% 392.37 C21H25N3 HCl CC1=CC2=C(C=C1)N(C3=C2CN(CC3)C)CCC4=CN=C(C=C4)C.Cl.Cl Ambient -20°C "Coughlan KS, Mitchem MR, Hogg MC, et al. ""Preconditioning"" with latrepirdine, an adenosine 5'-monophosphate-activated protein kinase activator, delays amyotrophic lateral sclerosis progression in SOD1(G93A) mice. Neurobiol Aging. 2015 Feb;36(2):1140-50. PMID: 25443289.

 

Shevtsova EF, Vinogradova DV, Kireeva EG, et al. Dimebon attenuates the Aβ-induced mitochondrial permeabilization. Curr Alzheimer Res. 2014;11(5):422-9. PMID: 24801220.

 

Weisová P, Alvarez SP, Kilbride SM, et al. Latrepirdine is a potent activator of AMP-activated protein kinase and reduces neuronal excitability. Transl Psychiatry. 2013 Oct 22;3:e317. PMID: 24150226.

 

Steele JW, Gandy S. Latrepirdine (Dimebon®), a potential Alzheimer therapeutic, regulates autophagy and neuropathology in an Alzheimer mouse model. Autophagy. 2013 Apr;9(4):617-8. PMID: 23380933.

 

Wu J, Li Q, Bezprozvanny I. Evaluation of Dimebon in cellular model of Huntington's disease. Mol Neurodegener. 2008 Oct 21;3:15. PMID: 18939977.

 

Grigorev VV, Dranyi OA, Bachurin SO. Comparative study of action mechanisms of dimebon and memantine on AMPA- and NMDA-subtypes glutamate receptors in rat cerebral neurons. Bull Exp Biol Med. 2003 Nov;136(5):474-7. PMID: 14968164.

" Not dangerous goods.

LKT D3352 Dinaciclib 5 mg 123.6 BRD binding agent, CDK1/2/5/9 inhibitor. SCH 727965 779353-01-4 ≥98% 396.49 C21H28N6O2 CCC1=C2N=C(C=C(N2N=C1)NCC3=C[N+](=CC=C3)[O-])N4CCCCC4CCO Ambient -20°C "Flynn J, Jones J, Johnson AJ, et al. Dinaciclib is a novel cyclin dependent kinase inhibitor with significant clinical activity in relapsed and refractory chronic lymphocytic leukemia. Leukemia. 2015 Feb 24. [Epub ahead of print]. PMID: 25708835.

 

Martin MP, Olesen SH, Georg GI, et al. Cyclin-dependent kinase inhibitor dinaciclib interacts with the acetyl-lysine recognition site of bromodomains. ACS Chem Biol. 2013 Nov 15;8(11):2360-5. PMID: 24007471.

 

Gojo I, Sadowska M, Walker A, et al. Clinical and laboratory studies of the novel cyclin-dependent kinase inhibitor dinaciclib (SCH 727965) in acute leukemias. Cancer Chemother Pharmacol. 2013 Oct;72(4):897-908. PMID: 23949430.

 

Feldmann G, Mishra A, Bisht S, et al. Cyclin-dependent kinase inhibitor Dinaciclib (SCH727965) inhibits pancreatic cancer growth and progression in murine xenograft models. Cancer Biol Ther. 2011 Oct 1;12(7):598-609. PMID: 21768779.

" Not dangerous goods.

LKT D3352 Dinaciclib 10 mg 193.2 BRD binding agent, CDK1/2/5/9 inhibitor. SCH 727965 779353-01-4 ≥98% 396.49 C21H28N6O2 CCC1=C2N=C(C=C(N2N=C1)NCC3=C[N+](=CC=C3)[O-])N4CCCCC4CCO Ambient -20°C "Flynn J, Jones J, Johnson AJ, et al. Dinaciclib is a novel cyclin dependent kinase inhibitor with significant clinical activity in relapsed and refractory chronic lymphocytic leukemia. Leukemia. 2015 Feb 24. [Epub ahead of print]. PMID: 25708835.

 

Martin MP, Olesen SH, Georg GI, et al. Cyclin-dependent kinase inhibitor dinaciclib interacts with the acetyl-lysine recognition site of bromodomains. ACS Chem Biol. 2013 Nov 15;8(11):2360-5. PMID: 24007471.

 

Gojo I, Sadowska M, Walker A, et al. Clinical and laboratory studies of the novel cyclin-dependent kinase inhibitor dinaciclib (SCH 727965) in acute leukemias. Cancer Chemother Pharmacol. 2013 Oct;72(4):897-908. PMID: 23949430.

 

Feldmann G, Mishra A, Bisht S, et al. Cyclin-dependent kinase inhibitor Dinaciclib (SCH727965) inhibits pancreatic cancer growth and progression in murine xenograft models. Cancer Biol Ther. 2011 Oct 1;12(7):598-609. PMID: 21768779.

" Not dangerous goods.

LKT D8276 Dutasteride 5 mg 84.3 5-α-Reductase inhibitor. Avodart 164656-23-9 ≥98% 528.53 C27H30F6N2O2 CC12CCC3C(C1CCC2C(=O)NC4=C(C=CC(=C4)C(F)(F)F)C(F)(F)F)CCC5C3(C=CC(=O)N5)C Ambient -20°C "Tsujimura A, Fukuhara S, Soda T, et al. Histologic evaluation of human benign prostatic hyperplasia treated by dutasteride: a study by xenograft model with improved severe combined immunodeficient mice. Urology. 2015 Jan;85(1):274.e1-8. PMID: 25444635.

 

Barkin J. Review of dutasteride/tamsulosin fixed-dose combination for the treatment of benign prostatic hyperplasia: efficacy, safety, and patient acceptability. Patient Prefer Adherence. 2011;5:483-90. PMID: 22003286.

 

Arena F. Dutasteride in the treatment of hormone refractory prostate cancer. Minerva Urol Nefrol. 2008 Jun;60(2):71-6. PMID: 18500220.

" Not dangerous goods.

LKT D8276 Dutasteride 25 mg 280.9 5-α-Reductase inhibitor. Avodart 164656-23-9 ≥98% 528.53 C27H30F6N2O2 CC12CCC3C(C1CCC2C(=O)NC4=C(C=CC(=C4)C(F)(F)F)C(F)(F)F)CCC5C3(C=CC(=O)N5)C Ambient -20°C "Tsujimura A, Fukuhara S, Soda T, et al. Histologic evaluation of human benign prostatic hyperplasia treated by dutasteride: a study by xenograft model with improved severe combined immunodeficient mice. Urology. 2015 Jan;85(1):274.e1-8. PMID: 25444635.

 

Barkin J. Review of dutasteride/tamsulosin fixed-dose combination for the treatment of benign prostatic hyperplasia: efficacy, safety, and patient acceptability. Patient Prefer Adherence. 2011;5:483-90. PMID: 22003286.

 

Arena F. Dutasteride in the treatment of hormone refractory prostate cancer. Minerva Urol Nefrol. 2008 Jun;60(2):71-6. PMID: 18500220.

" Not dangerous goods.

LKT E4912 EMD 1214063 5 mg 287.6 c-MET inhibitor. EMD1214063, MSC2156119J 1100598-32-0 ≥98% 492.57 C29H28N6O2 CN1CCC(CC1)COC2=CN=C(N=C2)C3=CC(=CC=C3)CN4C(=O)C=CC(=N4)C5=CC=CC(=C5)C#N Ambient "Bladt F, Friese-Hamim M, Ihling C, et al. The c-Met Inhibitor MSC2156119J Effectively Inhibits Tumor Growth in Liver Cancer Models. Cancers (Basel). 2014 Aug 19;6(3):1736-52. PMID: 25256830.

 

Bladt F, Faden B, Friese-Hamim M, et al. EMD 1214063 and EMD 1204831 constitute a new class of potent and highly selective c-Met inhibitors. Clin Cancer Res. 2013 Jun 1;19(11):2941-51. PMID: 23553846.

" Not dangerous goods.

LKT E4912 EMD 1214063 10 mg 460.6 c-MET inhibitor. EMD1214063, MSC2156119J 1100598-32-0 ≥98% 492.57 C29H28N6O2 CN1CCC(CC1)COC2=CN=C(N=C2)C3=CC(=CC=C3)CN4C(=O)C=CC(=N4)C5=CC=CC(=C5)C#N Ambient "Bladt F, Friese-Hamim M, Ihling C, et al. The c-Met Inhibitor MSC2156119J Effectively Inhibits Tumor Growth in Liver Cancer Models. Cancers (Basel). 2014 Aug 19;6(3):1736-52. PMID: 25256830.

 

Bladt F, Faden B, Friese-Hamim M, et al. EMD 1214063 and EMD 1204831 constitute a new class of potent and highly selective c-Met inhibitors. Clin Cancer Res. 2013 Jun 1;19(11):2941-51. PMID: 23553846.

" Not dangerous goods.

LKT F6803 FRAX486 5 mg 155.1 PAK inhibitor.Smo inhibitor. 1232030-35-1 ≥98% 522.4 C25H23Cl2FN6O 1/2H2O CCN1C2=NC(=NC=C2C=C(C1=O)C3=C(C=C(C=C3)Cl)Cl)NC4=CC(=C(C=C4)N5CCNCC5)F Ambient "Hayashi-Takagi A, Araki Y, Nakamura M, et al. PAKs inhibitors ameliorate schizophrenia-associated dendritic spine deterioration in vitro and in vivo during late adolescence. Proc Natl Acad Sci U S A. 2014 Apr 29;111(17):6461-6. PMID: 24706880.

 

Dolan BM, Duron SG, Campbell DA, et al. Rescue of fragile X syndrome phenotypes in Fmr1 KO mice by the small-molecule PAK inhibitor FRAX486. Proc Natl Acad Sci U S A. 2013 Apr 2;110(14):5671-6. PMID: 23509247.

" Not dangerous goods.

LKT F6803 FRAX486 10 mg 241.6 PAK inhibitor.Smo inhibitor. 1232030-35-1 ≥98% 522.4 C25H23Cl2FN6O 1/2H2O CCN1C2=NC(=NC=C2C=C(C1=O)C3=C(C=C(C=C3)Cl)Cl)NC4=CC(=C(C=C4)N5CCNCC5)F Ambient "Hayashi-Takagi A, Araki Y, Nakamura M, et al. PAKs inhibitors ameliorate schizophrenia-associated dendritic spine deterioration in vitro and in vivo during late adolescence. Proc Natl Acad Sci U S A. 2014 Apr 29;111(17):6461-6. PMID: 24706880.

 

Dolan BM, Duron SG, Campbell DA, et al. Rescue of fragile X syndrome phenotypes in Fmr1 KO mice by the small-molecule PAK inhibitor FRAX486. Proc Natl Acad Sci U S A. 2013 Apr 2;110(14):5671-6. PMID: 23509247.

" Not dangerous goods.

LKT G1408 GDC-0449 25 mg 50.6 Smo inhibitor. GDC0449, Vismodegib 879085-55-9 ≥98% 421.3 C19H14Cl2N2O3S CS(=O)(=O)C1=CC(=C(C=C1)C(=O)NC2=CC(=C(C=C2)Cl)C3=CC=CC=N3)Cl Ambient -20°C "Islam SS, Mokhtari RB, Noman AS, et al. Sonic hedgehog (Shh) signaling promotes tumorigenicity and stemness via activation of epithelial-to-mesenchymal transition (EMT) in bladder cancer. Mol Carcinog. 2015 Mar 1. [Epub ahead of print]. PMID: 25728352.

 

Erdem GU, Sendur MA, Ozdemir NY, et al. A comprehensive review of the role of Hedgehog pathway and Vismodegib in the management of Basal Cell Carcinoma. Curr Med Res Opin. 2015 Feb 17:1-45. PMID: 25690490.

 

Kim EJ, Sahai V, Abel EV, et al. Pilot clinical trial of hedgehog pathway inhibito GDC-0449 (vismodegib) in combination with gemcitabine in patients with metastatic pancreatic adenocarcinoma. Clin Cancer Res. 2014 Dec 1;20(23):5937-45. PMID: 25278454.

" Not dangerous goods.

LKT G1408 GDC-0449 100 mg 143.9 Smo inhibitor. GDC0449, Vismodegib 879085-55-9 ≥98% 421.3 C19H14Cl2N2O3S CS(=O)(=O)C1=CC(=C(C=C1)C(=O)NC2=CC(=C(C=C2)Cl)C3=CC=CC=N3)Cl Ambient -20°C "Islam SS, Mokhtari RB, Noman AS, et al. Sonic hedgehog (Shh) signaling promotes tumorigenicity and stemness via activation of epithelial-to-mesenchymal transition (EMT) in bladder cancer. Mol Carcinog. 2015 Mar 1. [Epub ahead of print]. PMID: 25728352.

 

Erdem GU, Sendur MA, Ozdemir NY, et al. A comprehensive review of the role of Hedgehog pathway and Vismodegib in the management of Basal Cell Carcinoma. Curr Med Res Opin. 2015 Feb 17:1-45. PMID: 25690490.

 

Kim EJ, Sahai V, Abel EV, et al. Pilot clinical trial of hedgehog pathway inhibitor DC-0449 (vismodegib) in combination with gemcitabine in patients with metastatic pancreatic adenocarcinoma. Clin Cancer Res. 2014 Dec 1;20(23):5937-45. PMID: 25278454.

" Not dangerous goods.

LKT G4662 GLPG-0634 5 mg 148.3 JAK1 inhibitor. GLPG0634, Filgotinib 1206161-97-8 ≥98% 425.5 C21H23N5O3S "c1cc(n2c(c1)nc(n2)NC(=O)C3CC3)c4ccc(cc4)CN5CCS(=O)(=O)CC5

" Ambient -20°C "Namour F, Diderichsen PM, Cox E, et al. Pharmacokinetics and Pharmacokinetic/Pharmacodynamic Modeling of Filgotinib (GLPG0634), a Selective JAK1 Inhibitor, in Support of Phase IIB Dose Selection. Clin Pharmacokinet. 2015 Feb 14. [Epub ahead of print]. PMID: 25681059.

 

Menet CJ, Fletcher SR, Van Lommen G, et al. Triazolopyridines as selective JAK1 inhibitors: from hit identification to GLPG0634. J Med Chem. 2014 Nov 26;57(22):9323-42. PMID: 25369270.

 

Norman P. Selective JAK inhibitors in development for rheumatoid arthritis. Expert Opin Investig Drugs. 2014 Aug;23(8):1067-77. PMID: 24818516.

" Not dangerous goods.

LKT G4662 GLPG-0634 10 mg 230.4 JAK1 inhibitor. GLPG0634, Filgotinib 1206161-97-8 ≥98% 425.5 C21H23N5O3S "c1cc(n2c(c1)nc(n2)NC(=O)C3CC3)c4ccc(cc4)CN5CCS(=O)(=O)CC5

" Ambient -20°C "Namour F, Diderichsen PM, Cox E, et al. Pharmacokinetics and Pharmacokinetic/Pharmacodynamic Modeling of Filgotinib (GLPG0634), a Selective JAK1 Inhibitor, in Support of Phase IIB Dose Selection. Clin Pharmacokinet. 2015 Feb 14. [Epub ahead of print]. PMID: 25681059.

 

Menet CJ, Fletcher SR, Van Lommen G, et al. Triazolopyridines as selective JAK1 inhibitors: from hit identification to GLPG0634. J Med Chem. 2014 Nov 26;57(22):9323-42. PMID: 25369270.

 

Norman P. Selective JAK inhibitors in development for rheumatoid arthritis. Expert Opin Investig Drugs. 2014 Aug;23(8):1067-77. PMID: 24818516.

" Not dangerous goods.

LKT G5216 GNE-7915 5 mg 132.6 LRRK2 inhibitor. GNE7915 1351761-44-8 ≥98% 443.4 C19H21F4N5O3 Ambient -20°C "Kavanagh ME, Doddareddy MR, Kassiou M. The development of CNS-active LRRK2 inhibitors using property-directed optimisation. Bioorg Med Chem Lett. 2013 Jul 1;23(13):3690-6. PMID: 23721803.

 

Estrada AA, Liu X, Baker-Glenn C, et al. Discovery of highly potent, selective, and brain-penetrable leucine-rich repeat kinase 2 (LRRK2) small molecule inhibitors. J Med Chem. 2012 Nov 26;55(22):9416-33. PMID: 22985112.

" Not dangerous goods.

LKT G5216 GNE-7915 10 mg 207.9 LRRK2 inhibitor. GNE7915 1351761-44-8 ≥98% 443.4 C19H21F4N5O3 Ambient -20°C "Kavanagh ME, Doddareddy MR, Kassiou M. The development of CNS-active LRRK2 inhibitors using property-directed optimisation. Bioorg Med Chem Lett. 2013 Jul 1;23(13):3690-6. PMID: 23721803.

 

Estrada AA, Liu X, Baker-Glenn C, et al. Discovery of highly potent, selective, and brain-penetrable leucine-rich repeat kinase 2 (LRRK2) small molecule inhibitors. J Med Chem. 2012 Nov 26;55(22):9416-33. PMID: 22985112.

" Not dangerous goods.

LKT G7232 GS-9973 5 mg 140.5 Syk inhibitor. GS9973, Entospletinib 1229208-44-9 ≥98% 411.46 C23H21N7O "c1cc(ccc1Nc2c3nccn3cc(n2)c4ccc5cn[nH]c5c4)N6CCOCC6

" Ambient -20°C "Sharman J, Hawkins M, Kolibaba K, et al. An open-label phase 2 trial of entospletinib (GS-9973), a selective Syk inhibitor, in chronic lymphocytic leukemia. Blood. 2015 Feb 18. Epub ahead of print]. PMID: 25696919.

 

Currie KS, Kropf JE, Lee T, et al. Discovery of GS-9973, a selective and orally efficacious inhibitor of spleen tyrosine kinase. J Med Chem. 2014 May 8;57(9):3856-73. PMID: 24779514.

 

Burke RT, Meadows S, Loriaux MM, et al. A potential therapeutic strategy for chronic lymphocytic leukemia by combining Idelalisib and GS-9973, a novel spleen tyrosine kinase (Syk) inhibitor. Oncotarget. 2014 Feb 28;5(4):908-15. PMID: 24659719.

" Not dangerous goods.

LKT G7232 GS-9973 10 mg 219.1 Syk inhibitor. GS9973, Entospletinib 1229208-44-9 ≥98% 411.46 C23H21N7O "c1cc(ccc1Nc2c3nccn3cc(n2)c4ccc5cn[nH]c5c4)N6CCOCC6

" Ambient -20°C "Sharman J, Hawkins M, Kolibaba K, et al. An open-label phase 2 trial of entospletinib (GS-9973), a selective Syk inhibitor, in chronic lymphocytic leukemia. Blood. 2015 Feb 18. Epub ahead of print]. PMID: 25696919.

 

Currie KS, Kropf JE, Lee T, et al. Discovery of GS-9973, a selective and orally efficacious inhibitor of spleen tyrosine kinase. J Med Chem. 2014 May 8;57(9):3856-73. PMID: 24779514.

 

Burke RT, Meadows S, Loriaux MM, et al. A potential therapeutic strategy for chronic lymphocytic leukemia by combining Idelalisib and GS-9973, a novel spleen tyrosine kinase (Syk) inhibitor. Oncotarget. 2014 Feb 28;5(4):908-15. PMID: 24659719.

" Not dangerous goods.

LKT G7444 GSK-1070916 5 mg 163 AurKB/C inhibitor. 942918-07-2 ≥98% 507.63 C30H33N7O "CCn1cc(c(n1)c2ccc(cc2)NC(=O)N(C)C)c3ccnc4c3cc([nH]4)c5cccc(c5)CN(C)C

" Ambient -20°C "Adams ND, Adams JL, Burgess JL, et al. Discovery of GSK1070916, a potent and selective inhibitor of Aurora B/C kinase. J Med Chem. 2010 May 27;53(10):3973-4001. PMID: 20420387.

 

Hardwicke MA, Oleykowski CA, Plant R, et al. GSK1070916, a potent Aurora B/C kinase inhibitor with broad antitumor activity in tissue culture cells and human tumor xenograft models. Mol Cancer Ther. 2009 Jul;8(7):1808-17. PMID: 19567821.

" "UN number: 3077     Class: 9     Packing Group: III

Proper shipping name: Environmentally hazardous substance, solid, n.o.s. (GSK-1070916)"

LKT G7444 GSK-1070916 10 mg 256.2 AurKB/C inhibitor. 942918-07-2 ≥98% 507.63 C30H33N7O "CCn1cc(c(n1)c2ccc(cc2)NC(=O)N(C)C)c3ccnc4c3cc([nH]4)c5cccc(c5)CN(C)C

" Ambient -20°C "Adams ND, Adams JL, Burgess JL, et al. Discovery of GSK1070916, a potent and selective inhibitor of Aurora B/C kinase. J Med Chem. 2010 May 27;53(10):3973-4001. PMID: 20420387.

 

Hardwicke MA, Oleykowski CA, Plant R, et al. GSK1070916, a potent Aurora B/C kinase inhibitor with broad antitumor activity in tissue culture cells and human tumor xenograft models. Mol Cancer Ther. 2009 Jul;8(7):1808-17. PMID: 19567821.

" "UN number: 3077     Class: 9     Packing Group: III

Proper shipping name: Environmentally hazardous substance, solid, n.o.s. (GSK-1070916)"

LKT G7240 GSK-2830371 5 mg 143.9 Wip1 inhibitor. 1404456-53-6 ≥98% 461.02 C23H29ClN4O2S Ambient -20°C "Richter M, Dayaram T, Gilmartin AG, et al. WIP1 Phosphatase as a Potential Therapeutic Target in Neuroblastoma. PLoS One. 2015 Feb 6;10(2):e0115635. PMID: 25658463.

 

Gilmartin AG, Faitg TH, Richter M, et al. Allosteric Wip1 phosphatase inhibition through flap-subdomain interaction. Nat Chem Biol. 2014 Mar;10(3):181-7. PMID: 24390428.

" Not dangerous goods.

LKT G7240 GSK-2830371 10 mg 224.7 Wip1 inhibitor. 1404456-53-6 ≥98% 461.02 C23H29ClN4O2S Ambient -20°C "Richter M, Dayaram T, Gilmartin AG, et al. WIP1 Phosphatase as a Potential Therapeutic Target in Neuroblastoma. PLoS One. 2015 Feb 6;10(2):e0115635. PMID: 25658463.

 

Gilmartin AG, Faitg TH, Richter M, et al. Allosteric Wip1 phosphatase inhibition through flap-subdomain interaction. Nat Chem Biol. 2014 Mar;10(3):181-7. PMID: 24390428.

" Not dangerous goods.

LKT G7241 GSK-461364 5 mg 143.9 PLK1 inhibitor. 929095-18-1 ≥98% 543.6 C27H28F3N5O2S "CC(c1ccccc1C(F)(F)F)Oc2cc(sc2C(=O)N)n3cnc4c3cc(cc4)CN5CCN(CC5)C

" Ambient -20°C "Yim H. Current clinical trials with polo-like kinase 1 inhibitors in solid tumors. Anticancer Drugs. 2013 Nov;24(10):999-1006. PMID: 23949254.

 

Pezuk JA, Brassesco MS, Morales AG, et al. Polo-like kinase 1 inhibition causes decreased proliferation by cell cycle arrest, leading to cell death in glioblastoma. Cancer Gene Ther. 2013 Sep;20(9):499-506. PMID: 23887645.

 

Olmos D, Barker D, Sharma R, et al. Phase I study of GSK461364, a specific and competitive Polo-like kinase 1 inhibitor, in patients with advanced solid malignancies. Clin Cancer Res. 2011 May 15;17(10):3420-30. PMID: 21459796.

" Not dangerous goods.

LKT G7241 GSK-461364 10 mg 224.7 PLK1 inhibitor. 929095-18-1 ≥98% 543.6 C27H28F3N5O2S "CC(c1ccccc1C(F)(F)F)Oc2cc(sc2C(=O)N)n3cnc4c3cc(cc4)CN5CCN(CC5)C

" Ambient -20°C "Yim H. Current clinical trials with polo-like kinase 1 inhibitors in solid tumors. Anticancer Drugs. 2013 Nov;24(10):999-1006. PMID: 23949254.

 

Pezuk JA, Brassesco MS, Morales AG, et al. Polo-like kinase 1 inhibition causes decreased proliferation by cell cycle arrest, leading to cell death in glioblastoma. Cancer Gene Ther. 2013 Sep;20(9):499-506. PMID: 23887645.

 

Olmos D, Barker D, Sharma R, et al. Phase I study of GSK461364, a specific and competitive Polo-like kinase 1 inhibitor, in patients with advanced solid malignancies. Clin Cancer Res. 2011 May 15;17(10):3420-30. PMID: 21459796.

" Not dangerous goods.

LKT G7242 GSK-690693 5 mg 143.9 Akt inhibitor. 937174-76-0 ≥98% 425.48 C21H27N7O3 "CCn1c2c(cnc(c2nc1c3c(non3)N)C#CC(C)(C)O)OCC4CCCNC4

" Ambient -20°C "Nguyen T, Coover RA, Verghese J, et al. Phenylalanine-Based Inactivator of AKT Kinase: Design, Synthesis, and Biological Evaluation. ACS Med Chem Lett. 2014 Mar 7;5(5):462-7. PMID: 24900862.

 

Carol H, Morton CL, Gorlick R, et al. Initial testing (stage 1) of the Akt inhibitor SK690693 by the pediatric preclinical testing program. Pediatr Blood Cancer. 2010 Dec 15;55(7):1329-37. PMID: 20740623.

 

Altomare DA, Zhang L, Deng J, et al. GSK690693 delays tumor onset and progression in genetically defined mouse models expressing activated Akt. Clin Cancer Res. 2010 Jan 15;16(2):486-96. PMID: 20075391.

" "UN number: 2811      Class: 6.1     Packing Group: III

Proper shipping name: Toxic solid, organic, n.o.s. (GSK-690693)"

LKT G7242 GSK-690693 10 mg 224.7 Akt inhibitor. 937174-76-0 ≥98% 425.48 C21H27N7O3 "CCn1c2c(cnc(c2nc1c3c(non3)N)C#CC(C)(C)O)OCC4CCCNC4

" Ambient -20°C "Nguyen T, Coover RA, Verghese J, et al. Phenylalanine-Based Inactivator of AKT Kinase: Design, Synthesis, and Biological Evaluation. ACS Med Chem Lett. 2014 Mar 7;5(5):462-7. PMID: 24900862.

 

Carol H, Morton CL, Gorlick R, et al. Initial testing (stage 1) of the Akt inhibitor SK690693 by the pediatric preclinical testing program. Pediatr Blood Cancer. 2010 Dec 15;55(7):1329-37. PMID: 20740623.

 

Altomare DA, Zhang L, Deng J, et al. GSK690693 delays tumor onset and progression in genetically defined mouse models expressing activated Akt. Clin Cancer Res. 2010 Jan 15;16(2):486-96. PMID: 20075391.

" "UN number: 2811      Class: 6.1     Packing Group: III

Proper shipping name: Toxic solid, organic, n.o.s. (GSK-690693)"

LKT H9862 Hypothemycin 1 mg 207.9 Polyketide found in Setophoma. 76958-67-3 ≥96% 378.37 C19H22O8 Ambient "El-Elimat T, Figueroa M, Raja HA, et al. Biosynthetically Distinct Cytotoxic Polyketides from Setophoma terrestris. European J Org Chem. 2015 Jan 1;2015(1):109-121. PMID: 25574154.

 

Xu L, Xue J, Wu P, et al. Antifungal activity of hypothemycin against Peronophythora litchii in vitro and in vivo. J Agric Food Chem. 2013 Oct 23;61(42):10091-5. PMID: 24106914.

 

Nishino M, Choy JW, Gushwa NN, et al. Hypothemycin, a fungal natural product, identifies therapeutic targets in Trypanosoma brucei [corrected]. Elife. 2013 Jul 9;2:e00712. PMID: 23853713.

" Not dangerous goods.

LKT H9862 Hypothemycin 5 mg 724.7 Polyketide found in Setophoma. 76958-67-3 ≥96% 378.37 C19H22O8 Ambient "El-Elimat T, Figueroa M, Raja HA, et al. Biosynthetically Distinct Cytotoxic Polyketides from Setophoma terrestris. European J Org Chem. 2015 Jan 1;2015(1):109-121. PMID: 25574154.

 

Xu L, Xue J, Wu P, et al. Antifungal activity of hypothemycin against Peronophythora litchii in vitro and in vivo. J Agric Food Chem. 2013 Oct 23;61(42):10091-5. PMID: 24106914.

 

Nishino M, Choy JW, Gushwa NN, et al. Hypothemycin, a fungal natural product, identifies therapeutic targets in Trypanosoma brucei [corrected]. Elife. 2013 Jul 9;2:e00712. PMID: 23853713.

" Not dangerous goods.

LKT I5210 INCB018424 5 mg 65.2 JAK1/2 inhibitor. Ruxolitinib 941678-49-5 ≥98% 306.37 C17H18N6 "c1c[nH]c2c1c(ncn2)c3cnn(c3)C(CC#N)C4CCCC4

" Ambient -20°C "Springuel L, Hornakova T, Losdyck E, et al. Cooperating JAK1 and JAK3 mutants increase resistance to JAK inhibitors. Blood. 2014 Dec 18;124(26):3924-31. PMID: 25352124.

 

Hazem SH, Shaker ME, Ashamallah SA, et al. The novel Janus kinase inhibitor ruxolitinib confers protection against carbon tetrachloride-induced hepatotoxicity via multiple mechanisms. Chem Biol Interact. 2014 Sep 5;220:116-27. PMID: 24973641.

 

Gavegnano C, Detorio M, Montero C, et al. Ruxolitinib and tofacitinib are potent and selective inhibitors of HIV-1 replication and virus reactivation in vitro. Antimicrob Agents Chemother. 2014;58(4):1977-86. PMID: 24419350.

" Not dangerous goods.

LKT I5210 INCB018424 25 mg 213.5 JAK1/2 inhibitor. Ruxolitinib 941678-49-5 ≥98% 306.37 C17H18N6 "c1c[nH]c2c1c(ncn2)c3cnn(c3)C(CC#N)C4CCCC4

" Ambient -20°C "Springuel L, Hornakova T, Losdyck E, et al. Cooperating JAK1 and JAK3 mutants increase resistance to JAK inhibitors. Blood. 2014 Dec 18;124(26):3924-31. PMID: 25352124.

 

Hazem SH, Shaker ME, Ashamallah SA, et al. The novel Janus kinase inhibitor ruxolitinib confers protection against carbon tetrachloride-induced hepatotoxicity via multiple mechanisms. Chem Biol Interact. 2014 Sep 5;220:116-27. PMID: 24973641.

 

Gavegnano C, Detorio M, Montero C, et al. Ruxolitinib and tofacitinib are potent and selective inhibitors of HIV-1 replication and virus reactivation in vitro. Antimicrob Agents Chemother. 2014;58(4):1977-86. PMID: 24419350.

" Not dangerous goods.

LKT I5210 INCB018424 50 mg 331.5 JAK1/2 inhibitor. Ruxolitinib 941678-49-5 ≥98% 306.37 C17H18N6 "c1c[nH]c2c1c(ncn2)c3cnn(c3)C(CC#N)C4CCCC4

" Ambient -20°C "Springuel L, Hornakova T, Losdyck E, et al. Cooperating JAK1 and JAK3 mutants increase resistance to JAK inhibitors. Blood. 2014 Dec 18;124(26):3924-31. PMID: 25352124.

 

Hazem SH, Shaker ME, Ashamallah SA, et al. The novel Janus kinase inhibitor ruxolitinib confers protection against carbon tetrachloride-induced hepatotoxicity via multiple mechanisms. Chem Biol Interact. 2014 Sep 5;220:116-27. PMID: 24973641.

 

Gavegnano C, Detorio M, Montero C, et al. Ruxolitinib and tofacitinib are potent and selective inhibitors of HIV-1 replication and virus reactivation in vitro. Antimicrob Agents Chemother. 2014;58(4):1977-86. PMID: 24419350.

" Not dangerous goods.

LKT L0528 LBH-589 5 mg 56.2 HDAC1/2/3/11 inhibitor. LBH589, Panobinostat 404950-80-7 ≥98% 349.43 C21H23N3O2 "Cc1c(c2ccccc2[nH]1)CCNCc3ccc(cc3)C=CC(=O)NO

" Ambient -20°C "Andreu-Vieyra CV, Berenson JR. The potential of panobinostat as a treatment option in patients with relapsed and refractory multiple myeloma. Ther Adv Hematol. 2014 Dec;5(6):197-210. PMID: 25469210.

 

Rhodes LV, Tate CR, Segar HC, et al. Suppression of triple-negative breast cancer metastasis by pan-DAC inhibitor panobinostat via inhibition of ZEB family of EMT master regulators. Breast Cancer Res Treat. 2014 Jun;145(3):593-604. PMID: 24810497.

 

Henrici A, Montalbano R, Neureiter D, et al. The pan-deacetylase inhibitor panobinostat suppresses the expression of oncogenic miRNAs in hepatocellular carcinoma cell lines. Mol Carcinog. 2013 Dec 23. [Epub ahead of print]. PMID: 24375802.

" Not dangerous goods.

LKT L0528 LBH-589 25 mg 185.4 HDAC1/2/3/11 inhibitor. LBH589, Panobinostat 404950-80-7 ≥98% 349.43 C21H23N3O2 "Cc1c(c2ccccc2[nH]1)CCNCc3ccc(cc3)C=CC(=O)NO

" Ambient -20°C "Andreu-Vieyra CV, Berenson JR. The potential of panobinostat as a treatment option in patients with relapsed and refractory multiple myeloma. Ther Adv Hematol. 2014 Dec;5(6):197-210. PMID: 25469210.

 

Rhodes LV, Tate CR, Segar HC, et al. Suppression of triple-negative breast cancer metastasis by pan-DAC inhibitor panobinostat via inhibition of ZEB family of EMT master regulators. Breast Cancer Res Treat. 2014 Jun;145(3):593-604. PMID: 24810497.

 

Henrici A, Montalbano R, Neureiter D, et al. The pan-deacetylase inhibitor panobinostat suppresses the expression of oncogenic miRNAs in hepatocellular carcinoma cell lines. Mol Carcinog. 2013 Dec 23. [Epub ahead of print]. PMID: 24375802.

" Not dangerous goods.

LKT L0528 LBH-589 50 mg 280.9 HDAC1/2/3/11 inhibitor. LBH589, Panobinostat 404950-80-7 ≥98% 349.43 C21H23N3O2 "Cc1c(c2ccccc2[nH]1)CCNCc3ccc(cc3)C=CC(=O)NO

" Ambient -20°C "Andreu-Vieyra CV, Berenson JR. The potential of panobinostat as a treatment option in patients with relapsed and refractory multiple myeloma. Ther Adv Hematol. 2014 Dec;5(6):197-210. PMID: 25469210.

 

Rhodes LV, Tate CR, Segar HC, et al. Suppression of triple-negative breast cancer metastasis by pan-DAC inhibitor panobinostat via inhibition of ZEB family of EMT master regulators. Breast Cancer Res Treat. 2014 Jun;145(3):593-604. PMID: 24810497.

 

Henrici A, Montalbano R, Neureiter D, et al. The pan-deacetylase inhibitor panobinostat suppresses the expression of oncogenic miRNAs in hepatocellular carcinoma cell lines. Mol Carcinog. 2013 Dec 23. [Epub ahead of print]. PMID: 24375802.

" Not dangerous goods.

LKT M2409 MGCD-0103 5 mg 50.6 HDAC inhibitor. Mocetinostat 726169-73-9 ≥98% 396.44 C23H20N6O "c1ccc(c(c1)N)NC(=O)c2ccc(cc2)CNc3nccc(n3)c4cccnc4

" Ambient -20°C "Nural-Guvener HF, Zakharova L, Nimlos J, et al. HDAC class I inhibitor, Mocetinostat, reverses cardiac fibrosis in heart failure and diminishes CD90+ cardiac myofibroblast activation. Fibrogenesis Tissue Repair. 2014 Jul 2;7:10. PMID: 25024745.

 

Kumar P, Tripathi S, Pandey KN. Histone deacetylase inhibitors modulate the transcriptional regulation of guanylyl cyclase/natriuretic peptide receptor-a gene: interactive roles of modified histones, histone acetyltransferase, p300, AND Sp1. J Biol Chem. 2014 Mar 7;289(10):6991-7002. PMID: 24451378.

 

El-Khoury V, Pierson S, Szwarcbart E, et al. Disruption of autophagy by the histone deacetylase inhibitor MGCD0103 and its therapeutic implication in B-cell chronic lymphocytic leukemia. Leukemia. 2014 Aug;28(8):1636-46. PMID: 24418989.

 

Cavasin MA, Demos-Davies K, Horn TR, et al. Selective class I histone deacetylase inhibition suppresses hypoxia-induced cardiopulmonary remodeling through an antiproliferative mechanism. Circ Res. 2012 Mar 2;110(5):739-48. PMID: 22282194.

 

Younes A, Oki Y, Bociek RG, et al. Mocetinostat for relapsed classical Hodgkin's lymphoma: an open-label, single-arm, phase 2 trial. Lancet Oncol. 2011 Dec;12(13):1222-8. PMID: 22033282.

" Not dangerous goods.

LKT M2409 MGCD-0103 25 mg 168.5 HDAC inhibitor. Mocetinostat 726169-73-9 ≥98% 396.44 C23H20N6O "c1ccc(c(c1)N)NC(=O)c2ccc(cc2)CNc3nccc(n3)c4cccnc4

" Ambient -20°C "Nural-Guvener HF, Zakharova L, Nimlos J, et al. HDAC class I inhibitor, Mocetinostat, reverses cardiac fibrosis in heart failure and diminishes CD90+ cardiac myofibroblast activation. Fibrogenesis Tissue Repair. 2014 Jul 2;7:10. PMID: 25024745.

 

Kumar P, Tripathi S, Pandey KN. Histone deacetylase inhibitors modulate the transcriptional regulation of guanylyl cyclase/natriuretic peptide receptor-a gene: interactive roles of modified histones, histone acetyltransferase, p300, AND Sp1. J Biol Chem. 2014 Mar 7;289(10):6991-7002. PMID: 24451378.

 

El-Khoury V, Pierson S, Szwarcbart E, et al. Disruption of autophagy by the histone deacetylase inhibitor MGCD0103 and its therapeutic implication in B-cell chronic lymphocytic leukemia. Leukemia. 2014 Aug;28(8):1636-46. PMID: 24418989.

 

Cavasin MA, Demos-Davies K, Horn TR, et al. Selective class I histone deacetylase inhibition suppresses hypoxia-induced cardiopulmonary remodeling through an antiproliferative mechanism. Circ Res. 2012 Mar 2;110(5):739-48. PMID: 22282194.

 

Younes A, Oki Y, Bociek RG, et al. Mocetinostat for relapsed classical Hodgkin's lymphoma: an open-label, single-arm, phase 2 trial. Lancet Oncol. 2011 Dec;12(13):1222-8. PMID: 22033282.

" Not dangerous goods.

LKT M2409 MGCD-0103 50 mg 252.8 HDAC inhibitor. Mocetinostat 726169-73-9 ≥98% 396.44 C23H20N6O "c1ccc(c(c1)N)NC(=O)c2ccc(cc2)CNc3nccc(n3)c4cccnc4

" Ambient -20°C "Nural-Guvener HF, Zakharova L, Nimlos J, et al. HDAC class I inhibitor, Mocetinostat, reverses cardiac fibrosis in heart failure and diminishes CD90+ cardiac myofibroblast activation. Fibrogenesis Tissue Repair. 2014 Jul 2;7:10. PMID: 25024745.

 

Kumar P, Tripathi S, Pandey KN. Histone deacetylase inhibitors modulate the transcriptional regulation of guanylyl cyclase/natriuretic peptide receptor-a gene: interactive roles of modified histones, histone acetyltransferase, p300, AND Sp1. J Biol Chem. 2014 Mar 7;289(10):6991-7002. PMID: 24451378.

 

El-Khoury V, Pierson S, Szwarcbart E, et al. Disruption of autophagy by the histone deacetylase inhibitor MGCD0103 and its therapeutic implication in B-cell chronic lymphocytic leukemia. Leukemia. 2014 Aug;28(8):1636-46. PMID: 24418989.

 

Cavasin MA, Demos-Davies K, Horn TR, et al. Selective class I histone deacetylase inhibition suppresses hypoxia-induced cardiopulmonary remodeling through an antiproliferative mechanism. Circ Res. 2012 Mar 2;110(5):739-48. PMID: 22282194.

 

Younes A, Oki Y, Bociek RG, et al. Mocetinostat for relapsed classical Hodgkin's lymphoma: an open-label, single-arm, phase 2 trial. Lancet Oncol. 2011 Dec;12(13):1222-8. PMID: 22033282.

" Not dangerous goods.

LKT M4102 MK-1775 5 mg 140.5 Wee1 inhibitor. 955365-80-7 ≥98% 500.6 C27H32N8O2 "CC(C)(c1cccc(n1)n2c3c(cnc(n3)Nc4ccc(cc4)N5CCN(CC5)C)c(=O)n2CC=C)O

" Ambient -20°C "Qi W, Xie C, Li C, et al. CHK1 plays a critical role in the anti-leukemic activity of the wee1 inhibitor MK-1775 in acute myeloid leukemia cells. J Hematol Oncol. 2014 Aug 1;7:53. PMID: 25084614.

 

Van Linden AA, Baturin D, Ford JB, et al. Inhibition of Wee1 sensitizes cancer cells to antimetabolite chemotherapeutics in vitro and in vivo, independent of p53 functionality. Mol Cancer Ther. 2013 Dec;12(12):2675-84. PMID: 24121103.

 

Hirai H, Iwasawa Y, Okada M, et al. Small-molecule inhibition of Wee1 kinase by MK-1775 selectively sensitizes p53-deficient tumor cells to DNA-damaging agents. Mol Cancer Ther. 2009 Nov;8(11):2992-3000. PMID: 19887545.

" Not dangerous goods.

LKT M4102 MK-1775 10 mg 219.1 Wee1 inhibitor. 955365-80-7 ≥98% 500.6 C27H32N8O2 "CC(C)(c1cccc(n1)n2c3c(cnc(n3)Nc4ccc(cc4)N5CCN(CC5)C)c(=O)n2CC=C)O

" Ambient -20°C "Qi W, Xie C, Li C, et al. CHK1 plays a critical role in the anti-leukemic activity of the wee1 inhibitor MK-1775 in acute myeloid leukemia cells. J Hematol Oncol. 2014 Aug 1;7:53. PMID: 25084614.

 

Van Linden AA, Baturin D, Ford JB, et al. Inhibition of Wee1 sensitizes cancer cells to antimetabolite chemotherapeutics in vitro and in vivo, independent of p53 functionality. Mol Cancer Ther. 2013 Dec;12(12):2675-84. PMID: 24121103.

 

Hirai H, Iwasawa Y, Okada M, et al. Small-molecule inhibition of Wee1 kinase by MK-1775 selectively sensitizes p53-deficient tumor cells to DNA-damaging agents. Mol Cancer Ther. 2009 Nov;8(11):2992-3000. PMID: 19887545.

" Not dangerous goods.

LKT M5877 Motesanib Diphosphate 5 mg 73.1 VEGFR, PDGFR, c-Kit, RET inhibitor. 857876-30-3 ≥98% 569.44 C22H23N5O 2H3O4P "CC1(CNc2c1ccc(c2)NC(=O)c3cccnc3NCc4ccncc4)C.OP(=O)(O)O.OP(=O)(O)O

" Ambient -20°C "Ellis PM, Al-Saleh K. Multitargeted anti-angiogenic agents and NSCLC: clinical update and future directions. Crit Rev Oncol Hematol. 2012 Oct;84(1):47-58. PMID: 22405734.

 

Coxon A, Ziegler B, Kaufman S, et al. Antitumor activity of motesanib alone and in combination with cisplatin or docetaxel in multiple human non-small-cell lung cancer xenograft models. Mol Cancer. 2012 Sep 19;11:70. PMID: 22992329.

 

Coxon A, Bready J, Kaufman S, et al. Anti-tumor activity of motesanib in a medullary thyroid cancer model. J Endocrinol Invest. 2012 Feb;35(2):181-90. PMID: 21422803.

 

Raghav KP, Blumenschein GR. Motesanib and advanced NSCLC: experiences and expectations. Expert Opin Investig Drugs. 2011 Jun;20(6):859-69. PMID: 21534718.

 

Polverino A, Coxon A, Starnes C, et al. AMG 706, an oral, multikinase inhibitor that selectively targets vascular endothelial growth factor, platelet-derived growth factor, and kit receptors, potently inhibits angiogenesis and induces regression in tumor xenografts. Cancer Res. 2006 Sep 1;66(17):8715-21. PMID: 16951187.

" "UN number: 3077     Class: 9     Packing Group: III

Proper shipping name: Environmentally hazardous substance, solid, n.o.s. (Motesanib diphosphate)"

LKT M5877 Motesanib Diphosphate 25 mg 252.8 VEGFR, PDGFR, c-Kit, RET inhibitor. 857876-30-3 ≥98% 569.44 C22H23N5O 2H3O4P "CC1(CNc2c1ccc(c2)NC(=O)c3cccnc3NCc4ccncc4)C.OP(=O)(O)O.OP(=O)(O)O

" Ambient -20°C "Ellis PM, Al-Saleh K. Multitargeted anti-angiogenic agents and NSCLC: clinical update and future directions. Crit Rev Oncol Hematol. 2012 Oct;84(1):47-58. PMID: 22405734.

 

Coxon A, Ziegler B, Kaufman S, et al. Antitumor activity of motesanib alone and in combination with cisplatin or docetaxel in multiple human non-small-cell lung cancer xenograft models. Mol Cancer. 2012 Sep 19;11:70. PMID: 22992329.

 

Coxon A, Bready J, Kaufman S, et al. Anti-tumor activity of motesanib in a medullary thyroid cancer model. J Endocrinol Invest. 2012 Feb;35(2):181-90. PMID: 21422803.

 

Raghav KP, Blumenschein GR. Motesanib and advanced NSCLC: experiences and expectations. Expert Opin Investig Drugs. 2011 Jun;20(6):859-69. PMID: 21534718.

 

Polverino A, Coxon A, Starnes C, et al. AMG 706, an oral, multikinase inhibitor that selectively targets vascular endothelial growth factor, platelet-derived growth factor, and kit receptors, potently inhibits angiogenesis and induces regression in tumor xenografts. Cancer Res. 2006 Sep 1;66(17):8715-21. PMID: 16951187.

" "UN number: 3077     Class: 9     Packing Group: III

Proper shipping name: Environmentally hazardous substance, solid, n.o.s. (Motesanib diphosphate)"

LKT M5877 Motesanib Diphosphate 50 mg 393.2 VEGFR, PDGFR, c-Kit, RET inhibitor. 857876-30-3 ≥98% 569.44 C22H23N5O 2H3O4P "CC1(CNc2c1ccc(c2)NC(=O)c3cccnc3NCc4ccncc4)C.OP(=O)(O)O.OP(=O)(O)O

" Ambient -20°C "Ellis PM, Al-Saleh K. Multitargeted anti-angiogenic agents and NSCLC: clinical update and future directions. Crit Rev Oncol Hematol. 2012 Oct;84(1):47-58. PMID: 22405734.

 

Coxon A, Ziegler B, Kaufman S, et al. Antitumor activity of motesanib alone and in combination with cisplatin or docetaxel in multiple human non-small-cell lung cancer xenograft models. Mol Cancer. 2012 Sep 19;11:70. PMID: 22992329.

 

Coxon A, Bready J, Kaufman S, et al. Anti-tumor activity of motesanib in a medullary thyroid cancer model. J Endocrinol Invest. 2012 Feb;35(2):181-90. PMID: 21422803.

 

Raghav KP, Blumenschein GR. Motesanib and advanced NSCLC: experiences and expectations. Expert Opin Investig Drugs. 2011 Jun;20(6):859-69. PMID: 21534718.

 

Polverino A, Coxon A, Starnes C, et al. AMG 706, an oral, multikinase inhibitor that selectively targets vascular endothelial growth factor, platelet-derived growth factor, and kit receptors, potently inhibits angiogenesis and induces regression in tumor xenografts. Cancer Res. 2006 Sep 1;66(17):8715-21. PMID: 16951187.

" "UN number: 3077     Class: 9     Packing Group: III

Proper shipping name: Environmentally hazardous substance, solid, n.o.s. (Motesanib diphosphate)"

LKT N5072 NMS-1286937 5 mg 151.7 PLK1 inhibitor. NMS1286937, NMS-P937 1034616-18-6 ≥98% 532.52 C24H27F3N8O3 "CN1CCN(CC1)c2ccc(c(c2)Nc3ncc4c(n3)-c5c(c(nn5CCO)C(=O)N)CC4)OC(F)(F)F

" Ambient -20°C "Sero V, Tavanti E, Vella S, et al. Targeting polo-like kinase 1 by NMS-P937 in osteosarcoma cell lines inhibits tumor cell growth and partially overcomes drug resistance. Invest New Drugs. 2014 Dec;32(6):1167-80. PMID: 25193492.

 

Casolaro A, Golay J, Albanese C, et al. The Polo-Like Kinase 1 (PLK1) inhibitor NMS-P937 is effective in a new model of disseminated primary CD56+ acute monoblastic leukaemia. PLoS One. 2013;8(3):e58424. PMID: 23520509.

 

Valsasina B, Beria I, Alli C, et al. NMS-P937, an orally available, specific small-molecule polo-like kinase 1 inhibitor with antitumor activity in solid and hematologic malignancies. Mol Cancer Ther. 2012 Apr;11(4):1006-16. PMID: 22319201.

 

Beria I, Bossi RT, Brasca MG, et al. NMS-P937, a 4,5-dihydro-1H-pyrazolo[4,3-h]quinazoline derivative as potent and selective Polo-like kinase 1 inhibitor. Bioorg Med Chem Lett. 2011 May 15;21(10):2969-74. PMID: 21470862.

" "UN number: 3077     Class: 9     Packing Group: III

Proper shipping name: Environmentally hazardous substance, solid, n.o.s. (NMS-1286937)"

LKT N5072 NMS-1286937 10 mg 230.4 PLK1 inhibitor. NMS1286937, NMS-P937 1034616-18-6 ≥98% 532.52 C24H27F3N8O3 "CN1CCN(CC1)c2ccc(c(c2)Nc3ncc4c(n3)-c5c(c(nn5CCO)C(=O)N)CC4)OC(F)(F)F

" Ambient -20°C "Sero V, Tavanti E, Vella S, et al. Targeting polo-like kinase 1 by NMS-P937 in osteosarcoma cell lines inhibits tumor cell growth and partially overcomes drug resistance. Invest New Drugs. 2014 Dec;32(6):1167-80. PMID: 25193492.

 

Casolaro A, Golay J, Albanese C, et al. The Polo-Like Kinase 1 (PLK1) inhibitor NMS-P937 is effective in a new model of disseminated primary CD56+ acute monoblastic leukaemia. PLoS One. 2013;8(3):e58424. PMID: 23520509.

 

Valsasina B, Beria I, Alli C, et al. NMS-P937, an orally available, specific small-molecule polo-like kinase 1 inhibitor with antitumor activity in solid and hematologic malignancies. Mol Cancer Ther. 2012 Apr;11(4):1006-16. PMID: 22319201.

 

Beria I, Bossi RT, Brasca MG, et al. NMS-P937, a 4,5-dihydro-1H-pyrazolo[4,3-h]quinazoline derivative as potent and selective Polo-like kinase 1 inhibitor. Bioorg Med Chem Lett. 2011 May 15;21(10):2969-74. PMID: 21470862.

" "UN number: 3077     Class: 9     Packing Group: III

Proper shipping name: Environmentally hazardous substance, solid, n.o.s. (NMS-1286937)"

LKT N8660 NVP-AUY922 5 mg 134.8 Isoxazole derivative; HSP90 inhibitor. VER-52296 747412-49-3 ≥98% 465.54 C26H31N3O5 "CCNC(=O)c1c(c(on1)c2cc(c(cc2O)O)C(C)C)c3ccc(cc3)CN4CCOCC4

" Ambient -20°C "Kim SH, Kang JG, Kim CS, et al. Novel Heat Shock Protein 90 Inhibitor NVP-AUY922 Synergizes With the Histone Deacetylase Inhibitor PXD101 in Induction of Death of Anaplastic Thyroid Carcinoma Cells. J Clin Endocrinol Metab. 2015 Feb;100(2):E253-61. PMID: 25389633.

 

Taniguchi H, Hasegawa H, Sasaki D, et al. Heat shock protein 90 inhibitor NVP-AUY922 exerts potent activity against adult T-cell leukemia-lymphoma cells. Cancer Sci. 2014 Dec;105(12):1601-8. PMID: 25263741.

 

Eccles SA, Massey A, Raynaud FI, et al. NVP-AUY922: a novel heat shock protein 90 inhibitor active against xenograft tumor growth, angiogenesis, and metastasis. Cancer Res. 2008 Apr 15;68(8):2850-60. PMID: 18413753.

" Not dangerous goods.

LKT N8660 NVP-AUY922 10 mg 207.9 Isoxazole derivative; HSP90 inhibitor. VER-52296 747412-49-3 ≥98% 465.54 C26H31N3O5 "CCNC(=O)c1c(c(on1)c2cc(c(cc2O)O)C(C)C)c3ccc(cc3)CN4CCOCC4

" Ambient -20°C "Kim SH, Kang JG, Kim CS, et al. Novel Heat Shock Protein 90 Inhibitor NVP-AUY922 Synergizes With the Histone Deacetylase Inhibitor PXD101 in Induction of Death of Anaplastic Thyroid Carcinoma Cells. J Clin Endocrinol Metab. 2015 Feb;100(2):E253-61. PMID: 25389633.

 

Taniguchi H, Hasegawa H, Sasaki D, et al. Heat shock protein 90 inhibitor NVP-AUY922 exerts potent activity against adult T-cell leukemia-lymphoma cells. Cancer Sci. 2014 Dec;105(12):1601-8. PMID: 25263741.

 

Eccles SA, Massey A, Raynaud FI, et al. NVP-AUY922: a novel heat shock protein 90 inhibitor active against xenograft tumor growth, angiogenesis, and metastasis. Cancer Res. 2008 Apr 15;68(8):2850-60. PMID: 18413753.

" Not dangerous goods.

LKT N8662 NVP-BGJ398 5 mg 67.4 FGFR inhibitor. BGJ398, BGJ-398 872511-34-7 ≥98% 560.48 C26H31Cl2N7O3 "CCN1CCN(CC1)c2ccc(cc2)Nc3cc(ncn3)N(C)C(=O)Nc4c(c(cc(c4Cl)OC)OC)Cl

" Ambient -20°C "Turkington RC, Longley DB, Allen WL, et al. Fibroblast growth factor receptor 4 (FGFR4): a targetable regulator of drug resistance in colorectal cancer. Cell Death Dis. 2014 Feb 6;5:e1046. PMID: 24503538.

 

Wöhrle S, Weiss A, Ito M, et al. Fibroblast growth factor receptors as novel therapeutic targets in SNF5-deleted malignant rhabdoid tumors. PLoS One. 2013 Oct 30;8(10):e77652. PMID: 24204904.

 

Konecny GE, Kolarova T, O'Brien NA, et al. Activity of the fibroblast growth factor receptor inhibitors dovitinib (TKI258) and NVP-BGJ398 in human endometrial cancer cells. Mol Cancer Ther. 2013 May;12(5):632-42. PMID: 23443805.

 

Wöhrle S, Henninger C, Bonny O, et al. Pharmacological inhibition of fibroblast growth factor (FGF) receptor signaling ameliorates FGF23-mediated hypophosphatemic rickets. J Bone Miner Res. 2013 Apr;28(4):899-911. PMID: 23129509.

 

Guagnano V, Furet P, Spanka C, et al. Discovery of 3-(2,6-dichloro-3,5-dimethoxy-phenyl)-1--1-methyl-urea (NVP-BGJ398), a potent and selective inhibitor of the fibroblast growth factor receptor family of receptor tyrosine kinase. J Med Chem. 2011 Oct 27;54(20):7066-83. PMID: 21936542.

" Not dangerous goods.

LKT N8662 NVP-BGJ398 25 mg 219.1 FGFR inhibitor. BGJ398, BGJ-398 872511-34-7 ≥98% 560.48 C26H31Cl2N7O3 "CCN1CCN(CC1)c2ccc(cc2)Nc3cc(ncn3)N(C)C(=O)Nc4c(c(cc(c4Cl)OC)OC)Cl

" Ambient -20°C "Turkington RC, Longley DB, Allen WL, et al. Fibroblast growth factor receptor 4 (FGFR4): a targetable regulator of drug resistance in colorectal cancer. Cell Death Dis. 2014 Feb 6;5:e1046. PMID: 24503538.

 

Wöhrle S, Weiss A, Ito M, et al. Fibroblast growth factor receptors as novel therapeutic targets in SNF5-deleted malignant rhabdoid tumors. PLoS One. 2013 Oct 30;8(10):e77652. PMID: 24204904.

 

Konecny GE, Kolarova T, O'Brien NA, et al. Activity of the fibroblast growth factor receptor inhibitors dovitinib (TKI258) and NVP-BGJ398 in human endometrial cancer cells. Mol Cancer Ther. 2013 May;12(5):632-42. PMID: 23443805.

 

Wöhrle S, Henninger C, Bonny O, et al. Pharmacological inhibition of fibroblast growth factor (FGF) receptor signaling ameliorates FGF23-mediated hypophosphatemic rickets. J Bone Miner Res. 2013 Apr;28(4):899-911. PMID: 23129509.

 

Guagnano V, Furet P, Spanka C, et al. Discovery of 3-(2,6-dichloro-3,5-dimethoxy-phenyl)-1--1-methyl-urea (NVP-BGJ398), a potent and selective inhibitor of the fibroblast growth factor receptor family of receptor tyrosine kinase. J Med Chem. 2011 Oct 27;54(20):7066-83. PMID: 21936542.

" Not dangerous goods.

LKT N8662 NVP-BGJ398 50 mg 337.1 FGFR inhibitor. BGJ398, BGJ-398 872511-34-7 ≥98% 560.48 C26H31Cl2N7O3 "CCN1CCN(CC1)c2ccc(cc2)Nc3cc(ncn3)N(C)C(=O)Nc4c(c(cc(c4Cl)OC)OC)Cl

" Ambient -20°C "Turkington RC, Longley DB, Allen WL, et al. Fibroblast growth factor receptor 4 (FGFR4): a targetable regulator of drug resistance in colorectal cancer. Cell Death Dis. 2014 Feb 6;5:e1046. PMID: 24503538.

 

Wöhrle S, Weiss A, Ito M, et al. Fibroblast growth factor receptors as novel therapeutic targets in SNF5-deleted malignant rhabdoid tumors. PLoS One. 2013 Oct 30;8(10):e77652. PMID: 24204904.

 

Konecny GE, Kolarova T, O'Brien NA, et al. Activity of the fibroblast growth factor receptor inhibitors dovitinib (TKI258) and NVP-BGJ398 in human endometrial cancer cells. Mol Cancer Ther. 2013 May;12(5):632-42. PMID: 23443805.

 

Wöhrle S, Henninger C, Bonny O, et al. Pharmacological inhibition of fibroblast growth factor (FGF) receptor signaling ameliorates FGF23-mediated hypophosphatemic rickets. J Bone Miner Res. 2013 Apr;28(4):899-911. PMID: 23129509.

 

Guagnano V, Furet P, Spanka C, et al. Discovery of 3-(2,6-dichloro-3,5-dimethoxy-phenyl)-1--1-methyl-urea (NVP-BGJ398), a potent and selective inhibitor of the fibroblast growth factor receptor family of receptor tyrosine kinase. J Med Chem. 2011 Oct 27;54(20):7066-83. PMID: 21936542.

" Not dangerous goods.

LKT N8663 NVP-LDE225 Diphosphate 5 mg 129.3 Smo inhibitor. Erismodegib, Sonidegib 1218778-77-8 ≥98% 681.49 C26H26F3N3O3 2H3O4P "Cc1c(cccc1C(=O)Nc2ccc(nc2)N3CC(OC(C3)C)C)c4ccc(cc4)OC(F)(F)F.OP(=O)(O)O.OP(=O)(O)O

" Ambient -20°C "Ferguson J, Hannam S, Toholka R, et al. Hair Loss and Hedgehog Inhibitors - A Class Effect? Br J Dermatol. 2014 Dec 18. [Epub ahead of print]. PMID: 25523648.

 

D'Amato C, Rosa R, Marciano R, et al. Inhibition of Hedgehog signalling by NVP-LDE225 (Erismodegib) interferes with growth and invasion of human renal cell carcinoma cells. Br J Cancer. 2014 Sep 9;111(6):1168-79. PMID: 25093491.

 

Nanta R, Kumar D, Meeker D, et al. NVP-LDE-225 (Erismodegib) inhibits epithelial-mesenchymal transition and human prostate cancer stem cell growth in NOD/SCID IL2Rγ null mice by regulating Bmi-1 and microRNA-128. Oncogenesis. 2013 Apr 8;2:e42. PMID: 23567619.

" Not dangerous goods.

LKT N8663 NVP-LDE225 Diphosphate 10 mg 200 Smo inhibitor. Erismodegib, Sonidegib 1218778-77-8 ≥98% 681.49 C26H26F3N3O3 2H3O4P "Cc1c(cccc1C(=O)Nc2ccc(nc2)N3CC(OC(C3)C)C)c4ccc(cc4)OC(F)(F)F.OP(=O)(O)O.OP(=O)(O)O

" Ambient -20°C "Ferguson J, Hannam S, Toholka R, et al. Hair Loss and Hedgehog Inhibitors - A Class Effect? Br J Dermatol. 2014 Dec 18. [Epub ahead of print]. PMID: 25523648.

 

D'Amato C, Rosa R, Marciano R, et al. Inhibition of Hedgehog signalling by NVP-LDE225 (Erismodegib) interferes with growth and invasion of human renal cell carcinoma cells. Br J Cancer. 2014 Sep 9;111(6):1168-79. PMID: 25093491.

 

Nanta R, Kumar D, Meeker D, et al. NVP-LDE-225 (Erismodegib) inhibits epithelial-mesenchymal transition and human prostate cancer stem cell growth in NOD/SCID IL2Rγ null mice by regulating Bmi-1 and microRNA-128. Oncogenesis. 2013 Apr 8;2:e42. PMID: 23567619.

" Not dangerous goods.

LKT N8760 NVP-TAE684 5 mg 129.3 ALK, c-Fes, LRRK2 inhibitor. TAE684 761439-42-3 ≥98% 614.21 C30H40ClN7O3S "CC(C)S(=O)(=O)c1ccccc1Nc2c(cnc(n2)Nc3ccc(cc3OC)N4CCC(CC4)N5CCN(CC5)C)Cl

" Ambient -20°C "Hellwig S, Miduturu CV, Kanda S, et al. Small-molecule inhibitors of the c-Fes protein-tyrosine kinase. Chem Biol. 2012 Apr 20;19(4):529-40. PMID: 22520759.

 

Zhang J, Deng X, Choi HG, et al. Characterization of TAE684 as a potent LRRK2 kinase inhibitor. Bioorg Med Chem Lett. 2012 Mar 1;22(5):1864-9. PMID: 22335897.

 

Cerchietti L, Damm-Welk C, Vater I, et al. Inhibition of anaplastic lymphoma kinase (ALK) activity provides a therapeutic approach for CLTC-ALK-positive human diffuse large B cell lymphomas. PLoS One. 2011 Apr 8;6(4):e18436. PMID: 21494621.

 

Galkin AV, Melnick JS, Kim S, et al. Identification of NVP-TAE684, a potent, selective, and efficacious inhibitor of NPM-ALK. Proc Natl Acad Sci U S A. 2007 Jan 2;104(1):270-5. Erratum in: Proc Natl Acad Sci U S A. 2007 Feb 6;104(6):2025. PMID: 17185414.

" Not dangerous goods.

LKT N8760 NVP-TAE684 10 mg 196.7 ALK, c-Fes, LRRK2 inhibitor. TAE684 761439-42-3 ≥98% 614.21 C30H40ClN7O3S "CC(C)S(=O)(=O)c1ccccc1Nc2c(cnc(n2)Nc3ccc(cc3OC)N4CCC(CC4)N5CCN(CC5)C)Cl

" Ambient -20°C "Hellwig S, Miduturu CV, Kanda S, et al. Small-molecule inhibitors of the c-Fes protein-tyrosine kinase. Chem Biol. 2012 Apr 20;19(4):529-40. PMID: 22520759.

 

Zhang J, Deng X, Choi HG, et al. Characterization of TAE684 as a potent LRRK2 kinase inhibitor. Bioorg Med Chem Lett. 2012 Mar 1;22(5):1864-9. PMID: 22335897.

 

Cerchietti L, Damm-Welk C, Vater I, et al. Inhibition of anaplastic lymphoma kinase (ALK) activity provides a therapeutic approach for CLTC-ALK-positive human diffuse large B cell lymphomas. PLoS One. 2011 Apr 8;6(4):e18436. PMID: 21494621.

 

Galkin AV, Melnick JS, Kim S, et al. Identification of NVP-TAE684, a potent, selective, and efficacious inhibitor of NPM-ALK. Proc Natl Acad Sci U S A. 2007 Jan 2;104(1):270-5. Erratum in: Proc Natl Acad Sci U S A. 2007 Feb 6;104(6):2025. PMID: 17185414.

" Not dangerous goods.

LKT O0400 Obatoclax 5 mg 76.4 BH3 mimetic; Bcl-2 and Bcl-xl inhibitor. GX15-070 803712-67-6 ≥98% 317.38 C20H19N3O Ambient "Liang LZ, Ma B, Liang YJ, et al. Obatoclax induces Beclin 1- and ATG5-dependent apoptosis and autophagy in adenoid cystic carcinoma cells. Oral Dis. 2014 Dec 8. [Epub ahead of print]. PMID: 25482163.

 

Arellano ML, Borthakur G, Berger M, et al. A phase II, multicenter, open-label study of obatoclax mesylate in patients with previously untreated myelodysplastic syndromes with anemia or thrombocytopenia. Clin Lymphoma Myeloma Leuk. 2014 Dec;14(6):534-9. PMID: 25052051.

 

Koehler BC, Scherr AL, Lorenz S, et al. Pan-Bcl-2 inhibitor obatoclax delays cell cycle progression and blocks migration of colorectal cancer cells. PLoS One. 2014 Sep 5;9(9):e106571. PMID: 25192188.

 

Lieber J, Ellerkamp V, Vogt F, et al. BH3-mimetic drugs prevent tumour onset in an orthotopic mouse model of hepatoblastoma. Exp Cell Res. 2014 Mar 10;322(1):217-25. PMID: 24355809.

" Not dangerous goods.

LKT O0400 Obatoclax 25 mg 280.9 BH3 mimetic; Bcl-2 and Bcl-xl inhibitor. GX15-070 803712-67-6 ≥98% 317.38 C20H19N3O Ambient "Liang LZ, Ma B, Liang YJ, et al. Obatoclax induces Beclin 1- and ATG5-dependent apoptosis and autophagy in adenoid cystic carcinoma cells. Oral Dis. 2014 Dec 8. [Epub ahead of print]. PMID: 25482163.

 

Arellano ML, Borthakur G, Berger M, et al. A phase II, multicenter, open-label study of obatoclax mesylate in patients with previously untreated myelodysplastic syndromes with anemia or thrombocytopenia. Clin Lymphoma Myeloma Leuk. 2014 Dec;14(6):534-9. PMID: 25052051.

 

Koehler BC, Scherr AL, Lorenz S, et al. Pan-Bcl-2 inhibitor obatoclax delays cell cycle progression and blocks migration of colorectal cancer cells. PLoS One. 2014 Sep 5;9(9):e106571. PMID: 25192188.

 

Lieber J, Ellerkamp V, Vogt F, et al. BH3-mimetic drugs prevent tumour onset in an orthotopic mouse model of hepatoblastoma. Exp Cell Res. 2014 Mar 10;322(1):217-25. PMID: 24355809.

" Not dangerous goods.

LKT O0400 Obatoclax 50 mg 426.9 BH3 mimetic; Bcl-2 and Bcl-xl inhibitor. GX15-070 803712-67-6 ≥98% 317.38 C20H19N3O Ambient "Liang LZ, Ma B, Liang YJ, et al. Obatoclax induces Beclin 1- and ATG5-dependent apoptosis and autophagy in adenoid cystic carcinoma cells. Oral Dis. 2014 Dec 8. [Epub ahead of print]. PMID: 25482163.

 

Arellano ML, Borthakur G, Berger M, et al. A phase II, multicenter, open-label study of obatoclax mesylate in patients with previously untreated myelodysplastic syndromes with anemia or thrombocytopenia. Clin Lymphoma Myeloma Leuk. 2014 Dec;14(6):534-9. PMID: 25052051.

 

Koehler BC, Scherr AL, Lorenz S, et al. Pan-Bcl-2 inhibitor obatoclax delays cell cycle progression and blocks migration of colorectal cancer cells. PLoS One. 2014 Sep 5;9(9):e106571. PMID: 25192188.

 

Lieber J, Ellerkamp V, Vogt F, et al. BH3-mimetic drugs prevent tumour onset in an orthotopic mouse model of hepatoblastoma. Exp Cell Res. 2014 Mar 10;322(1):217-25. PMID: 24355809.

" Not dangerous goods.

LKT O1200 Odanacatib 5 mg 163 Cathepsin K inhibitor. MK0822 603139-19-1 ≥98% 525.56 C25H27F4N3O3S "CC(C)(CC(C(=O)NC1(CC1)C#N)NC(c2ccc(cc2)c3ccc(cc3)S(=O)(=O)C)C(F)(F)F)F

" Ambient -20°C "Bone HG, Dempster DW, Eisman JA, et al. Odanacatib for the treatment of postmenopausal osteoporosis: development history and design and participant characteristics of LOFT, the Long-Term Odanacatib Fracture Trial. Osteoporos Int. 2015 Feb;26(2):699-712. PMID: 25432773.

 

Hao L, Chen W, McConnell M, et al. A small molecule, Odanacatib, inhibits inflammation and bone loss caused by endodontic disease. Infect Immun. 2015 Jan 12. [Epub ahead of print]. PMID: 25583522.

 

Gauthier JY, Chauret N, Cromlish W, et al. The discovery of odanacatib (MK-0822), a selective inhibitor of cathepsin K. Bioorg Med Chem Lett. 2008 Feb 1;18(3):923-8. PMID: 18226527.

" "UN number: 3077     Class: 9     Packing Group: III

Proper shipping name: Environmentally hazardous substance, solid, n.o.s. (Odanacatib)"

LKT O1200 Odanacatib 10 mg 247.2 Cathepsin K inhibitor. MK0822 603139-19-1 ≥98% 525.56 C25H27F4N3O3S "CC(C)(CC(C(=O)NC1(CC1)C#N)NC(c2ccc(cc2)c3ccc(cc3)S(=O)(=O)C)C(F)(F)F)F

" Ambient -20°C "Bone HG, Dempster DW, Eisman JA, et al. Odanacatib for the treatment of postmenopausal osteoporosis: development history and design and participant characteristics of LOFT, the Long-Term Odanacatib Fracture Trial. Osteoporos Int. 2015 Feb;26(2):699-712. PMID: 25432773.

 

Hao L, Chen W, McConnell M, et al. A small molecule, Odanacatib, inhibits inflammation and bone loss caused by endodontic disease. Infect Immun. 2015 Jan 12. [Epub ahead of print]. PMID: 25583522.

 

Gauthier JY, Chauret N, Cromlish W, et al. The discovery of odanacatib (MK-0822), a selective inhibitor of cathepsin K. Bioorg Med Chem Lett. 2008 Feb 1;18(3):923-8. PMID: 18226527.

" "UN number: 3077     Class: 9     Packing Group: III

Proper shipping name: Environmentally hazardous substance, solid, n.o.s. (Odanacatib)"

LKT O7333 OSI-906 5 mg 65.2 IGF-1R and InsR inhibitor. OSI906, Linsitinib 867160-71-2 ≥98% 421.49 C26H23N5O "CC1(CC(C1)c2nc(c3n2ccnc3N)c4ccc5ccc(nc5c4)c6ccccc6)O

" Ambient -20°C "Bendell JC, Jones SF, Hart L, et al. A phase Ib study of linsitinib (OSI-906), a dual inhibitor of IGF-1R and IR tyrosine kinase, in combination with everolimus as treatment for patients with refractory metastatic colorectal cancer. Invest New Drugs. 2015 Feb;33(1):187-93. PMID: 25335932.

 

Rao W, Li H, Song F, et al. OVA66 increases cell growth, invasion and survival via regulation of IGF-1R-MAPK signaling in human cancer cells. Carcinogenesis. 2014 Jul;35(7):1573-81. PMID: 24667688.

 

Mulvihill MJ, Cooke A, Rosenfeld-Franklin M, et al. Discovery of OSI-906: a selective and orally efficacious dual inhibitor of the IGF-1 receptor and insulin receptor. Future Med Chem. 2009 Sep;1(6):1153-71. PMID: 21425998.

" Not dangerous goods.

LKT O7333 OSI-906 25 mg 219.1 IGF-1R and InsR inhibitor. OSI906, Linsitinib 867160-71-2 ≥98% 421.49 C26H23N5O "CC1(CC(C1)c2nc(c3n2ccnc3N)c4ccc5ccc(nc5c4)c6ccccc6)O

" Ambient -20°C "Bendell JC, Jones SF, Hart L, et al. A phase Ib study of linsitinib (OSI-906), a dual inhibitor of IGF-1R and IR tyrosine kinase, in combination with everolimus as treatment for patients with refractory metastatic colorectal cancer. Invest New Drugs. 2015 Feb;33(1):187-93. PMID: 25335932.

 

Rao W, Li H, Song F, et al. OVA66 increases cell growth, invasion and survival via regulation of IGF-1R-MAPK signaling in human cancer cells. Carcinogenesis. 2014 Jul;35(7):1573-81. PMID: 24667688.

 

Mulvihill MJ, Cooke A, Rosenfeld-Franklin M, et al. Discovery of OSI-906: a selective and orally efficacious dual inhibitor of the IGF-1 receptor and insulin receptor. Future Med Chem. 2009 Sep;1(6):1153-71. PMID: 21425998.

" Not dangerous goods.

LKT O7333 OSI-906 50 mg 331.5 IGF-1R and InsR inhibitor. OSI906, Linsitinib 867160-71-2 ≥98% 421.49 C26H23N5O "CC1(CC(C1)c2nc(c3n2ccnc3N)c4ccc5ccc(nc5c4)c6ccccc6)O

" Ambient -20°C "Bendell JC, Jones SF, Hart L, et al. A phase Ib study of linsitinib (OSI-906), a dual inhibitor of IGF-1R and IR tyrosine kinase, in combination with everolimus as treatment for patients with refractory metastatic colorectal cancer. Invest New Drugs. 2015 Feb;33(1):187-93. PMID: 25335932.

 

Rao W, Li H, Song F, et al. OVA66 increases cell growth, invasion and survival via regulation of IGF-1R-MAPK signaling in human cancer cells. Carcinogenesis. 2014 Jul;35(7):1573-81. PMID: 24667688.

 

Mulvihill MJ, Cooke A, Rosenfeld-Franklin M, et al. Discovery of OSI-906: a selective and orally efficacious dual inhibitor of the IGF-1 receptor and insulin receptor. Future Med Chem. 2009 Sep;1(6):1153-71. PMID: 21425998.

" Not dangerous goods.

LKT O7992 OTX-015 5 mg 219.1 BRD2/3/4 inhibitor. Y-803 202590-98-5 ≥98% 491.99 C25H22ClN5O2S Cc1c(sc-2c1C(=N[C@H](c3n2c(nn3)C)CC(=O)Nc4ccc(cc4)O)c5ccc(cc5)Cl)C Ambient -20°C "Boi M, Gaudio E, Bonetti P, et al. The BET Bromodomain Inhibitor OTX015 Affects Pathogenetic Pathways in Preclinical B-cell Tumor Models and Synergizes with Targeted Drugs. Clin Cancer Res. 2015 Apr 1;21(7):1628-38.PMID: 25633213.

 

Noel JK, Iwata K, Ooike S, et al. Development of the BET bromodomains inhibitor OTX015. Mol Cancer Ther. 2013 Nov:12;C244.

 

Boi M, Todaro M, Vurchio V, et al. OTX015, a bromodomains and extraterminal inhibitor, represents a novel agent for ALK positive anaplastic large cell lymphoma. Mol Cancer Ther. 2013 Nov:12;A219.

" Not dangerous goods.

LKT O7992 OTX-015 10 mg 337.1 BRD2/3/4 inhibitor. Y-803 202590-98-5 ≥98% 491.99 C25H22ClN5O2S Cc1c(sc-2c1C(=N[C@H](c3n2c(nn3)C)CC(=O)Nc4ccc(cc4)O)c5ccc(cc5)Cl)C Ambient -20°C "Boi M, Gaudio E, Bonetti P, et al. The BET Bromodomain Inhibitor OTX015 Affects Pathogenetic Pathways in Preclinical B-cell Tumor Models and Synergizes with Targeted Drugs. Clin Cancer Res. 2015 Apr 1;21(7):1628-38.PMID: 25633213.

 

Noel JK, Iwata K, Ooike S, et al. Development of the BET bromodomains inhibitor OTX015. Mol Cancer Ther. 2013 Nov:12;C244.

 

Boi M, Todaro M, Vurchio V, et al. OTX015, a bromodomains and extraterminal inhibitor, represents a novel agent for ALK positive anaplastic large cell lymphoma. Mol Cancer Ther. 2013 Nov:12;A219.

" Not dangerous goods.

LKT P0344 Palbociclib Isethionate 5 mg 106.8 CDK4/6 inhibitor. PD03329, PF00080665-73 827022-33-3 ≥98% 573.66 C24H29N7O2  C2H6O4S "Cc1c2cnc(nc2n(c(=O)c1C(=O)C)C3CCCC3)Nc4ccc(cn4)N5CCNCC5.C(CS(=O)(=O)O)O

" Ambient -20°C "Vaughn DJ, Hwang W, Lal P, et al. Phase 2 trial of the cyclin-dependent kinase 4/6 inhibitor palbociclib in patients with retinoblastoma protein-expressing germ cell tumors. Cancer. 2014 Dec 18. [Epub ahead of print]. PMID: 25522918.

 

DiRocco DP, Bisi J, Roberts P, et al. CDK4/6 inhibition induces epithelial cell cycle arrest and ameliorates acute kidney injury. Am J Physiol Renal Physiol. 2014 Feb 15;306(4):F379-88. PMID: 24338822.

 

Barton KL, Misuraca K, Cordero F, et al. PD-0332991, a CDK4/6 inhibitor, significantly prolongs survival in a genetically engineered mouse model of brainstem glioma. PLoS One. 2013 Oct 2;8(10):e77639. PMID: 24098593.

 

Fry DW, Harvey PJ, Keller PR, et al. Specific inhibition of cyclin-dependent kinase 4/6 by PD 0332991 and associated antitumor activity in human tumor xenografts. Mol Cancer Ther. 2004 Nov;3(11):1427-38. PMID: 15542782.

" "UN number: 2811     Class: 6.1     Packing Group: III

Proper shipping name: Toxic solid, organic, n.o.n. (Palbociclib isethionate)"

LKT P0344 Palbociclib Isethionate 10 mg 168.5 CDK4/6 inhibitor. PD0332, PF00080665-73 827022-33-3 ≥98% 573.66 C24H29N7O2  C2H6O4S "Cc1c2cnc(nc2n(c(=O)c1C(=O)C)C3CCCC3)Nc4ccc(cn4)N5CCNCC5.C(CS(=O)(=O)O)O

" Ambient -20°C "Vaughn DJ, Hwang W, Lal P, et al. Phase 2 trial of the cyclin-dependent kinase 4/6 inhibitor palbociclib in patients with retinoblastoma protein-expressing germ cell tumors. Cancer. 2014 Dec 18. [Epub ahead of print]. PMID: 25522918.

 

DiRocco DP, Bisi J, Roberts P, et al. CDK4/6 inhibition induces epithelial cell cycle arrest and ameliorates acute kidney injury. Am J Physiol Renal Physiol. 2014 Feb 15;306(4):F379-88. PMID: 24338822.

 

Barton KL, Misuraca K, Cordero F, et al. PD-0332991, a CDK4/6 inhibitor, significantly prolongs survival in a genetically engineered mouse model of brainstem glioma. PLoS One. 2013 Oct 2;8(10):e77639. PMID: 24098593.

 

Fry DW, Harvey PJ, Keller PR, et al. Specific inhibition of cyclin-dependent kinase 4/6 by PD 0332991 and associated antitumor activity in human tumor xenografts. Mol Cancer Ther. 2004 Nov;3(11):1427-38. PMID: 15542782.

" "UN number: 2811     Class: 6.1     Packing Group: III

Proper shipping name: Toxic solid, organic, n.o.n. (Palbociclib isethionate)"

LKT P0344 Palbociclib Isethionate 25 mg 320.3 CDK4/6 inhibitor. PD0332 PF00080665-73 827022-33-3 ≥98% 573.66 C24H29N7O2  C2H6O4S "Cc1c2cnc(nc2n(c(=O)c1C(=O)C)C3CCCC3)Nc4ccc(cn4)N5CCNCC5.C(CS(=O)(=O)O)O

" Ambient -20°C "Vaughn DJ, Hwang W, Lal P, et al. Phase 2 trial of the cyclin-dependent kinase 4/6 inhibitor palbociclib in patients with retinoblastoma protein-expressing germ cell tumors. Cancer. 2014 Dec 18. [Epub ahead of print]. PMID: 25522918.

 

DiRocco DP, Bisi J, Roberts P, et al. CDK4/6 inhibition induces epithelial cell cycle arrest and ameliorates acute kidney injury. Am J Physiol Renal Physiol. 2014 Feb 15;306(4):F379-88. PMID: 24338822.

 

Barton KL, Misuraca K, Cordero F, et al. PD-0332991, a CDK4/6 inhibitor, significantly prolongs survival in a genetically engineered mouse model of brainstem glioma. PLoS One. 2013 Oct 2;8(10):e77639. PMID: 24098593.

 

Fry DW, Harvey PJ, Keller PR, et al. Specific inhibition of cyclin-dependent kinase 4/6 by PD 0332991 and associated antitumor activity in human tumor xenografts. Mol Cancer Ther. 2004 Nov;3(11):1427-38. PMID: 15542782.

" "UN number: 2811     Class: 6.1     Packing Group: III

Proper shipping name: Toxic solid, organic, n.o.n. (Palbociclib isethionate)"

LKT P2012 PF-04217903 5 mg 121.4 Triazolopyrazine; c-MET inhibitor. PF04217903 1159490-85-3 ≥98% 372.38 C19H16N8O Ambient -20°C "Sennino B, Ishiguro-Oonuma T, Schriver BJ, et al. Inhibition of c-Met reduces lymphatic metastasis in RIP-Tag2 transgenic mice. Cancer Res. 2013 Jun 15;73(12):3692-703. PMID: 23576559.

 

Zou HY, Li Q, Lee JH, et al. Sensitivity of selected human tumor models to PF-04217903, a novel selective c-Met kinase inhibitor. Mol Cancer Ther. 2012 Apr;11(4):1036-47. PMID: 22389468.

 

Timofeevski SL, McTigue MA, Ryan K, et al. Enzymatic characterization of c-Met receptor tyrosine kinase oncogenic mutants and kinetic studies with aminopyridine and triazolopyrazine inhibitors. Biochemistry. 2009 Jun 16;48(23):5339-49. PMID: 19459657.

" Not dangerous goods.

LKT P2012 PF-04217903 10 mg 179.8 Triazolopyrazine; c-MET inhibitor. PF04217903 1159490-85-3 ≥98% 372.38 C19H16N8O Ambient -20°C "Sennino B, Ishiguro-Oonuma T, Schriver BJ, et al. Inhibition of c-Met reduces lymphatic metastasis in RIP-Tag2 transgenic mice. Cancer Res. 2013 Jun 15;73(12):3692-703. PMID: 23576559.

 

Zou HY, Li Q, Lee JH, et al. Sensitivity of selected human tumor models to PF-04217903, a novel selective c-Met kinase inhibitor. Mol Cancer Ther. 2012 Apr;11(4):1036-47. PMID: 22389468.

 

Timofeevski SL, McTigue MA, Ryan K, et al. Enzymatic characterization of c-Met receptor tyrosine kinase oncogenic mutants and kinetic studies with aminopyridine and triazolopyrazine inhibitors. Biochemistry. 2009 Jun 16;48(23):5339-49. PMID: 19459657.

" Not dangerous goods.

LKT P6004 PP-242 5 mg 95.6 mTOR inhibitor. Pp242, Torkinib 1092351-67-1 ≥98% 308.34 C16H16N6O "CC(C)n1c2c(c(n1)c3cc4cc(ccc4[nH]3)O)c(ncn2)N

" Ambient -20°C "Shi F, Yang X, Gong Y, et al. The antileukemia roles of PP242 alone or in combination with daunorubicin in acute leukemia. Anticancer Drugs. 2015 Apr;26(4):410-21. PMID: 25535978.

 

Zhang X, Wang X, Qin L, et al. The dual mTORC1 and mTORC2 inhibitor PP242 shows strong antitumor activity in a pheochromocytoma PC12 cell tumor model. Urology. 2015 Jan;85(1):273.e1-7. PMID: 25440763.

 

Xing X, Zhang L, Wen X, et al. PP242 suppresses cell proliferation, metastasis, and angiogenesis of gastric cancer through inhibition of the PI3K/AKT/mTOR pathway. Anticancer Drugs. 2014 Nov;25(10):1129-40. PMID: 25035961.

" Not dangerous goods.

LKT P6004 PP-242 10 mg 140.5 mTOR inhibitor. Pp242, Torkinib 1092351-67-1 ≥98% 308.34 C16H16N6O "CC(C)n1c2c(c(n1)c3cc4cc(ccc4[nH]3)O)c(ncn2)N

" Ambient -20°C "Shi F, Yang X, Gong Y, et al. The antileukemia roles of PP242 alone or in combination with daunorubicin in acute leukemia. Anticancer Drugs. 2015 Apr;26(4):410-21. PMID: 25535978.

 

Zhang X, Wang X, Qin L, et al. The dual mTORC1 and mTORC2 inhibitor PP242 shows strong antitumor activity in a pheochromocytoma PC12 cell tumor model. Urology. 2015 Jan;85(1):273.e1-7. PMID: 25440763.

 

Xing X, Zhang L, Wen X, et al. PP242 suppresses cell proliferation, metastasis, and angiogenesis of gastric cancer through inhibition of the PI3K/AKT/mTOR pathway. Anticancer Drugs. 2014 Nov;25(10):1129-40. PMID: 25035961.

" Not dangerous goods.

LKT P6004 PP-242 25 mg 320.3 mTOR inhibitor. Pp242, Torkinib 1092351-67-1 ≥98% 308.34 C16H16N6O "CC(C)n1c2c(c(n1)c3cc4cc(ccc4[nH]3)O)c(ncn2)N

" Ambient -20°C "Shi F, Yang X, Gong Y, et al. The antileukemia roles of PP242 alone or in combination with daunorubicin in acute leukemia. Anticancer Drugs. 2015 Apr;26(4):410-21. PMID: 25535978.

 

Zhang X, Wang X, Qin L, et al. The dual mTORC1 and mTORC2 inhibitor PP242 shows strong antitumor activity in a pheochromocytoma PC12 cell tumor model. Urology. 2015 Jan;85(1):273.e1-7. PMID: 25440763.

 

Xing X, Zhang L, Wen X, et al. PP242 suppresses cell proliferation, metastasis, and angiogenesis of gastric cancer through inhibition of the PI3K/AKT/mTOR pathway. Anticancer Drugs. 2014 Nov;25(10):1129-40. PMID: 25035961.

" Not dangerous goods.

LKT P9870 Pyridostatin Hydrochloride 5 mg 118 G-quadruplex ligand; DNA breakage inducer. Pyridostatin Trihydrochloride 1085412-37-8 ≥98% 896.3 C31H32N8O5 5.5 HCl 5.5 H2O Ambient -20°C "Marchand A, Granzhan A, Iida K, et al. Ligand-Induced Conformational Changes with Cation Ejection upon Binding to Human Telomeric DNA G-Quadruplexes. J Am Chem Soc. 2015 Jan 21;137(2):750-6. PMID: 25525863.

 

Murat P, Zhong J, Lekieffre L, et al. G-quadruplexes regulate Epstein-Barr virus-encoded nuclear antigen 1 mRNA translation. Nat Chem Biol. 2014 May;10(5):358-64. PMID: 24633353.

 

McLuckie KI, Di Antonio M, Zecchini H, et al. G-quadruplex DNA as a molecular target for induced synthetic lethality in cancer cells. J Am Chem Soc. 2013 Jul 3;135(26):9640-3. PMID: 23782415.

 

Müller S, Sanders DA, Di Antonio M, et al. Pyridostatin analogues promote telomere dysfunction and long-term growth inhibition in human cancer cells. Org Biomol Chem. 2012 Aug 28;10(32):6537-46. PMID: 22790277.

" Not dangerous goods.

LKT P9870 Pyridostatin Hydrochloride 10 mg 185.4 G-quadruplex ligand; DNA breakage inducer. Pyridostatin Trihydrochloride 1085412-37-8 ≥98% 896.3 C31H32N8O5 5.5 HCl 5.5 H2O Ambient -20°C "Marchand A, Granzhan A, Iida K, et al. Ligand-Induced Conformational Changes with Cation Ejection upon Binding to Human Telomeric DNA G-Quadruplexes. J Am Chem Soc. 2015 Jan 21;137(2):750-6. PMID: 25525863.

 

Murat P, Zhong J, Lekieffre L, et al. G-quadruplexes regulate Epstein-Barr virus-encoded nuclear antigen 1 mRNA translation. Nat Chem Biol. 2014 May;10(5):358-64. PMID: 24633353.

 

McLuckie KI, Di Antonio M, Zecchini H, et al. G-quadruplex DNA as a molecular target for induced synthetic lethality in cancer cells. J Am Chem Soc. 2013 Jul 3;135(26):9640-3. PMID: 23782415.

 

Müller S, Sanders DA, Di Antonio M, et al. Pyridostatin analogues promote telomere dysfunction and long-term growth inhibition in human cancer cells. Org Biomol Chem. 2012 Aug 28;10(32):6537-46. PMID: 22790277.

" Not dangerous goods.

LKT P9870 Pyridostatin Hydrochloride 25 mg 387.7 G-quadruplex ligand; DNA breakage inducer. Pyridostatin Trihydrochloride 1085412-37-8 ≥98% 896.3 C31H32N8O5 5.5 HCl 5.5 H2O Ambient -20°C "Marchand A, Granzhan A, Iida K, et al. Ligand-Induced Conformational Changes with Cation Ejection upon Binding to Human Telomeric DNA G-Quadruplexes. J Am Chem Soc. 2015 Jan 21;137(2):750-6. PMID: 25525863.

 

Murat P, Zhong J, Lekieffre L, et al. G-quadruplexes regulate Epstein-Barr virus-encoded nuclear antigen 1 mRNA translation. Nat Chem Biol. 2014 May;10(5):358-64. PMID: 24633353.

 

McLuckie KI, Di Antonio M, Zecchini H, et al. G-quadruplex DNA as a molecular target for induced synthetic lethality in cancer cells. J Am Chem Soc. 2013 Jul 3;135(26):9640-3. PMID: 23782415.

 

Müller S, Sanders DA, Di Antonio M, et al. Pyridostatin analogues promote telomere dysfunction and long-term growth inhibition in human cancer cells. Org Biomol Chem. 2012 Aug 28;10(32):6537-46. PMID: 22790277.

" Not dangerous goods.

LKT P3469 Pirfenidone 10 mg 67.4 Collagen synthesis inhibitor. 53179-13-8 ≥98% 185.22 C12H11NO "Cc1ccc(=O)n(c1)c2ccccc2

" Ambient -20°C "Xiang XH, Jiang TP, Zhang S, et al. Pirfenidone inhibits proliferation, arrests the cell cycle, and downregulates heat shock protein 47 and collagen type I in rat hepatic stellate cells in vitro. Mol Med Rep. 2015 Mar 3. [Epub ahead of print]. PMID: 25738437.

 

Cottin V, Maher T. Long-term clinical and real-world experience with pirfenidone in the treatment of idiopathic pulmonary fibrosis. Eur Respir Rev. 2015 Mar;24(135):58-64. PMID: 25726556.

 

Iyer SN, Wild JS, Schiedt MJ, et al. Dietary intake of pirfenidone ameliorates bleomycin-induced lung fibrosis in hamsters. J Lab Clin Med. 1995 Jun;125(6):779-85. PMID: 7539478.

" Not dangerous goods.

LKT P3469 Pirfenidone 50 mg 235.9 Collagen synthesis inhibitor. 53179-13-8 ≥98% 185.22 C12H11NO "Cc1ccc(=O)n(c1)c2ccccc2

" Ambient -20°C "Xiang XH, Jiang TP, Zhang S, et al. Pirfenidone inhibits proliferation, arrests the cell cycle, and downregulates heat shock protein 47 and collagen type I in rat hepatic stellate cells in vitro. Mol Med Rep. 2015 Mar 3. [Epub ahead of print]. PMID: 25738437.

 

Cottin V, Maher T. Long-term clinical and real-world experience with pirfenidone in the treatment of idiopathic pulmonary fibrosis. Eur Respir Rev. 2015 Mar;24(135):58-64. PMID: 25726556.

 

Iyer SN, Wild JS, Schiedt MJ, et al. Dietary intake of pirfenidone ameliorates bleomycin-induced lung fibrosis in hamsters. J Lab Clin Med. 1995 Jun;125(6):779-85. PMID: 7539478.

" Not dangerous goods.

LKT P3469 Pirfenidone 250 mg 561.8 Collagen synthesis inhibitor. 53179-13-8 ≥98% 185.22 C12H11NO "Cc1ccc(=O)n(c1)c2ccccc2

" Ambient -20°C "Xiang XH, Jiang TP, Zhang S, et al. Pirfenidone inhibits proliferation, arrests the cell cycle, and downregulates heat shock protein 47 and collagen type I in rat hepatic stellate cells in vitro. Mol Med Rep. 2015 Mar 3. [Epub ahead of print]. PMID: 25738437.

 

Cottin V, Maher T. Long-term clinical and real-world experience with pirfenidone in the treatment of idiopathic pulmonary fibrosis. Eur Respir Rev. 2015 Mar;24(135):58-64. PMID: 25726556.

 

Iyer SN, Wild JS, Schiedt MJ, et al. Dietary intake of pirfenidone ameliorates bleomycin-induced lung fibrosis in hamsters. J Lab Clin Med. 1995 Jun;125(6):779-85. PMID: 7539478.

" Not dangerous goods.

LKT R0247 Raltegravir 5 mg 118 HIV integrase inhibitor. MK-0518 518048-05-0 ≥98% 444.42 C20H21FN6O5 "Cc1nnc(o1)C(=O)NC(C)(C)c2nc(c(c(=O)n2C)O)C(=O)NCc3ccc(cc3)F

" Ambient -20°C "Taramasso L, Madeddu G, Ricci E, et al. Raltegravir-based therapy in a cohort of HIV/HCV co-infected individuals. Biomed Pharmacother. 2015 Feb;69:233-6. PMID: 25661363.

 

Mouscadet JF, Tchertanov L. Raltegravir: molecular basis of its mechanism of action. Eur J Med Res. 2009 Nov 24;14 Suppl 3:5-16. PMID: 19959411.

 

Hicks C, Gulick RM. Raltegravir: the first HIV type 1 integrase inhibitor. Clin Infect Dis. 2009 Apr 1;48(7):931-9. PMID: 19231980.

" Not dangerous goods.

LKT R0247 Raltegravir 10 mg 222.5 HIV integrase inhibitor. MK-0518 518048-05-0 ≥98% 444.42 C20H21FN6O5 "Cc1nnc(o1)C(=O)NC(C)(C)c2nc(c(c(=O)n2C)O)C(=O)NCc3ccc(cc3)F

" Ambient -20°C "Taramasso L, Madeddu G, Ricci E, et al. Raltegravir-based therapy in a cohort of HIV/HCV co-infected individuals. Biomed Pharmacother. 2015 Feb;69:233-6. PMID: 25661363.

 

Mouscadet JF, Tchertanov L. Raltegravir: molecular basis of its mechanism of action. Eur J Med Res. 2009 Nov 24;14 Suppl 3:5-16. PMID: 19959411.

 

Hicks C, Gulick RM. Raltegravir: the first HIV type 1 integrase inhibitor. Clin Infect Dis. 2009 Apr 1;48(7):931-9. PMID: 19231980.

" Not dangerous goods.

LKT R5212 RN-486 1 mg 241.6 Btk inhibitor. RN486 1242156-23-5 ≥98% 606.69 C35H35FN6O3 Ambient -20°C "Zhao X, Huang W, Wang Y, et al. Discovery of novel Bruton's tyrosine kinase (BTK) inhibitors bearing a pyrrolo[2,3-d]pyrimidine scaffold. Bioorg Med Chem. 2015 Feb 15;23(4):891-901. PMID: 25596757. 

 

Hartkamp LM, Fine JS, van Es IE, et al. Btk inhibition suppresses agonist-induced human macrophage activation and inflammatory gene expression in RA synovial tissue explants. Ann Rheum Dis. 2014 Apr 24. [Epub ahead of print]. PMID: 24764451.

 

Wang J, Lau KY, Jung J, et al. Bruton's tyrosine kinase regulates TLR9 but not TLR7 signaling in human plasmacytoid dendritic cells. Eur J Immunol. 2014 Apr;44(4):1130-6. PMID: 24375473.

 

Xu D, Kim Y, Postelnek J, et al. RN486, a selective Bruton's tyrosine kinase inhibitor, abrogates immune hypersensitivity responses and arthritis in rodents. J Pharmacol Exp Ther. 2012 Apr;341(1):90-103. PMID: 22228807.

" "UN number: 3077     Class: 9     Packing Group: III

Proper shipping name: Environmentally hazardous substance, solid, n.o.s. (RN-486)"

LKT R5212 RN-486 5 mg 365.2 Btk inhibitor. RN486 1242156-23-5 ≥98% 606.69 C35H35FN6O3 Ambient -20°C "Zhao X, Huang W, Wang Y, et al. Discovery of novel Bruton's tyrosine kinase (BTK) inhibitors bearing a pyrrolo[2,3-d]pyrimidine scaffold. Bioorg Med Chem. 2015 Feb 15;23(4):891-901. PMID: 25596757. 

 

Hartkamp LM, Fine JS, van Es IE, et al. Btk inhibition suppresses agonist-induced human macrophage activation and inflammatory gene expression in RA synovial tissue explants. Ann Rheum Dis. 2014 Apr 24. [Epub ahead of print]. PMID: 24764451.

 

Wang J, Lau KY, Jung J, et al. Bruton's tyrosine kinase regulates TLR9 but not TLR7 signaling in human plasmacytoid dendritic cells. Eur J Immunol. 2014 Apr;44(4):1130-6. PMID: 24375473.

 

Xu D, Kim Y, Postelnek J, et al. RN486, a selective Bruton's tyrosine kinase inhibitor, abrogates immune hypersensitivity responses and arthritis in rodents. J Pharmacol Exp Ther. 2012 Apr;341(1):90-103. PMID: 22228807.

" "UN number: 3077     Class: 9     Packing Group: III

Proper shipping name: Environmentally hazardous substance, solid, n.o.s. (RN-486)"

LKT R5749 Romidepsin 1 mg 337.1 HDAC inhibitor. FK228, Istodax, Depsipeptide, FR901228 128517-07-7 ≥98% 540.7 C24H36N4O6S2 "CC=C1C(=O)NC(C(=O)OC2CC(=O)NC(C(=O)NC(CSSCCC=C2)C(=O)N1)C(C)C)C(C)C

" Ambient -20°C "Foss F, Coiffier B, Horwitz S, et al. Tolerability to romidepsin in patients with relapsed/refractory T-cell lymphoma. Biomark Res. 2014 Sep 8;2:16. PMID: 25279222.

 

Satwani P, Bavishi S, Saha A, et al. Upregulation of NKG2D ligands in acute lymphoblastic leukemia and non-Hodgkin lymphoma cells by romidepsin and enhanced in vitro and in vivo natural killer cell cytotoxicity. Cytotherapy. 2014 May 20. [Epub ahead of print]. PMID: 24856896.

 

Wei DG, Chiang V, Fyne E, et al. Histone deacetylase inhibitor romidepsin induces HIV expression in CD4 T cells from patients on suppressive antiretroviral therapy at concentrations achieved by clinical dosing. PLoS Pathog. 2014 Apr 10;10(4):e1004071. PMID: 24722454.

 

Karthik S, Sankar R, Varunkumar K, et al. Romidepsin induces cell cycle arrest, apoptosis, histone hyperacetylation and reduces matrix metalloproteinases 2 and 9 expression in bortezomib sensitized non-small cell lung cancer cells. Biomed Pharmacother. 2014 Apr;68(3):327-34. PMID: 24485799.

 

Ueda H, Nakajima H, Hori Y, et al. FR901228, a novel antitumor bicyclic depsipeptide produced by Chromobacterium violaceum No. 968. I. Taxonomy, fermentation, isolation, physico-chemical and biological properties, and antitumor activity. J Antibiot (Tokyo). 1994 Mar;47(3):301-10. PMID: 7513682.

" Not dangerous goods.

LKT R5749 Romidepsin 5 mg 1447.1 HDAC inhibitor. FK228, Istodax, Depsipeptide, FR901228 128517-07-7 ≥98% 540.7 C24H36N4O6S2 "CC=C1C(=O)NC(C(=O)OC2CC(=O)NC(C(=O)NC(CSSCCC=C2)C(=O)N1)C(C)C)C(C)C

" Ambient -20°C "Foss F, Coiffier B, Horwitz S, et al. Tolerability to romidepsin in patients with relapsed/refractory T-cell lymphoma. Biomark Res. 2014 Sep 8;2:16. PMID: 25279222.

 

Satwani P, Bavishi S, Saha A, et al. Upregulation of NKG2D ligands in acute lymphoblastic leukemia and non-Hodgkin lymphoma cells by romidepsin and enhanced in vitro and in vivo natural killer cell cytotoxicity. Cytotherapy. 2014 May 20. [Epub ahead of print]. PMID: 24856896.

 

Wei DG, Chiang V, Fyne E, et al. Histone deacetylase inhibitor romidepsin induces HIV expression in CD4 T cells from patients on suppressive antiretroviral therapy at concentrations achieved by clinical dosing. PLoS Pathog. 2014 Apr 10;10(4):e1004071. PMID: 24722454.

 

Karthik S, Sankar R, Varunkumar K, et al. Romidepsin induces cell cycle arrest, apoptosis, histone hyperacetylation and reduces matrix metalloproteinases 2 and 9 expression in bortezomib sensitized non-small cell lung cancer cells. Biomed Pharmacother. 2014 Apr;68(3):327-34. PMID: 24485799.

 

Ueda H, Nakajima H, Hori Y, et al. FR901228, a novel antitumor bicyclic depsipeptide produced by Chromobacterium violaceum No. 968. I. Taxonomy, fermentation, isolation, physico-chemical and biological properties, and antitumor activity. J Antibiot (Tokyo). 1994 Mar;47(3):301-10. PMID: 7513682.

" Not dangerous goods.

LKT P0276 Peptide 401 0.5 mg 300.1 Antimicrobial peptide found in bee and wasp venom. Mast Cell Degranulating Peptide 32908-73-9 ≥95% 2583.28 C110H188N40O24S4 CCC(C)C1C(=O)NC(CSSCC(C(=O)NC(C(=O)NC2CSSCC(C(=O)NC(C(=O)NC(C(=O)N1)CCCCN)CCCNC(=N)N)NC(=O)C(NC(=O)C(NC(=O)C3CCCN3C(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC2=O)CCCCN)CCCNC(=N)N)CC4C=NC=N4)C(C)C)C(C)CC)CCCCN)CC5C=NC=N5)C(C)CC)CC(=O)N)NC(=O)C(CCCCN)NC(=O)C(C(C)CC)N)C(=O)NCC(=O)NC(CCCCN)C(=O)NC(CC(=O)N)C(=O)N Ambient -20°C "Banks BE, Dempsey CE, Vernon CA, et al. Anti-inflammatory activity of bee venom peptide 401 (mast cell degranulating peptide) and compound 48/80 results from mast cell degranulation in vivo. Br J Pharmacol. 1990 Feb;99(2):350-4. PMID: 2328399.

 

Ennis M, Atkinson G, Pearce FL. Inhibition of histamine release induced by compound 48/80 and peptide 401 in the presence and absence of calcium. Implications for the mode of action of anti-allergic compounds. Agents Actions. 1980 Jun;10(3):222-8. PMID: 6157320.

 

Hanson JM, Morley J, Soria-Herrera C. Anti-inflammatory property of 401 (MCD-peptide), a peptide from the venom of the bee Apis mellifera (L.). Br J Pharmacol. 1974 Mar;50(3):383-92. PMID: 4152780.

"

LKT P0276 Peptide 401 1 mg 510 Antimicrobial peptide found in bee and wasp venom. Mast Cell Degranulating Peptide 32908-73-9 ≥95% 2583.28 C110H188N40O24S4 CCC(C)C1C(=O)NC(CSSCC(C(=O)NC(C(=O)NC2CSSCC(C(=O)NC(C(=O)NC(C(=O)N1)CCCCN)CCCNC(=N)N)NC(=O)C(NC(=O)C(NC(=O)C3CCCN3C(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC2=O)CCCCN)CCCNC(=N)N)CC4C=NC=N4)C(C)C)C(C)CC)CCCCN)CC5C=NC=N5)C(C)CC)CC(=O)N)NC(=O)C(CCCCN)NC(=O)C(C(C)CC)N)C(=O)NCC(=O)NC(CCCCN)C(=O)NC(CC(=O)N)C(=O)N Ambient -20°C "Banks BE, Dempsey CE, Vernon CA, et al. Anti-inflammatory activity of bee venom peptide 401 (mast cell degranulating peptide) and compound 48/80 results from mast cell degranulation in vivo. Br J Pharmacol. 1990 Feb;99(2):350-4. PMID: 2328399.

 

Ennis M, Atkinson G, Pearce FL. Inhibition of histamine release induced by compound 48/80 and peptide 401 in the presence and absence of calcium. Implications for the mode of action of anti-allergic compounds. Agents Actions. 1980 Jun;10(3):222-8. PMID: 6157320.

 

Hanson JM, Morley J, Soria-Herrera C. Anti-inflammatory property of 401 (MCD-peptide), a peptide from the venom of the bee Apis mellifera (L.). Br J Pharmacol. 1974 Mar;50(3):383-92. PMID: 4152780.

"

LKT P0276 Peptide 401 2.5 mg 900.1 Antimicrobial peptide found in bee and wasp venom. Mast Cell Degranulating Peptide 32908-73-9 ≥95% 2583.28 C110H188N40O24S4 CCC(C)C1C(=O)NC(CSSCC(C(=O)NC(C(=O)NC2CSSCC(C(=O)NC(C(=O)NC(C(=O)N1)CCCCN)CCCNC(=N)N)NC(=O)C(NC(=O)C(NC(=O)C3CCCN3C(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC2=O)CCCCN)CCCNC(=N)N)CC4C=NC=N4)C(C)C)C(C)CC)CCCCN)CC5C=NC=N5)C(C)CC)CC(=O)N)NC(=O)C(CCCCN)NC(=O)C(C(C)CC)N)C(=O)NCC(=O)NC(CCCCN)C(=O)NC(CC(=O)N)C(=O)N Ambient -20°C "Banks BE, Dempsey CE, Vernon CA, et al. Anti-inflammatory activity of bee venom peptide 401 (mast cell degranulating peptide) and compound 48/80 results from mast cell degranulation in vivo. Br J Pharmacol. 1990 Feb;99(2):350-4. PMID: 2328399.

 

Ennis M, Atkinson G, Pearce FL. Inhibition of histamine release induced by compound 48/80 and peptide 401 in the presence and absence of calcium. Implications for the mode of action of anti-allergic compounds. Agents Actions. 1980 Jun;10(3):222-8. PMID: 6157320.

 

Hanson JM, Morley J, Soria-Herrera C. Anti-inflammatory property of 401 (MCD-peptide), a peptide from the venom of the bee Apis mellifera (L.). Br J Pharmacol. 1974 Mar;50(3):383-92. PMID: 4152780.

"

LKT B6918 Brevetoxin 3 5 mg 8792.6 Polyether neurotoxin found in Karenia brevis; Nav1.4/1.5 Na+ channel activator. PbTx-3 85079-48-7 ≥95% 897.2 C50H72O14 CC1CC2C(CC3(C(O2)CC4C(O3)C(=CC(=O)O4)C)C)OC5C1OC6CC7C(CC8C(O7)(CC=CC9C(O8)CC1C(O9)CC2C(O1)(C(CC(O2)CC(=C)CO)O)C)C)(OC6(CC5)C)C Ambient -20°C Soluble in acetone, ethyl acetate, ethanol, and methanol. "Zaias J, Fleming LE, Baden DG, et al. Repeated exposure to aerosolized brevetoxin-3 induces prolonged airway hyperresponsiveness and lung inflammation in sheep. Inhal Toxicol. 2011 Mar;23(4):205-11. PMID: 21456953.

 

Liberona JL, Cárdenas JC, Reyes R, et al. Sodium-dependent action potentials induced by brevetoxin-3 trigger both IP3 increase and intracellular Ca2+ release in rat skeletal myotubes. Cell Calcium. 2008 Sep;44(3):289-97. PMID: 18276006.

 

Cao Z, George J, Baden DG, et al. Brevetoxin-induced phosphorylation of Pyk2 and Src in murine neocortical neurons involves distinct signaling pathways. Brain Res. 2007 Dec 12;1184:17-27. PMID: 17963734.

 

Radwan FF, Ramsdell JS. Characterization of in vitro oxidative and conjugative metabolic pathways for brevetoxin (PbTx-2). Toxicol Sci. 2006 Jan;89(1):57-65. PMID: 16221966.

 

Colman JR, Ramsdell JS. The type B brevetoxin (PbTx-3) adversely affects development, cardiovascular function, and survival in Medaka (Oryzias latipes) embryos. Environ Health Perspect. 2003 Dec;111(16):1920-5. PMID: 14644667.

 

Bottein Dechraoui MY, Ramsdell JS. Type B brevetoxins show tissue selectivity for voltage-gated sodium channels: comparison of brain, skeletal muscle and cardiac sodium channels. Toxicon. 2003 Jun;41(7):919-27. PMID: 12782093.

 

Berman FW, Murray TF. Brevetoxins cause acute excitotoxicity in primary cultures of rat cerebellar granule neurons. J Pharmacol Exp Ther. 1999 Jul;290(1):439-44. PMID: 10381810.

 

Jeglitsch G, Rein K, Baden DG, et al. Brevetoxin-3 (PbTx-3) and its derivatives modulate single tetrodotoxin-sensitive sodium channels in rat sensory neurons. J Pharmacol Exp Ther. 1998 Feb;284(2):516-25. PMID: 9454792.

" "UN number: 3462     Class: 6.1     Packing Group: II

Proper shipping name: Toxins, extracted from living sources, solid, n.o.s. (Brevetoxin 3)"

LKT M5853 Moniliformin 5 mg 1395.3 Mycotoxin produced by species of Fusarium; potential pyruvate dehydrogenase inhibitor. 3-hydroxycyclobut-3-ene-1,2-dione 31876-38-7 ≥98% 98.06 C4H2O3 C1=C(C(=O)C1=O)O Ambient 4°C water, methanol "Scarpino V, Blandino M, Negre M, et al. Moniliformin analysis in maize samples from North-West Italy using multifunctional clean-up columns and the LC-MS/MS detection method. Food Addit Contam Part A Chem Anal Control Expo Risk Assess. 2013;30(5):876-84. PMID: 23731218.

 

Ficheux AS, Sibiril Y, Parent-Massin D. Effects of beauvericin, enniatin b and moniliformin on human dendritic cells and macrophages: an in vitro study. Toxicon. 2013 Sep;71:1-10. PMID: 23685117.

 

von Bargen KW, Lohrey L, Cramer B, et al. Analysis of the Fusarium mycotoxin moniliformin in cereal samples using 13C2-moniliformin and high-resolution mass spectrometry. J Agric Food Chem. 2012 Apr 11;60(14):3586-91. PMID: 22428531.

 

Zhang A, Cao JL, Yang B, et al. Effects of moniliformin and selenium on human articular cartilage metabolism and their potential relationships to the pathogenesis of Kashin-Beck disease. J Zhejiang Univ Sci B. 2010 Mar;11(3):200-8. PMID: 20205306.

 

Chen LY, Tian XL, Yang B. A study on the inhibition of rat myocardium glutathione peroxidase and glutathione reductase by moniliformin. Mycopathologia. 1990 May;110(2):119-24. PMID: 2366852.

 

Gathercole PS, Thiel PG, Hofmeyr JH. Inhibition of pyruvate dehydrogenase complex by moniliformin. Biochem J. 1986 Feb 1;233(3):719-23. PMID: 3707519.

" "UN number: 3462     Class: 6.1     Packing Group: II

Proper shipping name: Toxins, extracted from living sources, solid, n.o.s. (Moniliformin)"

LKT K0021 K252a 5 mg 842.6 Staurosporine analog; PKC inhibitor, TrkA/B antagonist. SF 2370 99533-80-9 ≥98% 467.48 C27H21N3O5 CC12C(CC(O1)N3C4=CC=CC=C4C5=C6C(=C7C8=CC=CC=C8N2C7=C53)CNC6=O)(C(=O)OC)O Ambient 4°C "Readily soluble in chloroform, acetonitrile, acetone, dioxane, tetrahydrofuran, pyridine;

soluble in ethanol, methanol, 1-propanol, ethyl acetate and n-butanol;

insoluble in water, 2-propanol" "El-Hashim AZ, Jaffal SM, Al-Rashidi FT, et al. Nerve growth factor enhances cough via a central mechanism of action. Pharmacol Res. 2013 Aug;74:68-77. PMID: 23742790.

 

Cardenas-Aguayo Mdel C, Kazim SF, Grundke-Iqbal I, et al. Neurogenic and neurotrophic effects of BDNF peptides in mouse hippocampal primary neuronal cell cultures. PLoS One. 2013;8(1):e53596. PMID: 23320097.

 

Sugiya H, Putney JW Jr. Protein kinase C-dependent and -independent mechanisms regulating the parotid substance P receptor as revealed by differential effects of protein kinase C inhibitors. Biochem J. 1988 Dec 1;256(2):677-80. PMID: 2464997.

 

Hashimoto S. K-252a, a potent protein kinase inhibitor, blocks nerve growth factor-induced neurite outgrowth and changes in the phosphorylation of proteins in PC12h cells. J Cell Biol. 1988 Oct;107(4):1531-9. PMID: 2844830.

" Xi Not dangerous goods.

LKT A6925 L-Arginine Ethyl Ester Dihydrochloride 5 g 39.4 Arginine source used to increase NO production. 36589-29-4 ≥98% 275.18 C8H18N4O2 Ambient -20°C "Shin S, Mohan S, Fung HL. Intracellular L-arginine concentration does not determine NO production in endothelial cells: implications on the ""L-arginine paradox"". Biochem Biophys Res Commun. 2011 Nov 4;414(4):660-3. PMID: 21986532.

 

Knecht KR, Milam S, Wilkinson DA, et al. Time-dependent action of carbon monoxide on the newborn cerebrovascular circulation. Am J Physiol Heart Circ Physiol. 2010 Jul;299(1):H70-5. PMID: 20435844.

" Not dangerous goods.

LKT A6925 L-Arginine Ethyl Ester Dihydrochloride 25 g 140.5 Arginine source used to increase NO production. 36589-29-4 ≥98% 275.18 C8H18N4O2 Ambient -20°C "Shin S, Mohan S, Fung HL. Intracellular L-arginine concentration does not determine NO production in endothelial cells: implications on the ""L-arginine paradox"". Biochem Biophys Res Commun. 2011 Nov 4;414(4):660-3. PMID: 21986532.

 

Knecht KR, Milam S, Wilkinson DA, et al. Time-dependent action of carbon monoxide on the newborn cerebrovascular circulation. Am J Physiol Heart Circ Physiol. 2010 Jul;299(1):H70-5. PMID: 20435844.

" Not dangerous goods.

LKT A0001 A-803467 10 mg 84.3 Nav1.8 Na+ channel blocker, potential Nav1.5 Na+ channel blocker. 944261-79-4 357.79 C19H16ClNO4 "COc1cc(cc(c1)OC)NC(=O)c2ccc(o2)c3ccc(cc3)Cl

" Ambient -20°C "Rahman W, Dickenson AH. Osteoarthritis-dependent changes in antinociceptive action of Nav1.7 and Nav1.8 sodium channel blockers: An in vivo electrophysiological study in the rat. Neuroscience. 2015 Jun 4;295:103-16. PMID: 25818052.

 

Han Z, Jiang Y, Xiao F, et al. The effects of A-803467 on cardiac Nav1.5 channels. Eur J Pharmacol. 2015 May 5;754:52-60. PMID: 25701724.

 

Liu XD, Yang JJ, Fang D, et al. Functional upregulation of Nav1.8 sodium channels on the membrane of dorsal root Ganglia neurons contributes to the development of cancer-induced bone pain. PLoS One. 2014 Dec 11;9(12):e114623. PMID: 25503076.

 

Qi B, Wei Y, Chen S, et al. Nav1.8 channels in ganglionated plexi modulate atrial fibrillation inducibility. Cardiovasc Res. 2014 Jun 1;102(3):480-6. PMID: 24419303.

" Not dangerous goods.

LKT A0001 A-803467 50 mg 292.1 Nav1.8 Na+ channel blocker, potential Nav1.5 Na+ channel blocker. 944261-79-4 357.79 C19H16ClNO4 "COc1cc(cc(c1)OC)NC(=O)c2ccc(o2)c3ccc(cc3)Cl

" Ambient -20°C "Rahman W, Dickenson AH. Osteoarthritis-dependent changes in antinociceptive action of Nav1.7 and Nav1.8 sodium channel blockers: An in vivo electrophysiological study in the rat. Neuroscience. 2015 Jun 4;295:103-16. PMID: 25818052.

 

Han Z, Jiang Y, Xiao F, et al. The effects of A-803467 on cardiac Nav1.5 channels. Eur J Pharmacol. 2015 May 5;754:52-60. PMID: 25701724.

 

Liu XD, Yang JJ, Fang D, et al. Functional upregulation of Nav1.8 sodium channels on the membrane of dorsal root Ganglia neurons contributes to the development of cancer-induced bone pain. PLoS One. 2014 Dec 11;9(12):e114623. PMID: 25503076.

 

Qi B, Wei Y, Chen S, et al. Nav1.8 channels in ganglionated plexi modulate atrial fibrillation inducibility. Cardiovasc Res. 2014 Jun 1;102(3):480-6. PMID: 24419303.

" Not dangerous goods.

LKT B5044 BML-277 5 mg 84.3 Arylbenzimidazole; CHK2 inhibitor. 516480-79-8 ≥98% 363.8 C20H14ClN3O2 Ambient Arienti KL, Brunmark A, Axe FU, et al. Checkpoint kinase inhibitors: SAR and radioprotective properties of a series of 2-arylbenzimidazoles. J Med Chem. 2005 Mar 24;48(6):1873-85. PMID: 15771432. Not dangerous goods.

LKT B5044 BML-277 25 mg 337.1 Arylbenzimidazole; CHK2 inhibitor. 516480-79-8 ≥98% 363.8 C20H14ClN3O2 Ambient Arienti KL, Brunmark A, Axe FU, et al. Checkpoint kinase inhibitors: SAR and radioprotective properties of a series of 2-arylbenzimidazoles. J Med Chem. 2005 Mar 24;48(6):1873-85. PMID: 15771432. Not dangerous goods.

LKT B8676 BVT-2733 5 mg 78.6 11β-HSD1 inhibitor. BVT2733 376640-41-4 428.96 C17H21ClN4O3S2 "Cc1c(cccc1Cl)S(=O)(=O)Nc2nc(cs2)CC(=O)N3CCN(CC3)C

" Ambient "Zhang L, Dong Y, Zou F, et al. 11β-Hydroxysteroid dehydrogenase 1 inhibition attenuates collagen-induced arthritis. Int Immunopharmacol. 2013 Nov;17(3):489-94. PMID: 23938253.

 

Wu L, Qi H, Zhong Y, et al. 11β-Hydroxysteroid dehydrogenase type 1 selective inhibitor BVT.2733 protects osteoblasts against endogenous glucocorticoid induced dysfunction. Endocr J. 2013;60(9):1047-58. PMID: 23759754.

 

Alberts P, Engblom L, Edling N, et al. Selective inhibition of 11beta-hydroxysteroid dehydrogenase type 1 decreases blood glucose concentrations in hyperglycaemic mice. Diabetologia. 2002 Nov;45(11):1528-32. PMID: 12436336.

" Not dangerous goods.

LKT B8676 BVT-2733 25 mg 320.3 11β-HSD1 inhibitor. BVT2733 376640-41-4 428.96 C17H21ClN4O3S2 "Cc1c(cccc1Cl)S(=O)(=O)Nc2nc(cs2)CC(=O)N3CCN(CC3)C

" Ambient "Zhang L, Dong Y, Zou F, et al. 11β-Hydroxysteroid dehydrogenase 1 inhibition attenuates collagen-induced arthritis. Int Immunopharmacol. 2013 Nov;17(3):489-94. PMID: 23938253.

 

Wu L, Qi H, Zhong Y, et al. 11β-Hydroxysteroid dehydrogenase type 1 selective inhibitor BVT.2733 protects osteoblasts against endogenous glucocorticoid induced dysfunction. Endocr J. 2013;60(9):1047-58. PMID: 23759754.

 

Alberts P, Engblom L, Edling N, et al. Selective inhibition of 11beta-hydroxysteroid dehydrogenase type 1 decreases blood glucose concentrations in hyperglycaemic mice. Diabetologia. 2002 Nov;45(11):1528-32. PMID: 12436336.

" Not dangerous goods.

LKT P2100 PF-06447475 5 mg 73.1 LRRK2 inhibitor. 1527473-33-1 305.13 C17H15N5O Ambient "Daher JP, Abdelmotilib HA, Hu X, et al. LRRK2 Pharmacological Inhibition Abates α-Synuclein Induced Neurodegeneration. J Biol Chem. 2015 Jun 15. [Epub ahead of print]. PMID: 26078453.

 

Henderson JL, Kormos BL, Hayward MM, et al. Discovery and preclinical profiling of 3-[4-(morpholin-4-yl)-7H-pyrrolo[2,3-d]pyrimidin-5-yl]benzonitrile (PF-06447475), a highly potent, selective, brain penetrant, and in vivo active LRRK2 kinase inhibitor. J Med Chem. 2015 Jan 8;58(1):419-32. PMID: 25353650.

" "UN number: 2811     Class: 6.1     Packing Group: III

Proper shipping name: Toxic solid, organic, n.o.s. (PF06447475)"

LKT P2100 PF-06447475 25 mg 280.9 LRRK2 inhibitor. 1527473-33-1 305.13 C17H15N5O Ambient "Daher JP, Abdelmotilib HA, Hu X, et al. LRRK2 Pharmacological Inhibition Abates α-Synuclein Induced Neurodegeneration. J Biol Chem. 2015 Jun 15. [Epub ahead of print]. PMID: 26078453.

 

Henderson JL, Kormos BL, Hayward MM, et al. Discovery and preclinical profiling of 3-[4-(morpholin-4-yl)-7H-pyrrolo[2,3-d]pyrimidin-5-yl]benzonitrile (PF-06447475), a highly potent, selective, brain penetrant, and in vivo active LRRK2 kinase inhibitor. J Med Chem. 2015 Jan 8;58(1):419-32. PMID: 25353650.

" "UN number: 2811     Class: 6.1     Packing Group: III

Proper shipping name: Toxic solid, organic, n.o.s. (PF06447475)"

LKT A1592 ADX-47273 5 mg 235.9 mGluR5 positive modulator. 851881-60-2 369.36 C20H17F2N3O2 "c1cc(ccc1c2nc(on2)C3CCCN(C3)C(=O)c4ccc(cc4)F)F

" Ambient "Ahnaou A, Langlois X, Steckler T, et al. Negative versus positive allosteric modulation of metabotropic glutamate receptors (mGluR5): indices for potential pro-cognitive drug properties based on EEG network oscillations and sleep-wake organization in rats. Psychopharmacology (Berl). 2015 Mar;232(6):1107-22. PMID: 25323624.

 

Xu J, Zhu Y, Kraniotis S, et al. Potentiating mGluR5 function with a positive allosteric modulator enhances adaptive learning. Learn Mem. 2013 Jul 18;20(8):438-45. PMID: 23869026.

 

Kroker KS, Rast G, Rosenbrock H. Differential effect of the mGlu5 receptor positive allosteric modulator ADX-47273 on early and late hippocampal LTP. Neuropharmacology. 2011 Sep;61(4):707-14. PMID: 21640734.

 

Schlumberger C, Pietraszek M, Gravius A, et al. Comparison of the mGlu(5) receptor positive allosteric modulator ADX47273 and the mGlu(2/3) receptor agonist LY354740 in tests for antipsychotic-like activity. Eur J Pharmacol. 2009 Nov 25;623(1-3):73-83. PMID: 19765575.

 

Liu F, Grauer S, Kelley C, et al. ADX47273 [S-(4-fluoro-phenyl)--methanone]: a novel metabotropic glutamate receptor 5-selective positive allosteric modulator with preclinical antipsychotic-like and procognitive activities. J Pharmacol Exp Ther. 2008 Dec;327(3):827-39. PMID: 18753411.

" "UN number: 3077     Class: 9     Packing Group: III

Proper shipping name: Environmentally hazardous substance, solid, n.o.s. (ADX47273)"

LKT A1592 ADX-47273 25 mg 814.6 mGluR5 positive modulator. 851881-60-2 369.36 C20H17F2N3O2 "c1cc(ccc1c2nc(on2)C3CCCN(C3)C(=O)c4ccc(cc4)F)F

" Ambient "Ahnaou A, Langlois X, Steckler T, et al. Negative versus positive allosteric modulation of metabotropic glutamate receptors (mGluR5): indices for potential pro-cognitive drug properties based on EEG network oscillations and sleep-wake organization in rats. Psychopharmacology (Berl). 2015 Mar;232(6):1107-22. PMID: 25323624.

 

Xu J, Zhu Y, Kraniotis S, et al. Potentiating mGluR5 function with a positive allosteric modulator enhances adaptive learning. Learn Mem. 2013 Jul 18;20(8):438-45. PMID: 23869026.

 

Kroker KS, Rast G, Rosenbrock H. Differential effect of the mGlu5 receptor positive allosteric modulator ADX-47273 on early and late hippocampal LTP. Neuropharmacology. 2011 Sep;61(4):707-14. PMID: 21640734.

 

Schlumberger C, Pietraszek M, Gravius A, et al. Comparison of the mGlu(5) receptor positive allosteric modulator ADX47273 and the mGlu(2/3) receptor agonist LY354740 in tests for antipsychotic-like activity. Eur J Pharmacol. 2009 Nov 25;623(1-3):73-83. PMID: 19765575.

 

Liu F, Grauer S, Kelley C, et al. ADX47273 [S-(4-fluoro-phenyl)--methanone]: a novel metabotropic glutamate receptor 5-selective positive allosteric modulator with preclinical antipsychotic-like and procognitive activities. J Pharmacol Exp Ther. 2008 Dec;327(3):827-39. PMID: 18753411.

" "UN number: 3077     Class: 9     Packing Group: III

Proper shipping name: Environmentally hazardous substance, solid, n.o.s. (ADX47273)"

LKT S6800 SR1001 5 mg 84.3 RORα/γ inverse agonist. 1335106-03-0 ≥98% 477.4 C15H13F6N3O4S2 Ambient -20°C "Solt LA, Banerjee S, Campbell S, et al. ROR inverse agonist suppresses insulitis and prevents hyperglycemia in a mouse model of type 1 diabetes. Endocrinology. 2015 Mar;156(3):869-81. PMID: 25560829.

 

Beurel E, Harrington LE, Jope RS. Inflammatory T helper 17 cells promote depression-like behavior in mice. Biol Psychiatry. 2013 Apr 1;73(7):622-30. PMID: 23174342.

 

Solt LA, Kumar N, Nuhant P, et al. Suppression of TH17 differentiation and autoimmunity by a synthetic ROR ligand. Nature. 2011 Apr 28;472(7344):491-4. PMID: 21499262.

" Not dangerous goods.

LKT S6800 SR1001 25 mg 365.2 RORα/γ inverse agonist. 1335106-03-0 ≥98% 477.4 C15H13F6N3O4S2 Ambient -20°C "Solt LA, Banerjee S, Campbell S, et al. ROR inverse agonist suppresses insulitis and prevents hyperglycemia in a mouse model of type 1 diabetes. Endocrinology. 2015 Mar;156(3):869-81. PMID: 25560829.

 

Beurel E, Harrington LE, Jope RS. Inflammatory T helper 17 cells promote depression-like behavior in mice. Biol Psychiatry. 2013 Apr 1;73(7):622-30. PMID: 23174342.

 

Solt LA, Kumar N, Nuhant P, et al. Suppression of TH17 differentiation and autoimmunity by a synthetic ROR ligand. Nature. 2011 Apr 28;472(7344):491-4. PMID: 21499262.

" Not dangerous goods.

LKT S6800 SR1001 100 mg 1095.5 RORα/γ inverse agonist. 1335106-03-0 ≥98% 477.4 C15H13F6N3O4S2 Ambient -20°C "Solt LA, Banerjee S, Campbell S, et al. ROR inverse agonist suppresses insulitis and prevents hyperglycemia in a mouse model of type 1 diabetes. Endocrinology. 2015 Mar;156(3):869-81. PMID: 25560829.

 

Beurel E, Harrington LE, Jope RS. Inflammatory T helper 17 cells promote depression-like behavior in mice. Biol Psychiatry. 2013 Apr 1;73(7):622-30. PMID: 23174342.

 

Solt LA, Kumar N, Nuhant P, et al. Suppression of TH17 differentiation and autoimmunity by a synthetic ROR ligand. Nature. 2011 Apr 28;472(7344):491-4. PMID: 21499262.

" Not dangerous goods.

LKT T3196 Thymoquinone 1 g 39.4 Phytochemical from Nigella sativa. 2-Isopropyl-5-methylbenzo-1,4-quinone 2-Isopropyl-5-methyl-1,4-benzoquinone 490-91-5 ≥98% 164.2 C10H12O2 "CC1=CC(=O)C(=CC1=O)C(C)C

" Ambient Ambient "Linjawi SA, Khalil WK, Hassanane MM, et al. Evaluation of the protective effect of Nigella sativa extract and its primary active component thymoquinone against DMBA-induced breast cancer in female rats. Arch Med Sci. 2015 Mar 16;11(1):220-9. PMID: 25861310.

 

ElKhoely A, Hafez HF, Ashmawy AM, et al. Chemopreventive and therapeutic potentials of thymoquinone in HepG2 cells: mechanistic perspectives. J Nat Med. 2015 Mar 22. [Epub ahead of print]. PMID: 25796541.

 

Pejman L, Omrani H, Mirzamohammadi Z, et al. Thymoquinone, the main constituent of Nigella sativa, affects adenosine receptors in asthmatic guinea pigs. Iran J Basic Med Sci. 2014 Dec;17(12):1012-9. PMID: 25859306.

 

Mehri S, Shahi M, Razavi BM, et al. Neuroprotective effect of thymoquinone in acrylamide-induced neurotoxicity in Wistar rats. Iran J Basic Med Sci. 2014 Dec;17(12):1007-11. PMID: 25859305.

" Not dangerous goods.

LKT T3196 Thymoquinone 5 g 129.3 Phytochemical from Nigella sativa. 2-Isopropyl-5-methylbenzo-1,4-quinone 2-Isopropyl-5-methyl-1,4-benzoquinone 490-91-5 ≥98% 164.2 C10H12O2 "CC1=CC(=O)C(=CC1=O)C(C)C

" Ambient Ambient "Linjawi SA, Khalil WK, Hassanane MM, et al. Evaluation of the protective effect of Nigella sativa extract and its primary active component thymoquinone against DMBA-induced breast cancer in female rats. Arch Med Sci. 2015 Mar 16;11(1):220-9. PMID: 25861310.

 

ElKhoely A, Hafez HF, Ashmawy AM, et al. Chemopreventive and therapeutic potentials of thymoquinone in HepG2 cells: mechanistic perspectives. J Nat Med. 2015 Mar 22. [Epub ahead of print]. PMID: 25796541.

 

Pejman L, Omrani H, Mirzamohammadi Z, et al. Thymoquinone, the main constituent of Nigella sativa, affects adenosine receptors in asthmatic guinea pigs. Iran J Basic Med Sci. 2014 Dec;17(12):1012-9. PMID: 25859306.

 

Mehri S, Shahi M, Razavi BM, et al. Neuroprotective effect of thymoquinone in acrylamide-induced neurotoxicity in Wistar rats. Iran J Basic Med Sci. 2014 Dec;17(12):1007-11. PMID: 25859305.

" Not dangerous goods.

LKT N6272 NPS-2143 Hydrochloride 5 mg 101.1 Ca2+-sensing receptor antagonist. 324523-20-8 ≥98% 445.38 C24H25ClN2O2 HCl Ambient -20°C "Dal Prà I, Chiarini A, Pacchiana R, et al. Calcium-Sensing Receptors of Human Astrocyte-Neuron Teams: Amyloid-β-Driven Mediators and Therapeutic Targets of Alzheimer's Disease. Curr Neuropharmacol. 2014 Jul;12(4):353-64. PMID: 25342943.

 

Dal Prà I, Armato U, Chioffi F, et al. The Aβ peptides-activated calcium-sensing receptor stimulates the production and secretion of vascular endothelial growth factor-A by normoxic adult human cortical astrocytes. Neuromolecular Med. 2014 Dec;16(4):645-57. PMID: 24948534.

 

Yamamura A. Pathological function of Ca2+-sensing receptor in pulmonary arterial hypertension. J Smooth Muscle Res. 2014;50:8-17. PMID: 24770445.

 

Nakajima S, Hira T, Hara H. Calcium-sensing receptor mediates dietary peptide-induced CCK secretion in enteroendocrine STC-1 cells. Mol Nutr Food Res. 2012 May;56(5):753-60. PMID: 22648622.

 

Nemeth EF, Delmar EG, Heaton WL, et al. Calcilytic compounds: potent and selective Ca2+ receptor antagonists that stimulate secretion of parathyroid hormone. J Pharmacol Exp Ther. 2001 Oct;299(1):323-31. PMID: 11561095.

 

Gowen M, Stroup GB, Dodds RA, et al. Antagonizing the parathyroid calcium receptor stimulates parathyroid hormone secretion and bone formation in osteopenic rats. J Clin Invest. 2000 Jun;105(11):1595-604. PMID: 10841518.

" "UN number: 3077     Class: 9     Packing Group: III

Proper shipping name: Environmentally hazardous substance, solid, n.o.s. (NPS-2143 hydrochloride)"

LKT N6272 NPS-2143 Hydrochloride 25 mg 426.9 Ca2+-sensing receptor antagonist. 324523-20-8 ≥98% 445.38 C24H25ClN2O2 HCl Ambient -20°C "Dal Prà I, Chiarini A, Pacchiana R, et al. Calcium-Sensing Receptors of Human Astrocyte-Neuron Teams: Amyloid-β-Driven Mediators and Therapeutic Targets of Alzheimer's Disease. Curr Neuropharmacol. 2014 Jul;12(4):353-64. PMID: 25342943.

 

Dal Prà I, Armato U, Chioffi F, et al. The Aβ peptides-activated calcium-sensing receptor stimulates the production and secretion of vascular endothelial growth factor-A by normoxic adult human cortical astrocytes. Neuromolecular Med. 2014 Dec;16(4):645-57. PMID: 24948534.

 

Yamamura A. Pathological function of Ca2+-sensing receptor in pulmonary arterial hypertension. J Smooth Muscle Res. 2014;50:8-17. PMID: 24770445.

 

Nakajima S, Hira T, Hara H. Calcium-sensing receptor mediates dietary peptide-induced CCK secretion in enteroendocrine STC-1 cells. Mol Nutr Food Res. 2012 May;56(5):753-60. PMID: 22648622.

 

Nemeth EF, Delmar EG, Heaton WL, et al. Calcilytic compounds: potent and selective Ca2+ receptor antagonists that stimulate secretion of parathyroid hormone. J Pharmacol Exp Ther. 2001 Oct;299(1):323-31. PMID: 11561095.

 

Gowen M, Stroup GB, Dodds RA, et al. Antagonizing the parathyroid calcium receptor stimulates parathyroid hormone secretion and bone formation in osteopenic rats. J Clin Invest. 2000 Jun;105(11):1595-604. PMID: 10841518.

" "UN number: 3077     Class: 9     Packing Group: III

Proper shipping name: Environmentally hazardous substance, solid, n.o.s. (NPS-2143 hydrochloride)"

LKT C3352 Cinacalcet Hydrochloride 5 mg 50.6 Ca2+-sensing receptor agonist. 364782-34-3 ≥98% 393.87 C22H22F3N HCl "CC(c1cccc2c1cccc2)NCCCc3cccc(c3)C(F)(F)F.Cl

" Ambient Ambient "Kuczera P, Adamczak M, Machnik G, et al. Treatment with Cinacalcet Increases Plasma Adiponectin Concentration in Hemodialysed Patients with Chronic Kidney Disease and Secondary Hyperparathyroidism. Endocr Pract. 2015 Mar 18:1-22. [Epub ahead of print]. PMID: 25786554.

 

Wu M, Tang RN, Liu H, et al. Cinacalcet attenuates the renal endothelial-to-mesenchymal transition in rats with adenine-induced renal failure. Am J Physiol Renal Physiol. 2014 Jan 1;306(1):F138-46. PMID: 24154694.

" Not dangerous goods.

LKT C3352 Cinacalcet Hydrochloride 25 mg 163 Ca2+-sensing receptor agonist. 364782-34-3 ≥98% 393.87 C22H22F3N HCl "CC(c1cccc2c1cccc2)NCCCc3cccc(c3)C(F)(F)F.Cl

" Ambient Ambient "Kuczera P, Adamczak M, Machnik G, et al. Treatment with Cinacalcet Increases Plasma Adiponectin Concentration in Hemodialysed Patients with Chronic Kidney Disease and Secondary Hyperparathyroidism. Endocr Pract. 2015 Mar 18:1-22. [Epub ahead of print]. PMID: 25786554.

 

Wu M, Tang RN, Liu H, et al. Cinacalcet attenuates the renal endothelial-to-mesenchymal transition in rats with adenine-induced renal failure. Am J Physiol Renal Physiol. 2014 Jan 1;306(1):F138-46. PMID: 24154694.

" Not dangerous goods.

LKT C3352 Cinacalcet Hydrochloride 100 mg 505.6 Ca2+-sensing receptor agonist. 364782-34-3 ≥98% 393.87 C22H22F3N HCl "CC(c1cccc2c1cccc2)NCCCc3cccc(c3)C(F)(F)F.Cl

" Ambient Ambient "Kuczera P, Adamczak M, Machnik G, et al. Treatment with Cinacalcet Increases Plasma Adiponectin Concentration in Hemodialysed Patients with Chronic Kidney Disease and Secondary Hyperparathyroidism. Endocr Pract. 2015 Mar 18:1-22. [Epub ahead of print]. PMID: 25786554.

 

Wu M, Tang RN, Liu H, et al. Cinacalcet attenuates the renal endothelial-to-mesenchymal transition in rats with adenine-induced renal failure. Am J Physiol Renal Physiol. 2014 Jan 1;306(1):F138-46. PMID: 24154694.

" Not dangerous goods.

LKT F4432 FLI-06 5 mg 84.3 Dihydropyridine; γ-secretase inhibitor. 1,4,5,6,7,8-Hexahydro-2,7,7-trimethyl-4-(4-nitrophenyl)-5-oxo-3-quinolinecarboxylic acid cyclohexyl ester 313967-18-9 ≥98% 438.52 C25H30N2O5 Ambient -20°C Krämer A, Mentrup T, Kleizen B, et al. Small molecules intercept Notch signaling and the early secretory pathway. Nat Chem Biol. 2013 Nov;9(11):731-8. PMID: 24077179. Not dangerous goods.

LKT F4432 FLI-06 25 mg 359.5 Dihydropyridine; γ-secretase inhibitor. 1,4,5,6,7,8-Hexahydro-2,7,7-trimethyl-4-(4-nitrophenyl)-5-oxo-3-quinolinecarboxylic acid cyclohexyl ester 313967-18-9 ≥98% 438.52 C25H30N2O5 Ambient -20°C Krämer A, Mentrup T, Kleizen B, et al. Small molecules intercept Notch signaling and the early secretory pathway. Nat Chem Biol. 2013 Nov;9(11):731-8. PMID: 24077179. Not dangerous goods.

LKT L9701 LY-450139 5 mg 185.4 GHS-R1a agonist, γ-secretase inhibitor. Semagacestat 425386-60-3 ≥98% 361.44 C19H27N3O4 Ambient -20°C "Beggiato S, Giuliani A, Sivilia S, et al. CHF5074 and LY450139 sub-acute treatments differently affect cortical extracellular glutamate levels in pre-plaque Tg2576 mice. Neuroscience. 2014 Apr 25;266:13-22. PMID: 24530449.

 

Doody RS, Raman R, Farlow M, et al. A phase 3 trial of semagacestat for treatment of Alzheimer's disease. N Engl J Med. 2013 Jul 25;369(4):341-50. PMID: 23883379.

 

Schellekens H, McNamara O, Dinan TG, et al. Semagacestat, a γ-secretase inhibitor, activates the growth hormone secretagogue (GHS-R1a) receptor. J Pharm Pharmacol. 2013 Apr;65(4):528-38. PMID: 23488781.

" Not dangerous goods.

LKT L9701 LY-450139 25 mg 634.8 GHS-R1a agonist, γ-secretase inhibitor. Semagacestat 425386-60-3 ≥98% 361.44 C19H27N3O4 Ambient -20°C "Beggiato S, Giuliani A, Sivilia S, et al. CHF5074 and LY450139 sub-acute treatments differently affect cortical extracellular glutamate levels in pre-plaque Tg2576 mice. Neuroscience. 2014 Apr 25;266:13-22. PMID: 24530449.

 

Doody RS, Raman R, Farlow M, et al. A phase 3 trial of semagacestat for treatment of Alzheimer's disease. N Engl J Med. 2013 Jul 25;369(4):341-50. PMID: 23883379.

 

Schellekens H, McNamara O, Dinan TG, et al. Semagacestat, a γ-secretase inhibitor, activates the growth hormone secretagogue (GHS-R1a) receptor. J Pharm Pharmacol. 2013 Apr;65(4):528-38. PMID: 23488781.

" Not dangerous goods.

LKT L9701 LY-450139 50 mg 1067.3 GHS-R1a agonist, γ-secretase inhibitor. Semagacestat 425386-60-3 ≥98% 361.44 C19H27N3O4 Ambient -20°C "Beggiato S, Giuliani A, Sivilia S, et al. CHF5074 and LY450139 sub-acute treatments differently affect cortical extracellular glutamate levels in pre-plaque Tg2576 mice. Neuroscience. 2014 Apr 25;266:13-22. PMID: 24530449.

 

Doody RS, Raman R, Farlow M, et al. A phase 3 trial of semagacestat for treatment of Alzheimer's disease. N Engl J Med. 2013 Jul 25;369(4):341-50. PMID: 23883379.

 

Schellekens H, McNamara O, Dinan TG, et al. Semagacestat, a γ-secretase inhibitor, activates the growth hormone secretagogue (GHS-R1a) receptor. J Pharm Pharmacol. 2013 Apr;65(4):528-38. PMID: 23488781.

" Not dangerous goods.

LKT M4200 MK-0752 1 mg 56.2 γ-Secretase inhibitor. 471905-41-6 ≥98% 442.9 C21H21ClF2O4S "c1cc(ccc1S(=O)(=O)C2(CCC(CC2)CCC(=O)O)c3cc(ccc3F)F)Cl

" Ambient -20°C "Hoffman LM, Fouladi M, Olson J, et al. Phase I trial of weekly MK-0752 in children with refractory central nervous system malignancies: a pediatric brain tumor consortium study. Childs Nerv Syst. 2015 Aug;31(8):1283-9. PMID: 25930724.

 

Olson RE, Albright CF. Recent progress in the medicinal chemistry of gamma-secretase inhibitors. Curr Top Med Chem. 2008;8(1):17-33. PMID: 18220929.

" Not dangerous goods.

LKT M4200 MK-0752 5 mg 269.6 γ-Secretase inhibitor. 471905-41-6 ≥98% 442.9 C21H21ClF2O4S "c1cc(ccc1S(=O)(=O)C2(CCC(CC2)CCC(=O)O)c3cc(ccc3F)F)Cl

" Ambient -20°C "Hoffman LM, Fouladi M, Olson J, et al. Phase I trial of weekly MK-0752 in children with refractory central nervous system malignancies: a pediatric brain tumor consortium study. Childs Nerv Syst. 2015 Aug;31(8):1283-9. PMID: 25930724.

 

Olson RE, Albright CF. Recent progress in the medicinal chemistry of gamma-secretase inhibitors. Curr Top Med Chem. 2008;8(1):17-33. PMID: 18220929.

" Not dangerous goods.

LKT M4200 MK-0752 25 mg 837.1 γ-Secretase inhibitor. 471905-41-6 ≥98% 442.9 C21H21ClF2O4S "c1cc(ccc1S(=O)(=O)C2(CCC(CC2)CCC(=O)O)c3cc(ccc3F)F)Cl

" Ambient -20°C "Hoffman LM, Fouladi M, Olson J, et al. Phase I trial of weekly MK-0752 in children with refractory central nervous system malignancies: a pediatric brain tumor consortium study. Childs Nerv Syst. 2015 Aug;31(8):1283-9. PMID: 25930724.

 

Olson RE, Albright CF. Recent progress in the medicinal chemistry of gamma-secretase inhibitors. Curr Top Med Chem. 2008;8(1):17-33. PMID: 18220929.

" Not dangerous goods.

LKT D1773 Deshydroxy LY-411575 5 mg 89.9 γ-Secretase inhibitor. YO-01027, Dibenzazepine 209984-56-5 ≥98% 463.48 C26H23F2N3O3 Ambient -20°C "Petersen N, Reimann F, van Es JH, et al. Targeting development of incretin-producing cells increases insulin secretion. J Clin Invest. 2015 Jan;125(1):379-85. PMID: 25500886.

 

Xiao Z, Zhang J, Peng X, et al. The Notch γ-secretase inhibitor ameliorates kidney fibrosis via inhibition of TGF-β/Smad2/3 signaling pathway activation. Int J Biochem Cell Biol. 2014 Oct;55:65-71. PMID: 25150830.

 

Zheng YH, Li FD, Tian C, et al. Notch γ-secretase inhibitor dibenzazepine attenuates angiotensin II-induced abdominal aortic aneurysm in ApoE knockout mice by multiple mechanisms. PLoS One. 2013 Dec 16;8(12):e83310. PMID: 24358274.

" Not dangerous goods.

LKT D1773 Deshydroxy LY-411575 25 mg 365.2 γ-Secretase inhibitor. YO-01027, Dibenzazepine 209984-56-5 ≥98% 463.48 C26H23F2N3O3 Ambient -20°C "Petersen N, Reimann F, van Es JH, et al. Targeting development of incretin-producing cells increases insulin secretion. J Clin Invest. 2015 Jan;125(1):379-85. PMID: 25500886.

 

Xiao Z, Zhang J, Peng X, et al. The Notch γ-secretase inhibitor ameliorates kidney fibrosis via inhibition of TGF-β/Smad2/3 signaling pathway activation. Int J Biochem Cell Biol. 2014 Oct;55:65-71. PMID: 25150830.

 

Zheng YH, Li FD, Tian C, et al. Notch γ-secretase inhibitor dibenzazepine attenuates angiotensin II-induced abdominal aortic aneurysm in ApoE knockout mice by multiple mechanisms. PLoS One. 2013 Dec 16;8(12):e83310. PMID: 24358274.

" Not dangerous goods.

LKT D0260 DAPT 5 mg 78.6 γ-Secretase inhibitor. GSI-IX 208255-80-5 ≥98% 432.47 C23H26F2N2O4 Ambient -20°C Liu J, Mao Z, Huang J, et al. Blocking the NOTCH pathway can inhibit the growth of CD133-positive A549 cells and sensitize to chemotherapy. Biochem Biophys Res Commun. 2014 Feb 21;444(4):670-5. PMID: 24502949. Not dangerous goods.

LKT D0260 DAPT 25 mg 280.9 γ-Secretase inhibitor. GSI-IX 208255-80-5 ≥98% 432.47 C23H26F2N2O4 Ambient -20°C Liu J, Mao Z, Huang J, et al. Blocking the NOTCH pathway can inhibit the growth of CD133-positive A549 cells and sensitize to chemotherapy. Biochem Biophys Res Commun. 2014 Feb 21;444(4):670-5. PMID: 24502949. Not dangerous goods.

LKT P4782 PluriSln 1 5 mg 61.8 Stearoyl-coA desaturase 1 inhibitor. NSC 14613 91396-88-2 ≥98% 213.24 C12H11N3O Ambient "Zhang L, Pan Y, Qin G, et al. Inhibition of stearoyl-coA desaturase selectively eliminates tumorigenic Nanog-positive cells: improving the safety of iPS cell transplantation to myocardium. Cell Cycle. 2014;13(5):762-71. PMID: 24394703.

 

Ben-David U, Gan QF, Golan-Lev T, et al. Selective elimination of human pluripotent stem cells by an oleate synthesis inhibitor discovered in a high-throughput screen. Cell Stem Cell. 2013 Feb 7;12(2):167-79. PMID: 23318055.

" Not dangerous goods.

LKT P4782 PluriSln 1 10 mg 103.3 Stearoyl-coA desaturase 1 inhibitor. NSC 14613 91396-88-2 ≥98% 213.24 C12H11N3O Ambient "Zhang L, Pan Y, Qin G, et al. Inhibition of stearoyl-coA desaturase selectively eliminates tumorigenic Nanog-positive cells: improving the safety of iPS cell transplantation to myocardium. Cell Cycle. 2014;13(5):762-71. PMID: 24394703.

 

Ben-David U, Gan QF, Golan-Lev T, et al. Selective elimination of human pluripotent stem cells by an oleate synthesis inhibitor discovered in a high-throughput screen. Cell Stem Cell. 2013 Feb 7;12(2):167-79. PMID: 23318055.

" Not dangerous goods.

LKT P4782 PluriSln 1 25 mg 213.5 Stearoyl-coA desaturase 1 inhibitor. NSC 14613 91396-88-2 ≥98% 213.24 C12H11N3O Ambient "Zhang L, Pan Y, Qin G, et al. Inhibition of stearoyl-coA desaturase selectively eliminates tumorigenic Nanog-positive cells: improving the safety of iPS cell transplantation to myocardium. Cell Cycle. 2014;13(5):762-71. PMID: 24394703.

 

Ben-David U, Gan QF, Golan-Lev T, et al. Selective elimination of human pluripotent stem cells by an oleate synthesis inhibitor discovered in a high-throughput screen. Cell Stem Cell. 2013 Feb 7;12(2):167-79. PMID: 23318055.

" Not dangerous goods.

LKT P4782 PluriSln 1 50 mg 331.5 Stearoyl-coA desaturase 1 inhibitor. NSC 14613 91396-88-2 ≥98% 213.24 C12H11N3O Ambient "Zhang L, Pan Y, Qin G, et al. Inhibition of stearoyl-coA desaturase selectively eliminates tumorigenic Nanog-positive cells: improving the safety of iPS cell transplantation to myocardium. Cell Cycle. 2014;13(5):762-71. PMID: 24394703.

 

Ben-David U, Gan QF, Golan-Lev T, et al. Selective elimination of human pluripotent stem cells by an oleate synthesis inhibitor discovered in a high-throughput screen. Cell Stem Cell. 2013 Feb 7;12(2):167-79. PMID: 23318055.

" Not dangerous goods.

LKT N3350 Nimorazole 5 mg 118 Nitroimidazole; hypoxic modifier and radiosensitizer. 6506-37-2 ≥98% 226.24 C9H14N4O3 c1c(n(cn1)CCN2CCOCC2)[N+](=O)[O-] Ambient "

Metwally MA, Frederiksen KD, Overgaard J. Compliance and toxicity of the hypoxic radiosensitizer nimorazole in the treatment of patients with head and neck squamous cell carcinoma (HNSCC). Acta Oncol. 2014 May;53(5):654-61. PMID: 24328536.

 

Overgaard J. Clinical evaluation of nitroimidazoles as modifiers of hypoxia in solid tumors. Oncol Res. 1994;6(10-11):509-18. PMID: 7620219.

 

Overgaard J, Overgaard M, Nielsen OS, et al. A comparative investigation of nimorazole and misonidazole as hypoxic radiosensitizers in a C3H mammary carcinoma in vivo. Br J Cancer. 1982 Dec;46(6):904-11. PMID: 7150484.

 

Wigfield AS. Trichomonal vaginitis. A 24-hr regimen of nimorazole compared with a 7-day regimen of metronidazole. Br J Vener Dis. 1975 Feb;51(1):54-6. PMID: 1092425.

" Not dangerous goods.

LKT N3350 Nimorazole 10 mg 196.7 Nitroimidazole; hypoxic modifier and radiosensitizer. 6506-37-2 ≥98% 226.24 C9H14N4O3 c1c(n(cn1)CCN2CCOCC2)[N+](=O)[O-] Ambient "

Metwally MA, Frederiksen KD, Overgaard J. Compliance and toxicity of the hypoxic radiosensitizer nimorazole in the treatment of patients with head and neck squamous cell carcinoma (HNSCC). Acta Oncol. 2014 May;53(5):654-61. PMID: 24328536.

 

Overgaard J. Clinical evaluation of nitroimidazoles as modifiers of hypoxia in solid tumors. Oncol Res. 1994;6(10-11):509-18. PMID: 7620219.

 

Overgaard J, Overgaard M, Nielsen OS, et al. A comparative investigation of nimorazole and misonidazole as hypoxic radiosensitizers in a C3H mammary carcinoma in vivo. Br J Cancer. 1982 Dec;46(6):904-11. PMID: 7150484.

 

Wigfield AS. Trichomonal vaginitis. A 24-hr regimen of nimorazole compared with a 7-day regimen of metronidazole. Br J Vener Dis. 1975 Feb;51(1):54-6. PMID: 1092425.

" Not dangerous goods.

LKT N3350 Nimorazole 25 mg 393.2 Nitroimidazole; hypoxic modifier and radiosensitizer. 6506-37-2 ≥98% 226.24 C9H14N4O3 c1c(n(cn1)CCN2CCOCC2)[N+](=O)[O-] Ambient "

Metwally MA, Frederiksen KD, Overgaard J. Compliance and toxicity of the hypoxic radiosensitizer nimorazole in the treatment of patients with head and neck squamous cell carcinoma (HNSCC). Acta Oncol. 2014 May;53(5):654-61. PMID: 24328536.

 

Overgaard J. Clinical evaluation of nitroimidazoles as modifiers of hypoxia in solid tumors. Oncol Res. 1994;6(10-11):509-18. PMID: 7620219.

 

Overgaard J, Overgaard M, Nielsen OS, et al. A comparative investigation of nimorazole and misonidazole as hypoxic radiosensitizers in a C3H mammary carcinoma in vivo. Br J Cancer. 1982 Dec;46(6):904-11. PMID: 7150484.

 

Wigfield AS. Trichomonal vaginitis. A 24-hr regimen of nimorazole compared with a 7-day regimen of metronidazole. Br J Vener Dis. 1975 Feb;51(1):54-6. PMID: 1092425.

" Not dangerous goods.

LKT N3350 Nimorazole 50 mg 561.8 Nitroimidazole; hypoxic modifier and radiosensitizer. 6506-37-2 ≥98% 226.24 C9H14N4O3 c1c(n(cn1)CCN2CCOCC2)[N+](=O)[O-] Ambient "

Metwally MA, Frederiksen KD, Overgaard J. Compliance and toxicity of the hypoxic radiosensitizer nimorazole in the treatment of patients with head and neck squamous cell carcinoma (HNSCC). Acta Oncol. 2014 May;53(5):654-61. PMID: 24328536.

 

Overgaard J. Clinical evaluation of nitroimidazoles as modifiers of hypoxia in solid tumors. Oncol Res. 1994;6(10-11):509-18. PMID: 7620219.

 

Overgaard J, Overgaard M, Nielsen OS, et al. A comparative investigation of nimorazole and misonidazole as hypoxic radiosensitizers in a C3H mammary carcinoma in vivo. Br J Cancer. 1982 Dec;46(6):904-11. PMID: 7150484.

 

Wigfield AS. Trichomonal vaginitis. A 24-hr regimen of nimorazole compared with a 7-day regimen of metronidazole. Br J Vener Dis. 1975 Feb;51(1):54-6. PMID: 1092425.

" Not dangerous goods.

LKT A8812 AWD 131-138 5 mg 101.1 GABA-A positive modulator. 188116-07-6 ≥98% 279.72 C13H14ClN3O2 c1cc(ccc1N2CC(=NC2=O)N3CCOCC3)Cl Ambient "Rundfeldt C, Löscher W. The pharmacology of imepitoin: the first partial benzodiazepine receptor agonist developed for the treatment of epilepsy. CNS Drugs. 2014 Jan;28(1):29-43. PMID: 24357084.

 

Löscher W, Hoffmann K, Twele F, et al. The novel antiepileptic drug imepitoin compares favourably to other GABA-mimetic drugs in a seizure threshold model in mice and dogs. Pharmacol Res. 2013 Nov;77:39-46. PMID: 24056205.

 

Yasar S, Bergman J, Munzar P, et al. Evaluation of the novel antiepileptic drug, AWD 131-138, for benzodiazepine-like discriminative stimulus and reinforcing effects in squirrel monkeys. Eur J Pharmacol. 2003 Apr 4;465(3):257-65. PMID: 12681437.

" Not dangerous goods.

LKT A8812 AWD 131-138 10 mg 191 GABA-A positive modulator. 188116-07-6 ≥98% 279.72 C13H14ClN3O2 c1cc(ccc1N2CC(=NC2=O)N3CCOCC3)Cl Ambient "Rundfeldt C, Löscher W. The pharmacology of imepitoin: the first partial benzodiazepine receptor agonist developed for the treatment of epilepsy. CNS Drugs. 2014 Jan;28(1):29-43. PMID: 24357084.

 

Löscher W, Hoffmann K, Twele F, et al. The novel antiepileptic drug imepitoin compares favourably to other GABA-mimetic drugs in a seizure threshold model in mice and dogs. Pharmacol Res. 2013 Nov;77:39-46. PMID: 24056205.

 

Yasar S, Bergman J, Munzar P, et al. Evaluation of the novel antiepileptic drug, AWD 131-138, for benzodiazepine-like discriminative stimulus and reinforcing effects in squirrel monkeys. Eur J Pharmacol. 2003 Apr 4;465(3):257-65. PMID: 12681437.

" Not dangerous goods.

留言框

  • 产品:

  • 留言内容:

  • 您的单位:

  • 您的姓名:

  • 联系电话:

  • 常用邮箱:

  • 详细地址:

  • 省份:

  • 验证码:

    请输入计算结果(填写阿拉伯数字),如:三加四=7
网站首页 公司简介 产品中心 招聘中心 技术支持 企业动态 联系我们 管理登陆
上海易汇生物科技有限公司主营:Eaivelly封板膜|Eaivelly八联管|Eaivelly针式过滤器|Eaivelly光学平盖|Eaivelly荧光定量|代理GE
GoogleSitemap ICP备案号:沪ICP备16010708号-3 技术支持:化工仪器网
张经理
  • 电话

    021-62962298

在线客服
扫一扫访问手机站扫一扫访问手机站
访问手机站